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Abstract 
 
Background 
 
Attention deficit hyperactivity disorder (ADHD) is a leading cause of child referrals to mental 
health services, and major risk factor for early criminality, school drop-out and exclusion. It 
imposes significant burdens on children, their families and a wide range of public services. 
 
Long-term evidence for the effectiveness of main and non-mainstream treatments is weak. 
Current approaches to generating evidence are expensive and slow. New approaches are 
required to identify treatments which can improve outcomes. This thesis rethinks the identi-
fication and testing of interventions to improve outcomes for ADHD. 
Methods.  
Using the Trials within Cohorts (TwiCs) approach, the Sheffield Treatments for ADHD Re-
search (STAR) project recruited a cohort of children with ADHD and collected outcomes at 0, 
6 & 12 months from carers and teachers. For the first randomised, controlled trial (RCT) 
embedded in the cohort an eligible proportion were randomly selected and offered treat-
ment by homeopaths, or nutritional therapists, additional to usual care. At 6 months, their 
outcomes (Conners Global ADHD Index) were compared with those not offered interven-
tions, and the feasibility of the methods and interventions assessed. 
Results 
Between September 2015/2016, the target number of 144 participants were recruited to 
the cohort. 124 were eligible for the 1st trial and randomised. 83 were offered a treatment 
of which 72 accepted and 50 attended 1+ appointments. 89/124 paired (baseline & 6-
months) carer and 31/100 paired teacher questionnaires were available for analysis. Teach-
ers’ responses were too few, and unstable, but there were preliminary indications of treat-
ments’ effectiveness according to carers: t = 1.08, p= .28 (-1.48, 4.81) SMD .425 for treat-
ment by homeopaths; t = 1.71, p = .09 (-.347, 5.89), SMD = .388 for treatment by nutritional 
therapists. No serious adverse events attributable to treatments were reported. 
The TwiCs approach was feasible but required some modifications. Return of carer ques-
tionnaires was improved by addition of an incentive. Delivery of treatments was feasible, 
but attendance rates affected by therapists’ contacting strategies, and one therapist 
dropped out.   
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Discussion 
A representative cohort was quickly recruited, and the first pilot RCT efficiently conducted.  
Attrition and uptake were comparable with other pragmatic studies in ADHD. Although 
therapists reported that delivery was challenging, 70% of participants accepting treatment 
received at least three consultations and reported they were helpful. No serious adverse 
events attributable to treatment occurred. 
Modifications are required to improve poor return of teacher outcomes, therapist’s contact-
ing strategies, crossover from treatment to usual care (40%), and cohort representativeness. 
Conclusion 
The TwiCs design can make an important contribution in the search to improve outcomes 
for those with ADHD. The STAR project demonstrated the feasibility of the TwiCs approach 
to pragmatic RCT design for testing interventions for children with ADHD. In the pilot RCT 
the novel interventions showed preliminary indications of effectiveness according to carers. 
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Chapter 1 Introduction  
1.1   An overview of the thesis 
Attention Deficit Hyperactivity Disorder (ADHD) is one of the most commonly diagnosed and 
treated childhood psychiatric disorders. Children with ADHD are hyperactive (fidgety and 
unable to sit still for long periods), and impulsive (doing things without stopping to think). 
They find it hard to concentrate and follow instructions, which is a particular problem at 
school, and to regulate their emotions, which is a problem at home, with their peers, and 
gets them into trouble. 
ADHD type behaviours have been described in medical literature for over 100 years 
(Reimherr, 2005). Heterogeneity (non-uniformity) is a feature of ADHD expression and chil-
dren often have a wide range of other diagnoses and co-occurring problems such as Autism 
Spectrum Conditions (ASCs), Conduct Disorders, sleep disorders, tics, gut dysbiosis, reading 
and other learning problems. A diverse range of risk factors are suggested in the literature 
including environmental exposures in utero, birth trauma, parental stress, and genetic sus-
ceptibility. 
Treating the condition is challenging. Many do not consider the condition to be curable, so 
interventions are offered to help to manage symptoms. The two types of interventions of-
fered by the NHS, recommended by NICE (2008), are behaviour change programmes and 
pharmaceutical medications.  Pharmaceutical medications are associated with common side 
effects, and tend to be discontinued, particularly by teenagers. They may not be effective 
over the long-term, or for up to 25% of the population, especially those with co-occurring 
autism. Behaviour change programmes, the first line of intervention offered in the UK for 
those with moderate ADHD, are costly, not universally available, considered less effective 
than pharmaceutical interventions at reducing core ADHD symptoms, and effects may not 
be sustained once programmes end. Neither intervention appears to be influencing the 
long-term negative outcomes associated with the condition. 
Interpreting and comparing the evidence, particularly the long-term evidence, for the effec-
tiveness of these two types of interventions is difficult for several reasons. Comparison is 
difficult largely because trials of drugs tend to be explanatory whereas trials of behaviour 
change programmes tend to be pragmatic. Trials were originally identified as being either 
explanatory or pragmatic by Schwartz and Lellouch (1967). Explanatory trials aim to evalu-
ate the efficacy of an intervention in a well-defined and controlled setting, in comparison to 
a placebo or another intervention. Pragmatic trials aim to test the effectiveness of an inter-
vention in broad routine clinical practice and measure “the extent to which a specific inter-
vention…. when deployed in the field in routine circumstances does what it is intended to 
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do for a specific population” (Last, Spasoff, & Harris, 2001). This means the two types of tri-
als are more/less tightly controlled, have more/less potential for bias, higher/lower ex-
pected effect sizes, and address different research questions.  
It is difficult to assess the ability of the two types of intervention to improve long-term out-
comes, because despite many RCTs having been conducted the majority are short-term. It is 
unclear whether the lack of evidence found in the few long-term studies conducted is due to 
adherence and acceptability issues or the lack of effectiveness of the interventions. Evi-
dence from short-term trials is used to make long-term treatment decisions. 
Current approaches to generating evidence are expensive and slow, and new approaches 
are required to identify treatments which can improve outcomes particularly in the long-
term. Not only do ADHD trials tend to be of short duration, but interventions are trialled 
one at a time, which is costly in terms of time and resources. Each trial recruits its 
own standalone population and often fail to recruit sufficient participants (McDonald, et al., 
2006) (Sully, Julious, & Nicholl, 2013). At the trial end, the trial population is disbanded, and 
for the next trial a new RCT is designed and new trial population recruited. Trials use differ-
ent comparators, have different aims, and often have tight inclusion and exclusion criteria, 
so it is difficult to be confident that results pertain to all those with ADHD which is associat-
ed with co-morbidities that are often exclusion criteria.  
Good quality evidence for interventions to improve long-term outcomes is needed. Not only 
do we need more long-term studies of the effectiveness of mainstream interventions, but 
novel treatments need to be trialled to see whether they might address treatment gaps, and 
the way that research is conducted needs re-thinking to address some of the issues de-
scribed above. This thesis rethinks the methods for creating evidence to assess the effec-
tiveness of treatments for ADHD to improve long-term outcomes. It takes a novel approach 
to trialling interventions, trials two novel interventions, and asks: “is the Trials within Co-
horts (TwiCs) design feasible to generate evidence about the effectiveness of interventions 
for ADHD?”, by pilot testing the effectiveness of the novel treatments using the TwiCs ap-
proach (Relton, O'Cathain, Nicholl, & Torgerson, 2010). 
The TwiCs design, also known as the cohort, multiple randomised controlled trial (cmRCT) 
design, is a new approach for testing interventions and improving outcomes. First a large 
observational cohort of patients with the condition of interest is recruited and their out-
comes regularly measured. Then for each randomised controlled trial, information from the 
cohort is used to identify eligible participants. Some eligible cohort participants are random-
ly selected and offered the trial intervention(s) additional to their usual care. The outcomes 
of the randomly selected groups are then compared with the outcomes of those eligible 
participants not selected and continuing with their usual care.  
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The design allows the comparative effectiveness testing of multiple interventions in a repre-
sentative population over the long-term. It enables accurate comparison of different types 
of intervention, since validity, population, comparator and outcomes are held constant for 
all interventions tested. It tests whether important, objective outcomes are improved over 
the long-term.  
The acceptability of interventions is tested, providing useful information about how ac-
ceptable they might be in practice. It uses an approach to informed consent whereby infor-
mation about interventions is provided only to the intervention group(s) after randomisa-
tion, aiding speedy recruitment of sufficient numbers (Viksveen, Relton, & Nicholl, 2017).  
The design is efficient and cost-effective because it provides a facility for multiple trials to be 
run, with economies of scale. Unequal randomisation can be used, reducing costs associated 
with treatments (Viksveen, Relton, & Nicholl, 2017). Once a cohort is in place, trials can be 
quickly and cheaply conducted, and there is reduced risk of trials run within existing cohorts 
failing to recruit. 
Running trials of both main and non-mainstream interventions using the TwiCs design can 
contribute to the evidence base regarding the potential of current and novel interventions 
to improve long-term outcomes for those with ADHD. 
1.2   Reflexivity and bias. 
Bias is a term used to describe a tendency towards a particular perspective. In conducting 
clinical research, researchers are urged to be upfront, explicit and transparent about their 
motivations for carrying out the research (Jadad & Enkin, 2007). Reflexivity refers to sensi-
tivity to the ways in which researchers may shape the research process, and it is suggested 
researchers should make any personal and intellectual biases plain at the outset (Mays & 
Pope, 2000). This section therefore addresses concerns about bias by taking a reflexive ap-
proach and describing my biography, beliefs and agenda as they relate to the research un-
dertaken in this thesis. I have endeavoured to make plain my personal viewpoints and expe-
riences which may affect my research. 
1.2.1 My background 
My primary training and career were in education.  After completing a B.Ed. in English Liter-
ature and Education at Cambridge University, I worked as a teacher (including with those 
with special educational needs), and parent educator within Sure Start, until my own four 
children were born. One formative post in St George’s Hospital psychiatric unit as a member 
of a team working with school refusing children, highlighted the difficulties in making tangi-
ble differences to these children’s lives. 
 19 
 When my children were small, I trained as a homeopath with a view to managing their first 
aid needs. My great aunt was a medically trained doctor and homeopath and I had been 
brought up using homeopathic remedies to manage our health. Whilst training, and under 
supervision, I provided homeopathic treatment to a nine-year-old child (consisting of three 
consultations over 18 weeks and individually tailored homeopathic remedies).  The child had 
a diagnosis of ADHD, nocturnal enuresis, history of attempted suicide, multiple warts, was 
illiterate, and had destroyed much of the family home. These symptoms and behaviours 
gradually disappeared over the homeopathic treatment period, during which time he learnt 
to read. This was a pivotal experience since it appeared to me that the child had experi-
enced greater improvements with treatment than anything I had previously provided in the 
classroom or as a parent educator. 
I wondered whether the improvement might be due to the homeopathic treatment, or to 
other factors. I wondered if homeopathic treatment might be generally effective for chil-
dren with ADHD, and what the evidence was for homeopathic treatment for ADHD? I con-
tinued to treat children with ADHD, but when I suggested homeopathic treatment to 
schools and educators, the usual response was scepticism and rebuttal. This led me to won-
der whether there was a problem with the evidence base. My experience with this child and 
subsequently with others has led me to explore systematically whether homeopathic treat-
ment is helpful for these children, what kind of evidence is needed to ascertain this and for 
this treatment to be considered as an option. 
To start answering some of my questions I undertook a BSc in Homeopathy at Thames Val-
ley University. For the research module I conducted a literature review of the trials of ho-
meopathy for ADHD. I then undertook a consecutive case series, whereby I recruited 20 
children with a diagnosis of ADHD to receive a year’s homeopathic treatment from myself, 
and their outcomes were documented. This received funding from Turner’s Court Youth 
Trust (an ex borstal supporting measures to prevent imprisonment) and matched funding 
from the Homeopathic Research Institute. The children appeared to benefit from the treat-
ment, but I understood that more robust research methods were needed. 
Whilst implementing the case series, I undertook an MSc in Research Methodology in Psy-
chology at Goldsmiths, University of London. At the suggestion of my tutors, having recruit-
ed 20 children to the treatment group, I then recruited a further 10 children as a control 
group. They received similar time and attention from myself but no homeopathic treatment. 
Carers of the children receiving homeopathic treatment reported statistically significant im-
provements compared to those receiving similar time and attention (section 4.3) (Fibert, 
Relton, Heirs, & Bowden, 2016). But I again realised that more rigorous research, using ran-
domisation, would be required for the results to be considered robust.  
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Parallel to this academic and clinical exploration, ADHD has had a personal impact on my 
family, with most of my husband’s family and two of my four daughters receiving a diagno-
sis of ADHD. One of my daughters initially managed her ADHD with Ritalin to help her com-
plete her undergraduate degree, but disliked how it made her feel and now manages it 
through a gluten and dairy free diet, nutritional supplementation and lifestyle. The other 
daughter did not experience improvements with either Ritalin or Atomoxetine (non-
methylphenidate based medication), undertook a course of CBT therapy, and is helped by 
anti-depressants. Both receive occasional homeopathic treatment. This has provided me 
with an intimate experience of the impact of diagnosis, management, pharmaceutical medi-
cation, behavioural programmes, nutritional supplementation, dietary changes and homeo-
pathic treatment. 
1.2.2 The implications of my experience 
My viewpoint that homeopathic treatment is helpful for children with ADHD has been influ-
enced by my biography, my academic, and my professional training. My varied career path 
as a teacher, parent educator, carer, homeopath and researcher has had a common thread, 
in being consistently motivated by a desire to improve outcomes for struggling children, and 
I have explored different careers with this aim in mind.   
I bring an in-depth understanding of ADHD and the interventions trialled from a construc-
tionist viewpoint, which contributes positively to the research process (Postholm & Madsen, 
2006). However, there is the potential for bias in that I may be tempted to seek confirma-
tion for my clinical, educational, familial and informal observations. For example, I believe I 
have observed multiple instances whereby homeopathic treatment and nutritional interven-
tions have facilitated improvements, but these improvements could have been due to other 
factors. Therefore objectivity, transparency and reflexivity have been required at all stages 
of the research process to minimise the potential impact of this view.  
Steps taken to reduce risk of bias include the independent procedures of ethical review, in-
dependent scientific review, and University of Sheffield research governance systems, which 
scrutinised all stages of the research process. The study was overseen by a steering commit-
tee of independent academics, researchers and clinicians.  The randomisation process was 
performed by independent researchers, and the trial protocol was published prior to trial 
start (http://www.isrctn.com/ISRCTN17723526). Study data are fully reported, and supervi-
sion provided by academics from diverse disciplines (public health, statistics, health eco-
nomics and psychology) with differing opinions on the interventions tested. 
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1.2.3   Epistemology 
For this PhD I have conducted empirical research, with the understanding that such 
knowledge is prioritised by decision makers, who value the primacy of the RCT as a method 
of establishing a causal link between intervention and outcome (Medical Research Council 
(MRC), 2000). However, other forms of knowledge have also been used. Anecdotal 
knowledge informed my initial research hypothesis, and authoritative knowledge was used 
when reviewing the professional literature. Logical knowledge was used outlining the re-
search problem to be addressed, interpreting the evidence base, and reasoning from find-
ings to conclusions. 
1.2.4   Ontology 
I have taken an essentially positivist, pragmatic perspective in conducting the empirical re-
search described in this thesis. However, I consider both interpretivist and empirical ap-
proaches are used in order to answer “real-world” research questions (Feilzer, 2010). I think 
that it is likely that empirical research into novel interventions is assessed through interpre-
tivist lenses, and that interpretation of such studies will be affected by individual 
knowledge, experience and belief. Therefore transparent understanding of the ontological 
perspectives of others, as well as my own can increase clarity.  
1.3   Aims and Objectives of the thesis 
This thesis addresses the question: “is the Trials within Cohorts (TwiCs) design feasible to 
generate evidence about the effectiveness of interventions for ADHD?”, 
The aim of this thesis is to assess the feasibility of the TwiCs design to provide information 
to enable the evaluation of treatments for ADHD. 
The objectives of this thesis are to: 
• describe ADHD, its impact across services, the range and effectiveness of main-
stream interventions, gaps in provision, and key issues 
• identify key stakeholder requirements to assess acceptability, clinical and cost effec-
tiveness of treatments 
• identify a range of novel treatments for ADHD that are being used which have some 
evidence for their effectiveness and select two to be tested 
• describe and review the evidence for these two selected treatments for ADHD: 
treatment by homeopaths and treatment by nutritional therapists  
• explore the key issues regarding trial designs for these interventions  
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• assess the feasibility, acceptability, deliverability, safety, clinical and cost effective-
ness of treatment by homeopaths and nutritional therapists for children with ADHD  
• assess the feasibility of the TwiCs design to efficiently test the comparative accepta-
bility, clinical and cost effectiveness of a wide range of treatments for children with 
ADHD by conducting a small-scale test of the methods and procedures   
• assess the feasibility of recruiting to time and target a cohort of children with a diag-
nosis of ADHD  
• assess the suitability, acceptability, and deliverability of the outcome measures  
• inform the sample size calculation for a full trial  
1.4   The audience for my research 
The audience for my research are those who make decisions and recommendations about 
treatment options and ways to improve outcomes for those with ADHD. This includes car-
ers, local councils, health professionals, ADHD researchers and ADHD research funders. A 
key audience is the National Institute for Health and Care Excellence (NICE) since families 
with children with ADHD tend to access health care provided free at the point of delivery by 
the National Health Service (NHS).  NICE assesses which treatments produce sufficient bene-
fit that the NHS should pay for them (https://www.nice.org.uk/about). Whilst guidelines are 
advisory and do not have legal force, they are very influential (Taylor, 2008).  
1.5   Rationale for the thesis 
An overview of the rationale for this thesis is provided here, with reference to sections in 
the thesis where the subject is discussed and referenced in depth. 
1.5.1  ADHD  
Improvement in the outcomes of those with ADHD is important from the perspective of the 
child, their family, and society. Children with ADHD are more likely to be in care, to suffer 
from post-traumatic disorders, have poor social skills and are at higher risk of negative out-
comes such as involvement in violent crimes, particularly at a young age (section 2.2).  This 
negative trajectory tends to start at school, where children with ADHD are more likely to be 
disruptive, excluded, low achievers and/or drop out, all of which are known risk factors for 
criminality, substance misuse and psychiatric disorders (section 2.2.4).  
Teenage years are particularly difficult for those with ADHD. They tend to stop taking their 
ADHD medications (section 2.3.1). At school they experience increased pressure to study for 
national exams, but tasks become less suited to them, particularly when distant completion 
dates are given for homework and longer-term application is required. They experience 
hormonal changes which exacerbate their emotional dysregulation. As with all teenagers, 
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they are increasingly influenced by peers and decreasingly influenced by carers, but their 
ADHD means they are less able to replace the supportive structure carers may have provid-
ed with their own structures.   
Families with children with ADHD are affected. Siblings experience elevated levels of bully-
ing. Parents are more likely to divorce, have drug and alcohol associations, affective disor-
ders or suffer from stress (section 2.2.2).  
Management of these issues strains education, health, criminal justice and social care sys-
tems. The highest costs are found in education (section 2.2.6) because in school children 
require considerable extra input compared to those without ADHD. ADHD is the most com-
mon reason for a referral to Child and Adult Mental Health Services (CAHMS) accounting for 
35.7 % of presentations (Health Service Executive (HSE), 2012) (Hayden, Flood, & 
McNicholas, 2016) and the most common reason for a follow up by UK CAMHS (Woodward, 
Dowdney, & Taylor, 1997). It is the largest risk factor for early criminality, and for disruptive 
behaviour in prisons (section 2.2.4).  
Effective treatments are needed to help children with ADHD, and the earlier the better if the 
spiral of negative outcomes is to be prevented.  
1.5.2 Mainstream Treatment 
Diagnosis, treatment and management of ADHD occurs primarily within the NHS, but educa-
tion, social care and criminal justice systems are also involved in treatment and manage-
ment. 
NICE guidance post ADHD diagnosis (National Institute for Health and Care Excellence 
(NICE), 2008) is to provide self-instruction manuals based on positive parenting and behav-
ioural techniques, and stress the value of a balanced diet, good nutrition and regular exer-
cise.  The first line of treatment for pre-school children and those with moderate impair-
ment is the offer of parent training or education programmes. The guidance states that drug 
treatment should only be offered to those severely impaired, and as the second line of 
treatment for those with moderate impairment who have refused or not responded suffi-
ciently to behaviour change programmes. In reality the majority of children are offered drug 
treatments after participating in behavioural programmes (section 2.3). 
Evidence suggests that both pharmaceutical and behavioural treatments are only effective 
whilst implemented and that compliance is poor, with teenagers particularly prone to dis-
continuing them (section 2.3). Medication is only licenced from age 6 in the UK, although 
ADHD symptoms often manifest well before this age (NICE, 2008).  Up to 25% of children do 
not respond to stimulant medication or behavioural interventions, particularly those with 
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concomitant ADHD and autism spectrum conditions (ASCs); and side effects of medication, 
such as nervousness, trouble sleeping, loss of appetite, weight loss, dizziness, nausea, vomit-
ing, mood swings, or headache, are common (www.NHS.uk) (section 2.3.1). 
There are long waiting lists for some NHS services, and patchy provision throughout the UK.  
Furthermore, associated co-morbidities are treated separately and drug side effects may 
also need treatment. For example, stimulant medication increases dopamine levels in the 
brain which may exacerbate sleep problems (section 2.3.1), leading to prescription of off-
label Melatonin.  
1.5.3 Non-mainstream treatments.  
These are treatments outside the realm of mainstream medicine. They are referred to in a 
variety of ways. For example as unconventional (Ng & Weisz, 2016), Complementary and 
Alternative Medicine (CAM) (Hall & Riccio, 2012), and Integrative Medicine (when conven-
tional and complementary approaches are brought together in a co-ordinated way” 
(https://nccih.nih.gov)).   
The most popular interventions across surveys of ADHD are: supplements, dietary changes, 
acupuncture, homeopathy, massage, craniosacral therapy, music therapy, equine therapy, 
secretin (a regulatory hormone) and chelation (a detoxification treatment) (section 2.3.4). 
The interventions are varied: some have been around for a long time (e.g. acupuncture, 
massage) but we don’t know how effective or relevant they are to ADHD; some therapies 
involve touch (craniosacral therapy); needles (acupuncture), some no touch (music therapy); 
some involve ingesting something (homeopathy, supplements); some involve modifying 
what is ingested (Gluten Free, Casein Free diets). 
Doctors are found to be uncomfortable recommending treatments about which they are 
unknowledgeable and untrained, without supportive empirical evidence (Akins, Angkustsiri, 
& Hansen, 2010), although a recent survey found that they had a high interest in using natu-
ral medicines in paediatrics (Huckstadt, 2017). Nevertheless, the use of non-mainstream 
treatments is increasing despite the concerns of physicians, and in addition to medication 
(section 2.3.4). Increases are especially seen where medical treatment is associated with 
adverse effects and for children with chronic conditions, which ADHD is considered to be. It 
is likely that non-mainstream interventions remain outside the mainstream whilst their evi-
dence base is poorly developed (section 2.3.4). 
Whilst the majority of carers of children with ADHD rely on treatments provided free at the 
point of delivery by the NHS, a number are trying other treatments and paying for them out 
of their own pocket (section 2.3.4). It is important that these non-mainstream approaches 
are assessed to see whether they might be supportive in the management of ADHD for sev-
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eral reasons. Carers are trying them, and evidence can inform their choices. Doctors need 
evidence in order to recommend them. And adjunctive novel treatments are required to 
address gaps in provision and reduce the burden on children, their families, and key social 
institutions.  
The lack of evidence, and its poor quality, are reasons why non-mainstream treatments re-
main outside the realm of conventional medicine. The following section looks at reasons 
why evidence is considered poor quality, and introduces key concepts for assessing the 
quality of evidence. 
1.5.4 Assessing and testing treatments  
The concept of validity was formulated by Kelly (Remmers, Shock, & Kelly, 1927) who stated 
that a test is valid if it measures what it claims to measure. Three types of validity are semi-
nal to this thesis: internal, external and ecological validity.  
A key consideration for assessors is the internal validity of trials. Internal validity refers to 
the extent to which the methods used to test an intervention are free of potential for bias. 
Explanatory trials, which aim to evaluate the efficacy of an intervention (that is whether it 
demonstrates positive benefits over a placebo or another intervention when tested under 
ideal conditions), tend to have high internal validity. This is because they have less potential 
for bias, and greater confidence that the results obtained are down to the measured inter-
vention.  
Pragmatic trials aim to test the effectiveness of an intervention, that is whether it works in 
everyday practice. Such trials tend to have high external validity. External validity refers to 
the extent to which the methods used to test an intervention are generalizable to real-world 
settings.  
Internal validity is prioritised by assessors and considered a pre-requisite before external 
validity is considered (Section 3.1.5) (Torgerson & Torgerson, 2008). NICE assessment pro-
cedures equate explanatory designs with study excellence. Good internal validity provides 
increased confidence in the effects measured. Unblinded, pragmatic studies are considered 
de facto low quality. Because researchers tend to prioritise internal validity when designing 
trials, tests of real-world effectiveness are few. 
This is problematic because it means that interpretation of an intervention’s effectiveness is 
influenced by its ability to be tested using trial designs with high internal validity such as 
double-blinded randomised placebo-controlled trials (RCTs), considered the gold standard 
of the evidence base. Interventions tested using pragmatic designs, appropriate for the as-
sessment of behaviour change programmes and most non-mainstream interventions, may 
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not be recommended by health care decision makers due to their de-facto poorer internal 
validity. 
Ecological validity refers to the core principles and concepts of an intervention. It refers to 
the extent of concordance between a trial design and the core principles of the intervention 
tested. The extent to which they are represented in a trial is important to assess the gener-
alisability of results regarding that intervention.  
Many non-mainstream treatments are considered complex, holistic, are individually tai-
lored, and/or therapist led. They tend to have interacting components that require viewing 
and testing as a synergistic network to achieve adequate ecological validity (Medical 
Research Council (MRC), 2000). This presents a challenge for trial designers in the context of 
the supremacy of the double-blinded placebo-controlled RCT.  Researchers therefore tend 
to focus on identifying an active ingredient using reductionist strategies (Verhoef, Mulkins, 
& Boon, 2005). It has been identified that this is mitigating against the development of an 
appropriate evidence base (Saks & Robinson, 2015) (MRC, 2000), and may be obscuring the 
fact that patients are helped by such types of interventions. 
A further consideration is that holistic or whole system approaches expect non-specific out-
comes. Their potential is considered to be to “promote and enhance wellbeing, resilience, 
and the realisation of an individual’s potential capacities for self-care, self-regulation and 
self-healing” (http://www.nhsggc.org.uk). Such effects may not be captured using treat-
ment-specific outcome measures (for example (Fibert, 2015a)). 
Individually tailored treatments may be particularly suitable for those with ADHD due to the 
condition’s heterogeneity and association with co-morbidities. Individually tailored ap-
proaches are delivered based on individual characteristics and preferences, and adjusted 
over time to optimize outcomes. Addressing multiple diagnoses through a single individually 
tailored therapeutic intervention may offer value for money as well as improved outcomes.  
However, running such trials is expensive, and funding difficult to procure, so often trials are 
small and underpowered. It can be difficult to standardise delivery when testing individual-
ised interventions, which are therapist led. Such trials are vulnerable to therapist effects and 
reduced model validity. Model validity is the extent of concordance between the trial study 
design and ideal practice (Mathie, van Wassenhoven, Jacobs, & Oberbaum, 2015). Further-
more, since interaction between therapist and patient is an essential component of treat-
ment, patients cannot be blinded to the intervention they receive. 
This research aims to facilitate a rigorous research facility to test all treatments being used 
by families, both main and non-mainstream, to provide useful information for key stake-
holders.  
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1.5.5  Rationale for the trial design 
Traditional double-blinded, placebo-controlled designs are very good at testing the specific 
effects of interventions, particularly drugs. Isolating their effects can provide knowledge for 
further development of existing treatments, development of novel interventions, and confi-
dence that the effects measured are due to the variable tested. They are at reduced risk of 
bias, meaning that there is less chance that a known or unknown variable(s) may be respon-
sible for the observed effect other than the intervention.  
In achieving methodological purity, direct relevance to clinical practice may be sacrificed. 
And such testing is unsuitable for exploring either the efficacy or effectiveness of complex, 
holistic, and/or individually tailored interventions. When such tests are applied, they do not 
test the efficacy of that intervention – that is its performance in an ideal situation. Rather, 
circumstances in such trials are the opposite of ideal because isolation of any of their inter-
twined, inextricably linked variables severely compromises ecological validity, as does 
standardisation of delivery in therapist-led interventions.   
To provide suitable information to enable the comparative evaluation of the effectiveness of 
treatments for ADHD to improve outcomes, a pragmatic (not explanatory) trial of effective-
ness (not efficacy) measuring real-world outcomes of interest (not surrogate markers, or 
just ADHD symptoms) is appropriate. Traditional double-blinded, placebo-controlled designs 
are unsuitable to answer questions about real-world effectiveness and cost effectiveness, or 
to compare all types of intervention.  
Key requirements of a potential pragmatic trial design are: to test treatments as delivered in 
the real-world in heterogeneous patient samples; to measure patient and stakeholder cen-
tred outcomes; to use real-world comparators; to be suitable to test multiple, diverse inter-
ventions comparatively; and to be acceptable to stakeholders (chapter 3). This means exter-
nal and ecological validity should be high, as treatment resembles that experienced in rou-
tine health care. The challenge with pragmatic trials is to provide a good balance of internal, 
external and ecological validity. Full generalizability can result in unreliable results, whilst 
the attempt to achieve methodological purity can result in clinically meaningless results, so 
achieving a creative tension is crucial. 
The TwiCs approach 
Key features of the TwiCs approach are the recruitment of a large observational cohort of 
people with the condition; regular measurement of outcomes for the whole cohort; and the 
capacity for multiple randomised controlled trials over time. For each RCT, eligible 
participants are identified from the cohort and some are randomly selected to be offered the 
trial intervention. The outcomes of the randomly selected patients are compared with the 
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outcomes of eligible participants not selected (that is, receiving usual care). The process of 
obtaining patient information and consent aims to replicate that in real-world routine health 
care (Relton, O'Cathain, Nicholl, & Torgerson, 2010). 
The approach enables reliable comparisons compared with trials using current RCT designs 
because all treatments have the same ‘treatment as usual’ comparator and measure the 
same outcomes. This is particularly pertinent in trials of ADHD where the two main treat-
ment categories (behavioural and pharmaceutical) require different trial designs, which are 
difficult to compare due to differing validity and consequent expectation of different effect 
sizes, and have different comparators.  
The design can provide useful, generalisable information to stakeholders because: it 
measures relevant real-world outcomes; the experience of participating in a trial closely re-
sembles routine care in that information about, and consent to try, potential treatments is 
provided as and when they are offered; and data on treatment refusers provides infor-
mation on the acceptability of the treatment.  Lower costs are incurred compared with 
standard designs, since once the cohort is established, it potentially allows rapid and cheap 
recruitment of patients for an RCT.  
The design may facilitate easier recruitment since there is no commitment or uncertainty 
about joining the cohort. Not only may lack of uncertainty improve recruitment, but partici-
pants are not told about treatments that they might not then receive, nor that their treat-
ment will be allocated by chance. Recruitment and follow-up are more characteristic of lon-
gitudinal observational studies. 
However, the design is still vulnerable to risk of bias, since many other potential variables 
are not controlled for. Since the offer of treatment is adjunctive, participants may be under-
taking other therapies which may influence results. Nor will it be possible to know which 
aspect of treatment was most influential, for example, whether therapist effects drove out-
comes.   
1.6   Thesis Design 
So far I have summarised the rationale for the doctoral work undertaken. I have described 
my background and explained why I have chosen to undertake this research. I have summa-
rised some of the problems affecting those with ADHD and those taking care of them, and 
the areas of unmet need. I have briefly described the mainstream treatments recommended 
by NICE and provided by the NHS, and the non-mainstream treatments carers are also using 
for their children with ADHD. I have explained why there is a need to rethink the way trials 
are conducted in order to obtain useful, comparative information about interventions to 
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improve outcomes. The TwiCs design is then described as a methodology which can poten-
tially provide such information.  
In the next chapter I describe ADHD and its impact in more depth: its impact on individuals 
and on family life, and the financial and social challenges the condition presents to public 
service providers. I look at current service provision in the UK and at treatments recom-
mended by NICE. I interrogate the evidence for the efficacy of pharmaceutical medication 
and behaviour change programmes in short-term studies and their long-term effectiveness.  
I explore the problems associated with current provision: evidence suggesting that children 
do not take pharmaceutical medication for extended periods; that medication has common 
side effects; that short-term evidence of efficacy may not translate into long-term effective-
ness; that provision of behavioural interventions is patchy across the country, costly, associ-
ated with attrition, and may only be effective whilst implemented.  
I argue that the condition is associated with long-term negative outcomes, which are not 
being impacted despite increases in provision of pharmaceutical medication. I suggest that 
novel interventions with the potential to improve areas of unmet need are needed.  
Non-mainstream treatments being used by carers are suggested as a starting point for such 
a search.  I review surveys of the interventions being used and select the therapeutic sys-
tems of Homeopathy and Nutrition as two treatment modalities being used with some pre-
liminary evidence supporting them.  
In chapter 3 I explore trial design issues in depth, to elucidate the necessary components of 
a trial design to achieve my stated aim of testing whether interventions might improve out-
comes. I look in more depth at the strengths and weaknesses of pragmatic and explanatory 
designs, focussing particularly on internal, external and ecological validity and the tensions 
across these. I explore how best to maximise and balance these tensions. Key requirements 
identified are that the effectiveness of real-world treatment is tested; that the sample is 
representative; that potential biases are controlled for; that effectiveness in areas of unmet 
need is measured; that outcomes are measured over the long-term; and that there is ade-
quate control, but not by placebo.   
A pragmatic trial design is identified as most suitable because it uses real-world treatment 
protocols; patient and stakeholder centred outcomes; heterogeneous patient samples; and 
real-world comparators. The implications of these for a trial of ADHD are discussed, and the 
TwiCs approach identified as being most appropriate to test whether multiple interventions 
might improve outcomes for children with ADHD. The advantages and disadvantages of the 
design, potential outcome measures, and recruitment strategies are explored. 
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Chapter 4 is a literature review of one of the interventions trialled - the therapeutic modali-
ty of homeopathy, considered a holistic, complex, non-specific intervention. Issues sur-
rounding the evidence base are discussed, particularly the poor ecological validity of trials to 
date. To know whether homeopathic treatment might improve outcomes, it is identified 
that the totality of the therapeutic system as experienced in real-life clinical practice needs 
to be tested. This intervention is termed ‘treatment by a homeopath’ and consists of a se-
ries of potentially therapeutic consultations and provision of individually tailored homeo-
pathic remedies.  
Chapter 5 is a literature review of the other intervention trialled - Nutritional Therapy. The 
theoretical basis for a nutritional approach is explored and the evidence base for the differ-
ent aspects of nutrition which have been tested is reviewed. A lack of comparative research 
studies testing the totality of the intervention, and the limitations of existing explanatory 
studies to provide suitable information for stakeholders about the effectiveness of a nutri-
tional approach is identified.  
The intervention is termed ‘treatment by a nutritional therapist’ and considered to consist 
of a series of potentially therapeutic consultations, advice about dietary exclusion and inclu-
sion, menu and lifestyle suggestions, and advice about and provision of individually tailored 
supplements.  
A fundamental tension between internal and external validity is found across the evidence 
base for both treatments, whereby studies representing optimal clinical treatment are con-
sidered at risk of bias and studies with reduced risk of bias do not represent clinical treat-
ment and are therefore inadequate to answer pragmatic stakeholder questions. 
Chapter 6 describes the methods used to address the research question of this thesis: "Is 
the TwiCs design feasible to generate evidence about the acceptability, clinical and cost ef-
fectiveness of interventions for ADHD?” A small-scale test of the methods and procedures 
to assess the feasibility of the design and interventions according to a priori specified pa-
rameters is described. 
The chapter describes the recruitment procedures to the observational cohort, named the 
STAR (Sheffield Treatments for ADHD Research) cohort.  The functional procedures for the 
three-armed pilot trial embedded in the cohort are then described, whereby (a) treatment 
by homeopaths and (b) treatment by nutritional therapists is compared to (c) treatment as 
usual. Study management procedures such as ethical consents, research governance, steer-
ing and management committee structures are outlined, including how potential risks are 
identified and managed. 
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Feasibility criteria and parameters are defined: the feasibility of recruiting a cohort of chil-
dren with a diagnosis of ADHD to time and target; recruiting therapists; the feasibility and 
acceptability of the study design; the feasibility, deliverability, safety and acceptability of the 
interventions; and the suitability, acceptability and deliverability of the outcome measures.  
Chapter 7 describes the results of recruitment to the cohort, and the pilot trial. The baseline 
characteristics of cohort participants, those randomised to treatments, and those having 
treatments, are compared for any systematic differences in population characteristics. 
Statistical analysis compares the interventions with usual care according to Intention to 
Treat (ITT) analysis using two methods: standardised mean differences to assess the clinical 
impact and calculate an effect size to enable sample size calculation; and multivariate re-
gression analysis, controlling for the effects of gender, age and ADHD severity, to assess sta-
tistical impact and calculate the unstandardised coefficients which will enable the cost ef-
fectiveness analysis.  
The primary outcome is Conners Global Index (CGI) and its two sub-scores assessing rest-
lessness/impulsivity and emotional lability. Health related quality of life is also measured, 
using the Child Health Utility (CHU 9D) with preference weights added.  
Chapter 8 explores the feasibility of the design and interventions according to the 13 a priori 
specified criteria. The characteristics of the STAR cohort are described to assess the repre-
sentativeness of the cohort. Rates of recruitment to the cohort and the RCT are described to 
identify whether recruitment was achieved within the specified time frame. Rates of uptake 
and attrition from treatments, and the safety of the interventions assesses their acceptabil-
ity. The acceptability and suitability of outcome measurements looks at levels of missing 
items. Whether suitable therapists could be recruited and deliver their interventions is de-
scribed, and therapists’ experiences summarised.  
In chapter 9, the research aims and context are reviewed and discussed. The feasibility of 
the TwiCs design is discussed in terms of its ability to recruit a representative sample of chil-
dren with ADHD and measure their outcomes of interest, and to serve as a recruitment facil-
ity for multiple trials of interventions for ADHD. Whether the design is feasible to generate 
evidence about the acceptability, clinical and cost effectiveness of interventions for ADHD is 
discussed by exploring the strengths and limitations of the pilot RCT. The strengths and 
weaknesses of the TwiCs design to contribute to areas of unmet need is discussed, and sug-
gestions to improve implementation of the design are made. 
Chapter 10 summarises the key findings and their potential contribution. The results in the 
context of the current political, economic and social climate are discussed, and some pro-
posals for next steps outlined. Recommendations to improve recruitment, adherence, out-
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come measurement and outcome collection are made. The implications of the results re-
garding progression to a full trial, and the future contribution of the STAR cohort are dis-
cussed. This chapter also includes a summary of my contribution to the conducted research, 
and my learning from the research endeavour.   
 33 
 
Chapter 2 ADHD  
This chapter describes the diagnosis of ADHD, and the short and long-term impact of a diag-
nosis on the child, their family, and the education, social services and criminal justice sys-
tems. It outlines the nature of the problems that need to be addressed if outcomes for chil-
dren with ADHD are to be improved. The second half of the chapter explores the evidence 
base for both main and non-mainstream interventions being used as treatments for children 
with ADHD.  
To do this I first read the NICE clinical guideline to diagnosis and management, originally 
published in 2008, and updated in 2016. This guideline provided a framework from which to 
explore issues highlighted by NICE in more depth, and enabled the identification of key re-
searchers and research hubs. I then explored their work, and further augmented this with 
information gained from systematic reviews on specific topics of interest found through 
Web of Science, Google Scholar, and Cochrane collaboration searches for ADHD. I also at-
tended two International ADHD conferences and two NICE workshops.  
When exploring the impact of ADHD on families and children is explored across the health 
system, education services, criminal justice system and social care system, I looked at what 
is offered by services, and what aspects of ADHD are and aren’t being helped by current 
provision within these systems. Where possible, UK statistics and evidence are used. Evi-
dence from other countries is referred to where no UK evidence is found. The most recent 
research and statistics are referenced where possible, however, much of the work defining 
and describing ADHD occurred in the 1990s. 
2.1   Description of ADHD 
2.1.1 Diagnosing ADHD 
The Diagnostic and Statistical Manual of Mental Disorders (DSM) lays out the criteria used 
by health professionals making a diagnosis of ADHD (American Psychiatric Association, 
2013). Diagnosis considers the behavioural symptoms of inattention, hyperactivity, and im-
pulsivity from the perspective of the observing clinician, the child’s home and school. Chil-
dren need to have been displaying symptoms for at least six months starting before the age 
of 12 in at least two settings.  
Those with a diagnosis of ADHD have difficulties with problem solving, planning, flexibility, 
sustained attention, response inhibition, working memory, motivational delay and mood 
regulation. They may have feelings of irritability, frequent outbursts, shifts from normal 
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mood to depression or excitement, a diminished ability to handle typical life stresses. These 
result in frequent feelings of being hassled and overwhelmed. 
A diagnosis may be classified into different subtypes: ‘predominantly inattentive’; predomi-
nantly hyperactive-impulsive; or ‘combined’ types. These classifications are debated, as is 
whether ADHD is indeed a single disorder For example, some suggest that combined types 
and inattentive types are distinct and unrelated (Barkley; 1997; Milich, 2001). Others debate 
whether the same diagnosis of ADHD should be given to both traumatised and untrauma-
tised children, where high levels of co-occurrence are found (Arshad, 2008; Wozniak, 1999). 
Whilst it is classified as a separate disorder, possibly because clinicians make categorical de-
cisions, it may be more accurate to consider it an umbrella term or an extreme of normal 
variation. Furthermore, a diagnosis is often an indication that there are other problems 
(Sonuga-Barke, in NICE, 2008).  
Co-diagnoses 
Criteria have changed over time. In 2013 DSM-5 allowed co-diagnoses of ADHD and autism, 
and since then many autistic children have received a diagnosis of ADHD. Initially emotional 
issues were considered core features in diagnosis (Clements, 1966; Wender, Reimherr, & 
Wood, 1981), however, since DSM-3 emotional lability has been considered an associated 
feature rather than a diagnostic criterion (Shaw, Stringaris, Nigg, & Leibenluft, 2014). Co-
morbid emotional issues receive separate diagnoses such as Oppositional Defiant Disorder, 
Conduct Disorder, Depression, Anxiety, and Attachment Disorder. 
Co-diagnoses are common. They were found in 40% of participants in the Multimodal 
Treatment of ADHD (MTA) study (MTA Cooperative Group, 1999). Psychiatric co-diagnoses 
were found in 65% of children in a meta-analysis of amphetamine-based treatment for 
ADHD (Punja, et al., 2016). A meta-analysis of methylphenidate treatment found that oppo-
sitional defiant disorder was the most commonly reported comorbidity (61 trials; range 
1.4% to 84%; mean 42%), followed by conduct disorder (49 trials; range 0% to 100%; mean 
24%) (Storebo, et al., 2015). 
Other co-diagnoses include: learning disorders (25% co-morbidity); neurological disorders 
such as tics and Tourette’s Syndrome (60%) (Gillberg, et al., 2004); anxiety disorder (33%), 
and depression (33%) (Mayes, et al., 2009); autism (50-75%) (Goldstein & Schwebach, 2004; 
Aman, Farmer, Hollway, & Arnold, 2008; Gadow, De Vincent, & Pomeroy, 2006). 
The prevalence of obesity is 40% higher in children and 70% higher in adults with ADHD 
compared with individuals without ADHD (Cortese, et al., 2016). 
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Autism Spectrum Conditions (ASCs) 
Autism is a common co-diagnosis (Ronald, Simonoff, Kuntsi, Asherson, & Plomin, 2008), and 
ADHD medications are widely prescribed. However, children with autism and ADHD may be 
more prone to the side effects of medication and experience less benefits than those with 
ADHD alone (Handen, 2000).  
Emotional dysregulation 
It has long been recognized that emotional dysregulation is common in ADHD. Emotional 
difficulties are described as falling into three categories: emotional dysregulation inherent in 
the disorder; comorbidity with other psychiatric disorders; and secondary emotional conse-
quences from impairments arising from the effect of ADHD and the comorbid disorders on 
the social environment (Wehmeier, Schacht, & Barkley, 2010). 
Emotional dysregulation is defined as inappropriate excessive emotional expression, with 
rapid, poorly controlled shifts in emotion (lability), and anomalous allocation of attention to 
emotional stimuli (Shaw, Stringaris, Nigg, & Leibenluft, 2014). Responses may be internal-
ised (withdrawn, moody, or sad) or externalised (volatile, aggressive, argumentative, and 
physical) (van Stralen, 2016). It is estimated to occur in 25%-45% of children and 30%-70% of 
adults with ADHD (Ana, Soriano, Fernandez, & Melia, 2008).  
2.1.2 Aetiological factors 
The aetiology of ADHD is considered to involve the interplay of multiple genetic, biological, 
psychosocial and environmental factors. These risk factors increase vulnerability additively 
and interactively, and once cumulative vulnerability exceeds a threshold, ADHD symptoms 
manifest.  Its heterogeneity is considered to result from different combinations of risk fac-
tors acting together, with no one causal factor considered sufficient to initiate the disorder 
(Biederman & Faraone, 2005). 
Genetic heritability is estimated at 71-75% (Faraone, Perlis, & Doyle, 2005; Nikolas & Burt, 
2010). Associated identified environmental influences are diverse, with increased incidence 
associated with exposures during pregnancy, birth, and post birth. Increased incidence in 
children has been found during pregnancy if their mothers: smoked (Linnet, Dalsgaard, & 
Obel, 2003; Silva, Colvin, & Hagemann, 2014); used alcohol (Mick, Biederman, Faraone, 
Sayer, & Kleinman, 2002); drugs (Ornoy, Segal, & Bar-Hamburger, 2001); paracetamol (Liew, 
Ritz, & Rebordosa, 2014); cell phones (Birks, et al., 2017); and/or were exposed to lead or 
pesticides (Rauh & Margolis, 2016). 
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 Adverse experiences during childbirth implicated include: maternal urinary tract infection, 
birth induction, experience of threatened pre-term labour (Silva, Colvin, & Hagemann, 
2014); very low birth weight (Botting, Powls, Cooke, & al., 1997); foetal hypoxia, and brain 
injury (Toren, Eldar, Sela, & al., 1996; Ana, Soriano, Fernandez, & Melia, 2008). 
Correlated post birth psychological influences include: severe early psychosocial adversity 
(McCann & Roy-Byrne, 2000); disrupted and discordant relationships (Biederman, 
Newcomb, & Sprich, 1991); severe institutional deprivation (Kennedy, et al., 2016), low pa-
ternal education, low income and maternal depression (Sagiv, Epstein, Bellinger, & al., 
2013). However, whilst adverse familial environments and parenting practices are observed 
in families of children with ADHD (Johnston & Mash, 2001), the extent to which they are 
casual factors remains unclear, and longitudinal evidence mixed (Tarver, Daley, & Sayal, 
2014). 
2.1.3 Pathology of ADHD 
ADHD is a neurobiological condition linked to an imbalance in neurotransmitters (often epi-
nephrine, norepinephrine, serotonin or dopamine) within the prefrontal cortex of the brain 
(Hoogman, 2017). These neurotransmitters are responsible for activating the areas of the 
brain needed for focus and concentration. A precise mechanism remains unclear, but neu-
roimaging studies show structural alterations in several brain regions (Hoogman, 2017) with 
exploratory lifespan modelling suggesting delay in maturation.  Regions are found to be un-
deractive and with weakened connections to other parts of the brain (Arnsten, 2009).  
Suggestions of possible physiological causes of low levels of neurotransmitters include: dys-
function in the manufacture of necessary compounds; their poor uptake into the brain; or 
increased transport out of the brain. Studies have found abnormalities and disturbances of 
glutamate/glutamine and creatine in the brain (Perlov, Philipsen, Hesslinger, & et, 2007; 
Carrey, MacMaster, Gaudet, & Schmidt, 2007). Essential fatty acids and phospholipids are 
both essential for normal neuronal structure and function (the myelin sheath insulating 
brain neurons is 75% phospholipids).  This underlying abnormality of fatty acid synthesis 
may be responsible for at least some features of ADHD (Richardson & Puri, 2000). This 
theory is explored in greater depth in chapter 5 (Nutrition). 
Despite emerging neurocognitive theories concerning pathology, there are currently no 
neurological markers for ADHD, nor likely to be. The disorder is defined by behaviour and 
diagnosis does not imply neurological disease. 
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2.1.4 Prevalence of ADHD 
Global prevalence of ADHD is estimated at 5.3% (Polanczyk, de Lima, Horta, & al., 2007), 
5.9% (Willcutt, 2012) to 7.2% (Thomas, Sanders, Doust, Beller, & Glasziou, 2015). UK preva-
lence was estimated to be 3.6% for boys and 0.9% for girls (Ford, Goodman, & Meltzer, 
2003). Recent prevalence estimates from the Millennium Cohort Study using 2008/2009 da-
ta found 1.4 % had ADHD, 1.7 % had an ASC, and 0.3 % had both (Russell, Rodgers, 
Ukoumunne, & Ford, 2014).  
Increased prevalence is noted with each edition of the DSM (Polanczyk, de Lima, Horta, & 
al., 2007). Increased medication usage is also noted: methylphenidate prescriptions in-
creased from 420,421 in 2007, to 793,749 in 2014 (NICE guideline update document, 2016).  
2.2   The impact of ADHD 
ADHD impacts significantly over the life span, on the separate disciplines of health care, ed-
ucation, criminality and social work. The most destructive consequences are arguably expe-
rienced within the home by individuals and families. Those diagnosed in childhood continue 
to show significantly worse educational, occupational, economic, and social outcomes three 
decades after initial diagnosis compared with age-matched controls (Klein, et al., 2012). It 
accounts for a sizeable amount of resource use and presents a major challenge to services 
(NICE, 2008).   
The association of ADHD with a variety of negative outcomes can be summarised as: aca-
demic failure; interpersonal relationship difficulties; reduction in quality of life; increased 
susceptibility to injury; substance abuse; involvement with the criminal justice system; and 
greater socioeconomic disadvantage (Russell, Ford, Rosenberg, & Kelly, 2014).  
2.2.1 Impact on the child with ADHD 
Children with ADHD struggle to fit in at home, where increased parent-teen conflict is re-
ported by both parents and teenagers (Edwards, Barkley, Laneri, Fletcher, & Metevia, 2001) 
and at school, where they typically experience academic failure, rejection by peers and low 
self-esteem (Harpin, 2005). They often have few friends (Gresham, MacMillan, Bocian, 
Ward, & Forness, 1998); are twice as likely to have ‘‘a severe lack of friendship’ (Meltzer, 
Gatward, Goodman, & Ford, 2000); to be rejected by peers (Hoza, et al., 2005); to be per-
ceived by teachers and peers as being less socially competent (DuPaul & Weylandt, 2006); 
and to experience more conflicts with peers and teachers (Faraone, Biederman, & 
Monuteaux, 2000). Many studies have found them to have poor social skills, e.g. (Bagwell, 
Molina, Pelham, & Hoza, 2001). 
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ADHD children are more likely to hurt themselves as pedestrians or cyclists, and sustain inju-
ries to multiple body regions (DiScala, Lescohier, Barthel, & Li, 1998). The more than double 
mortality found in those with ADHD compared to those without ADHD is driven by deaths 
from unnatural causes, especially accidents (Dalsgaard, et al., 2015). They have less sleep: 
25-50% have sleep problems (Owens, 2008), with more severe and prevalent sleep prob-
lems occurring in stimulant treated ADHD children than untreated children (Mohammadi, et 
al., 2012). They are less happy with their family and their lives overall than children without 
ADHD, with health-related quality of life about 6% lower (Peasgood, et al., 2016).  
Those with ADHD and emotional problems are significantly more impaired in peer relation-
ships, family life, occupational attainment, and academic performance than those with 
ADHD alone (Barkley, Murphy, & Fischer, 2010; van Stralen, 2016). For example, emotional 
problems have more impact than hyperactivity and inattention on well-being and self-
esteem (Riley, et al., 2006). They are better indicators of impairments in daily life than the 
level of ADHD (Melia, et al., 2006).  
Emotional dysregulation presages poor clinical outcome (Ana, Soriano, Fernandez, & Melia, 
2008; Green, Gilchrist, Burton, & Cox, 2000; Smalley, McGough, Moilanen, & al., 2007), and 
is a key factor in predicting later adverse life events (Barkley & Fischer, 2010). Persistence of 
ADHD is predicted by co-morbid psychiatric disorders (Ana, Soriano, Fernandez, & Melia, 
2008; Barkley R. A., Fischer, Smallish, & Fletcher, 2004).  Smalley et al. found it to be associ-
ated with anxiety (odds ratio 2.4), mood (odds ratio 2.9) and disruptive behavioural disor-
ders (odds ratio 17.3) (Smalley, McGough, Moilanen, & al., 2007). 
2.2.2 Impact on the home of the child with ADHD 
Having a child with ADHD is a risk factor for a variety of problems to be experienced by oth-
er members of the family. Studies have found it to be a risk factor for depression and sub-
stance abuse in parents (Cunningham & Boyle, 2002), marital conflict (Stormont-Spurgin & 
Zentall, 1995), and divorce (Schermerhorn, et al., 2012). It is hard to separate cause and ef-
fect. Given the heritability of ADHD it is likely that the relationship between parenting and 
child ADHD is bi-directional (Tarver, Daley, & Sayal, 2014). 
 Siblings report feeling victimised by aggressive acts of their sibling with ADHD (Kendall, 
1999) and experience lower happiness with life overall and with their family, and elevated 
bullying (Peasgood, et al., 2016).  Siblings have been found to be at increased risk of conduct 
and emotional disorders (Szatmari, Offord, & Boyle, 1989). 
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2.2.3 Impact of having ADHD on education 
School is frequently the first place where concern is raised leading to an ADHD diagnosis, 
because typical ADHD symptoms are a major disruption in the classroom and playground. 
Children may exhibit challenging classroom behaviour, significant time off-task, frequent 
rule violations, and fail to comply with teacher instructions (Atkins, Pelham, & Licht, 1989).  
A diagnosis of ADHD is associated with poorer grades and lower scores on standardized 
tests of academic ability compared to those without a diagnosis (Barry, Lyman, & Klinger, 
2002; Loe & Feldman, 2007). Up to 30% of children in the US repeat a grade in school 
(Barron, Evans, Baranik, Serpell, & Buvinger, 2006); and 10-35 % drop out (Barkley, 2006). 
Children with Special Educational Needs (SEN) (including ADHD) are over eight times more 
likely to be permanently excluded than pupils with no SEN (Department for Education and 
Skills, 2005); and a survey of 526 UK ADHD families (www.addiss.co.uk ) found 39% had had 
fixed term exclusions, and 11% were permanently excluded. A study by the Office for Na-
tional Statistics found having ADHD increased the odds of a child having been excluded by 
11 times (Meltzer, Gatward, Corbin, Goodman, & Ford, 2003). 
Children with ADHD have been found to be more impaired in behaviour, academic skills and 
social skills (Greenhill, Posner, Vaughan, & & Kratochvil, 2008). They often have associated 
learning difficulties such as increased deficits in early language development, literacy, and 
numeracy skills (DuPaul, McGoey, Eckert, & Van-Brakle, 2001).  
Classroom based interventions can have a positive impact on behaviour although not on 
educational outcomes (Purdie, Hattie, & Carroll, 2002). Teachers are not systematically 
trained to use specific strategies (NICE, 2008). Whilst training may not improve outcomes 
(Sayal, et al., 2010), provision of evidence based information about how to teach those with 
ADHD type behaviours may (Tymms & Merrell, 2006). Children with more severe ADHD may 
be entitled to a statement of special educational needs and either a support worker within 
mainstream education, or a place at a special school. Both incur significantly higher costs 
compared with regular education. 
Conflict between family and school (Mautone, Lefler, & Power, 2011) and teacher and pupil 
(Greene, Beszterczey, Katzenstein, Park, & Goring, 2002) are common. This puts additional 
strain on education systems: other children in the classroom are negatively impacted by the 
behaviour of their ADHD peers; teachers spend a significant amount of time managing and 
providing support to children with ADHD; children may experience reduced teaching quality 
when teachers focus on management of disruptive pupils; and teachers find dealing with 
ADHD behaviours stressful (Merrell & Tymms, 2007).  
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Children with ADHD have difficulty engaging in typical school activities: making and keeping 
friends, developing meaningful relationships, interacting appropriately in games, and tend 
to withdraw from social activities. They are more likely to be nominated by their peers as 
someone they would least like to be friends with (Hinshaw, 1995; Hoza, et al., 2005). 
2.2.4 Relationship with criminality 
A relationship is consistently found between ADHD and criminality when studying incarcer-
ated populations (Young, et al., 2011), ADHD populations (Mannuzza, Klein, & Moulton, 
2008) and taking an epidemiological perspective (Gudjonsson, Wells, & Young, 2010). Epi-
demiological studies suggest that ADHD is one of the six key childhood factors predicting 
offending and antisocial behaviour (Farrington, Loeber, & Ttofi, 2012). In ADHD populations, 
children are at elevated risk of offending (Barkley, Fischer, Smallish, & Fletcher, 2004).  
In incarcerated populations in the UK, there is an ADHD rate of 43% in 14-year-old youths 
(Young, Wells, & Gudjonsson, 2010). It was found to be the strongest predictor of violent 
offending, (above substance abuse), with a significantly larger number of offences than oth-
er prisoners (Young, et al., 2011) and a significantly younger onset of offending (16 v 19.5 
years).  Meta-analysis finds that 30.1% of youth and 26.2% of adult prison populations have 
a diagnosis of ADHD (Young, Moss, Sedgwick, Fridman, & Hodgkins, 2015). 
Relationship of ADHD with other risk factors 
Whilst it is undisputed is that ADHD is an important risk factor for the development of anti-
social behaviour, debate continues regarding its relationship with other risk factors. For ex-
ample, whether ADHD itself disposes children to antisocial behaviour, or is due to co-
occurring Conduct Disorder (CD) or Oppositional Defiant Disorder (ODD) (Polier, Vloet, & 
Herpertz-Dahlmann, 2012). Heroin and other substances are major risk factors for criminali-
ty (Young, et al., 2011). There is a three- to fourfold increase in the risk of substance misuse 
in children with ADHD, especially with co-occurring CD, and the onset of ADHD is found to 
precede the onset of substance use (Wilens T. , 2004). In her most recent criminality re-
search, Young (2016) found that despite controlling for emotional disorders, emotional 
problems were still the most predictive ADHD aspect regarding offending. 
Psychiatric problems are over-represented in prisoners (Fazel & Seewald, 2012) with the risk 
of developing co-morbid psychiatric disorders greater among offenders with ADHD (Young, 
Sedgwick, & Fridman, 2015). Their meta-analysis found high incidence in incarcerated adult 
and youth prisoners (see Table 1). 
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Table 1 - Co-occurring psychiatric disorders in prisoners with ADHD.  
 Conduct 
disorder 
Substance 
use disor-
der 
Mood dis-
order 
Depression Anxiety 
disorder 
Personality 
disorder 
Adults  29% 74% 66% 55% 68% 60% 
Youth 61% 70% 25% 13% 21%  
Information extracted from (Young, Sedgwick, & Fridman, Co-morbid psychiatric disorders among incarcerated ADHD popu-
lations: a meta-analysis, 2015).  
The pathway to criminality 
A diagnosis of ADHD is one of the risk factors associated with criminality along with low so-
cio-economic status, parent conviction, child and mother low IQ, maltreatment, and tem-
perament (UK government Youth Crime Action Plan, 2008), who found that the earlier of-
fending begins, the greater the odds of reoffending. Researchers agree that ADHD is a pre-
cursor to the development of other risk factors with a developmental cascade starting with 
a childhood diagnosis of ADHD, followed by school exclusion, adolescent antisocial disorder, 
substance abuse and on to criminality (Mannuzza, Klein, & Moulton, 2008; O’Regan, 2009).  
2.2.5 Relationship with social services 
Children with ADHD can come to the attention of social services for a variety of reasons. 
There is a high likelihood that their parents will have ADHD, and poor parenting is associat-
ed with parents with ADHD (Deault, 2010). Parents are more likely to be unemployed (NICE, 
2008); involved in substance abuse (Parker, 2005); and/or suffer from psychiatric disorders 
such as schizophrenia, substance abuse, depression and anti-social personality disorder 
(Pfiffner, McBurnett, Rathouz, & Judice, 2005).  
Since ADHD children are more likely to be excluded from school, social services become in-
volved. Since alcoholism and drug taking in pregnancy are risk indicators for the develop-
ment of ADHD, there will be a disproportionally high number of children with ADHD pre-
senting for fostering and adoption when their addicted parents are unable to care for them. 
Children in foster care were found to be 3 times more likely to be prescribed methylpheni-
date than children in the community (Zarin, Suarez, Pincus, Kupersanin, & Zito, 1998). 
2.2.6 The economic cost of ADHD 
An ADHD diagnosis is accompanied by significant cost implications. These have been ex-
plored in Europe and the US.  Studies in the US found families with ADHD children incurred 
over twice the per capita total costs compared to matched comparison families: $1465 v 
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$690 (Guevara, Lozano, Wickizer, Mell, & Gephart, 2001); $2,461 v $1,220 (Swensen, et al., 
2003) and $4,306 v $1,944 (Leibson, Katusic, Barbaresi, Ransom, & O'Brien, 2001). Costs in-
cluded medication expenditure, physician visits and behavioural interventions. The estimat-
ed annual total cost of ADHD in the U.S. is more than 50 billion dollars. This is similar to the 
societal cost of major depression and stroke (Pelham, Foster, & Robb, 2007). 
Whilst studies have identified some of the economic implications of the direct, associated 
and societal costs of ADHD, there are other likely costs which have not yet been assessed 
such as poor driving, high rates of traffic accidents, increased smoking and drug abuse, in-
creased presence in foster care, foetal alcohol and narcotic syndrome, and decreased life 
expectancy. Research is also needed to quantify indirect costs to others, such as being the 
victims of crime, drug incidents or traffic accidents; the impact on non-ADHD children of be-
ing in a class with ADHD children; and the health, wellbeing and job persistence of teachers 
of children with ADHD. 
Le (2014) most recently evaluated the economic consequences of ADHD in Europe (Table 2). 
He found thirteen studies looking at health care costs (n=7); cost to family members (n=1); 
education costs (n=2); social service costs (n=2); and family productivity losses (n=2).  
Table 2. Review of the cost of ADHD in Europe.  
 Cost (millions of euros) Percentage of total cost 
 
Annual national cost  1,041-1,529 71 ADHD patient. 29 
family members 
Child health care costs 
 
84 -377  8-25  
Family member’s health care costs  
 
161  11–15  
Productivity cost to family mem-
bers 
143-339 14-22 
Education  648  42–62  
Social service costs 4.3  0.3–0.4  
Information extracted from Le (2014) 
Doshi (2012) most recently evaluated the economic consequences of ADHD in the USA 
(Table 3). He found 19 studies looking at costs incurred by children with ADHD or their fami-
ly (n=11); health care costs (n=13); income and productivity costs (n=9); education cost 
(n=3); and justice system costs (n=2).  
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Table 3. Review of the cost of ADHD in the USA 
 Cost (billions of dollars) 
Annual national cost 
 
143-166 
Children 
 
38-72 
Children health care  
 
21-44 
Children education 
 
15-25 
Adults 
 
105-194 
Adult productivity and income loss 
 
87-138 
Family members 
 
33-43 
Information extracted from Doshi, (2012) 
The majority of cost lies outside health care. In Europe, education is the costliest category, 
as are family member ADHD-related health care costs and productivity losses, whilst health 
care costs of the child, although most investigated, are just 8–25 %, and social service costs 
0.3–0.4 %. (Table 2). The fact that most of the ADHD-related costs are outside health care 
and not restricted to the affected child has important policy-making implications. It is likely 
that the societal cost is far higher, but is as yet uncounted in Europe (Le, et al., 2014). Identi-
fied areas of impact and associated costs are summarised below. 
The workplace 
Workforce productivity costs in adults with ADHD in the US (Doshi, et al., 2012) were mostly 
attributable to income losses due to lack of full time employment and/or lower wages. 
ADHD in adulthood was associated with work-related problems such as poor job perfor-
mance, lower occupational status, less job stability, and increased absence days. 
 A European study projecting occupational consequences of children with ADHD when they 
become adults suggests that those diagnosed in their childhood lose an average €4,486 per 
year income due to lower wages (Knapp, King, Healey, & Thomas, 2011). 
School/Education costs 
School exclusion has significant financial consequences: Welsh Assembly Government 
(wales.gov.uk/statistics-and-research/exclusions-schools), estimated the cost of permanent 
exclusion at £300,000 per student, attributed to social care, probation, providing alternative 
education, and loss of future employment prospects, as well as costs to the community. 
Governmental statistics from 1996 to 1997 found that the cost of excluding students from 
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schools in England was £81 million compared with £34 million if they had continued with 
full-time education (New Policy Institute (NPI), 1998). 
In one longitudinal study in London, by age 28, children with childhood conduct problems 
had cost society 3.5 to 10 times more than a comparison group, mainly for costs associated 
with crime and education (Scott, Knapp, Henderson, & Maughan, 2001). 
Costs to families  
Children's ADHD is linked with as yet uncounted strains on the carer-child relationship: less 
marital satisfaction, more marital conflict, high parental stress, depression, and reduced 
health-related quality of life for family members (Mugno, Ruta, D’Arrigo, & Mazzone, 
2007) (Peasgood, et al., 2016). Family members of children with ADHD have 1.6 times as 
many medical claims as matched controls (Swensen, et al., 2003).  
Carers may need to miss work to meet with teachers or take their children to appointments. 
A study of parent perceptions found that the strongest predictor of whether they consid-
ered ADHD a serious problem was the impact of the child's behaviour on their employment 
patterns or chances of a career. Parents who perceived their child's ADHD to be a serious 
problem were 17.6 times more likely to say that their child's ADHD had a financial impact 
related to their work than carers who did not think ADHD was a serious problem (Sayal, 
Taylor, & Beecham, 2003).  
Criminality 
One study estimated the economic impact of criminality associated with ADHD to be 
$12,868 versus $498 (Swensen, et al., 2003). In the UK, costs to the criminal justice system 
were £20,000 compared to £200 for those without the disorder 
(http://www.adhdandjustice.co.uk/). The average annual cost of providing a prison place is 
£36, 000, rising to £57-£100,000 for young offenders (Prison Reform Trust, 2013). It costs 
£4,000 per child per annum to teach a child in a mainstream school, but £15,000 per child 
per annum in a Pupil Referral Unit.  
2.2.7 Summary of the impact of ADHD 
This section has described in detail the profound impact that having a diagnosis of ADHD has 
upon the health, wellbeing, employment, finances and prospects of diagnosed children and 
their families. Furthermore, significant costs are incurred to the different services managing 
them. It is likely that costs are even higher than estimated since most health economic stud-
ies look at health related costs, and the majority of the impact is felt outside health care.  
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The prospects of those diagnosed in childhood continue to be significantly worse than those 
of undiagnosed children into adulthood. A pathway towards criminality is likely to start with 
a diagnosis of ADHD and accompanying emotional dysregulation.  
In the next section I will describe the evidence base for the management and treatment 
strategies currently used to try and help those with ADHD, focussing particularly on their 
ability to address the negative long-term outcomes associated with the condition described 
in this section. 
2.3   Interventions for managing ADHD 
There is currently considered to be no cure for ADHD. Pharmaceutical and non-
pharmaceutical treatment options are offered for symptom management and to improve 
function. Pharmaceutical treatments include both stimulant and non-stimulant options, 
while recommended non-pharmaceutical treatments include a variety of behaviour change 
programmes for carers and/or those with ADHD. This section describes the evidence base 
for pharmaceutical, behavioural and non-mainstream treatments for ADHD. 
2.3.1 Pharmaceutical medications 
Numbers treated pharmaceutically have outstripped rates of diagnosis, doubling between 
2003 and 2008 in the UK (McCarthy, et al., 2012); and increasing nearly 700% between 1990 
and 1997 in the US (Doherty, Frankenberger, Fuhrer, & Snider, 2000). Cumulative 
methylphenidate dosage has increased 92% since the 1960s, 80% since the 1970s, and 56% 
since the 1980s (Swanson, et al., 2017). 
Stimulants such as methylphenidate (trade names Ritalin, Concerta, Equasym, Xenidate, 
Tranquilin or Medikinet), dexamfetamine and lisdexamfetamine dimesylate, and non-
stimulants (atomoxetine and guanfacine) are the main medications prescribed (NICE, 2008). 
They are available as immediate-release formulations requiring several doses daily, and 
more recently as once-daily extended-release formulations, which have been found to be 
better adhered to (Marcus, Wan, Kemner, & Olfson, 2005). Titration of dosage is required to 
maximise therapeutic beneﬁts and minimise adverse events. The ideal dose for cogni-
tive/academic functioning is considered to be lower than the ideal dose for behavioural 
functioning (Hale, et al., 2011). Children on higher doses may be better able to sit still and 
keep quiet, but less able to think acutely, whilst those on lower doses may be better able to 
think clearly, but less able to behave appropriately in the classroom. 
Short-term outcomes 
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The many randomised controlled trials testing pharmaceutical medication against placebos 
demonstrate large effect sizes. The most recent meta-analysis of methylphenidate treat-
ment(Storebo, et al., 2015) found it improved teacher-rated ADHD symptoms by a standard-
ised mean difference (SMD) of -0.77 (95% CI -0.90 to -0.64; 19 trials, mean duration 75 days, 
1698 participants). The most recent meta-analysis of amphetamine treatment (Punja, et al., 
2016) found it improved teacher-rated ADHD symptoms by a SMD of -0.55 ( -0.83 to -0.27; 5 
studies; 745 children/adolescents); parent ratings by a SMD -0.57 (-0.86 to -0.27; 7 studies; 
1247 children/adolescents), and clinician ratings by a SMD -0.84; 95% CI -1.32 to -0.36; 3 
studies; 813 children/adolescents).  
Both these Cochrane meta-analyses classified the evidence they synthesised as very low 
quality. Incomplete outcome data resulting from failure to report drop outs was considered 
problematic by Punja et al. (2016). Storebo et al. considered problematic: the incomplete 
reporting of results; the high possibility that people knew which treatment the children 
were taking; the varied results across trials for some outcomes; and the potential for Indus-
try bias (Storebo, et al., 2015).  
70-80% of children are found to profit from at least one psychostimulant in the short-term 
(Markowitz, Straughn, & Patrick, 2003). Pharmaceuticals have a signiﬁcant short-term im-
pact (> 2 months) on symptoms such as  classwork productivity, quality of completed work, 
number of problems completed on tests, improved quiz scores (Evans, et al., 2001; Pelham, 
et al., 2001); working memory (Strand, et al., 2012); organization, time management and 
planning (Abikoff, et al., 2004); aggressiveness (Sinzig, Döpfner, & Lehmkuhl, 2007);  hand-
writing (Tucha & Lange, 2001); gross motor co-ordination, impulsivity, and compliance with 
requests (Adesman & Wender, 1992).  
Pharmaceuticals may not address academic achievement (Corkum, McGonnell, & Schachar, 
2010; Langberg & Becker, 2012); antisocial behaviour or arrest rates (Wilens, et al., 2003); 
or social dysfunction (De Boo & Prins, 2007).  
Pharmaceutical management of emotional dysregulation 
The impact of pharmaceuticals on emotional dysregulation is less researched and estab-
lished (Mordre, Groholt, Kjelsberg, Sandstad, & Myhre, 2011). Manos et al. (2011) in their 
literature review of changes in emotions related to pharmaceuticals found that children 
have both positive and negative emotional responses. Their evaluation of 47 RCTs measur-
ing emotional regulation found positive effects in two, but the majority of studies noted 
emotional dysregulation as an adverse event. Shaw, Stringaris, Nigg, & Leibenluft, (2014) 
found five RCTs of pharmaceuticals in children assessing change in emotion regulation, with 
mixed results. 
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NICE consider psychostimulants effective in treating oppositional defiant disorder comorbid 
with ADHD (NICE, 2008). 
Long-term outcomes 
The long-term effectiveness of pharmaceutical treatment for ADHD remains in doubt 
(Tarver, Daley, & Sayal, 2014). Reviews find that poor adherence and persistence, comorbid-
ities and poor follow-up contribute to difficulties in measuring long-term effects and compli-
cate interpretation of results. Where lack of improvement in long-term outcomes is found, it 
is argued that it is unclear whether this is due to lack of medication adherence, or the inabil-
ity of medication to influence long-term outcomes. The most recent evidence on long-term 
outcomes from the Multimodal Treatment of ADHD (MTA) study suggests the latter: natu-
ralistic subgroups based on patterns of medication use (consistent, inconsistent, and negli-
gible) found that extended use of medication did not provide greater symptom-related ben-
efit but did result in reduced growth (Swanson, et al., 2017).  
The MTA study is the best-known, most recent and largest comparative study (N=579) of the 
long-term outcomes of ADHD. It investigated the relative effectiveness of 1) optimum stimu-
lant medication management, 2) behavioural treatment, 3) their combination, and 4) usual 
or ‘community’ care (which in the US typically meant pharmaceutical treatment). The pri-
mary outcome measure was unblinded carer and teacher symptom ratings.  
At 14 months, pharmaceutical management and combined treatment were superior to be-
havioural treatment or community care (MTA Cooperative Group, 1999). However, benefits 
dissipated after the 14-month treatment-by-protocol phase. By 36 months any trends had 
disappeared (Jensen, et al., 2007), and at 8 years participants were signiﬁcantly worse than 
a control group on 91% of measures (Molina, et al., 2009).  Collection of salivary samples 
found that only 50% of participants assigned pharmaceuticals were consistently adherent 
during the 14 months of the trial (Pappadopulos, et al., 2009), and were only on pharma-
ceuticals for 43 % of the days between baseline and 8-year follow up (Langberg & Becker, 
2012).  
The reasons why the original differences between groups disappeared has been extensive-
ly debated. Arguments range from: the pharmaceutical medication was no longer effec-
tive; all participants improved from treatment and improvement was sustained; the natural 
course of the disorder accounted for the improvement; treatment benefits were only main-
tained whilst medication management was maintained. The best interpretation may be that 
the data were confounded and conclusions difficult to draw (Shaw, et al., 2012).  
Where pharmaceuticals are adhered to, other studies have suggested that improvements 
are sustained. One 10-year study found a mean duration of treatment of 6 years, and along-
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side fewer disruptive disorders and less school failure (Biederman, Monuteaux, Spencer, 
Wilens, & Faraone, 2009). Charach et al. (2004) found that at 2 and 5-year follow-up, adher-
ent participants showed improvement in teacher-reported ADHD symptoms in comparison 
with non-adherent participants. Hechtman (2004) found that consistently monitored partic-
ipants whose medication use was actively titrated over a 1–2 year period maintained im-
provements in ADHD symptoms and academic outcomes.  
Systematic reviews of long-term outcomes have found that pharmaceutical treatment of 
ADHD improves life functioning, self-esteem, social function, core ADHD symptoms and ac-
ademic performance (Hodgkins, 2012; Arnold, 2015; Harpin, 2016; Parker, 2013; Langberg, 
2012). Hodgkins (2011) concluded that pharmaceutical treatment may reduce the negative 
impact that untreated ADHD has on life functioning but not to the point of normalization. 
Arnold, from the same team (Arnold, Hodgkins, Caci, Kahle, & Young, 2016) concluded that 
a combination of pharmaceutical and non-pharmaceutical treatment was most consistently 
associated with improved long-term outcomes, and that treatment cessation attenuated 
results. Harpin (2016) found that the majority of self-esteem and social function outcomes 
were improved. Parker (2013) found that that pharmaceutical and behavioural interventions 
were effective in managing core ADHD symptoms and academic performance at 14 months, 
but after that there was little evidence to suggest that the effects are maintained. 
Langberg (2012) found long-term pharmaceutical medication use to be associated with im-
provements of minimal educational or clinical signiﬁcance: 5 year gains were equivalent to 
.19 school years for maths and .29 school years for reading (Scheffler, et al., 2009). 
Regarding criminality, no systematic review was identified. In one cohort of 126 children, 
pharmaceutical medication did not reduce offending levels (Langley, et al., 2010). The MTA 
study concluded that cause-and-effect relationships between pharmaceutical treatment and 
delinquency are unclear, indeed by 24 and 36 months, more days of prescribed medication 
were associated with more serious delinquency (Molina, et al., 2007). 
In summary, studies suggest that if effective pharmaceutical treatment is maintained, bene-
fits may persist. Negative long-term prognoses are likely due to both lack of persistence with 
pharmaceutical medication, and its inability to normalise impairments. Those with ADHD 
continue to be at risk of negative long-term outcomes, and researchers continue to debate 
the risks and benefits of pharmaceutical treatments (NICE, 2008; Poulton, et al., 2013; 
Storebo, et al., 2015).  
Side effects of pharmaceutical medications 
Adverse side effects associated with pharmaceutical medication are common: decreased 
appetite, sleep disturbance, headache, abdominal pain, nausea and vomiting, depression, 
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anxiety, emotional outbursts, weight loss, delay in height gain, dizziness and increased 
blood pressure (Wigal, et al., 2006; Wolraich, McGuinn, & Doffing, 2007; 
http://www.nhs.uk//Conditions/Attention-deficit-hyperactivity disorder/Pages/Treatment. 
aspx. ) 
Children have also been found to be at risk of developing some type of tic (Doherty, Frank-
enberger, Fuhrer, & Snider, 2000).  In the MTA study 64.1 % of children studied suffered 
from one or more mild, moderate, or severe side effects (MTA Cooperative Group, 1999). In 
the meta-analysis of methylphenidate treatment children were found to be at 60% greater 
risk for trouble sleeping/sleep problems, and 266% greater risk for decreased appetite (Sto-
rebo, et al., 2015). In the meta-analysis of amphetamine treatment an 85% greater risk for 
decreased appetite was identified; 59% greater risk for insomnia/trouble sleeping; 13% 
greater risk of abdominal pain; and 26% greater risk of nausea/vomiting (Punja, et al., 2016). 
Serious adverse reactions, such as psychotic symptoms and mood disorders are thought to 
affect about 3% of children (MTA Cooperative Group, 1999; NICE, 2008; Pliszka, 1998). Sud-
den death, seizures and suicidal thoughts have also been reported (Vitiello, 2008; McCarthy, 
Cranswick, Potts, Taylor, & Wong, 2009; Eli Lilly and Company methylphenidate instruction 
leaflet, 2008).  
Reduced growth of 2-4 cm has recently been confirmed in those taking pharmaceutical 
medication continuously from childhood through adolescence compared to their non-ADHD 
peers (Swanson, et al., 2017; Poulton, et al., 2013). It is suggested that the effects of stimu-
lants on growth are dose-dependent (Graham, et al., 2011) which may explain why height 
reduction of treated children was not observed until recently (Biederman, Spencer, 
Monuteaux, & Faraone, 2010), since cumulative methylphenidate dosage has increased 92% 
since the 1960s (Swanson, et al., 2017).  
According to the carers of children with autism, pharmaceutical medications for ADHD 
cause more problems than they help (0.6:1 ratio of better: worse 
(http://www.autism.com/). Children may be more vulnerable to side effects and not experi-
ence positive benefits (Ghanizadeh, et al., 2012; Stigler, Desmond, Posey, Wiegand, & 
McDougle, 2004; Troost, et al., 2006). Those studies which do show the effectiveness of 
pharmaceutical medication tend to have used high functioning autism samples, tested non-
stimulant medication, be small, uncontrolled, and have potential confounders (Posey, et al., 
2006; Zeiner, Gjevik, & Weidle, 2011; Arnold, et al., 2006). 
Adherence to pharmaceutical medication 
The literature suggests a low persistence rate, (as discussed in the section above looking at 
long-term outcomes), and nonadherence to pharmaceutical medication to be the norm ra-
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ther than the exception (Langberg & Becker, 2012). Children in the UK have been found not 
to take pharmaceutical medication for longer than 6 months (Raman, et al., 2015), and stud-
ies in the US concur: 1 in 5 (Froehlich, et al., 2007) and 50% (Perwien, et al., 2004) discon-
tinue after the first prescription, and as discussed above (long-term outcomes) only 50 % of 
trial participants in the MTA study were adherent to their assigned medication 
(Pappadopulos, et al., 2009).  
Treatment adherence drops significantly in teenagers (McCarthy, et al., 2009), who are 
found to dislike taking pharmaceutical medication due to its side effects; don’t see a need 
for, or improvement from, medication; and/or dislike the attached social stigma (Brinkman, 
et al., 2012). Teenagers describe changes in their sense of self which lead them to want to 
discontinue use (Barbaresi, et al., 2006). According to a review of lack of adherence (Frank, 
Ozon, Nair, & Othee, 2015), their reasons for discontinuing are: “own wish, remission/don't 
need (19%); withdrawal of consent (16%), adverse effects (15%) of which the most common 
is reduction in weight and appetite; and, suboptimal effect (15%). 
Concerns regarding pharmaceutical medication 
Whilst pharmaceutical medication improves core symptoms and other important outcomes 
over the short-term, its dominance as a treatment option has always been a cause for con-
cern (Wright, 1997). The NICE guidelines were written in response to this concern according 
to personal communication with the Director of Guidelines. Carers have ethical concerns 
about the use of medication (Perring, 1997); unhappiness about using psychotropic medica-
tion in children; concerns about side effects and long-term harms; concerns that medication 
takes away individual responsibility for problems; and unease that the focus of treatment is 
on the child, not the interface between them and the social and educational systems (NICE, 
2008). Concerns are also raised about stimulant drug misuse and diversion (NICE, 2008), alt-
hough Mannuzza et al., (2008) and Biederman et al., (2008) found early treatment with 
stimulants did not contribute to later substance abuse. 
Other concerns, (also discussed above), are that the strong short-term effects of pharma-
ceutical medication measured are not sustained. Children do not adhere to their medication 
regimes, particularly when teenagers. Children may have secondary problems not resolved 
with pharmaceutical medication (Pelham & Gnagy, 1999) or caused by it (Owens, 2008). 
Pharmaceutical medication does not usually bring children within the clinically normal 
range; and a significant number of children (< 25%) fail to respond to it (Markowitz, 
Straughn, & Patrick, 2003). Furthermore, pharmaceutical medication is commonly associat-
ed with side effects such as sleep problems and decreased appetite (Storebo, et al., 2015), 
and reduced growth (Swanson, et al., 2017).  
Pharmaceutical medication costs 
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In the UK, the annual cost of prescribed pharmaceutical medications to the NHS in 2006 was 
roughly £29 million, a 20 % increase from the previous year. By 2010 with increased pre-
scription rates the cost to the NHS increased to £43.8 million (NICE, 2013). It is estimated 
that pharmaceutical medication expenditures for ADHD in the UK will have exceeded £78 
million by 2012 (Schlander, 2007) due to growing acceptance and intensity of pharma-
cotherapy and higher unit costs of medications (NICE, 2008). Initial assessment costs are es-
timated at £23 million, and follow up care excluding medication, £4 million annually (King, 
et al., 2006). 
The cost-effectiveness of pharmaceutical medication  
Treatment cost-effectiveness studies have primarily focused on methylphenidate use in the 
US, where it is found to be a cost-effective treatment option with ratios ranging from 
$15,509 to $27,766 per quality-adjusted life year (QALY) gained for short and medium-term 
benefits (Gilmore & Milne, 2001). In the UK the NICE technical analysis estimated the addi-
tional cost per QALY gained for methylphenidate compared to no treatment at £9,200 
(£4,700 to £28,200) (Lord & Paisley, 2000). It was concluded that pharmaceutical treatments 
are cost effective compared to no treatment, but a combination of pharmaceutical medica-
tion and psychological therapies are not (King, et al., 2006). Evidence of cost-effectiveness 
beyond 6 months is poorer due to difficulties in unpicking the effects of pharmaceutical 
medication and the effects of non-adherence. 
Behavioural treatment costs are far higher than pharmaceutical medication costs: the MTA 
study estimated that at 14 months pharmaceutical medicine costs were $1079 per child, 
and behavioural treatment costs $7176 (Jensen, et al., 2005). The following section reviews 
the evidence base for behavioural interventions. 
2.3.2 Behavioural change interventions 
Behavioural change programmes such as social skills training and cognitive behavioural 
therapy are recommended as treatment options in the UK (NICE, 2008). Parent training and 
education programmes aim to teach parents about behaviour management; increase their 
confidence in their ability to help their child; improve their relationship with their child; im-
prove children’s behaviour and peer relationships. They are designed to develop strategies 
to cope with difficult behaviour secondary to, or coexisting with, ADHD rather than address 
the core symptoms, and are considered particularly in pre-school years when medication is 
not licenced.   
Cognitive behavioural therapy (CBT) aims to help children (usually adolescents) manage 
problems by changing the way they think and behave. Social skills training involves children 
taking part in role play situations, aiming to teach them how to behave in social situations 
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by learning how their behaviour affects others. In the UK, there are a variety of ‘branded’ 
parenting programmes such as 123 Magic (Bloomfield & Kendall, 2010), Triple P (Nowak & 
Heinrichs, 2008), Incredible Years (Webster-Stratton, Jamila Reid, & Stoolmiller, 2008) and 
the New Forest Parenting Programme (NFPP) for pre-school children (Sonuga-Barke, Daley, 
Thompson, Laver-Bradbury, & Weeks, 2001). In Sheffield, the MAG (Managing ADHD Group) 
run by Sheffield Family Action is used. 
Programmes are usually in groups of 10-12 carers for 10-16 meetings of up to two hours 
each, but may vary (individual vs. group, session length, duration of treatment). What pro-
grammes have in common is the training of carers and/or children in behaviour manage-
ment techniques using positive reinforcement and rewards to encourage children to try to 
control their ADHD (The New England Comparative Effectiveness Public Advisory Council, 
2012). 
Assessment of outcomes for behavioural interventions 
Effect sizes in behaviour intervention trials vary as a function of design and comparator: be-
tween-group design effect sizes range from 0.03 to 1.31 (median 0.44); within-subject de-
signs from 0.10 to 2.39 (median 0.46); and single-subject case studies, which constitute the 
majority of the evidence, from 1.07 to 14.35 (median 3.46) (Pelham & Fabiano, 2008).  
Policy decision makers such as NICE use between-group studies to inform guidelines (NICE, 
2008), whilst advocates of behavioural interventions argue that other designs should be in-
cluded, since most medication studies are also within-subject short-term crossover studies 
(Conners, 2002; Fabiano, et al., 2009). Therefore the effectiveness of behavioural interven-
tions is contested. NICE conclude that although there are some gaps in the evidence base, 
interventions are beneficial, and some have demonstrated improvements in core ADHD 
symptoms (NICE, 2008). However, Cochrane reviews find little evidence of effectiveness and 
high risk of bias which compromises findings (Zwi, Jones, Thorgaard, York, & Dennis, 2011; 
Storebø, et al., 2011).  
Outcomes are influenced by: rater status, age, what is measured, what is compared, how 
long studies are, and what type of trial design is used. How study results are interpreted de-
pends upon opinions about the acceptability of aspects of study designs since behavioural 
interventions (possibly inevitably) are considered to have poor internal validity, and be at 
high risk of bias. Whether the quantity of poor quality studies is sufficient to mitigate for 
their poor quality is questioned (Sonuga-Barke, et al., 2013). 
Rater status as a moderator of treatment outcome 
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Studies tend to find more positive effects when assessments are made by unblinded par-
ents, but not by blinded raters (Sonuga-Barke, et al., 2013). Interpretations for this include: 
that unblinded raters are biased and overestimate treatment effects; that interventions in-
crease parental tolerance for ADHD or their ability to cope with its negative impact rather 
than decreasing symptom levels; that blinded measurements are less valid than more prox-
imal measurements; or that intervention effects do not generalize from the therapeutic set-
ting (e.g., the home) to other settings (e.g., school) (Daley, et al., 2014). 
Age as a moderator of treatment outcome 
Pre-schoolers’ carers participate in parenting courses; school age children participate in CBT 
courses, parenting programmes or family therapy; adults and teenagers participate in CBT 
based therapies. Age appears to be a moderator of treatment outcome and evidence for 
effectiveness is stronger for pre-schoolers and adults than school age children. 
In the UK, pharmaceutical medication is not licenced for pre-schoolers. In the USA, where it 
is, evidence suggests behavioural interventions are more effective than methylphenidate in 
reducing disruptive behaviours and ADHD symptoms (Mulqueen, Bartley, & Bloch, 2015; 
Charach, et al., 2013). In the UK, The NFPP has been found to increase levels of positive par-
enting and reduce mental health problems when implemented by motivated and trained 
health visitors with experience in childhood behaviour problems (Sonuga-Barke, Daley, 
Thompson, Laver-Bradbury, & Weeks, 2001), but not when delivered in a more standard 
community setting using non-specialist health visitors (Sonuga-Barke, Thompson, Daley, & 
Laver-Bradbury, 2004).   
In school age children, neither parenting programmes, CBT or family therapy have emerged 
as being as effective as pharmaceutical medication. Therefore in the interests of cost effec-
tiveness, pharmaceutical medication has increasingly become the predominant treatment. 
Few well-controlled studies of behavioural interventions for teenagers have been done 
(Pelham & Fabiano, 2008) and the results of those are equivocal. It is suggested that paucity 
of studies is because they have not been well received in practice.  
In adults, CBT programmes appear to be effective for ADHD symptoms and functioning, and 
pharmaceutical medication not to offer additional benefits (Weiss, et al., 2012). It is sug-
gested that adults may have obtained greater insight into their difficulties with ADHD and 
be receptive to learning better ways of coping.  
What is measured as a moderator of treatment outcome 
Behavioural interventions are generally not considered to decrease the core symptoms of 
ADHD, but to improve children’s functioning in areas not affected by medications, and these 
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are what tend to be measured. For example, in the MTA study, whilst medication alone sig-
nificantly decreased core symptoms of ADHD, only children who received behavioural 
treatment in addition to medication saw significant improvements in child social skills, car-
er-child relationships, and positive parenting practices (Hinshaw, et al., 2000). 
Improvements are found in children’s oppositional and aggressive symptoms, parenting, 
teacher-rated attention, aggression and social skills; observer-rated externalizing problems; 
behavioural functioning and academic performance; and decreased parental stress 
(Webster-Stratton, Reid, & Beauchaine, 2011; Langberg, et al., 2010; Williford & Shelton, 
2014). 
Control conditions as a moderator of treatment outcome 
Control conditions are considered to influence results. The majority of behavioural studies 
are single within-subject designs, comparing effects before and after, and these demon-
strate large effect sizes. In school settings such as the MTA study, the control condition was 
school as usual, where it is suggested that results were confounded since behavioural inter-
ventions are ubiquitously used in classroom settings (Gottfredson & Gottfredson, 2001; 
Walker, Ramsey, & Gresham, 2003). In other studies in controlled classroom settings where 
naturalistic contingencies were removed, the behaviour of ADHD children was found to de-
teriorate substantively (Fabiano, et al., 2009), and behavioural treatment effects conse-
quently magnified. Researchers argue that doing this employs a control condition that is 
comparable to a placebo condition in a drug study, and therefore a more valid comparison 
of the two treatments (Pelham & Fabiano, 2008). 
Behavioural interventions for emotional dysregulation 
There is some evidence that behavioural interventions may be helpful for emotional dysreg-
ulation. A systematic review of parent training interventions by Zwi et al. (2011) suggests a 
moderate effect on unblinded measures of internalising behaviours (e.g withdrawal and 
anxiety) according to two studies; but a non-significant effect on externalising behaviours 
(rule breaking, oppositional behaviour, aggression) according to three studies. However, the 
risk of bias was considered high because no studies provided information on randomisation 
and allocation concealment; and inevitably, blinding of participants, personnel or outcome 
assessors (who were most often the parents who had delivered the intervention) was im-
possible. 
Chan (2016) in another systematic review of ADHD treatments for adolescents found incon-
sistent small to medium effects on emotional aspects in adolescents according to five stud-
ies. Meta-analysis by Daley et al. (2014) (32 studies) found both blinded (SMD = .31) and 
unblinded improvements (SMD = .26) in conduct problems. 
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Adherence to behavioural interventions 
Adherence to behavioural interventions can be as problematic as adherence to pharmaceu-
tical medication. Whilst Daley et al. (2013) and Thompson et al. (2009) found that most car-
ers offered a place on a parenting course took it up, Taylor et al. (2015) found attendance to 
be 31–54 % of those recruited, and Barkley et al. (2000) found that one third of carers at-
tended no classes, and only 13% attended more than half.  
Reasons for attrition were found to be:  situational (transport, childcare, timing/venue); 
psychological (low self-confidence, fears of being judged a bad parent, stigma, shame, em-
barrassment, distrust); perceiving programmes as unhelpful, irrelevant or demanding; poor 
relationship with the therapist; problems implementing strategies; having an unsupportive 
family/partner; being a single and/or young carer; the intervention not a priority when 
faced with multiple challenges; and changes in circumstances (Scott, et al., 2010); (Koerting, 
et al., 2013). 
Concerns regarding behavioural interventions 
There are concerns about the sustainability of behavioural interventions, their inability to 
improve core ADHD symptoms, and the nature of the trials conducted. Gains may only be 
sustained whilst the behavioural interventions remain in place in the settings and during 
times when the child experiences difficulties (Barkley, 2006). Most reviews comparing 
pharmaceutical medication and behaviour change programmes conclude that pharmaceuti-
cal medication is more effective than behaviour modification (Hinshaw, 2007; Jadad, Boyle, 
Cunningham, Kim, & Schachar, 2000).   
Despite numerous studies of behavioural interventions, the evidence base is still disputed, 
largely because improvement tends to be found in unblinded not blinded ratings (NICE 
(2008), (discussed in greater depth in section 3.1.8).  The majority of trials with positive re-
sults compare before and after outcomes in the same unblinded subjects. Where trials 
compare medication with behavioural interventions, the behaviour arm does not appear to 
show improvements in ADHD symptoms, although does in other functional outcomes. 
Therefore ADHD experts question the effectiveness and utility of behavioural interventions 
which are labour intensive and costly. For example, the MTA’ s summer treatment pro-
gramme was conducted for 6–8 hours a day, five days a week, for many weeks (Wells, et al., 
2000) and incurred over twice medication costs. 
It is of concern that there are few studies of behavioural interventions for teenagers. It is 
likely that these are not being done because teenagers are not receptive to them since this 
is a time when many teenagers stop taking pharmaceutical medications, so there is an un-
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met treatment need during these years. The absence of acceptable interventions at this 
stage is likely to be contributing to poor long-term negative outcomes.  
2.3.3 Summary – mainstream treatments 
This section has interrogated the evidence for improvement of outcomes using mainstream 
treatments. The bulk of the evidence in support of both pharmaceutical medication and be-
havioural approaches suggests that whilst implemented, treatments may effectively palliate 
symptoms, making classroom and family life more manageable for the majority of children 
with ADHD. Despite these findings, long-term outcomes are not being substantially affected, 
and a negative prognosis is associated with a diagnosis despite large increases in pharma-
ceutical medication. This may be because in general, neither intervention type is accessed 
for long: pharmaceutical medications tend not to be taken for long periods, and behavioural 
interventions only last for 8 - 12 weeks.  
Comparisons of the long-term effectiveness of behavioural interventions and pharmaceuti-
cal medication suggest that behavioural interventions are less effective than pharmaceutical 
medications at improving core ADHD symptoms. However, it is argued that comparisons are 
biased since in studies, children continue to take pharmaceutical medication, but behav-
ioural interventions are only accessed for limited periods (Pelham & Fabiano, 2008).  
Nevertheless behavioural interventions are considered a useful supplement to pharmaceu-
tical medication despite evidence for their effectiveness and ability to effect long-term 
prognoses being disputed, and their being costly to implement. In the UK, although recom-
mended by NICE (2008), provision is inconsistent and variable with a lack of psychosocial 
services, assessment and treatment protocols. Neither intervention appears to be particu-
larly acceptable to those with ADHD. This may be an artefact of the condition, or a comment 
on the interventions, likely both. 
Much debate regarding interpretation of the evidence concerns trial design. This issue is 
discussed in greater depth in Chapter 3, and is seminal to the rationale for this thesis. Trials 
of medication, which demonstrate strong short-term effects, are accused of not transferring 
to real-life practice, including benefit/side effect ratios, or measuring long-term effective-
ness (Storebo, et al., 2015). Trials of behavioural interventions are accused of being prone to 
bias as carers supplying assessments are usually directly involved in treatment delivery.  
2.3.4 Non-mainstream treatments  
ADHD is a highly researched condition. Publications increased from 356 in 1985–89 to 6158 
in 2005–9. (Bishop, 2010). But the weight of this weighty evidence does not suggest that 
mainstream treatments are substantially influencing long-term negative outcomes. There is 
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a logical argument that resources might be better used exploring different interventions, 
such as the adjunctive treatments to which carers turn (section 1.5.3).  
Currently there is insufficient, inadequate evidence for the non-mainstream treatments they 
are using. What evidence there is generally takes the form of small, underpowered, poorly 
designed and reported studies (Whitehouse, 2013). This despite the fact that an estimated 
50,000 complementary practitioners work in the UK providing treatment to around 5 million 
patients a year (Budd & Mills, 2000). In 2000, the House of Lords identified as a public 
health issue that we do not have adequate knowledge of the putative benefits of these 
therapies (House of Lords Select Committee on Science and Technology, 2000).  
They identified that development of a robust evidence base for these under-researched in-
terventions is restricted by a lack of industry funding, and/or academic researchers to con-
duct such studies. A programme was put in place to mitigate for this within the Department 
of Health and ten fellowships ring fenced for the field of Complementary and Alternative 
Medicine (CAM). However, at the same time a successful campaign was implemented to 
prevent such potential CAM researchers from obtaining University degrees (which included 
research modules) in their CAM subjects (Anwar, Jim, Huckbody, & Hughes, 2001). The De-
partment of Health initiative no longer continues, and there continue to be few researchers 
with an understanding of or interest in CAM. 
Non-pharmaceutical treatments for their child’s ADHD are found to be preferred over 
pharmaceutical treatment by carers (Corkum, Rimer, & Schachar, 1999). Reasons include: 
looking for alternatives to conventional drugs (Baumgaertel, 1999; Brue & Oakland, 2002; 
Gross-Tsur, Lahad, & Shalev, 2003); minimising symptoms of ADHD; additional benefit when 
combined with conventional treatment; avoiding side effects of prescribed medication 
(Sinha & Efron, 2005; Hanson, Kalish, & Bunce, 2007);  seeking additional symptom relief; 
and dissatisfaction with conventional care (Bishop, Yardley, & Lewith, 2007). 
CAM are used alongside (complementary) or as a substitute (alternative) to conventional 
treatments and not routinely used by medical or other health professionals (Hall & Riccio, 
2012). The Cochrane collaboration describes CAM as “a broad domain of healing resources 
that encompasses all health systems, modalities, and practices and their accompanying the-
ories and beliefs,  other  than  those  intrinsic  to  the  politically  dominant  health  system  
of  a  particular  society  or  culture, defined  by  their  users  as  preventing  or  treating  ill-
ness  or  promoting  health  and  wellbeing.  Boundaries within CAM and between the CAM 
domain and that of the dominant system are not always sharp or fixed”͘ (Wieland, 
Manheimer, & Berman, 2011). 
The US National Center for Complementary and Integrative Health (NCCIH) divides CAM into 
three categories: natural products (such as diets and supplements); mind-body practices 
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(such as yoga, chiropractic and osteopathic manipulation, meditation, and massage thera-
py); and a third category of approaches which “may not neatly fit into either of these 
groups” but can be termed holistic or whole medicine systems: ayurvedic medi-
cine, traditional Chinese medicine, homeopathy, and naturopathy 
(https://nccih.nih.gov/health/integrative-health). 
 This third category takes a whole system or holistic approach suggesting interconnected-
ness (Koithan, Bell, Niemeyer, & Pincus, 2012) and considers all aspects (mental emotional, 
physical and general) of the patient as an individual. It has been defined as ‘‘an approach to 
health care ….. to maximize the patients’ capacity to achieve mental and physical balance 
and restore their own health, using individualised, non-reductionist approaches to diagnosis 
and treatment’’ (Verhoef, et al., 2005). Such holistic interventions which address a global 
constellation of symptoms (Foisy & Williams, 2011) may have a particular role to play in im-
proving ADHD outcomes due to its heterogeneity and association with co-occurrences. In 
comparison, pharmaceutical interventions try to eliminate or reduce the impact of a symp-
tom, and outcomes are considered to be linear. Holistic interventions require viewing and 
testing as a synergistic network.  
Prevalence of CAM usage 
To identify which non-mainstream treatments were being used by carers, an informal 
search was made for surveys of CAM use for ADHD using the search terms ADHD, survey, 
CAM (and specific CAM therapies) in Google Scholar, Web of Science, and cross referencing 
of any surveys found. No surveys were found documenting CAM use for ADHD in the UK, 
although a cross-sectional survey of all children in the south-west of England was found 
which reported that 17.9% under 16 had used some form of CAM. 
Nine surveys were found assessing CAM use for ADHD in Australia (n=3), the USA (n=4), 
Canada (n=1) and Israel (n=1) which are summarised in Table 4.  The frequency of CAM use 
in children with ADHD ranged from 12% to 71%, with lower estimates thought to be the re-
sult of comparatively narrower definitions of CAM (Weber & Newmark, 2007; Gross-Tsur, 
Lahad, & Shalev, 2003). CAM use may also vary depending on nationality since there is con-
sistency across the 3 Australian surveys, although less consistency across the 4 US surveys. 
CAM appears to be predominantly used alongside stimulant medication use, and this is also 
described in Table 4 . 
There are more surveys regarding the prevalence of CAM use in autism spectrum conditions 
(ASCs), which show higher and increasing use compared to CAM usage for ADHD. CAM use 
amongst ASC families in the USA was estimated to be 31% in 2003 (Levy, Mandell, Merhar, 
Ittenbach, & Pinto-Martin, 2003), 74% in 2007 (Hanson, Kalish, & Bunce, 2007) and 82% in 
2013 (Huang, Seshadri, Matthews, & Ostfeld, 2013).  
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ADHD surveys ask about different CAM therapies: most commonly about dietary interven-
tions (8/9); whilst 4/9 ask about homeopathy and chiropractic/osteopathy; and 3/9 ask 
about acupuncture, herbs, or yoga. Once the non-mainstream interventions used had been 
identified from the surveys summarised in Table 4, the evidence base for each intervention 
was explored.  The search strategy was to search Google Scholar, Web of Science and the 
Cochrane collaboration for peer reviewed meta-analyses, systematic reviews or RCTs (in 
that order) using the surveyed interventions, plus ADHD as search terms. Searches were 
conducted in 2014.Table 5 describes the evidence found for the surveyed CAM therapies.
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Table 4. Complementary and alternative medicine use according to surveys 
Study authors Venue No: in 
survey 
CAM 
use 
CAM interventions surveyed % taking phar-
maceutical med-
ication 
Stubberfield et 
al. (1999) 
Australia 290 64% Dietary interventions, chiropractic, optometry, use of coloured glasses, use of any other ther-
apy not specifically listed.  
69% 
Bussing et al. 
(2002) 
USA 822 12% Chiropractic, homeopathy, massage, acupuncture, faith healing n/a 
Gross-Tsur et al. 
(2003) 
Israel 120 28% Diet, homeopathy, acupuncture, biofeedback 80% 
(Chan, 
Rappaport, & 
Kemper, 2003) 
USA 114 54% Expressive (e.g., sensory integration, occupational therapy, art, music, dance), Dietary ma-
nipulation, Special exercises (e.g., yoga, tai chi), Relaxation techniques (e.g., meditation), 
Prayer, Biofeedback, Chiropractic, Herbal remedies, Massage, Healer, hypnosis 
51% 
(Concannon & 
Tang, 2005) 
Australia 278 71% Elimination diet, Fatty acid supplement, Vitamins, Behavioural optometry, herbal medicine, 
Allergy testing, Chiropractic, Sound therapy, Osteopathy, Acupuncture 
66% 
(Sinha & Efron, 
2005) 
Australia 75 67.6% Naturopathy, Herbal Therapy, Homeopathy, Dietary supplements, Modiﬁed diet, neurofeed-
back, Aromatherapy, Therapeutic Massage, Reiki/therapeutic touch, Special exercise, e.g. yo-
ga, behavioural Optometry, Chiropractic, Kinesiology, Osteopathy, Relaxation tape, Medita-
tion, Magnetic Pillow  
92% 
Johnston et al. 
(2005) 
Canada 73 50% Vitamin/naturopathy; diet/supplements; family therapy; neuro-feedback 81% 
Huang et al. 
(2013) 
USA 135 19.5% Dietary supplements, Sensory integration, Facilitated communication, Music therapy, Candida 
therapy, Gluten casein–free diet, intravenous secretin, Kinesiology, behaviour modiﬁcation, 
Vision therapy 
98% 
(Kemper, 
Gardiner, & 
Birdee, 2013) 
USA 483 36.2% Biofeedback, hypnosis, guided imagery, meditation, progressive relaxation, qi gong, stress 
management classes, tai chi, yoga; dietary supplements; chiropractic/osteopathic, massage; 
homeopathy, naturopathy, Ayurveda, Curandero, Espiritista, Hierbero, Yerbera, Shaman, Bo-
tanica, Native American healer/medicine man, Sobador 
n/a 
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Table 5. Evidence base for CAM therapies being used for ADHD 
Therapy RCTs Source Unblinded assessment  Blinded assessment  Risk of bias 
Dietary - 
fatty acids 
11 Meta-analysis:  (Sonuga-
Barke, et al., 2013) 
Carer/Teacher - SMD=0.21, 
95% CI=0.05, 0.36. Z=2.67, 
p=0.007 
Teacher/Carer - SMD=0.16, 95% 
CI=0.01, 0.31. Z=2.05, p=0.0 
Jadad rating 3+. Blinded assessment re-
mained signiﬁcant when analysis limited to 
9 trials with no/low medication SMD=0.17; 
95% CI=0.01, 0.34). 
Dietary - 
artificial col-
ours 
8 Meta-analysis: (Sonuga-
Barke, et al., 2013) 
Carer - SMD=0.32, 95% 
CI=0.06, 0.58. overall effect: 
Z=2.43, p=0.02 
Teacher/Carer – SMD=0.42, 95% 
CI=0.13, 0.70.  Z=2.86, p=0.004 
6 trials Jadad rating 3+ (i.e. fair). Restricting 
to 4 trials with blinded assessment: SMD 
(0.32) (95% CI=–0.13, 0.77) 
Dietary - 
restrictive 
elimination 
7 Meta-analysis:  (Sonuga-
Barke, et al., 2013) 
Carer/teacher -SMD=1.48, 
95% CI=0.35, 2.6. Z=2.55, 
p=0.01 
Teacher/Psychologist –SMD=0.51, 
95% CI=–0.02, 1.04.  Z=1.90, p=0.06 
Jadad rating 3+. Individuals were selected 
for their food sensitivities. 5/7 had blinded 
assessments 
Neurofeed-
back 
5 Meta-analysis: (Micoulaud 
Franchi, et al., 2014) 
Carer - SMD = −0.49 [−0.74, 
−0.24], 
Teacher -  SMD = −0.18 [−0.42, 
0.07], p = 0.15. 
 Jadad rating 3+ 4/5 studies. 1 study un-
blinded 
Homeo-
pathic medi-
cines 
4  Systematic review: (Heirs & 
Dean, 2009) 
none Carer (2 studies) -1.56 (CI -3.18, 0.06) Trial heterogeneity, lack of ecological validi-
ty 
Meditation 
therapies 
4 Systematic review: 
Krisanaprakornkit et al. 
(2010) 
Unblinded Teacher MD 2.72, 
95% CI -8.49 to 3.05 
none Unclear randomization method, unclear 
allocation concealment, no blinding, un-
clear attrition rate 
Acupuncture 3 Meta-analysis: (Li, et al., 
2011) 
Carer - Z=2.19 (P=0.03) none  unblinded, incomplete outcomes. 
Massage  1 RCT: (Khilnani, Field, & Her-
nandez-Reif, 2003) 
participants- happiness F(1, 
27) = 5.46, p < .05. 
Teachers - hyperactivity (pre-post 
test), F(1, 28) = 7.92, p < .01 
No randomisation description, no compara-
tive statistics 
Music Ther-
apy 
1 (Rickson, 2006). Pilot study Teachers - no differences 
between groups (no further 
information available) 
Residential social workers – no dif-
ferences between groups 
Unclear randomisation, no allocation con-
cealment or blinding 
SMD = Standard Mean Difference; CI = Confidence Interval. Jadad ratings assess methodological quality allocating trials scores between zero (very poor) and five (rigorous) (Jadad, et al., 1996)
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As can be seen from Table 5, nutritional interventions are the most surveyed and re-
searched, with some evidence (including blinded assessment) for the effectiveness of as-
pects of nutrition such as supplementation with fatty acids and restrictive elimination diets. 
Neurofeedback is the next most researched. It has developed within mainstream medicine 
so is not generally considered CAM. Homeopathic interventions are the next most re-
searched, with 4 RCTs according to a systematic review conducted in 2009. Meditation ther-
apies also have 4 RCTs. The remainder of the surveyed therapies have few or no RCTs.  It is 
clear that the CAM interventions being used are under researched, and the evidence pro-
duced generally rated low quality.  
The selected treatments 
The therapeutic modalities of homeopathy and nutrition were selected to be tested as two 
non-mainstream interventions being used by families with some promising preliminary evi-
dence. Both interventions can be considered whole medicine or ‘holistic’, non-specific ap-
proaches to health: general health is considered to be improved through either individually 
tailored nutritional intake, or through stimulation of self-cure by application of individually 
tailored, matching homeopathic remedies. 
The surveys showed that families both buy over the counter (OTC) nutritional supplements 
and homeopathic remedies, and also go to visit nutritional therapists and homeopaths for 
their children with ADHD (Table 4). Buying OTC products is more popular, cheaper, and eas-
ier to implement than visiting a therapist or implementing a dietary change (Kemper, 
Gardiner, & Birdee, 2013). In the US, OTC natural products were the most popular CAM 
health approach, used by 17.7% of the population, whilst special diets were used by 3%. 
OTC homeopathic products and/or visiting a homeopath was used by about 1.8% of children 
(2.2% of adults) (Clarke, 2015; Black, 2015). 
There are several reasons why visiting a nutritional therapist or homeopath is a better way 
of knowing whether that therapy might be helpful, rather than self-selection of OTC prod-
ucts. Therapists provide professional, tailored advice about which supplements/remedies 
might be most suitable, and professional knowledge about the process. Visiting a therapist 
is costlier than buying OTC products, but self-selection runs the likelihood of wrongly identi-
fying an appropriate remedy/supplement, and of misunderstanding the process, particularly 
since changes can take a while to occur. A personally tailored approach by a nutritional 
therapist is recommended since nutritional sensitivities (which can be varied and diverse) 
are found in some but not all of those with ADHD, (section 5.4.2), and there are concerns 
about unsupervised dietary changes during crucial growing periods.  A personally tailored 
approach by a homeopath is a key requirement for identification of an appropriate homeo-
pathic remedy (section 4.1.4).  
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The interventions were therefore termed ‘Treatment by Homeopaths’ and ‘Treatment by 
Nutritional Therapists’. ‘Treatment by a homeopath’ consists of a series of potentially ther-
apeutic consultations and provision of individually tailored homeopathic remedies. ‘Treat-
ment by a nutritional therapist’ also consists of a series of potentially therapeutic consulta-
tions; advice about dietary exclusion and inclusion; menu and lifestyle suggestions and sup-
port implementing them; and advice about and provision of individually tailored supple-
ments.  
Therapists 
NHS funded Integrative Medicine includes treatment by homeopaths (who are also doctors) 
and is available in Bristol, Glasgow and London, although under threat. Homeopathic treat-
ment is further available within the NHS from GPs also trained in homeopathy. However, 
the majority of treatment is accessed privately from professional homeopaths.  
Dietary advice about healthy eating is available from dieticians in some hospitals and GP 
practices. Nutritional therapy is practiced privately and within the NHS by doctors who have 
additional training in nutritional, ecological, and/or functional Medicine. But the majority of 
treatment is also accessed privately from professional nutritional therapists.   
2.4   Summary  
This chapter has described the diagnosis of ADHD, and the short and long-term impact of a 
diagnosis on the child, their family and the education, social services and criminal justice 
systems. The complexity of ADHD, with its sub-types, multiple common co-occurrences and 
causal pathways, emerges as a complicating issue for diagnosis and mainstream treatment 
because “clinicians are inevitably categorisers and so categorical diagnostic systems go with 
the grain of clinical practice” (Sonuga-Barke in NICE, 2008).  
The  evidence base for both main and non-mainstream interventions being used as treat-
ments for children with ADHD was explored. Long-term evidence for the effectiveness of 
main and non-mainstream treatments is weak. The evidence suggests that pharmaceutical 
medication helps symptom control and improves short-term outcomes, but adverse effects 
on sleep, appetite, and growth are common, and adherence poor.  The evidence for behav-
ioural change programmes suggests their adjunctive usefulness in the short-term, although 
the evidence continues to be disputed due to differing perspectives regarding trial design.  
There is minimal research into the non-mainstream alternatives carers try, and existing 
studies are underpowered and of varying quality.  
This chapter has demonstrated that there is a need to improve important, long-term out-
comes for those with ADHD. It has identified some of the difficulties with generating this 
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evidence.  There is a need for efficient ways of conducting high quality pragmatic, compara-
tive trials to both answer some of the outstanding questions about current mainstream 
management of ADHD and explore novel approaches that may be helpful.  
Two non-mainstream interventions being used by carers were identified. Both approaches 
can be classified as taking a holistic approach to health by addressing global constellations 
of symptoms on an individualised basis. It is suggested that such an approach may be useful 
and particularly appropriate for ADHD. In comparison, mainstream treatment approaches 
based on diagnostic criteria struggle with ADHD’s heterogeneity, and debate continues re-
garding categorisation.The evidence base for the two non-mainstream interventions select-
ed - treatment by a nutritional therapist and treatment by a homeopath, will be explored in 
chapters 4 and 5. Before that, in the following chapter, I will describe the rationale for the 
trial design.  
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Chapter 3 Research methods 
This chapter identifies some key criteria for a trial design to test whether interventions im-
prove outcomes for children with ADHD. It explores the appropriateness of the TwiCs design 
to match these criteria.  
3.1   Explanatory and pragmatic trial designs 
Whether to conduct a pragmatic or explanatory trial depends upon the purpose of the trial. 
In health care, explanatory trials are used to confirm or refute the existence of a particular 
hypothesised mechanism of action, provide maximal confidence that any effects seen are 
not due to other factors, and are relevant for regulatory drug approval. They answer the 
question “does this treatment work under ideal conditions?” (Sackett, 2011), that is in tight-
ly controlled circumstances, minimising the influence of other variables.  
Pragmatic trials are deployed in routine circumstances and are more relevant to policy eval-
uation and health care decisions of providers and patients. They are designed to provide in-
formation to enable decision makers to choose among available alternative interventions, 
and answer the question “does this intervention work under usual conditions?” (Torgerson 
& Torgerson, 2008). They use real-world treatment protocols, patient and stakeholder cen-
tred outcomes, heterogeneous patient samples and real-world comparators. They are less 
interested in the mechanisms of ‘how’ interventions work than ‘whether’ they work 
(Torgerson & Torgerson, 2008). The premise of pragmatic trials is that if an intervention is 
safe, effective, cost effective and helpful to patients, its implausibility is secondary to its 
therapeutic benefit.   
Schwartz & Lellouch initially clarified the essential differences between the two approaches 
50 years ago (Schwartz & Lelouch, 1967). However, despite arguments for pragmatic trials 
“if we want more evidence based practice, we need more practice based evidence” (Prasad, 
et al., 2013), “the lack of pragmatic trials is an important problem for clinicians and health 
care decision makers” (Tunis, Stryer, & Clancy, 2003), they are still neither widely accepted 
nor used. The following section explores some reasons why this might be, by exploring the 
advantages and disadvantages of each approach. 
It is usual for explanatory trials to precede pragmatic trials in staged evidence collection, 
whereby explanatory trials inform the development of effective interventions, and pragmat-
ic trials then evaluate their effectiveness in a real-world setting. Both approaches are im-
portant for a full understanding of clinical treatments and their real-life application. Howev-
er, not only are some interventions unsuited to efficacy testing, but evaluation in real-world 
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settings rarely occurs. Pragmatic trials make up just 1.2% of clinical trials (Treweek & 
Zwarenstein, 2009) so information from efficacy trials is used to inform decision making. 
More than half the interventions used in routine health care are still of unknown effective-
ness (BMJ http://clinicalevidence.bmj.com/x/set/static/cms/efficacy-categorisations.html). 
Pragmatic trials are rarely conducted in psychology departments where the majority of 
ADHD research is conducted, but are more common in public health departments, where 
this PhD is situated.  
Features of explanatory and pragmatic trials can be presented as polar opposites (see Table 
6). However, in reality designs tend not to be dichotomous (i.e either purely pragmatic or 
purely explanatory), but on a continuum from more to less pragmatic (Loudon, 2015). For 
example, explanatory trials may be conducted with pragmatic adjustments such as broader 
inclusion criteria and longer time frames to ensure they reflect the real-world. Pragmatic 
trials may include evaluation of blinded outcomes, and/or the addition of a blinded arm (for 
example, of homeopathic remedies or nutritional supplements) into the effectiveness trial 
design. 
Table 6. Explanatory and pragmatic trials: some archetypal features  
Explanatory trials Pragmatic trials 
Experimental setting Routine care setting 
Evaluate efficacy Compare effectiveness 
More suitable for acute conditions More suitable for chronic conditions 
Placebo-controlled Not placebo-controlled 
Patients blinded to minimise bias Patients unblinded to maximise synergy 
Aim to equalise non-specific effects Aim to optimise non-specific effects 
Standardised treatment, simple interven-
tions 
Routine treatment, complex interventions 
Practitioner skilled for standard protocol Practitioner skilled in routine care 
Usually short-term follow-up Often long-term follow-up 
High internal validity, lower external High external validity, lower internal 
Low relevance/impact on practice High relevance/impact on practice 
Homogenous group of patients Heterogeneous groups of patients 
May manage with smaller sample sizes May need larger sample sizes 
More commonly used Less commonly used 
(information extracted from MacPherson, 2004) 
Both approaches use randomisation, considered the ‘gold standard’ method for estimating 
effectiveness (Torgerson & Torgerson, 2008). 
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3.1.1 Advantages of an explanatory approach 
Research demonstrates the impact of expectation on participants and researchers. For ex-
ample, two systematic reviews conclude that in spite of a limited number of rigorous clinical 
studies there is considerable evidence that patient expectation influences their health out-
comes (Crow, et al., 1999; Mondloch, Cole, & Frank, 2001). Four randomized trials of acu-
puncture found that patients with high expectations were more likely to report better out-
comes than patients with lower expectations (Linde, et al., 2007). 
Expectations can influence both within-group changes (from baseline to follow-up) and be-
tween-group differences (between verum and placebo): trial participants with positive atti-
tudes towards a tested intervention may measure larger changes than trials in agnostic 
samples. High expectations can lead to high response rates in placebo control groups mak-
ing it more difficult to detect additional specific effects. Explanatory approaches have higher 
internal validity (defined in section 1.5.4), giving greater confidence that the answers ob-
tained are attributable to the specific variable measured, and reducing the potential for bi-
ases such as Hawthorne effects (knowledge that participants are in a trial) or ascertainment 
biases, to influence the outcome. 
Using a placebo comparator and blinding helps separate out specific and non-specific effects 
and ensures that trial results are not simply explained by regression to the mean, natural 
history of the complaint, attention from a health professional, or participant’s belief they 
feel better because they are taking an active treatment (Foster & Little, 2012).  
Further advantages of explanatory designs are that they may avoid differential attrition (un-
less the treatment has common side effects). They may address performance biases, as par-
ticipants are less likely to look for another intervention if allocated a control intervention. 
They guard against a type 1 error, that is concluding an intervention is effective when it is 
not (Foster & Little, 2012).  
Tightly controlled studies reduce statistical variation, and selection of a homogeneous group 
of patients for whom the treatment is likely to work best, ensures that if there is an effect, it 
will be seen. Such trials are preferred by NICE, and other referees and funding bodies 
(Torgerson & Torgerson 2008). They are more common, and better understood. 
3.1.2 Disadvantages of an explanatory approach 
Explanatory trials are less suited to answer questions about real-world effectiveness and 
cost effectiveness because results are less generalisable. Studies may have poor external 
validity (defined in section 1.5.4), in that trial populations may not be broadly representative 
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because relatively narrow groups of participants are used; and interventions may not re-
semble those offered in real-life practice. 
If tested interventions are dissimilar to treatments received in clinical practice, results may 
not accurately predict treatments as experienced in real-life. Researchers document con-
cern that explanatory randomised trials are poor predictors of the real-world effectiveness 
of the interventions they test (Saunders, Byrne, & Guthrie, 2013; Treweek & Zwarenstein, 
2009; Travers, Marsh, & Williams, 2007; Rothwell, 2005). It is argued that if studies cannot 
be extrapolated beyond the trial population and variables, they may not be worth doing 
(Berk, 2005). Studies tend to test interventions for short amounts of time, which provides 
unreliable estimates for health care decision makers about long-term effects and ability to 
improve long-term outcomes. 
Further disadvantages of explanatory designs are that outcomes may be less relevant to pa-
tients, for example, if surrogate outcomes are used. There may be difficulties in recruitment 
due to the use of deception. The ecological validity (defined in section 1.5.4) of the interven-
tion tested may be poor, almost inevitably so if that intervention is complex. Explanatory 
approaches are particularly unsuited to testing complex interventions since components are 
interrelated and interact. Teasing out and separately testing individual components runs the 
risk of a type 2 error in these cases, that is not finding an effect where one exists.  
3.1.3 Advantages of a pragmatic approach 
Pragmatic approaches are offered as a solution to the external validity problem of explana-
tory trials in that they retain the rigour of randomisation (thus eliminate selection bias) but 
retain the characteristics of normal clinical practice (Relton, O'Cathain, Nicholl, & Torgerson, 
2010). Pragmatic approaches measuring real-world outcomes of interest (such as educa-
tional attainment or criminality) in representative populations (such as those with co-
diagnoses and/or involved in criminality) over the long-term provide information for stake-
holders such as health care purchasers, providers and patients making choices about treat-
ment. 
Evaluation of economic impact fits well with pragmatic designs. If the overarching purpose 
of health care trials is to help the wider population improve their health, pragmatic trials 
can help facilitate decision-making about whether therapies should be utilised more widely 
(Torgerson & Torgerson, 2008). They shrink the gap between research and practice (Weitz, 
2015), by being more likely to have higher external and ecological validity. That is, they de-
liver evidence of effectiveness in everyday clinical contexts, so generalise better to normal 
clinic settings. The current paucity of such trials is considered a problem for health care de-
cision makers (Tunis, Stryer, & Clancy, 2003).  
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They are a more appropriate trial design where the use of a placebo control to separate 
specific from non-specific effects is problematic, such as when complex interventions are 
tested. Indeed pragmatic trials are specifically recommended for complex interventions by 
advisory bodies such as the MRC (Craig, et al., 2008), who advise testing the effectiveness of 
complex interventions before unpacking the black box and exploring the efficacy of individ-
ual components. 
Results can help us understand more about the acceptability of the intervention to patients 
since intention to treat analysis is used. Patients may be more likely to volunteer for such 
trials since they will not be asked to agree to the possibility of being offered a placebo 
treatment. Such approaches also address ethical issues associated with placebo controls in 
that no sham treatments are offered (Lofthouse, Arnold, Hersch, Hurt, & DeBeus, 2012). 
3.1.4 Disadvantages of a pragmatic approach 
Pragmatic approaches have reduced internal validity, being unlikely to use blinding, which is 
highly problematic since internal validity is considered a pre-requisite to other validities 
(Torgerson & Torgerson, 2008). The extent to which the therapeutic relationship contributes 
to any overall benefit remains unknown after a pragmatic trial. The treatment effect is di-
luted due to the use of ITT analysis (groups are compared as randomized). The actual effect 
of the intervention is a secondary analysis, and also risks being a diluted estimate, since 
other non-specific effects experienced in real-life are not controlled, such as patients chang-
ing treatments. Treatment may not be maximally effective in patients already taking medi-
cations or other interventions. 
Pragmatic trials are less suited to answering questions about modes of action because spe-
cific variables are not isolated for testing, and it is difficult to ascertain precisely to what re-
sults are attributable.  Increased resources may be needed for the larger sample sizes re-
quired.  
3.1.5 Validity 
A key consideration when selecting a trial design, briefly mentioned above, and defined in 
section 1.5.4, is validity. This issue is further explored here, particularly regarding relevance 
to pragmatic and explanatory trials of interventions for ADHD. Ideally a trial is well balanced 
in terms of its internal, external and ecological validity, however, in practice there is a trade-
off and inevitable tension between these three. For example, there is inevitably some 
sacrifice of internal validity in a pragmatic trial to achieve greater generalisability; and some 
sacrifice of external and/or ecological validity to achieve greater internal validity. 
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Contributors to poor external validity according to the PRECIS tool for assessment of degree 
of pragmatism (Loudon, 2015) are: eligibility criteria, recruitment, setting, organisation, flex-
ibility (delivery), flexibility (adherence), follow-up, primary outcome, and primary analysis. 
Contributors to poor internal validity according to the Cochrane tool for assessment of risk 
of bias, are: selection bias, performance bias, detection bias, attrition bias and reporting bi-
as (Higgins, Gøtzsche, & Jüni, 2011). Contributors to poor ecological validity vary according 
to the intervention tested. 
Systematic reviews generally assess internal validity, but rarely assess external or ecological 
validity, and if they do, do so as a secondary consideration. There is no similarly well-
integrated tool for their assessment. Examples of tools assessing external validity are: 
(Downs & Black, 1998): PRECIS (Loudon, 2015) and RITES (Wieland, et al., 2017). 
Next, I will discuss the different types of validity with relation to ADHD research and the two 
interventions selected to be tested. 
3.1.6 External validity 
There will always be problems moving between the group and the individual. A criticism 
levelled at pragmatic trials is that by having broad inclusion criteria, it is not possible to 
know specifically to whom results apply (Torgerson & Torgerson, 2008). However, conduct-
ing sub-group analyses can address this, and it is arguably a greater problem that interven-
tions are not tested on populations that they are then applied to. For example, the most 
common exclusion criteria in trials of methylphenidate (according to data extracted from 
the appendix of the most recent Cochrane meta-analysis of the benefits and harms of 
methylphenidate) (Storebo, et al., 2015) are tic disorders, autism, low IQ, anxiety, and a his-
tory of substance abuse. But it is common for those with ADHD to have psychiatric disorders 
(Schmidt & Petermann, 2009), autism (Gillberg, et al., 2004); and tics (Ronald, Simonoff, 
Kuntsi, Asherson, & Plomin, 2008). Storebo, (2015) found that 16/38 parallel group and 
14/147 cross-over trials excluded children and adolescents with any other co-occurring di-
agnosis, despite at least 40% of those with ADHD having co-occurring diagnoses (section 
2.1.2). 
Ensuring representative participants in trials of interventions for ADHD where we want the 
results to be generalizable, requires as broad a representation of the condition as possible. 
This means representation within all the troublesome spheres where ADHD manifests, such 
as the criminal justice system, special schools, social work and all social strata. It also means 
allowance of any co-occurring diagnoses. Effort may be required to ensure that breadth of 
condition is represented: for example, specifically trying to recruit hard to reach, at risk 
populations. 
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Setting and organisation can contribute to poor external validity. Consent procedures for 
trials may be onerous and daunting, and contribute to recruitment difficulties per se, as well 
as not recruiting representative populations. Failure to recruit is an identified problem. For 
example, the Shire study (Peasgood, et al., 2016) planned 1,000 and recruited 450.  My case 
series (described in section 4.3), recruited all intervention participants but only 50% of 
planned control participants. An ongoing RCT (Brulé, 2016) has had to double expected re-
cruitment time. Simple consent procedures mirroring real-life health care may improve re-
cruitment of those most in need but not generally engaged with services or research.  
3.1.7 Ecological validity 
The ecological validity of interventions is prioritised when a pragmatic design is used. 
Ecological validity has historically been a particular problem for CAM research: trials at-
tempt to measure the effects of an ‘active’ ingredient by isolating variables and not ac-
knowledging their interactiveness.  
For the therapeutic modality of homeopathy to be applied according to its core principles, it 
needs to include the principles of the potentiation, similitude and individualisation (section 
4.1.4) (Relton, O'Cathain, & Thomas, 2008). The majority of homeopathy trials (217/267, 
82.5%) are placebo-controlled, testing the efficacy of standardised homeopathic products, 
without applying core principles. Just 5.3 % (14/267) test the effects of homeopathic treat-
ment in clinical practice (Mathie, Hacke, Clausen, Nicolai, & Riley, 2013).   
For a rounded nutritional approach to be applied, all the identified influential elements of 
that approach need to be present, such as dietary inclusion, exclusion and supplementation. 
To date, trials have assessed elements of nutrition separately, assessing exclusion diets, in-
clusion diets, and individual or multi-nutrients. Researchers agree that separately these 
cannot address the nutritional issues associated with those with ADHD (Chapter 5). 
3.1.8 Internal validity 
Randomisation is a core contributor to internal validity since it ensures any allocation biases 
are eliminated at baseline by unbiased selection of participants to each group based on 
chance, with potential confounders randomly distributed across groups. Whilst a limitation 
of randomisation is that it is based on probability, so it cannot be assumed that groups will 
be similar, it is considered one of the most powerful research tools (Torgerson & Torgerson, 
2008).  RCTs are considered the best study designs by NICE although in their absence, inter-
nally/externally controlled before and after trials, and interrupted time–series may also be 
considered (NICE, 2008). Studies such as my comparative case series (Fibert, Relton, Heirs, & 
Bowden, 2016), where groups were allocated consecutively, are considered at risk of bias. 
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Pragmatic trials are at risk of performance and detection biases since knowledge of 
allocated interventions by participants and some personnel is inevitable when blinding, 
sham comparators or placebos are not used.  Whilst Higgins states that “it would not be 
reasonable to consider the trial as low quality because of the absence of blinding” (Higgins, 
Gøtzsche, & Jüni, 2011), nonetheless, they routinely are. 
Expectation bias is an issue when measuring carer-rated outcomes, as frequently occurs in 
non-pharmacological ADHD research. Carers may inevitably know the intervention status of 
their child and outcomes influenced by their knowledge of, and involvement in that inter-
vention. Expectation bias can be addressed in a variety of ways: questionnaires can ascer-
tain carers’ expectations of treatment; outcomes may be measured by a different assessor 
who is blind to treatment status (such as a teacher or other health professional); objective 
outcomes such criminality, school attendance and/or disruption and associated costs, not 
subject to observation biases can be measured. Hawthorne effects - knowledge that 
participants are in a trial - may also modify behaviour and contribute to reduced internal 
validity.  
In ADHD research, debate surrounds the blinded and unblinded collection of outcomes. For 
example, it was found that non-pharmaceutical intervention results are strongly influenced 
by whether outcomes were blinded, leading to the conclusion that unblinded assessments 
may be inﬂated because raters have an investment in treatment success because the carers 
supplying assessments were directly involved in treatment delivery (Sonuga-Barke, et al., 
2013). However, there are also difficulties with using blinded teacher reports: they are diffi-
cult to procure because of teachers’ workloads; multiple teachers work with the same stu-
dent; teachers may not observe subtle behaviour changes in large classrooms; some behav-
iours may be inhibited in classrooms; and school holidays (Biederman, Faraone, Monuteaux, 
& Grossbard, 2004).  
An emerging viewpoint is that reliance on blinded outcomes only gives a partial view of the 
value of health care, and that the impact of health on wellbeing should also be measured, 
by asking patients themselves. Patient reported outcome measures (PROMs) are being sug-
gested to become the new currency for comparative assessment of clinical care by 
European decision makers (Coulter, 2017). There are however, some problems associated 
with asking ADHD children directly, which are discussed in section 3.4.5. 
Resentful demoralisation may occur when participants have a strong preference for an 
intervention and/or are allocated an intervention they didn’t want, therefore provision of 
equally attractive alternatives is aimed at. Treatment by homeopaths is likely to be a less 
attractive option than treatment by nutritional therapists due to its reduced acceptability.  
High rates of loss to follow up, attrition and non-adherence are contributors to dilution of 
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the treatment effect and an important source of bias. These are likely to be higher in 
pragmatic trials due to less tight control,and broader inclusion criteria. There may be a 
specific issue in ADHD populations where attrition from studies occurs, and chaotic 
parenting and lack of long-term planning and commitment can be a feature.  Larger sample 
sizes may be required to compensate for this. 
3.1.9 Therapist effects 
When assessing the effectiveness of treatment by therapists any effects found may parsi-
moniously be attributed to the therapist rather than the therapy. A personal discussion with 
the Director of Guidelines at NICE revealed a preference for drug treatments because of 
confidence that the results obtained in placebo-controlled trials pertained to the action of 
the tested drug and not the therapist delivering it. He was also concerned with the repro-
ducibility of interventions delivered by therapists. This section discusses some possible anal-
ysis and design strategies to address this concern. 
 Explanatory trials control for therapist effects, but pragmatic trials do not necessarily. The 
concern is that outcomes may be clustered according to therapist which can lead to inflated 
standard errors, p‐values, wider confidence intervals, reduction in the effective sample size, 
and reduction in the power of the study. 
Potential strategies to manage this are to perform cluster level analysis comparing the mean 
outcome per cluster; use a random effects approach; use a population-averaged approach 
with coefficients estimated using generalised estimating equations (GEEs); or ignore the 
clustering and use statistical methods and models that assume the outcomes are independ-
ent (Walters, 2010). Walter’s comparison of these approaches found little difference be-
tween the estimates of the regression coefficients for the treatment effect and confidence 
intervals for the continuous outcomes. Therefore suggests that the marginal model (that is 
the average difference in treatment effect between intervention and control groups) should 
be chosen as this best answers the research question. 
However sub-group analysis of participants nested within therapists, using a random effects 
approach would also be useful, but this requires larger sample sizes, which needs taking into 
account for power calculation. Treatment by a homeopath and treatment by a nutritional 
therapist are both therapist led interventions. Because therapist effects are an issue for 
NICE, I will now explore some possible design solutions. In my case series homeopathic 
treatment was compared with similar time and attention (Fibert, Relton, Heirs, & Bowden, 
2016). I visited control families and had an empathetic chat with them of a similar duration 
to the homeopathic consultations. Another solution is to conduct multiple trials of therapist 
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led interventions using the same population and trial design. In this way, therapist effects 
are held constant. 
A third solution might be to use multiple therapists, and/or to randomly select them from a 
pool of therapists, which can reduce the influence of individual therapists on the outcome 
(MacPherson, 2004) and address the concern with reproducibility. Describing the interven-
tion and its components using checklists such as those created by Mohler et al. (2012), and 
Hoffmann et al. (2014) can also be helpful. Checklists include the name of  the intervention; 
the rationale of essential elements; the materials, training and venue; the procedures used 
and who provided them (expertise, background, and training); the mode of delivery (indi-
vidual or group); the location; the number of sessions, over what period of time, schedule, 
duration, intensity, or dose; any individual tailoring (what, why, when, and how); any modi-
fications during the course of the study; levels of adherence (how and by whom, and any 
strategies to maintain or improve fidelity); and finally, the extent to which the intervention 
was delivered as planned. 
3.1.10 Explanatory and pragmatic trials of interventions for ADHD  
The status of ADHD pharmaceutical medication trials mirrors that of trials in general, in that 
we have substantial explanatory information about the efficacy of pharmaceutical interven-
tions for children with ADHD, but lack sufficient information about their real-life application. 
In the absence of pragmatic trials, evidence from the explanatory trials dominates evalua-
tions and decision making: almost all trials of methylphenidate compare it to a placebo and 
are less than six months duration (average duration 75 days) (Storebo, et al., 2015). Reliance 
on such trials is likely to be affecting the quality of decision making, for example by selection 
of an intervention lacking evidence of long-term effectiveness, and non-selection of inter-
ventions that can’t be tested using explanatory designs.  
Comparing the evidence for the effectiveness of the two types of mainstream intervention 
used to treat ADHD to improve long-term outcomes is difficult: drug trials tend to be tested 
in tightly controlled conditions, and compared to placebos, whereas trials of behaviour 
change programmes tend to be tested as experienced in practice, and compared to usual 
care. This means the two types of trials are more/less tightly controlled, have more/less po-
tential for bias, higher/lower expected effect sizes, and answer different research questions 
(section 2.3).  
Assessing the effectiveness of the two non-mainstream interventions selected to be tested 
is also difficult. What RCT evidence there is compares aspects of the interventions, for ex-
ample, a homeopathic remedy, or a nutritional supplement, with placebos. This information 
is unhelpful to stakeholders wanting to know if interventions improve outcomes because: 
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the homeopathic remedy should ideally be individually tailored; and it is unlikely that any 
one nutrient is a panacea. 
Treatment by a homeopath and treatment by a nutritional therapist are both delivered by 
therapists. Both conduct consultations of similar duration and provide pills (supplements or 
homeopathic remedies) to be taken in between consultations. Therefore, several variables 
which may parsimoniously considered the ‘active’ ingredient (the time and attention of an 
empathetic therapist; ingestion of a pill), are held constant across the two therapies. A big 
difference is that the two interventions are not similarly acceptable, since homeopathy as a 
therapeutic system is largely discredited in the UK, whilst a nutritional approach is gaining 
credence and already recommended by NICE.  
3.1.11 Comparing explanatory and pragmatic approaches in ADHD research 
The current system is inefficient, with trials conducted separately, one at a time, at great 
expense, providing information to stakeholders which may not translate into real-life. Be-
cause trials are conducted in different, often unrepresentative research populations it is dif-
ficult to be confident that results pertain to all those with ADHD.  
There are difficulties comparing the effectiveness of the two types of mainstream interven-
tions used because the levels of evidence generated are dissimilar. The level of control ex-
erted in a study influences the magnitude of the effect (Gold, et al., 2017). Pragmatic trial 
results are likely to be compared unfavourably with explanatory trial results.  Pragmatic tri-
als are likely to measure diluted specific treatment effects, and exert less control, so the ef-
fect size is less than in an explanatory trial. 
On the other hand, it is common to see a falling off of effect in clinical practice of the results 
of explanatory trials, which suggests that effect sizes in more explanatory trials may be in-
flated compared to their effect in clinical practice. It may be that the evidence generated is 
the same, but the difference measured concerns the degree of pragmatism of the trial de-
sign. This situation is pertinent to the two main interventions for ADHD: behavioural (tested 
using pragmatic designs) and pharmaceutical (tested using explanatory designs).  
Whilst both explanatory and pragmatic trials have a role to play in the development of evi-
dence based interventions, the lack of pragmatic trials is concerning, and information from 
such trials needed. A further benefit of pragmatic designs is that they measure the accepta-
bility of the offer of the intervention because they use Intention To Treat analysis. This in-
formation can be particularly useful for stakeholders making treatment decisions for those 
with ADHD, since children and their families can be hard to engage, treat, and retain; evi-
dence suggests current interventions are not complied with long-term; and interpretation of 
results is therefore complicated. 
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In the next selection I will describe the potential of the TwiCs approach to address some of 
these issues. 
3.2   The TwiCs design 
3.2.1 Description of the design 
The TwiCs design was outlined in section 1.1. Its essential features and novelty are de-
scribed below, using diagrammatic and explanatory information extracted from the intro-
ductory paper by Relton, O'Cathain, Nicholl, & Torgerson (2010). 
The ‘cohort multiple randomised controlled trial’ design, now known as ‘Trials within Co-
horts’ (TwiCs), firstly recruits a large observational cohort of patients with the condition of 
interest (N) (Figure 1) and regularly measures their outcomes. For each randomised con-
trolled trial, information from the cohort is used to identify all eligible patients (NA). Some 
eligible patients (nA) are randomly selected and offered the trial intervention. The outcomes 
of these randomly selected patients (nA) are then compared with the outcomes of eligible 
patients not randomly selected; that is, those receiving usual care (NA − nA). This process 
can be repeated for further randomised controlled trials (for example, NB). 
Figure 1. The cohort multiple randomised controlled trial design (Relton, O'Cathain, Nicholl, & 
Torgerson, 2010) 
 
The design has several innovative features: recruitment of an observational cohort of pa-
tients to be used as a multiple trials facility; random selection of some rather than all partic-
ipants; and patient centred information and consent procedures. It is best suited to trials 
where treatment as usual is compared with the offer of treatment; outcomes can be easily 
measured and collected; and conditions where many trials will be conducted. 
3.2.2 Use of TwiCs 
TwiCs methodology was piloted in the homeopathic treatment of menopausal women 
(Relton, 2009) and is currently being used in multiple funded trials and studies 
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(https://www.TwiCs.global/). Cohorts have been set up for conditions such as cancer, scle-
roderma, lower back pain, mesothelioma, depression and HIV. Non-condition-specific co-
horts have been set up in populations such as those born in Bradford, living in Yorkshire, 
and attending Toronto SickKids hospital. Cohorts of specific at-risk populations have been 
set up such as the offspring of those with severe mental illness, those attending hospital 
with violence related injuries, those with skull deformation, the elderly, and those using 
drugs. A wide variety of interventions are being trialled in these cohorts, such as: podiatry to 
prevent falls in the elderly; stereotactic body radiotherapy for those with spinal metastases; 
exercise for those recovering from breast cancer treatment; and parenting courses for those 
with severe mental illnesses.   
It has grown quite fast in the field of clinical research into the effectiveness of homeopathic 
treatment. Its effectiveness in three clinical areas has been tested: Irritable Bowel Syndrome 
conducted within the IBS cohort at Barnsley NHS Foundation Trust Hospital (Peckham, et al., 
2014); long-term depression, conducted within the South Yorkshire Cohort (Viksveen, 
Relton, & Nicholl, 2017); and menopausal hot flushes (Relton, O'Cathain, & Nicholl, 2012), 
where the cohort was specifically recruited. It has thus far not been utilised for research into 
nutritional interventions or ADHD. 
Use of TwiCs for children 
TwiCs methodology is being used in several studies aiming to improve long-term outcomes 
in cohorts of children in Canada, the Netherlands and the UK. There are four studies using 
the TwiCs design in Canada, with trials being conducted testing whether interventions re-
duce long-term negative outcomes. FORBOW (Families Overcoming Risks and Building Op-
portunities)  recruits a cohort of offspring of parents with severe mental illness and aims to 
test multiple interventions to reduce their risk of developing mood or psychotic disorders 
(Uher, et al., 2014).  The CEDAR Project is recruiting a cohort of young indigenous people 
who use drugs in Canada and testing the impact of mHealth (health care via mobile phones) 
to see if it reduces their risk of developing HIV.  
TARGet Kids! (The Applied Research Group for Kids) is the third Canadian cohort of children. 
It enrols children aged 0-5 years who visit the SickKids Hospital in Toronto, with the aim of 
linking early life exposures to health problems including obesity, micronutrient deficiencies, 
and developmental problems by conducting research within the cohort 
(http://www.targetkids.ca/our-research). TARget started off as an observational study and 
conducted several trials using standard approaches to informed consent. It is now convert-
ing the cohort so studies can be conducted using a TwiCs approach, and is in the process of 
receiving approval for the first trial testing full fat or semi-skimmed milk to prevent obesity. 
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The fourth Canadian cohort is a cohort of youth visiting the emergency Department of Man-
itoba hospital in Alberta, Canada with a violence related injury, which is a particular problem 
in this province. Youth are recruited to the cohort on admission, and then randomised to a 
trial of intensive, wraparound care, initiated at the time of their visit, whilst the control arm 
receive standard care.  
HEADS (HElmet therapy Assessment in infants with Deformed Skulls) is a cohort of children 
with skull deformation in the Netherlands. An RCT embedded within the cohort is testing 
the effectiveness of Helmet therapy (van Wijk, Boere-Boonekamp, Groothuis-Oudshoorn, an 
Vlimmeren, & Jzerman, 2012).   
BIBBS (Born in Bradford Better Start Study) has received £49 million in Big Lottery funding to 
recruit 5,000 babies, and their mothers, and mother's partners, living in Bradford, and im-
plement 22 interventions for children aged 0-3, aimed at improving health and social out-
comes in social and emotional development; communication and language development; 
and nutrition and obesity (Dickerson, et al., 2016). 
Ethical approval for TwiCs 
Patients, clinicians and NHS Research Ethics Committees have found the TwiCs design to be 
acceptable: key findings from an international symposium on the ethics of the design 
(Relton, et al., 2017) were that it is possible to make the case to ethics committees that 
TwiCs designs are appropriate and ethical. Some bioethicists argue that the design may in-
deed be ethically superior to previous post-randomization consent designs and can have 
important advantages over traditional trial designs (Kim, Flory, & Relton, 2017).  
3.2.3 Differences between TwiCs and standard designs 
The design differs in terms of recruitment, capacity for multiple trials and the process of ob-
taining consents. Recruitment procedures are different in that participants are initially re-
cruited to a cohort where they are generally not told about treatments they might not re-
ceive, or that any treatment they are offered was allocated by chance.   
The process of obtaining patient information and consent aims to replicate that in real-
world routine health care rather than address the needs of trial design. All cohort patients 
consent to provide observational data at the outset; however, consent to try a particular 
intervention is sought only from those offered that intervention. This replicates routine 
health care where clinicians provide patients with the information they need at the time 
they need it. (Relton, O'Cathain, Nicholl, & Torgerson, 2010). This attempts to tackle issues 
associated with standard designs such as those outlined in section 3.1.8. For example, pa-
tients not randomly selected act as a virtual treatment as usual (TAU) control group, so are 
 79 
not aware of having missed out, which addresses the issue of resentful demoralisation. The 
capacity for multiple randomised controlled trials over time using patients from the same 
cohort is unique to the design.  
3.2.4 Advantages of the TwiCs design 
The TwiCs design has the potential for multiple trials which can be conducted long after this 
PhD is completed, providing ongoing, objective information to stakeholders. Long-term 
outcomes are collected as standard which can provide ongoing information about the 
natural history of the condition and usual care, as well as increased comparability between 
each trial conducted within the cohort. This is an improvement over trials conducted using 
current randomised controlled trial designs, which trial interventions one at a time and 
struggle to compare them. All treatments have the same ‘treatment as usual’ comparator 
and assess the same core outcomes. As such it has the potential to answer important out-
standing questions about the long-term effectiveness of current interventions for ADHD, as 
well as provide preliminary evidence about the non-mainstream interventions tried by car-
ers. Furthermore, when a variety of interventions are compared using the same design, bi-
ases such as Hawthorne effects, expectation and other biases are equally distributed across 
groups.  
A further advantage is its combination of robust design and pragmatism, providing robust 
evidence which clinicians can apply to their usual clinical populations. Running multiple tri-
als is relatively cheap once the cohort is set up, and multiple interventions can be compared 
cheaply and efficiently according to similar criteria. Unequal randomisation with larger 
numbers in the usual care group can enable adequately powered trials to be run more 
cheaply by saving on treatment costs.  
Recruitment may be increased since those recruiting to the cohort have no further 
expectations. The potential for reporting bias may be reduced when using TwiCs methodol-
ogy in comparison with other pragmatic RCT designs, because control participants do not 
know that they serve as control participants. Reporting biases can only occur in the 
experimental arm (van der Velden, et al., 2017).  
It has already been demonstrated that the TwiCs design is suitable for capturing the effects 
of homeopathy. Furthermore, data on treatment refusers provides information on the 
acceptability of treatments and thus the generalisability of the trial results. 
3.2.5 Disadvantages of the design 
Only participants allocated to the intervention arm are asked for informed consent, which 
happens after they have been randomised to the intervention. An identified problem is that 
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these participants may then refuse the intervention being trialled, resulting in crossover 
from the treatment to the usual care arm, and dilution of any treatment effects due to the 
use of ITT analysis. The proportion of non-compliance in the experimental arm is expected 
to be higher in the TwiCs design compared with traditional RCT designs (van der Velden, et 
al., 2017). This may particularly affect trials testing unpopular, time-consuming or inconven-
ient interventions. 
All the criticisms levelled at pragmatic designs discussed in section 3.1.4 pertain to the use 
of the TwiCs design. 
3.3   The suitability of the TwiCs design to test the effectiveness of interventions to 
improve outcomes for those with ADHD 
I have identified that a pragmatic (v explanatory) trial of effectiveness (v efficacy) measuring 
real-world outcomes of interest (v surrogate markers, or just ADHD symptoms) is required, 
to test whether interventions improve outcomes for children with ADHD, and evaluate 
whether they provide a cost-effective way to augment incomplete symptom relief, improve 
long-term negative outcomes, and inform decision makers.  
Due to the range of potential treatments being used for ADHD, there is a need for multiple 
trials which can be cheaply and efficiently performed. Such trials must be capable of testing 
and comparing any type of treatment as experienced in the real-world, such as therapist 
led, whole system, and/or complex interventions as well as pharmaceutical drug treat-
ments.  
The TwiCs design fulfils these key requirements, which are discussed in more depth below. 
3.3.1 A trial design suitable to test multiple interventions. 
Aggregation of data from clinical trials of different therapeutic approaches plays an im-
portant role in clinical decision making, treatment guidelines, and health policy. Trial design, 
comparator choice and degree of pragmatism all influence the levels of evidence generated 
(Gold, et al., 2017). Comparing designs which generate similar levels of evidence, are simi-
larly pragmatic, and share the same comparator, allows different therapeutic approaches to 
be more easily compared. Conversely, as occurs currently, and as described in section 3.1, 
comparing interventions via studies generating different types and therefore levels of evi-
dence leads to the risk of type 2 errors (failure to detect an effect that is present). 
A design which tests multiple interventions keeping levels of control and other design fea-
tures the same across studies can provide useful comparative information to stakeholders. 
There is an unmet need for research exploring the long-term outcomes of those with ADHD. 
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TwiCs methodology is demonstrating that it can usefully be employed in cohorts of children 
at risk of negative outcomes, and embed preventative intervention trials.  
3.3.2 A design suitable to test the effectiveness of any kind of treatment 
Designs need to be suitable to assess the effectiveness of single element interventions such 
as drugs and supplements, and therapist led interventions such as behavioural programmes 
and holistic interventions, since these characterise both conventional and unconventional 
approaches being used by families. 
Interventions with interacting components are difficult to blind, standardise, reproduce and 
assess. The network of key components of the intervention must be represented; 
interventions tailored to patient’s individual needs can only be standardised to a limited 
extent; practitioners, participants or families (who are often assessors) cannot be blinded 
because they are essentially involved in delivery; and reproduction may be difficult because 
not only are interventions individually tailored, they are also influenced by practitioner 
expertise. Testing them as experienced in the real-world mitigates for these problems. 
The only way to objectively compare different types of interventions such as 
pharmaceutical, behavioural, and/or holistic interventions, is to compare their effectiveness 
in real-world clinical practice. A design suitable to assess the efficacy of pharmaceutical 
medications is not suitable to assess the efficacy of most other interventions. But a 
pragmatic design can test the effectiveness of any kind of intervention as experienced in 
clinical practice. 
For example, most trials of pharmaceutical drugs control for the impact of many non-
specific factors: by using identical placebo treatment comparators; blinding participants, 
physicians and investigators; having tight inclusion/exclusion criteria; and testing over short 
time spans which reduces attrition, regression to the mean, and the effects of life events.   
Behavioural intervention trials by comparison cannot easily control for the impact of these 
factors, and both intervention and comparator groups are more likely to be influenced by 
extraneous variables. They cannot use placebo comparisons, cannot blind participants or 
physicians, nor can they test over short time periods (since interventions take at least 8 
weeks to administer). Trials of behavioural interventions instead try to measure the efficacy 
of their interventions by controlling factors such as: clinician expertise, programme fidelity, 
exclusion of participants unlikely to benefit, managing child behavioural and developmental 
factors, and maternal and demographic factors (Daley & O'Brian, 2013). 
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3.3.3 A trial design suitable to assess the effectiveness of treatment in real-world 
populations 
Stakeholders need to know how effective interventions might be for real-world populations: 
families need to know whether it is worth their while investing their time and resources on 
them; commissioners need trials with real-world populations, including those generating 
negative outcomes, to decide whether treatments are worth commissioning.  
Trials run in reduced populations are likely to be unrepresentative of clinical populations, 
thus excluding many of those who will use the intervention. Those excluded are often those 
most in need, such as substance users and those with low IQs. If a design is to assess wheth-
er outcomes can be improved, it needs to specifically include rather than exclude those with 
these co-occurring diagnoses, where helpful interventions are most needed. 
Pragmatic trials with their broad inclusion criteria can provide information about whether 
efficacious interventions for children with single ADHD diagnoses are effective in popula-
tions with additional co-occurring diagnoses.  
3.3.4 A trial design which can identify and measure real-world outcomes of interest 
to stakeholders  
Improving long-term negative outcomes is a fundamental driver of this research, which aims 
to provide useful evidence to inform real-world decision making by the variety of stakehold-
ers involved in the management of ADHD. This compares with the measurement of specific 
effects or surrogate outcomes which informs understanding of mechanisms. Neither public 
health stakeholders nor patients are primarily interested in the efficacy of different compo-
nents, their mechanism of action, or the amount of change due to the patient/therapist re-
lationship. They are more interested in whether interventions might augment incomplete 
symptom relief and improve outcomes. As such measurement of outcomes of importance to 
policy makers, such as criminality and educational performance are needed. Selection of 
appropriate outcomes is considered later in this chapter. 
3.3.5 A trial design needs to be acceptable to stakeholders. 
For this research to be useful, I have argued that it needs to be acceptable to NICE, the na-
tional clinical stakeholder because families of those with ADHD tend to access help via the 
NHS. Local authority decision makers also rely on NHS clinicians’ guidance. NICE assesses 
which treatments produce sufficient benefit that the NHS should pay for them. Guidelines 
are advisory and do not have legal force but are very influential (Taylor, 2008).  
 83 
The 2008 Guidelines are currently being updated, for publication in 2018.  To understand 
how guidelines are devised, I read the NICE ADHD clinical practice guideline(NICE, 2008); 
attended the NICE ADHD clinical guideline update workshop on Nutrition (Hopkins, 2015); 
and the ADHD stakeholder workshop to inform the guideline update 
(www.nice.org.uk/.../documents/workshop-notes-2). I also attended several meetings with 
Dr Gillian Leng, Deputy Director of NICE, and Professor Mark Baker, Director of Clinical 
Guidelines.  
Clinical practice guidelines (CPGs), are developed by development groups, using GRADE cri-
teria (Grades of Recommendation, Assessment, Development and Evaluation) (Higgins & 
Deeks, 2011). Clinical questions are initially identified by the CPG development group, and 
then the best design to answer each question is identified (NICE, 2008). It is therefore not 
possible for a researcher to determine a priori what a question might be and then design a 
trial to meet requirements.  
Evidence may be excluded if a trial does not fit the criteria. For example, in the guideline 
update for dietary interventions, comparisons between dietary and pharmaceutical or psy-
chological interventions were not permitted (Hopkins, 2015). The majority of studies of 
elimination diets were excluded because they were either conducted in the incorrect popu-
lation, used an incorrect comparator, an incorrect study design, lasted under 2 weeks, or 
were not in English. This left just two studies by a single author (Pelsser, Buitelaar, & 
Savelkoul, 2009) for consideration. 
About GRADE 
GRADE considers within-study risk of bias (methodological quality), directness of evidence, 
heterogeneity, precision of effect estimates and risk of publication bias. Four levels of quali-
ty are possible, with ratings downgraded depending on: limitations in design and implemen-
tation (lack of allocation concealment, blinding, large loss to follow-up, trials stopped early 
for benefit, selective reporting of outcomes); indirectness of evidence (indirect population, 
intervention, control, outcomes); unexplained heterogeneity or inconsistency of results 
(studies yield widely differing estimates of effect); imprecision of results (wide confidence 
intervals, studies include few participants and few events); or high probability of publication 
bias (investigators fail to report studies or outcomes that show no effect). 
GRADE assessments can be interpreted differently with emphasis put on different aspects, 
exemplified by GRADE assessments in three meta-analyses of methylphenidate for ADHD 
(Punja, et al., 2016) (Storebo, et al., 2015) (National Institute for Health and Care Excellence 
(NICE), 2008). Punja graded the evidence low to very low, with studies downgraded if: > 50% 
of studies had a high risk of bias; the outcome included comparisons of different ampheta-
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mine derivatives and release formulations, had significant statistical heterogeneity (I² > 
50%), or wide confidence intervals.  
Storebo also graded the evidence very low, but because it was possible for people to know 
which treatment children took, reporting of results was incomplete, or some outcomes var-
ied across trials.  
NICE graded the evidence moderate to low because studies were short, inclusion and exclu-
sion of co-existing conditions not made explicit, most studies compared drugs with place-
bos, and adverse events were reported infrequently and poorly. These three analyses 
demonstrate that despite the aim of objectivity and clarity in assessment of the evidence, 
results are still subject to interpretation. Largely similar conclusions regarding the levels of 
evidence were reached, but for different reasons. 
NICE guidelines for ADHD 
NICE considers that best available evidence should take account of clinical and cost effec-
tiveness and the patient perspective. Outcomes can be: quality of life, ADHD symptoms, 
cognitive outcomes, functional status, mental health, peer relationships, academic out-
comes, family relationships, self-esteem, care needs, safety, and perceived control of symp-
toms. Comparators can be waiting list, no treatment, usual care, or a placebo intervention. 
Studies can be RCTs and systematic reviews, and interventions needed to have a GRADE de-
fault minimally important difference of -0.5/0.5 standard deviations for continuous out-
comes. 
Cost effective interventions are those offering health gains per £ spent compared to the 
best alternative, calculated by estimating the ratio between the cost of the intervention 
(expressed in £’s) and the benefit produced in terms of years lived in full health (expressed 
in Quality Adjusted Life Years (QALYs). NICE’s ‘threshold,’ over which treatments are less 
likely to be recommended, is between £20,000 and £30,000 per QALY. There was no de-
scription in the guidelines of how the patient perspective should be taken into account. 
3.4   Outcome Measurement 
This is an outcome focussed research study. The research question asks how outcomes 
might be improved for those with ADHD, with the emphasis on improving outcomes (not on 
the efficacy of interventions). Identifying important outcomes and how to measure them is 
the topic of this section. Acceptable measures to NICE (section 1.5.3, NICE, 2008) are quality 
of life, ADHD symptoms, cognitive outcomes, functional status, mental health, peer rela-
tionships, academic outcomes, family relationships, self-esteem, care needs, safety, and 
perceived control of symptoms. 
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When using the TwiCs methodology, measurement needs to be as un-burdensome as possi-
ble, via easy and quick to complete questionnaires collecting important information simply 
and efficiently.  
Outcome measures need to be appropriate to measure change from four perspectives: (1) 
that of the condition being tested; (2) that of the intervention being tested; (3) that of those 
most affected by the condition (the child and his/her family); and (4) that of public health 
stakeholders and decision makers.  That means (1) measuring core ADHD symptoms; (2) 
ensuring measurements are sensitive and broad enough to capture changes by the non-
specific interventions selected; (3) identifying outcomes of interest to those affected by 
ADHD and ways to measure them; and (4) identifying outcomes of importance to health 
care decision makers, and appropriate ways of measuring them. These four perspectives will 
now be considered. 
3.4.1 Measuring core ADHD symptoms  
Measurement of core ADHD symptoms is routine in clinical trials of ADHD and important for 
comparison purposes and for assessment by decision makers, although it is expected that 
successful treatment of ADHD will address not only symptomatic improvement but also 
impairment in social functioning (NICE, 2008). 
Table 7 identifies the outcome measures which have been used to measure the effects of 
conventional medication, psychological interventions, polyunsaturated fatty acids and 
homeopathy. Information was extracted from the NICE Clinical Practice Guideline (2008); 
the most recent meta-analysis of PUFAs (Puri & Martins, 2014);  and the Cochrane 
systematic review of homeopathy (Heirs & Dean, 2009). 
 Table 7. Outcome measures used in interventions for ADHD 
Systematic review Primary Outcome meas-
urement 
Secondary Measure-
ments 
Heirs & Dean (2009) Homeopathic 
remedy v placebo remedy 
CGI-Parent/Teacher, CPRS-
R:L 
VLMT, QCB, WISC, 
CPRS, CGI-T, CPT, 
ADHD-SC4, MYMOP 
NICE (2008) Pooled methylpheni-
date v placebo (N=12) 
Core ADHD symptoms 
teacher/carer. CPRS, SNAP 
? 
NICE (2008) Pooled atomoxetine v 
placebo (N=10) 
Core ADHD symptoms (to-
tal) teacher/carer. CPRS, 
SNAP 
? 
NICE (2009) Pooled psychological 
interventions v control (TAU, wait 
Core ADHD symptoms, 
CPRS, SNAP. teacher+carer-
Conduct, social skills, 
emotional 
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list, no Treatment) (N=10) rated (end of T’ment/3-6 
months post T’ment) 
Puri (2014) Pooled Polyunsaturat-
ed fatty acids (N=18) 
Conners (various), CBCL 
,RBPC,DBD Carer/teacher 
Inattention, hyperac-
tivity 
CGI-P (Conners Global Index-parent); CGI-T (Conners Global Index-Teacher); CPRS:-R:L (Conners Par-
ent rating scale, revised, long; CPRS-R:S (Conners Parent rating scale, revised, short); PSQ (Conners 
Parent symptom questionnaire); CGI-SS (clinical global impression-severity scale); CGI-IS (clinical 
global impression-Improvement scale); CCT Children’s checking task; QCB (Questionnaire of Change 
of Behaviour); VLMT(auditory learning test); WISC (Wechsler intelligence test); CPT (continuous per-
formance test); ADHD-SC4 (Stimulant Side Effects Checklist); ACTeRS (ADD-H Comprehensive Teacher 
Rating Scale); ADHD-RS (ADHD rating scale); CBCL (Child Behavior Checklist); DBD (Disruptive Behav-
ior Disorders rating scale); RBPC (Revised Behavior Problem Checklist); SNAP (Swanson, Nolan & Pel-
ham ADHD rating scale. MYMOP (Measure your own medical outcome profile). 
Conners Rating Scales. 
The most common outcome measurements identified above were Conners Rating Scales in 
various formats. Most studies used short forms, recommended by Conners for clinical trials 
(Conners, 2009). Three short measures (all available for completion by carers and teachers) 
are: the 10 item Conners Global Index (C3GI) (favoured in homeopathy studies); the 18 item 
DSM ADHD criteria (favoured in trials of fatty acids and medication); and  the 12 item 
Conners’ ADHD index (Table 8).  
The Conners Handbook states that “although in the past there have been differences in the 
psychometric properties of the Conners forms that may have led some practitioners to 
prefer one version over another, the current versions are all about equivalent in terms of 
strength of norms, reliability and validity” (p14, Conners, 2009). 
Table 8. Individual items in three short Conners ADHD measures. 
CGI-Total (10) DSMIV ADHD criteria (18) ADHD Index (12)  
Fidgeting  Fidgets with hands or feet or 
squirms in seat 
Fidgets with hands or feet or 
squirms in seat 
Leaves his/her seat at school 
when not supposed to at school 
Leaves seat in classroom or oth-
er situation where remaining 
seated is expected 
Inattentive, easily dis-
tracted 
Is distracted when things are go-
ing on around him/her 
Inattentive, easily distracted  
Distractibility/attention span a 
problem 
Has trouble keeping attention fo-
cussed when playing or working 
Gets distracted when given in-
structions to do something 
Fails to finish things 
he/she starts 
Has trouble finishing schoolwork 
or chores 
Does not follow through instruc-
tions/fails to complete HW, 
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chores, duties 
Has problems organising tasks and 
activities 
Messy or disorganised at home 
or school 
Excitable, impulsive Gives answers to questions before 
the questions are completed 
Only attends something he’s 
very interested in 
Restless or overactive Is restless or overactive Avoids/expresses reluc-
tance/has difficulties engaging 
in tasks that require sustained 
mental effort 
Is always on the go 
Disturbs other children Has trouble playing or doing lei-
sure activities quietly 
Easily frustrated in efforts 
Interrupts others when they are 
working or playing 
Cries often and easily Does not like homework where 
he/she has to think a lot 
Short attention span 
Temper outbursts; explo-
sive, unpredictable behav-
iour 
Has trouble listening to what peo-
ple say to him/her 
Has trouble concentrating in 
class 
Mood changes quickly and 
drastically 
Is forgetful in daily activities  
Demands must be met 
immediately – easily frus-
trated 
Talks too much  
 Loses things necessary for tasks 
and activities  
 
 Has trouble waiting in line or tak-
ing turns 
 
 Makes careless mistakes or has 
trouble paying attention to details 
 
It was decided to use CGI due to its measurement of emotional aspects, and since the 
measure has been used in three trials of individualised homeopathic remedies and appears 
to be sufficiently sensitive. The CGI has a two-factor structure described as rest-
less/impulsive (7 items) and emotional lability (3 items) (Conners, 2009). 
The three questions constituting the emotional lability sub-scale score are: ‘temper out-
bursts- explosive, unpredictable behaviour’; ‘mood changes quickly and drastically’; and 
‘cries often and easily’. The remaining seven questions constituting the restless/impulsive 
sub-score are: ‘excitable, impulsive’; ‘restless, overactive’; ‘inattentive, easily distracted’; 
‘fidgeting’; ‘disturbs other children’; ‘demands must be met immediately – easily frustrated’; 
‘fails to finish things he/she starts’) (Conners, 2009). 
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The measure has convergent validity, correlating with other measures of psychopathology 
and the Conner’s ADHD Rating Scale (Kao & Thomas, 2010), and discriminative validity, ac-
curately distinguishing between the general population and those with ADHD (Conners, 
2009). 
Swanson, Nolan & Pelham Questionnaire (SNAP-IV) 
This questionnaire is similar to Conners 18 item DSM criteria, but much cheaper. It was 
developed by MTA researchers and the psychometric properties and clinical utility of the 
SNAP-IV have been demonstrated in multiple studies since its introduction in 2001 (Bussing, 
et al., 2011). SNAP-IV was added after the study had been running for 6 months, on the 
advice of the steering committee chairman, who suggested that CGI scores may not be 
considered adequate indications of specific ADHD improvement. 
The SNAP-IV 18 item scale consists of DSMV ADHD items Inattention (items 1-9) and 
hyperactivity/impulsivity (items 10-18). Symptom severity is rated on a 4 point scale. The 
average is calculated by totalling the scores and dividing by the number of items for each 
subset. Scores below 13 (out of 27)  are not considered clinically significant; between 13 and 
17 considered mild symptoms; 18-22 moderate symptoms; and 23-27 severe symptoms. 
3.4.2 Completion of outcome measures  
Although pragmatic trials do not generally collect blinded outcomes, the decision was made 
to collect outcomes from both carers and (probably blinded) teachers. The term ‘probably 
blinded’ was used because there is a small chance teachers may ascertain the child’s status 
anecdotally. Measurement of blinded outcomes was considered important due to concern 
about ascertainment biases, and despite concern that measuring teachers’ observations 
over the long-term may be problematic: teachers change and schools have holidays 
(Biederman et al., 2004); return of questionnaires is poor (Brazier, et al., 2014); teachers 
may not observe the kinds of changes expected; busy teachers in large classrooms may not 
observe subtle changes. Therefore the  feasibility of collecting and using blinded teacher 
outcomes was assessed. 
3.4.3 Measures of importance to those directly affected by ADHD 
Cunningham (2007) argues that measurement of adaptive function is important and a better 
predictor of impact on long-term outcomes than ADHD symptoms. It can be measured via 
the Home situations questionnaire (DuPaul & Barkley, 1992), the Impairment Rating Scale 
(Fabiano, Pelham, & Waschbusch, 2006), or the Strengths and Difficulties Questionnaire 
(SDQ) (Goodman, Lamping, & Ploubidis, 2010) which categorizes strengths and difficulties 
into five scales: emotional problems, conduct problems, hyperactivity, peer problems and 
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prosocial behaviour. It is one of the most widely used brief questionnaires for assessing 
child mental health problems. 
It was important to measure emotional lability, as an important driver of negative outcomes 
of those with ADHD (Young, Taylor, & Gudjonsson, 2016). Measurement is possible via a 
sub-set of the SDQ (5 items) or the CGI (3 items) described above. Another measure is the 
affective reactivity index (ARI) (Stringaris, et al., 2012) which consists of 7 items: is easily an-
noyed by others; often loses his/her temper; stays angry for a long time; is angry most of 
the time; gets angry frequently; loses temper easily; overall, irritability causes him/her prob-
lems. 
The decision was made to use the emotional lability subscale in the CGI and not add the 
SDQ, ARI or an adaptive function questionnaire as a further measure, in order to reduce the 
questionnaire filling burden on participants.  
3.4.4 Objective Measures of importance to decision makers 
Decision makers are concerned about the use of state funded facilities such as the NHS, so-
cial care, criminal justice system, and education. It was decided to ask participants about the 
number of visits to these institutions, any psychosocial interventions they had taken part in, 
and about all the medications taken by the child. 
Criminality might also be measured by accessing official criminal records obtained from the 
Ministry of Justice; using the YCAP validated outcome measure; or real-life measurements 
of numbers of arrests, convictions, aggressive offences, felony charges, incarcerations, re-
offence rates. However, it was decided that such detailed questions might be off-putting to 
carers; and the process of obtaining the permissions required to access criminal records too 
time consuming at this stage, but may be considered in the future. 
ADHD has a high impact in schools, so it was decided to ask teachers to rate levels of class-
room disturbance, absenteeism, exclusion and extra resource use such as learning support 
assistance in the Teacher Questionnaire (Appendix 1b). Like accessing criminality records, 
accessing education records was considered too time consuming at this stage but may be 
considered in the future. 
3.4.5 Health-Related Quality of Life measurement. 
Policy makers such as NICE use preference-based measures to examine the cost-
effectiveness of interventions in terms of cost per Quality Adjusted Life Year (QALY). A vali-
dated quality of life measure is needed to generate QALYs. Furthermore, Health Related 
Quality of Life (HRQOL) is increasingly recognised as an important outcome in itself. It is de-
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fined as “an individual's subjective perception of the impact of health status, including dis-
ease and treatment, on physical, psychological, and social functioning”. (Leidy, Rich & Gen-
este, 1999) and most appropriately assessed from the patient's perspective (Coghill, 2011). 
The rationale is that assessment of the patient's perspective provides insights into treat-
ment benefits that may be obscured when filtered through the clinician's perspective 
(Coghill, 2011); and that since what people care about is their wellbeing and ability to play 
an active role in society, that’s what should be measured (Coulter, 2017). 
There are several problems associated with measuring HRQOL in children. These include the 
influence of age related language development, reading ability and conceptual understand-
ing. Reading ability influences whether children can complete questionnaires (Rebok, et al., 
2001). Age has an effect on understanding of concepts: aged between 4 and 6 children can 
report about concrete domains like pain and medication use, whereas only older children 
can describe the emotional impact of their illness (Wallander, Schmitt, & Koot, 2001).  
Proxy-reported outcome measures for children are discouraged (Food and Drug 
Administration (FDA), 2009), due to concerns about the concordance between proxy and 
child ratings (Theunissen, et al., 1998). However, almost all paediatric psychopharmacology 
trials measuring HRQOL use carer-rated measures. ADHD seriously compromises HRQOL ac-
cording to carers, with robust negative effects reported consistently which rate the HRQOL 
of their children as 1.5 - 2 SD below appropriate population norms (Coghill, 2011). Children 
with ADHD rate their own HRQOL less negatively than their carers and sometimes do not 
consider themselves as having impaired HRQOL (Coghill, 2011). 
Since it is recommended that HRQOL outcomes are included in treatment studies (Coghill, 
2011), it was decided to include a HRQOL measure. It is argued that HRQOL outweighs sim-
ple short-term symptom reduction as the most important treatment outcome for ADHD; 
and such outcomes are used to generate cost-effectiveness estimates. It was decided to use 
proxy ratings: due to the wide age range included in this study; since the other outcomes 
are completed by carers; and since proxy HRQOL is measured in the majority of ADHD re-
search. Which measure to use is considered next.  
HRQOL measures 
Examples of HRQOL measures used in studies of medication are: AIM-C (Manos, Frazier, & 
Landgraf, 2009), CHQ (Child Health Questionnaire) (Landgraf, Abetz, & Ware, 1999), CHIP-CE 
(Child Health Illness Profile-Child Edition) (Prasad, Harpin, & Poole, 2007), GIPD (Global Im-
pression of Perceived Difficulties) (Wehmeier, Schacht, & Barkley, 2010), PedsQL (Pediatric 
Quality of Life Inventory) (Varni & Burwinkle, 2006). One ADHD specific measure of HRQOL 
has been developed (ADHD Impact Module (AIM)) (Landgraf, 2007) but is specifically for 
adults with ADHD.  
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Studies investigating the impact of medication treatments on HRQOL in ADHD support a 
positive short-term effect of medication (largely atomoxetine) that to some extent mirror 
their effects on ADHD symptoms (Coghill, 2010). No ADHD clinical trials of psycho-social 
treatments, homeopathy or nutrition measuring HRQOL were found. 
It was decided to use the HRQOL measure Child Health Utility (CHU 9D) which was devel-
oped in Sheffield (Stevens, 2010), on the advice of Sheffield based researchers who have 
used it in an ADHD study (Peasgood, et al., 2016). They compared CHU 9D, EQ-5D-Y, (using 
the adult tariff), and the Weiss satisfaction scale. They recommended CHU 9D but with res-
ervations, since they had a lower response to CHU 9D than EQ-5D-Y. This was driven by 
question 6 on school and home work: my child has no/a few/ some/ many problems / can’t 
do their homework today, which mostly adolescents failed to answer. The measure was 
completed by the child, and it was hypothesised that word 'today' was taken literally when 
it might be a weekend, day off, the child excluded from school or not receiving homework.  
The researchers did not recommend EQ5D despite a large effect size driven by issues with 
self-care/dressing/washing, because although the children reported fairly high levels of 
problems, it was felt that these were different to those considered when the tariff was de-
rived: children with ADHD have difficulties due to reluctance and difficulty following instruc-
tions rather than physical impairment. Their study identified a high level of sleep problems 
and they recommended inclusion of a question about sleep. One item in CHU 9D asks about 
sleep and it was decided to analyse this separately: ‘last night my child had no/ a few/ 
some/ many problems sleeping/could not sleep at all’.  
CHU 9D 
CHU 9D is a paediatric generic preference-based measure of health-related quality of life for 
children aged 7 to 17, which was developed from qualitative interviews with school age 
children.  It has nine attributes: worried, sad, pain, tired, annoyed, schoolwork/homework, 
sleep, daily routine and able to join in activities, with five response levels for each.  
The preference weights were derived from the application of the standard gamble method 
from 300 members of the UK adult population (Stevens, 2010).  This gave estimates for the 
importance of change in one item versus change in another item and versus extending years 
of life, as perceived by adults. The tariff generated a score for each CHU 9D health state on a 
scale on which 0 is equivalent to being dead and 1 represents full health.  
The standard gamble method and valuation by adults (despite the descriptive system being 
for children) is in line with NICE recommendations (NICE, 2004). This is because it is found 
that there are challenges eliciting utility values from children (Ungar & Gerber, 2010), and 
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attempts made to value the CHU 9D with 11–13 year olds found that the standard gamble 
method did not perform well (Ratcliffe, Couzner, & Flynn, 2011). 
The original preference weights were developed to be completed by the children them-
selves, but adolescent and proxy preference weights for the CHU 9D have since been gener-
ated. 
3.5   A pilot study, a feasibility study or a full trial? 
At the start of this PhD, the plan was to conduct a full trial, building upon the pilot work of 
the case series already conducted (Fibert, Relton, Heirs, & Bowden, 2016). However, such a 
plan was considered too ambitious for a PhD, and some feasibility questions remained: 
could sufficient and suitable therapists be recruited? would the trial design be feasible and 
acceptable? could recruitment of a representative sample of children with ADHD be accom-
plished? were the selected outcome measures suitable, deliverable and acceptable? 
Therefore, a further pilot study assessing the feasibility of the design and measures was de-
signed. The distinction between a pilot study and a feasibility study is not clear cut. All pilot 
studies are feasibility studies, but not all feasibility studies are pilot studies (Eldridge, et al., 
2016). Feasibility studies ask whether something could be done, should we proceed with it, 
and if so, how? Pilot studies do the same but are smaller scale studies of future full scale 
studies. This work fulfils both criteria.  
Arain and colleagues (Arain, Campbell, Cooper, & Lancaster, 2010) define feasibility studies 
as pieces of research done before a main study to estimate important parameters needed 
to design the main study, such as: the standard deviation of the outcome measure to esti-
mate sample size; the willingness of participants to be randomised and of clinicians to re-
cruit participants; the number of eligible patients; the characteristics of the proposed out-
come measure; follow-up rates, response rates to questionnaires, and adher-
ence/compliance rates. Feasibility studies for randomised controlled trials may not them-
selves be randomised. 
A pilot study is considered to be a version of the main study run in miniature to test wheth-
er the components of the main study can all work together to ensure recruitment, randomi-
sation, treatment, and follow-up assessments all run smoothly. It may be the first phase of a 
substantive study to which pilot data can contribute (an internal pilot) or set aside (an ex-
ternal pilot) (Arain, et al, 2010).  
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3.6    Summary 
In this chapter I have discussed shortcomings in current approaches to generating evidence, 
which are that they are expensive, slow, interventions are not easily comparable, and not 
answering questions of interest to those wanting to improve long-term negative outcomes. I 
argue that new approaches to evidence generation are required in order to identify treat-
ments which can improve outcomes for ADHD.  
I have justified the choice to conduct a more pragmatic as opposed to a more explanatory 
trial, and the rationale for a TwiCs approach to pragmatic trial design allowing multiple trials 
to be embedded within a cohort. Some key design issues were identified and discussed, 
such as recruitment of a representative sample, measurement of outcomes of importance 
to stakeholders, and the requirements of NICE, as the national adviser regarding NHS treat-
ments. Potential outcome measures were identified and the rationale for the selected out-
comes was described.  
Having identified and described the TwiCs trial design, in the next two chapters I will de-
scribe the two interventions selected: their evidence base and any particular considerations.  
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Chapter 4 Homeopathy 
This chapter describes one of the interventions selected to be tested using the TwiCs design. 
It explains exactly why the trial intervention is described as ‘treatment by a homeopath’, 
rather than ‘homeopathy’ or ‘homeopathic remedies’. It describes the therapeutic system: 
the fundamental principles upon which homeopathy is based, the principles by which reme-
dies are made and the principles by which a prescription is made. The different ways that 
homeopathic treatment is accessed and implemented is outlined. The safety of homeopathy 
is assessed. A literature review of homeopathy for ADHD is conducted, and the evidence 
base for the different aspects of homeopathy tested is critiqued in terms of their internal, 
ecological and model validity. Poor ecological validity is postulated as an explanation for re-
search findings. Finally, the comparative consecutive case series preceding this study is 
briefly described, with regard to the preliminary feasibility it provides. 
4.1   Definition and description 
Homeopathy (greek: homoios meaning same or similar, pathos meaning suffering) is “a sys-
tem of therapeutics founded by Samuel Hahnemann (1755-1843) based on the Law of Simi-
lars whereby ‘like cures like’ (Fisher, 2012). Diseases are treated by highly diluted substanc-
es that cause, in healthy persons, symptoms like those of the disease to be treated” 
(https://meshb.nlm.nih.gov/#/record/ui?ui=D006705 accessed 13/1/17). It is postulated 
that “nano-amounts effect significant change over long periods” (Barnes & Winterson, 
2007). 
The therapeutic system consists of several interacting components: homeopathic medicines 
known as remedies, the homeopathic consultation, and the principles of homeopathy 
(Relton, O'Cathain, & Thomas, 2008). Homeopathic remedies are made from material sub-
stances from multiple sources (e.g. extracts from plants, animals, minerals or chemicals). 
Nano-doses of these substances are made up by a process known as potentisation which 
involves repeated dilutions, with sucussion (vigorous shaking) between each dilution (Fisher, 
2012). The dilution ratio is one part medicinal substance to 99 parts water, with a specific 
number of sucussions between each dilution. Centesimal (C), millesimal (M) and 50 millesi-
mal (LM) scales are used. The standard interval range for remedies is : 6C, 9C, 12C, 15C, 30C, 
200C, 1M, 10M, 50M, LM. In many cases medicines are diluted to such an extent that no 
molecules of the original substance can be identified.  
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Homeopathic treatment involves an in-depth consultation with a practitioner, where infor-
mation about the patient’s physical, general, mental and emotional symptoms are gathered. 
The patient’s presenting symptoms are then matched with an appropriate homeopathic 
remedy. There is some similarity between consultations carried out by homeopaths and 
psychological interventions, such as the amount of time given to patients, practitioners’ 
empathy, and patients’ disclosure of problems. However, homeopathic treatment differs 
from psychological interventions in a number of ways, particularly with regards to the ho-
meopath’s focus on the patients’ symptoms and complaints and the prescription of a ho-
meopathic remedy. 
The principle of potentisation is colloquially known as the principle of the ‘minimum dose’, 
whereby the more the remedy is potentised and succussed, the more effective or potent it 
becomes. Its implausibility has given rise to much scientific controversy about homeopathic 
treatment. Hahnemann initially used doses similar to those used in contemporary conven-
tional medicine, but gradually reduced the size of his doses after empirical observation, to 
‘ultramolecular dilutions’ (Fisher, 2012). 
The principle of similitude is colloquially known as ‘like cures like’ or ‘similia similibus curen-
tur’. This principle considers that a substance which can produce a spectrum of symptoms in 
a healthy person may cure the same spectrum of symptoms in a sick person. If symptoms 
are correctly matched, then the person is stimulated to heal themselves.  The principle is 
similar to that of hormesis: the stimulatory or beneficial effects of small doses of toxins 
(Fisher, 2012), and has been known of since ancient times: “by similar (homoia) means a 
disease arises and by administering similar things health is restored from sickness” (Hippoc-
rates). It has correspondences in conventional medicine, for example immunisation, and 
methylphenidate, which is a stimulant used to treat an over-stimulated nervous system.   
The principle of individualisation is colloquially known as ‘the patient not the cure’ (Blackie, 
1978). The matching of substance to symptom is patient rather than condition specific. Pa-
tients with the same diagnosis are likely to receive different remedies. For example allium 
cepa (onion) may be prescribed to treat a presentation of weepy hay fever, or natrum muri-
aticum (salt) prescribed for a presentation of hayfever with violent, frequent sneezing. The 
in-depth consultation between a homeopath and a patient ascertains the symptoms to be 
matched to enable the individually tailored prescription. 
4.1.1 Use and provision of homeopathy 
In the UK, treatment by a homeopath is practiced both by medically qualified homeopathic 
practitioners and by professional homeopaths. Treatment by a homeopath is available in 
some NHS hospitals, from some NHS GPs who have undertaken extra training, and privately.  
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Individually tailored remedies are obtained from homeopaths, and homeopathic remedies  
can also be bought over the counter or ordered from homeopathic pharmacies. These ge-
neric remedies are selected according to possible clinical indications, and typically constitute 
a ‘catch all’ approach (e.g. a hay fever complex contains a basket of remedies useful in 
common manifestations of hay fever). They are widely used; more easily trialled being ‘per 
protocol’ treatments; and cheaper, since the main cost of homeopathic treatment is in-
curred in the consultation. However, they are easy to select inappropriately when the rem-
edy(ies) do not cover the patient’s specific symptoms. Taking inappropriately matching 
remedies generally means there is no reaction. For this reason the effectiveness of Over-
The-Counter (OTC) purchased remedies is likely to be reduced compared to the effective-
ness of individually tailored remedies since prescription is generic rather than specific. 
4.1.2 The safety of homeopathy 
Seven reviews of the evidence of the safety of homeopathy indicate that homeopathic rem-
edies may cause mild to moderate transient side-effects, but not strong or persisting side-
effects (Bornhöft, et al., 2006; Dantas & Rampes, 2000; European Central Council of 
Homeopaths, 2009; Grabia & Ernst, 2003; Woodward, 2005). No interactions with conven-
tional drugs have been reported. A potential reported risk involves delay in referral for nec-
essary conventional examination and/or treatment (Posadzki, Alotaibi, & Ernst, 2012). How-
ever, evidence indicates that such cases are rare (European Central Council of Homeopaths, 
2009). Only one study to date has systematically documented the occurrence of adverse 
events during homeopathic treatment for ADHD (Jacobs, Williams, Girard, Njike, & Katz, 
2005), and found none in either group. 
4.1.3 Different methods used by homeopaths 
Over time, a variety of methods to arrive at individually tailored prescriptions have been de-
veloped, and generally homeopaths apply a pluralistic approach. Some different, unusual 
methodologies have been trialled for ADHD: Sensation methodology (Jacobs, et al., 2005) 
was not found to be effective; and Boenningausen methodology (Frei, et al., 2005), which 
was trialled during a pilot phase exploring methodologies to achieve optimal clinical effec-
tiveness (Frei, Thurneysen, von Ammon, & Jacobs, 2006) and was found to be effective. 
There is considerable scope to explore different methods and understand which ones may 
lead to more effective outcomes. 
4.1.4 Treatment by a homeopath 
Homeopathy, as practiced in clinics, may be considered to include the following three inter-
acting components qualifying it to be considered a complex intervention (Relton, O'Cathain, 
& Thomas, 2008):  
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1. the homeopathic remedy  
2. the therapeutic consultation  
3. the application of the principles of homeopathy  
The three components are inextricably linked, in that the therapeutic consultation is neces-
sary for identification of the correct homeopathic remedy, which is applied according to the 
principles of homeopathy. The extent to which interacting components are included in trials 
is considered when the treatment’s ecological validity is assessed (4.2.6, Table 12). 
4.1.5 The testing of the therapeutic system of homeopathy 
Homeopathy research is still in its infancy, and there is considerable scope to explore opti-
mum research designs. Most RCTs of homeopathy to date test generic homeopathic reme-
dies, that is without consultations or application of homeopathic principles. Up to 2013 
there were a total of 137 placebo-controlled RCTs published in peer reviewed journals of 
which 96 were of generic remedies. This means the significant majority of homeopathy trials 
have very poor ecological validity.  
41 trials have tested the efficacy of individually tailored homeopathic remedies, whereby 
the active arm typically received components 1,2 and 3, and the placebo arm received com-
ponents 2 and 3. These trials have better ecological validity. There are just 12 RCTs with 
good ecological validity, whereby components 1, 2 and 3 are present in the verum arm but 
not in the comparison arm (Mathie, Hacke, Clausen, Nicolai, & Riley, 2013).  
Regardless of positive or negative outcomes, systematic reviews and meta-analyses of the 
trials of homeopathy all conclude that the homeopathy used in trials is unlikely to reflect 
usual practice (Kleijnen, Knipschild, & Ter Riet, 1991; Linde, et al., 1997; Cucherat, Haugh, 
Gooch, & Boissel, 2000; Ernst, 2002; Dean, 2004).  
The absence of all components of the therapeutic system in trials is an explanation for why 
such trials can fail to demonstrate efficacy and may be contributing to the heated debate 
which surrounds the therapy. Furthermore, homeopathic treatment is regarded as a pro-
cess, therefore blinding the practitioner, or limiting remedy testing to single remedies con-
tributes to reduced ecological validity (Relton, 2013). 
Observational surveys may better capture the broad effects of homeopathic treatment: the 
Bristol Homeopathic Hospital analysed 23,000 outpatient consultations from 1997 to 2003 
(Spence, Thompson, & Barron, 2005) and found > 50% self-rated health improvements and 
>70% clinical improvements. 66% of children rated their health as ‘better’ or ‘much better’ 
and 80% stated a degree of improvement. Similar improvement ratings were seen in Tun-
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bridge Wells homeopathic hospital in 74% of 1372 patients (Clover, 2000); and in Liverpool 
in 76.6% of 1100 patients (Richardson, 2001).  
Surveys may succeed in capturing improvements under homeopathic treatment, and have 
large sample sizes, but evidence is low quality due to use of patient reported, unvalidated 
outcomes and lack of randomisation. Of even lower quality are the descriptive case studies 
which are the principle means by which homeopaths communicate the effectiveness of their 
treatment (e.g Fibert, 2015b) 
A study of relevance to this thesis was conducted in conjunction with local authorities 
(McLean & Garland, 2005). Treatment by a homeopath was provided to 10 children selected 
by 10 schools as being in danger of exclusion. The study used a simple, objective measure 
(school exclusion), and no children were excluded. However, again there was no comparator 
and the study has not been published in a peer reviewed journal. 
It is postulated that homeopathic treatment might be broadly helpful for children with 
ADHD, who tend to present heterogeneously and with co-occurring diagnoses, because the 
therapy takes a holistic approach, and treatment responses are expected to be global and 
non-specific. Furthermore, the ability to treat co-occurrent diagnoses within one therapeu-
tic modality is considered by homeopaths to be a strength of their approach. One study of 
43 multimorbid patients (with at least 3 co-occurrences) has been conducted, which found 
those treated homeopathically experienced 47% improvement after one month and 63% 
after two months, rating each symptom’s intensity on a scale of 0-10 (Frei, 2015).  
Measurement of specific improvements in specific conditions may not capture the global 
health improvements expected to occur during homeopathic treatment. For example in one 
case (Fibert, 2015a) from my case series (Fibert, Relton, Heirs, & Bowden, 2016) a child pre-
sented with diagnoses of ADHD, autism, ODD, dyslexia, hypertonia, recurrent ear infections, 
sleep apnoea, eczema, asthma, allergies (dairy products, nuts, bees and wasps), constipa-
tion, tics, chronic pneumonia, and collapse of left lung. Only improvements in ADHD were 
measured despite improvements in the other conditions.  
4.1.6 The cost effectiveness of homeopathic treatment 
Cost-effectiveness studies of homeopathic treatment for a variety of conditions suggest that 
integration of homeopathy is associated with better outcomes for equivalent costs. (eg 
(Trichard, Chaufferin, Dubreuil, Nicoloyannis, & Duru, 2004; Witt, et al., 2005). 
Informal cost-effectiveness indications for ADHD suggest reduced costs compared to con-
ventional treatment. The therapy is relatively cheap to implement: the majority of the cost 
is the consultation and homeopathic remedies are included in that cost. Annual costs for my 
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case series (2010-12) were approximately £300 per child comprising consultation costs @ 
£55 for a first consultation and £35 for follow ups (Fibert, 2016).  
An evaluation of homeopathic treatment compared to stimulant treatment in Switzerland 
for ADHD found homeopathy costs to be 75% of stimulant costs in the ﬁrst year, and 50% in 
following years.  Over a ten year period homeopathic treatment per single child cost CHF 
2120 ($ 1705) compared to CHF 3650 ($2920) with stimulant therapy (von Ammon, 2012). 
Cost benefit analysis of children in danger of exclusion (McLean & Garland, 2005) found 
homeopathy to be associated with less than half the costs (£6713) compared with main-
stream behaviour support (£15120). 
4.2   A literature review of homeopathy for ADHD  
This section reviews the evidence base for homeopathy and ADHD. Since considerable het-
erogeneity exists between studies, meta-analysis was not conducted.  
4.2.1 Search methods for the literature review 
Inclusion criteria were: all published primary studies of efficacy and effectiveness, random-
ised, quasi randomised, not randomised, cohort studies and case studies greater than n=1. 
Studies had to include at least one aspect of homeopathy (the homeopathic remedy, the 
homeopathic consultation, or the application of the principles of homeopathy). They could 
use any method and prescribe any number of homeopathic remedies.  Trials could be of any 
duration, and participants any age, including adults. 
Studies could measure ADHD as a primary or a secondary measure. They could use any 
comparator, (eg placebo, treatment as usual, baseline or another intervention) and any out-
come measure: validated or non-validated; self, carer, clinician or teacher-rated; specific 
measure of ADHD or generalised improvement rating, measure of wellbeing, or quality of 
life; measurement of accompanying symptoms such as anxiety, anger, opposition, or school 
performance.  
Exclusion criteria were editorials and commentaries; studies where the intervention did not 
conform to any homeopathic principles; and studies with no outcome measurement. 
Search strategy  
Databases were searched from 1960 to 2016 using the terms: “homeopathy” AND “ADHD" 
OR "attention deficit" OR "hyper kinetic" OR "HKD", inception – 2016. The following data 
bases were searched: MEDLINE, AMED, BIOSIS, BMC CAM: BMC Complementary and Alter-
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native Medicine, CAMbase, CINAHL, CENTRAL, ECH, ERIC, Embase, Hominform, IDHDR, 
PsycINFO, RCCM.  
In addition, hand searching of the following was conducted:  English language homeopathy 
journals; experts publishing studies in the field (Professor Frei, Professor von Ammon, Dr 
Jacobs); university websites where homeopathy research for ADHD was known to have 
been conducted (Bern, Washington and Johannesburg); homeopathy and complementary 
therapy conference proceedings (the International Conference for Complementary Medi-
cine Research; the Homeopathy Research Institute; and the Children’s Complementary 
Therapies Network).  
Quality assessment of studies 
Studies were assessed for their internal validity using the Cochrane collaboration’s tool for 
assessing risk of bias (Higgins, 2011)1. They were assessed for their ecological validity ac-
cording to the extent to which three identified components of homeopathy were present 
(Relton, O'Cathain, & Thomas, 2008)2 (section 4.1.4). They were assessed for their model 
validity (the degree to which design and setting corresponds to best practice), using recom-
mendations set out by Mathie (2013)3 
                                                        
1 Domain I: selection bias, random sequence generation.  Domain II: selection bias, concealment of allocation sequence Domain III: per-
formance bias, blinding of participants and researchers Domain IV: detection bias, blinding of outcome assessment Domain V: attrition 
bias, incomplete outcome data. Domain VI: reporting bias, selective reporting of outcomes Judgement is made as to whether risk of bias is 
high, low or unclear. 
2 Domain I: The homeopathic medicine. Domain II: The therapeutic consultation. Domain III: The application of the principles of  
homeopathy 
3 Domain I: A significant body of accredited homeopaths would support the rational for the intervention. Domain II: The homeopathy used 
in the trial is based on homeopathic principles plus available literature sources. Domain III: The practitioner is a suitably  qualified and 
experienced homeopath. Domain IV: The outcome measure reflects the main effects expected of the intervention. Domain V: The 
outcome measure is capable of detecting change. Domain VI: The length of follow-up for the main outcome measure is appropriate to 
detect the intended effect of the intervention 
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4.2.2   Results of the literature search 
A Prisma flow chart outlines the results of search strategy at each stage.  
 
 
 
 
 
 
 
 
 
 
4.2.3 Description of studies 
See Appendix 11. Ten studies were identified as eligible for inclusion, summarised in Table 
9. Three categories of study were identified: RCTs of standardised homeopathic products; 
RCTs of generic homeopathic products; and non-randomised case series. 
Category 1 (generic homeopathic products): (Razlog, Pellow, & White, 2012 & Strauss, 
2000). 
Category 2 (studies of individually tailored homeopathic remedies): four RCTs (Lamont, 
1997; Frei, et al., 2005; Jacobs, Williams, Girard, Njike, & Katz, 2005; Oberai, Varanasi, 
Mishra, Singh, & Nayak, 2013).  
Category 3 (case series): four case series (Fibert, Relton, Heirs, & Bowden, 2016; Barvalia, 
Oza, Patil, Agarwal, & Mehta, 2014; Brulé, et al., 2014; Frei & Thurneysen, 2001).  
Records identified through database searching 
(n=121) 
Records identified through other sources 
(n=7) 
Records after duplicates, citations and secondary 
sources removed (n=17) 
Records screened (n=17) 
Records excluded from 
main review: not published 
(n=6) 
Full-text articles assessed for eli-
gibility (n=11) 
Full-text articles excluded 
(n=1): not homeopathy  
Studies eligible for inclusion 
(n=10) 
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Table 9. Summary of the homeopathy studies for ADHD 
Category Study and venue What is tested Research design Comparator Measurement 
Duration of 
study Statistical results 
1 Strauss, 2000. S.A Generic compound 
product 
DB-pc-RCT Placebo pill CPRS 2 months SMD -0.17 (CI -
1.05, 0.71) 
1 Razlog, 2012. S.A Non-Individualised 
homeopathic remedy 
DB-pc-RCT Placebo pill CPRS 3 weeks  Pre/post test 
mean  15.89, 
13.89 
2 Lamont, 1997. 
U.S.A 
Individually tailored 
homeopathic remedies 
SB-pc-RCT Placebo pill Unvalidated lik-
ert scale 
40 days SMD -0.65 (CI -
1.27, -0.03) 
2 Frei 2005. Switzer-
land 
Individually tailored 
homeopathic remedies 
DB-pc-RCT Placebo pill CGI-P 5 months SMD -1.67 (CI -
3.32, -0.02)  
2 Jacobs, 2005. 
U.S.A 
Individually tailored 
homeopathic remedies 
DB-pc-RCT Placebo pill CPRS 18 wks  SMD 0.17 (CI -
0.43, 0.77) 
2 Oberai, 2013. In-
dia 
Individually tailored 
homeopathic remedies 
DB-pc-RCT Placebo pill CPRS  1 year SMD= .51 (GLM) 
0.48 p= .0001  
3 Frei 2001. Switzer-
land 
Homeopathic treat-
ment 
Case series baseline CPRS 3.5 months Pre/post test 
mean 20.6, 9.27 
3 Barvalia, 2011. 
India 
Homeopathic treat-
ment 
Self-controlled 
pre-post interven-
tion 
6 months usual 
care 
 AHS 1 ½ years F 210.599 (p = 
.0001 
3 Brule, 2014. Cana-
da 
Homeopathic treat-
ment 
Case series baseline CPRS 1 year Pre/post-test me-
dian 85.5, 74.0  
3 Fibert, 2016. U.K Homeopathic treat-
ment 
Controlled case 
series 
Similar time and 
attention 
CPRS  1 year  F 9.06, p=.005 
SB = single blinded; DB = double-blinded. Pc = placebo-controlled.  Rating Scale. AHS: Autism Hyperactivity Score. CPRS: Conners Parent Rating Scale. CGI-P: 
Conners Global Index-Parent. SMD = standardised mean difference
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The studies were methodologically heterogeneous: whilst half used conventional homeo-
pathic methodologies, half used unusual methodologies or tested unusual standardised 
products, unlikely to be used in real-life clinical practice (Table 10). 
Table 10. The heterogeneity of homeopathic methodologies and products used in homeopathy ADHD 
studies. 
Standardised homeopathic products  Individualised homeopathic remedies 
Generic remedy Generic compound reme-
dy 
Conventional  Unconventional  (not taught 
or commonly used in the UK) 
Razlog, 2012 (va-
leriana officinalis) 
Strauss, 2000 (selenium 
homaccord) 
Lamont, 1997 Frei, 2001 and 2005 (Boen-
ninghausen methodology) 
  Brule, 2014 Jacobs, 2005 (Sensation 
methodology) 
  Oberai, 2013  
  Fibert, 2016  
  Barvalia, 2011  
4.2.4 Population characteristics of included studies 
A total of 515 participants (minimum study population 20, maximum 115) took part: 50 in 
RCTs of standardised homeopathic remedies; 290 in RCTs of individualised homeopathic 
remedies; and 175 in case series. Children were aged 5 - 16. Studies were conducted in 
South Africa, the USA, Switzerland, UK, India and Canada (Table 9).  
4.2.5 Design Characteristics 
RCTs of homeopathic remedies were placebo-controlled, which meant an identical looking 
placebo pill of the standard or individually tailored remedy. One case series compared ho-
meopathic treatment with similar time and attention (Fibert, Relton, Heirs, & Bowden, 
2016); two case series compared homeopathic treatment with baseline (Frei & Thurneysen, 
2001 & Brulé, et al., 2014); and one within subjects study compared 6 months observation 
with 1 year of homeopathic treatment (Barvalia, Oza, Patil, Agarwal, & Mehta, 2014).  
All RCTs were blinded. Three were double-blinded: either practitioner and participants (as-
sessors) were blinded (Frei, et al., 2005 & Jacobs, Williams, Girard, Njike, & Katz, 2005); or 
participants and teachers (assessors) were blinded (Oberai, Varanasi, Mishra, Singh, & 
Nayak, 2013). Three RCTs were single blinded whereby participants (assessors) were blinded 
(Lamont, 1997; Razlog, Pellow, & White, 2012; Strauss, 2000). No blinding occurred in the 
Case Series.   
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Length of study varied between 21 and 547 days (Table 9). All studies except two used Con-
ner’s questionnaires as their primary outcome measurement (Conners, 2009). The other 
measures used were an unvalidated rating scale ranging from -2 to +2 (Lamont, 1997), and 
the autism hyperactivity scale (reduction in hyperactivity, impulsivity, tantrums & self-
injurious behaviour) (Barvalia, Oza, Patil, Agarwal, & Mehta, 2014). 
One study used a double crossover design (Frei, et al., 2005) based on pilot findings (Frei & 
Thurneysen, 2001) that homeopathic effects were undetectable one month after stopping 
the homeopathic remedy. For this unusual design all participants’ individually tailored ho-
meopathic remedies were found pre-trial based on 50% remission of symptoms. Then par-
ticipants were randomised and took either a homeopathic remedy or placebo remedy for 6 
weeks to achieve the crossover design. One study had a single crossover design (Lamont, 
1997) whereby placebo participants subsequently received homeopathic remedies. The 
other RCTs and one case series had parallel arms but no crossover.  
Some studies documented the number of ‘tries’ it took to find a homeopathic remedy which 
participants responded to. Frei (2006) found it took a median of 3 tries (range 1-9); Brule 
(2014) found it took an average 1.68 (range 1-5); and Oberai (2013) found it took only one. 
Results may reflect practitioner expertise.  
4.2.6 Methodological quality   
Internal Validity 
Risk of Bias is assessed as high, low, or unclear (Higgins, Gøtzsche, & Jüni, 2011) (Table 11). 
Most RCTs published adequate descriptions of random sequence procedures, allocation 
concealment procedures, attrition, outcome assessment, data, and were double-blinded. 
One study randomised by alternation (Lamont, 1997). This study was also at risk of bias due 
to single blinding and use of an unvalidated outcome measurement.   
The two RCTs of generic remedies were deemed at high, confirmed risk of selective report-
ing since positive results in the narrative description did not tally with statistical results. On-
ly intervention change scores were described and discussed with no statistical comparison 
of the placebo arm despite it being a component of the trial design. Examination of the data 
found no significant difference between placebo and change scores (both improved) 
(Razlog, Pellow, & White, 2012; Strauss, 2000). 
Case series and the within-subject study were at risk of bias due to lack of randomisation or 
blinding.
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Table 11. Risk of bias of homeopathy studies for ADHD 
 Strauss, 
2000 
Razlog, 
2012 
Lamont, 1997 Frei 
2005 
Jacobs, 
2005 
Oberai, 2013 Frei 
2001 
Barvalia, 
2011 
Brule, 
2012 
Fibert, 2016 
Selection bias: random 
sequence generation 
low Low Unclear (alternate 
assignment) 
low low low high high  high Unclear (consecu-
tive assignment) 
Selection bias: allocation 
concealment 
low Low Unclear (PI knew allo-
cation) 
low low Unclear (PI knew 
allocation) 
high high high high 
Performance bias: blind-
ing of participants & 
researchers 
low Low Unclear. Participants 
but not researchers 
blinded 
low low Unclear. Partici-
pants but not re-
searchers blinded 
high high high high 
Detection bias: blinding 
of outcome assessment 
unclear Unclear high  low low low high high high high 
Attrition bias: incom-
plete outcome data 
high High low low low low low low low low 
Reporting bias: selective 
reporting 
high High low low low low low low low low 
Judgement is made as to whether risk of bias is high, low or unclear ( (Higgins, Gøtzsche, & Jüni, 2011). 
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Table 12. Ecological validity of homeopathy studies for ADHD 
 Strauss,2000 Razlog, 2012 Lamont, 
1997 
Frei, 
2005 
Jacobs, 
2005 
Oberai, 
2013 
Frei 
2001 
Barvalia, 
2011 
Brule, 
2014 
Fibert, 
2016 
The homeopathic remedy No No Yes Yes Yes Yes Yes Yes Yes Yes 
The therapeutic consulta-
tion. 
No No Unclear: 
one consult 
No Yes Yes Yes Yes Yes Yes 
The application of the 
principles of homeopathy 
No: no individualisa-
tion, no similimum 
No: no individualisa-
tion, no similimum 
Yes Yes Yes Yes Yes Yes Yes Yes 
                                                                         Judgement is made as to whether each element is included: yes, no or unclear  (Relton, O'Cathain, & Thomas, 2008) 
Table 13. Model validity of homeopathy studies for ADHD 
Study name Strauss, 2000 Razlog, 
2012 
Lamont, 
1997 
Frei 2005 Jacobs, 2005 Oberai, 
2013 
Frei 
2001 
Barvalia, 
2011 
Brule, 
2014 
Fibert, 
2016 
Homeopaths would support the 
rationale 
No No Yes Unclear Unclear Yes Yes Yes Yes Yes 
Intervention consistent with 
homeopathic principles 
No No Yes Unclear: no 
consultation 
Unclear: infre-
quent prescribing 
Yes Yes Yes Yes Yes 
Suitably qualified and experi-
enced homeopath. 
No No Yes Yes Yes Yes Yes Yes Yes Yes 
Main outcome measure reflects  
key effects 
Yes Yes No Yes Yes Yes Yes Yes Yes Yes 
Outcome measure capable of 
detecting change 
Yes Yes Unclear Yes Yes Yes Yes Yes Yes Yes 
Length of follow-up appropriate Yes Yes No  Yes Unclear  Yes Yes Yes Yes Yes 
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Ecological Validity.  
Homeopathic aspects considered were consultation, remedies, and principles (Relton, 
O'Cathain, & Thomas, 2008). 
All participants received one pre-trial consultation in two RCTs (Frei, et al., 2005 & Lamont, 
1997). All participants received two consultations during the treatment period in two RCTs 
(Oberai, et al., 2013 & Jacobs, et al., 2005). Treatment groups received consultations every 
6-8 weeks in Case Series; there were no consultations in RCTs of generic products.  
The potencies and frequency of administration of the homeopathic remedies varied. Two 
studies gave low potencies twice daily (Strauss, 2000 & Razlog, Pellow, & White, 2012). Four 
studies gave LM potencies administered daily (Frei & Thurneysen, 2001; Frei, et al., 2005; 
Oberai, et al., 2013; Brulé, et al., 2014). Lamont (1997) used 200C potencies administered 
daily. Jacobs et al.(2005) used a single dose of a 1M potency. Potency and frequency of dos-
age was varied in two studies (Fibert, et al., 2016 & Barvalia, et al., 2014).  
The two RCTs of generic homeopathic remedies have very poor ecological validity. Arguably 
they should not be included in systematic reviews assessing the effectiveness of homeo-
pathic treatment for ADHD (e.g. Heirs & Dean, 2009). Results from these studies pertain to 
the suitability of the generic remedies tested, not the effectiveness of the therapeutic sys-
tem.  
The lack of homeopathic consultations in some RCTs influences their ecological validity since 
neither the process of treatment nor appropriate selection and assessment of remedies is 
allowed. The best ecological validity occurs in case series. 
Model validity  
Model validity was adequate across most domains apart from consistency to homeopathic 
principles (covered in the previous section).  Table 14 summarises the Internal, Ecological 
and Model Validity of studies. This was done numerically: high scores represent poor inter-
nal, external or model validity, and low scores represent good internal, external or model 
validity. Failure to represent each domain scored 2; unclear or partial representation scored 
1; achievement of the domain scored 0.  
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Table 14. Summary of the Internal, ecological and model validity of studies 
Category Study and venue Internal Validity Ecological validity Model Validity TOTAL SCORE 
1 Strauss, 2000 5 6 7 18 
1 Razlog, et al., 2012 5 6 7 18 
2 Lamont, 1997 5 1 4 10 
2 Jacobs, et al., 2005 0 0 3 3 
2 Frei, et al., 2005 0 4 4 8 
2 Oberai, et al., 2013 3 0 0 3 
3 Frei, et al., 2001 8 0 0 8 
3 Barvalia, et al., 2011 8 0 0 8 
3 Brule, et al., 2014 8 0 0 8 
3 Fibert, et al., 2016 7 0 0 7 
Low scores indicate better validity 
4.2.7 Discussion of the identified studies 
Two RCTs had a good balance of ecological, model and internal validity according to their 
low total scores in Table 14.  In both cases, homeopathic treatment occurred according to 
usual practice meaning they had good ecological validity. One of these RCTs had reduced 
model validity because only one dose of the homeopathic remedies was given (Jacobs, et 
al., 2005). The other had reduced internal validity (Oberai, et al., 2011) because the assessor 
was not blinded. 
Studies were generally heterogeneous, with moderators such as consultation, homeopathic 
methodology, homeopathic consultation, frequency of dosage, application of homeopathic 
principles, and study design, all potential confounders. 
RCTs of standard homeopathic products 
The two RCTs of standardised homeopathic products have poor internal, ecological and 
model validity and show no evidence of being efficacious. Both came from MSc studies con-
ducted by trialists inexperienced in either homeopathy or trial methodology.  
RCTs of personally tailored homeopathic remedies 
The RCTS of individually tailored homeopathic remedies largely achieved a satisfactory bal-
ance of internal, ecological and model validity, although Jacobs used an unusual homeo-
pathic methodology, and doses of homeopathic remedies were infrequent, as recommend-
ed for this methodology. It is argued that this explained the lack of statistically significant 
differences found in this study (Frei, Thurneysen, von Ammon, & Jacobs, 2006) since other 
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studies found that homeopathic remedies require taking frequently. Frei based his crosso-
ver trial design around pilot finding that effects could not be detected one month after 
remedies were stopped; Lamont found half his participants had relapsed 2 months after trial 
end; and Razlog reported scores worsening the week after treatment stopped.  
Frei’s RCT has good internal validity, but model validity is unclear due to the cross-over as-
pect of the trial design, because homeopaths would assume some carry over effects. This 
study did not allow any change in the homeopathic remedy, which is unlike usual practice. 
Oberai’s study found highly significant statistical differences compared to the other studies. 
This may reflect the expertise of the practitioners (homeopathy is common in India); high 
fidelity (despite using Intention to Treat methodology, little attrition occurred); or biased 
reporting/recording. The study was only single blinded, and the Principal Investigator knew 
the sequence allocation, which reduced its internal validity. 
The use of an unvalidated outcome measurement, quasi-randomisation and single blinding 
by Lamont (1997) requires these results to be treated with caution.  
Case series 
All the unblinded Case Series are inevitably at risk of bias. They are, however, representative 
of homeopathic treatment as experienced in clinical practice, and can provide an estimate 
of carer-rated effects of treatment by a homeopath for their child.    
4.2.8 Statistical Results of the identified studies 
Meta-analysis was not conducted due to the heterogeneity of identified studies. Table 9 
itemises the statistical results. In summary: 
• Two RCTs of standardised homeopathic remedies prescribed daily found no differ-
ence between placebo and verum remedies as reported by carers blind to treatment 
status (Razlog, Pellow, & White, 2012 & Strauss, 2000) 
• An RCT of individualised homeopathic remedies prescribed infrequently according to 
unusual methods found no statistically signiﬁcant difference between verum and 
placebo remedies according to blinded carers and teachers (Jacobs, et al., 2005) 
• Three RCTs of individualised homeopathic remedies prescribed daily found a statisti-
cally signiﬁcant beneﬁt according to blinded carers (Frei, et al., 2005 & Lamont, 
1997) and blinded carers and teachers (Oberai, et al., 2013) however, one study used 
a non-validated measure (Lamont, 1997) 
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• One within-subject study in children with autism found a significant effect on their 
hyperactivity symptoms according to an independent clinical psychologist (Barvalia, 
et al., 2014) 
• Three case series’ found statistically significant differences between homeopathic 
treatment and similar time and attention (Fibert, Relton, Heirs, & Bowden, 2016) or 
baseline (Brulé, et al., 2014 & Frei & Thurneysen, 2001) according to unblinded car-
ers  
4.2.9 Level of evidence generated by the identified studies 
In order to determine what level of evidence currently exists, the Oxford University Levels of 
Evidence were used (Table 15). 
Table 15. Levels of Evidence  
Level I the existence of meta-analyses and/or systematic positive reviews 
Level IIa controlled multiplied experiments, randomised, positive results 
Level IIb some controlled experiments, randomised,  positive results 
Level IIIa study with multiple cohorts, positive results 
Level IIIb study with some cohorts, positive results 
Level IV opinion of experts (clinical and daily cases) 
Taken from (Howick, et al., 2011) 
According to these criteria, and depending on how many constitutes ‘some’, there is level 
IIb evidence that individualised homeopathic remedies are efficacious. There is level IIIb ev-
idence for case series documenting the effectiveness of treatment by homeopaths as expe-
rienced in clinical practice. There is no evidence that the standardised homeopathic reme-
dies tested are efficacious for ADHD. 
Implications for potential trial designs 
The RCTs represented here supposedly tested the efficacy of homeopathic remedies, that is, 
performing under ideal conditions, in comparison with placebo remedies. However, they do 
not perform under ideal conditions, since remedies are not prescribed optimally, that is, ac-
cording to homeopathic principles. Furthermore, usual treatment protocols are not ob-
served (regular consultations, freedom to vary remedy, potency and/or dosage according to 
individual need). The measured effects of homeopathic remedies are therefore likely to be 
underestimates. 
Studies are not informing us about the effectiveness of homeopathic treatment as experi-
enced in clinical practice. They are not trials of effectiveness as recommended by the MRC 
for complex interventions (Medical Research Council, 2000), the Cochrane systematic re-
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view of homeopathy for ADHD (Heirs & Dean, 2009) and for CAM research in general (Witt, 
et al., 2012). Nevertheless, such studies are used to decide whether treatment by homeo-
paths for children with ADHD is effective. 
Another issue is that studies tend to use only one homeopathic physician, one homeopathic 
method, or one particular homeopathic remedy. They therefore relate to the effectiveness 
of that particular method/practitioner or remedy. To test whether use of the therapeutic 
system of homeopathy might improve outcomes requires testing its real-world effective-
ness. This means using a variety of practitioners, prescribing according to a variety of meth-
ods, and freedom to manage prescriptions.  
Those studies which best represent the therapeutic system (meaning that they have good 
ecological validity) are Case Series. However, they are at increased risk of bias due to lack of 
randomisation, comparator or blinded outcome measurement. An important consideration 
is how to reduce the risk of bias and retain the integrity of the therapeutic system. 
4.3   Preliminary feasibility: a comparative consecutive case series  
4.3.1 Description of study (Fibert, Relton, Heirs, & Bowden, 2016) 
20 Children with a diagnosis of ADHD were consecutively recruited from a variety of venues 
to receive homeopathic consultations every 6 weeks and take homeopathic remedies be-
tween consultations, for one year. To fulfil the requirements for an MSc dissertation, 10 
children were subsequently recruited for comparison, and received similar length visits from 
the same homeopath for 4 months consisting of a supportive chat, but not homeopathic 
case taking or homeopathic remedies. 
Carers completed Conner’s Parent Rating Scale, revised long version (CPRS-R: L) every 3 
months (Conners, 2009) and the patient generated ‘Measure your Own Medical Outcome 
Profile’ (MYMOP) (Paterson & Britten, 2000) at the end of each consultation. 
Three families did not fit eligibility criteria and new families were recruited, and three fami-
lies did not complete one year of treatment due to relationship breakup (N=2) and ill health 
of a sibling (N=1). 
Improvements were observed from baseline to 1 year: t (17) = 6.94, p=.000) with the 
greatest change from baseline to four months (mean change 8.80, p = .001.) A two way 
mixed ANOVA comparing treatment group with control group found a significant interaction 
between group and treatment over time (Wilks Lambda = .721 F (1, 28) = 10.85, p= .003). 
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4.3.2 The feasibility of the methods used to conduct the comparative case series 
This study explored the feasibility of: the outcome measures; of treatment by a homeopath, 
homeopathic methodologies and time required to observe changes; of recruitment of 
treatment and control arms; recruitment strategies and venues; recruitment of a repre-
sentative ADHD population; and deliverability of the intervention. Feasibility findings in-
formed the methods used for the STAR pilot feasibility study. 
Treatment by one homeopath was associated with improvements after 4 months, and in-
creased improvements at 1 year. It was found that usual classical homeopathic methodolo-
gies were suitable as long as homeopathic remedies were frequently taken. A novel meth-
odology based on isopathic prescriptions of perceived environmental stressors was found to 
be particularly effective where individually indicated (Fibert, 2015b). Recruitment of treat-
ment participants was successful and feasible, but recruitment of control participants only 
recruited half the participants.  
 Recruitment via ADHD support groups and charities was successful where a positive and 
personal relationship was established with leaders. Recruitment via schools was ineffective, 
and recruitment from the NHS was not possible since ethical approval was not requested.  
Recruitment of the ‘at need’ population was achieved by recruiting from agencies dealing 
with children in trouble, such as police support agencies and social services. It was a surprise 
observation that the few children involved with the criminal justice system at the start of 
treatment reduced their involvement. 
Attending appointments was problematic for some participants, particularly the ‘at need’ 
group, but visiting patients in their own home did not improve attendance. Best venue was 
a clinic already known to the family such as an agency clinic. Worst venue was the family 
home where participants were frequently distracted or absent, had the TV on, it was costlier 
and less time efficient to the homeopath.  
Taking homeopathic remedies was generally acceptable and well implemented, although 
some participants took remedies inappropriately, lost them, or stopped taking them after a 
while. Regular consultations allowed for adjustment and correction and were considered 
important for this population for these reasons. CPRS-R: L was found to be too long and in 
too small print for patients, but MYMOP was liked by carers and older children. Both CPRS-
R: L and MYMOP appeared to be sensitive to change. 
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4.3.3 Implications of the methods used for future research 
Treatment by a homeopath was feasible, but results must be treated with caution since out-
comes were collected by carers, aware of their child’s treatment status. 4 months was suffi-
cient time to demonstrate results. Since results in the treatment group continued to im-
prove, and given that lack of long-term effectiveness of current interventions is a problem, 
measurement of the long-term effectiveness of treatment by homeopaths is important. 
Recruitment of controls was difficult and strategies to improve this need exploring.  Delivery 
of the intervention was challenging. Using known venues, prioritising consistency, strategies 
to manage missed appointments, lost remedies, and increased understanding of ADHD may 
be helpful. Although less sensitive, the CPRS-R: S (10 items) may be a more suitable out-
come measure than CPRS-R: L (80 items) due to its shorter length. Since it was observed 
that the intervention was associated with improved levels of criminality and anger, changes 
in these areas should be measured. 
4.4   Summary 
This chapter has systematically reviewed the research literature for homeopathy and ADHD. 
Results suggest that the generic homeopathic remedies valeriana and selenium homichord 
cannot be recommended as treatments for ADHD since there is no evidence they are effica-
cious.  The remainder of the studies do suggest that individually tailored homeopathic rem-
edies may be efficacious when implemented according to usual treatment protocols. One 
unusual homeopathic methodology (Sankaran methodology) may not be suitable, but an-
other (Boenninghausen methodology) may be. Case series reports document that carers 
find treatment by homeopaths helpful. 
Trials of homeopathy to date have prioritised the evaluation of the specific effects of a sin-
gle element of this multi-component treatment. Trials investigating overall treatment ef-
fects in clinical settings have been neglected (Witt, et al., 2012) despite being recommend-
ed. This review has highlighted the limitations of explanatory trial designs to provide useful 
information for stakeholders as to whether treatment by homeopaths might be helpful. 
There is a fundamental tension between internal and ecological validity, whereby studies 
representing optimum homeopathic treatment are at risk of bias and studies with reduced 
risk of bias are not representing homeopathic treatment.  
Case Series results of treatment by homeopaths are of limited generalisability due to risk of 
selection biases (no randomisation); performance biases (homeopaths, researchers and/or 
participants not blinded); outcome assessment biases (outcomes measured by carers or cli-
nicians who knew the child’s treatment status); and Hawthorne effects). 
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Evidence generation has proceeded in the wrong order according to MRC recommendations 
to commence with trials exploring the effectiveness of complex interventions and only after 
effectiveness is established, explore the efficacy of separate elements. To assess whether 
homeopathic treatment might be helpful for people with ADHD, and provide useful infor-
mation for stakeholders, good quality, well controlled studies of the effectiveness of treat-
ment by homeopaths are required.  
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Chapter 5 Nutritional therapy  
5.1   Background 
This chapter describes the second intervention selected to be tested using the TwiCs design. 
It explores the evidence base and hypothesised mechanisms of action regarding nutritional 
interventions. It explains the rationale for describing the intervention as ‘treatment by a nu-
tritional therapist’. 
 The role of diet in ADHD has received considerably more research attention than the role of 
homeopathic treatment. It was first postulated in the 1970s by an American paediatrician, 
who found that his hyperactive patients improved with the elimination of salicylates, artifi-
cial colours and flavours, and petroleum based preservatives (Feingold, 1975).  
Dietary factors in ADHD are researched in a variety of ways: by hypothesising explanations 
for the association between diet and ADHD; by exploring the association of poor diet with 
ADHD and exacerbation of symptoms when certain foods are introduced; and by exploring 
whether ADHD symptoms might be improved by making positive changes to the diet. This 
chapter will review the evidence from these three perspectives, with more systematic ex-
ploration of the latter category, as being most related to this intervention focussed study.  
5.2   Hypotheses for the association between diet and ADHD 
Several theories have been proposed to explain the association between diet and hyperac-
tivity: poor diet, metabolic and/or mitochondrial dysfunction, immune-mediated hypersen-
sitivity, gastro-intestinal inflammation and/or gut sensitivity, abnormality of fatty acid me-
tabolism, and amino acid deficiency (Pellow, Solomon, & Barnard, 2011). However, while 
some neuro-imaging studies show anatomical differences, findings are inconsistent. 
It is likely that both a lack of available nutrients and an inability to assimilate available nutri-
ents optimally are implicated in the dietary association with ADHD. It is suggested that peo-
ple with ADHD have a higher need for nutrients for optimal brain functioning which is exac-
erbated by the fact that they are consuming diets depleted in nutrients (Rucklidge & 
Johnstone, 2016). 
5.2.1 Poor diet and the expression of psychiatric symptoms 
Diet-related deﬁciencies and/or malabsorption of nutrients can result in the expression of 
psychiatric symptoms (Kaplan, Rucklidge, Romijn, & McLeod, 2015).  Poor diet and resultant 
nutrient deficiencies may lead to oxidative stress and altered neurone plasticity. Deficiencies 
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of zinc, magnesium, glutathione, and/or omega-3 fatty acids, for instance, have been linked 
to poor concentration, memory, and learning problems (Dufault, Schnoll, & Lukiw, 2009). 
One theory posits that B group vitamins have a similar molecular structure to dopamine ag-
onists such as methylphenidate - which inhibit the dopamine transporter (DAT) function, 
thus increasing dopamine at the synapse (Shaw, Rucklidge, & Hughes, 2010). B group vita-
mins may work together with minerals such as zinc, to inhibit DAT function (Lepping & 
Huber, 2010). 
5.2.2  Metabolic and/or mitochondrial dysfunction 
Neurotransmitters go through many metabolic steps to ensure synthesis, uptake, and 
breakdown, requiring enzymes dependent upon multiple coenzymes. Ames found that in-
born errors of metabolism reduce the binding affinity of enzymes, which lowers the rate of 
metabolic reactions and hinders the synthesis and function of neurotransmitters (Ames, 
Elson-Schwab, & Silver, 2002).  
Energy metabolism of neurons and glia cells (under the direct control of mitochondria), is 
highly dependent on the availability of a range of nutrients (McNally, Bhagwagar, & 
Hannestad, 2008). For example, magnesium, calcium, and several B vitamins are required as 
cofactors in the degradation of blood glucose via glycogenesis, and for aerobic metabolism 
in the respiratory chain in the mitochondria (Huskisson, Maggini, & Ruf, 2007). 
Mitochondrial disorders are characterized by decreased production of adenosine triphos-
phate (ATP) the source of all cellular energy. Brain tissue in particular requires high levels of 
ATP for metabolism, including for the production of neurotransmitters. Manufacture of ATP 
may be compromised in ADHD (Gardner & Boles, 2005; Russell, et al., 2006; Young, 2007).  
5.2.3 Immune-mediated hypersensitivity 
Exposure to sensitising foods can increase inflammatory mediators and neuropeptides in 
the blood. Hypersensitive children may show symptoms of irritability, sleep disturbances 
and hyperactivity-impulsivity (Pellow, Solomon, & Barnard, 2011; Pelsser, Buitelaar, & 
Savelkoul, 2009). Stevenson (2010) suggested that some children with ADHD may have al-
terations in histamine genes, impacting their response to certain food additives. The func-
tion of the histamine receptor is known to affect hyperactivity levels in animals and influ-
ence dopamine release in the prefrontal cortex (Stevenson, 2010). 
5.2.4 Gastro-intestinal inflammation and/or gut sensitivity 
The gastrointestinal tract is one of the most energy-dependent and vulnerable organs. Its 
integrity is essential for proper nutrient absorption and function. Compromised gut flora 
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may lead to proliferation of opportunistic, pathogenic bacteria, viruses and fungi in the di-
gestive tract, producing toxic substances which risk being absorbed into the blood stream 
and carried to the brain (Wilson & Tyburski, 1998; Samonis, et al., 1994). Mental disorders 
such as depression and anxiety have been found to be comorbid with celiac disease 
(Jackson, Eaton, Cascella, Fasano, & Kelly, 2012), and a growing body of research suggests 
that inflammation may play a role in psychiatric illness (Kaplan, Rucklidge, Romijn, & 
McLeod, 2015; McNally, Bhagwagar, & Hannestad, 2008).   
5.2.5 Abnormality of fatty acid metabolism or lack of dietary essential fatty acids 
Either abnormal fatty acid metabolism or a lack of essential fatty acids are postulated to be 
implicated in ADHD. A lack of fatty acids might impair communication between cells, leading 
to cognitive deficit (Pellow, Solomon, & Barnard, 2011). Fatty acids are essential for the flex-
ibility of cell membranes. The myelin sheath, which insulates every neuron in the brain, con-
sists of 75% phospholipids, with each molecule having an attached saturated and unsaturat-
ed omega-3 or omega-6 fatty acid. Their ratio is found to be a marker of health status. The 
brain and nervous system depend heavily on them, especially during childhood, which is a 
critical development period. Dietary deficiency during this time may increase the risk of de-
veloping ADHD-type symptoms (Haag, 2003).  
Abnormalities of dopamine neurotransmission are associated with ADHD, and the function-
ing of neurotransmitters and receptors influenced by the lipid content of membranes. Ome-
ga-3 fatty acids, specifically docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), 
appear to improve neurotransmitter reception in the brain. DHA, in particular, protects neu-
rons and glia by maintaining neural plasticity via induction of brain-derived neurotrophic 
factor (BDNF), a protein formed within the brain.  
Modern grain based western diets have a fatty acid balance of 20 (omega 6):1 (omega 3), 
compared with 2: 1 in pre-agricultural diets based on animal and marine products, plants, 
nuts and seeds. This imbalance is considered to be a risk factor for ADHD. ADHD children 
may also have an inability to metabolize essential fatty acids (EFAs) correctly and frequently 
present with symptoms of EFA deficiency symptoms, which include dry hair and skin, ecze-
ma, recurrent infections, increased thirst and behavioural problems, temper tantrums, 
learning, health and sleep problems (Burgess, Stevens, Zhang, & Peck, 2000). 
5.2.6 Amino acid deficiency 
 Amino acids are the building blocks of proteins, as well as precursors for most of the neuro-
transmitters in the brain. Certain amino acids need to be taken in through the diet; and low 
protein diets may foster amino acid deficiency symptoms (Pellow, Solomon, & Barnard, 
2011). Many of the amino acids needed by the body to manufacture neurotransmitters, 
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such as phenylalanine, tyrosine, and tryptophan, are found to be low in the blood of adults 
and children with ADHD (Dufault, Schnoll, & Lukiw, 2009; Bornstein, Baker, & Carroll, 1990). 
Deficiencies of these neurotransmitter precursors, together with their vitamin and mineral 
cofactors, may result in ADHD-type symptoms (Harding, Judah, & Gant, 2003). 
5.2.7 Mineral deficiency 
 Deficiencies in zinc, iron, calcium, magnesium, and selenium have been found in children 
with ADHD (Dufault, Schnoll, & Lukiw, 2009; Kozielec & Starobrat-Hermelin, 1997). For ex-
ample, high levels of copper and a disturbance in the zinc: copper ratio were found in many 
ADHD children  (Viktorinova, Trebaticka, & Paduchova, 2009). Zinc and iron are associated 
with dopamine metabolism, so a deficiency may be associated with impairment in dopa-
minergic transmission.  
Consumption of certain artificial food additives can lead to nutrient deficiencies, particularly 
of zinc, in some individuals, which may exacerbate anxiety and conduct disorder problems 
(Oner, Oner, & Bozkurt, 2010; Pellow, Solomon, & Barnard, 2011). Furthermore exposure to 
metals such as lead, cadmium, mercury and aluminium have been linked to ADHD, and min-
erals such as zinc are needed to help metabolize and eliminate heavy metals (Dufault, 
Schnoll, & Lukiw, 2009). 
5.3   Associations between poor diets and ADHD 
Negative dietary factors found to be implicated in ADHD are: consumption of artificial food 
additives (Nigg, Lewis, Edinger, & Falk, 2012; Schab & Trinh, 2004); food sensitivities 
(Pelsser, Frankena, Toorman, & Rodrigues Pereira, 2017); trace element deficiencies (Hurt, 
Arnold, & Lofthouse, 2011), including iron (Cortese, Angriman, Lecendreux, & Konofal, 
2012); fatty acid deficiencies (Schuchardt, Huss, Stauss-Grabo, & Hahn, 2010); a ‘Western’ 
style of diet (Howard, et al., 2011); poor nutrition generally (Melchior, et al., 2012); and 
malnutrition in infancy (Galler, et al., 2012), whereby children malnourished in the first six 
months of life were found to be at greater risk for ADHD symptoms 30 years later compared 
with children not exposed to such risk. 
Unhealthy diets such as those high in saturated fats, refined sugars, and processed food and 
low in fruit and vegetables are associated with a higher incidence of ADHD (Howard, et al., 
2011). Howard found that a population-based cohort of 14-year olds consuming a ‘Western’ 
diet (high intake of total and saturated fats, refined sugars, and sodium, and low intake of 
omega-3 fatty acids, fibre and folate), had higher rates of ADHD.  
Meta-analyses conclude that artificial dyes and preservatives (sodium benzoate in particu-
lar), can trigger hyperactivity and inattentiveness, with younger children more prone than 
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older children, and that the greater the exposure the greater the effect found (Schab & 
Trinh, 2004). A relationship between certain food additives and exacerbation of ADHD like 
symptoms was found in 3-year olds (Bateman, et al., 2004) and 8–9 year olds (McCann, 
Barrett, & Cooper, 2007). An association between low omega-3 levels and having ADHD has 
also been found (Hawkey & Nigg, 2014). 
Recently a relationship has been found between lower adherence to the Mediterranean diet 
and ADHD diagnoses (Ríos-Hernández, Alda, Farran-Codina, Ferreira-García, & Izquierdo-
Pulido, 2017). The research team postulated that the relationship between poor diet and 
ADHD is bi-directional in that those with attention deficits, impulsive tendencies and diffi-
culties using long-term motivators to inform short-term decision making, may make poorer 
food choices than those without.  
Foods consumed today may not have the same nutrient composition as 50–100 years ago: 
for example, the mineral composition of 20 fruits and vegetables grown in the 1940s com-
pared to the same fruits and vegetables grown in the 1990s showed significant reduction of 
four minerals in the tested vegetables, and three minerals in the tested fruits (Mayer, 1997). 
Furthermore, it is suggested that high yield crops produced with fertilizers, irrigation, and 
other environmental manipulations contain reduced nutrient concentrations (Davis, 2009). 
 Glyphosate has been specifically implicated in the depletion of minerals in plants (Bellaloui, 
Reddy, Zablotowicz, Abbas, & Abel, 2009), and manganese in cows (Samsel & Seneff, 2015). 
 It has been postulated that increases in autism are associated with increased glyphosate 
usage it being “the only pesticide whose usage rates have gone up exactly in step with the 
rise in autism, and it is the most used herbicide on the planet” (Beecham & Seneff, 2016). 
Animal studies suggest that it induces impaired thyroid function. Neurological diseases can 
be explained by manganese deficiency (Samsel & Seneff, 2015). 
5.4   Improving ADHD using nutrition 
It is suggested that single nutrient interventions do not have adequate impact on the com-
plex array of biochemical pathways that may be aberrant in ADHD. Furthermore, admin-
istration of one nutrient may cause an imbalance in other nutrients; and one nutrient is un-
likely to resolve all vulnerabilities (Rucklidge, Johnstone, & Kaplan, 2009). 
This section systematically reviews the research evidence for the effectiveness of nutritional 
interventions to improve ADHD symptoms. Studies with any type of comparator were in-
cluded if they compared the effects of any or all aspects of a nutritional intervention such 
as: excluding food allergens, food chemicals, individually identified food substances or 
commonly provoking substances in normal diets; adding single supplemental nutrients such 
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as polyunsaturated fatty acids (PUFAs), zinc or magnesium; adding multi-nutrients; or a nu-
tritional approach amalgamating any or all of these.  
5.4.1 Search methods for the literature review 
Web of science, Cochrane and google scholar were searched using the search terms ADHD 
AND nutrition AND meta-analysis OR systematic review OR RCT. A nutrition website 
(https://www.fabresearch.org) was also searched.  Inclusion criteria were: all published 
primary studies of efficacy and effectiveness, randomised, quasi randomised, not random-
ised, cohort studies and case studies greater than N=1. Studies could include any aspect of 
nutrition. Trials could be of any duration, and participants of any age, including adults. 
Studies could measure ADHD symptoms as a primary or a secondary measure. They could 
use any comparator, (eg placebo, treatment as usual, baseline or another intervention) and 
any outcome measure: validated or non-validated; self, carer, clinician or teacher-rated; 
specific measure of ADHD or generalised improvement rating, measure of wellbeing, or 
quality of life; measurement of accompanying symptoms such as anxiety, anger, opposition, 
or school performance. Exclusion criteria were editorials, commentaries and studies with no 
outcome measurement. 
The level of evidence available was considered. Meta-analyses and systematic reviews were 
considered first. If no systematic reviews were found, individual RCT evidence was consid-
ered next. Where no RCTs had been conducted, then lower level evidence was described. 
5.4.2 Search results 
Seventeen meta-analyses were found in twelve articles. Seven investigated the effects of 
poly-unsaturated fatty acids (PUFAs) (Gillies, Sinn, Lad, Leach, & Ross, 2012; Bloch & 
Qawasmi, 2011; Puri & Martins, 2014; Hawkey & Nigg, 2014; Sonuga-Barke, et al., 2013; 
Cooper, Tye, Kuntsi, Vassos, & Asherson, 2015; Pelsser, Frankena, Toorman, & Rodrigues 
Pereira, 2017). One examined the effects of sugar (Wolraich, Wilson, & White, 1995). Four 
examined the effects of artificial food colour elimination (Sonuga-Barke, et al., 2013; 
Pelsser, Frankena, Toorman, & Rodrigues Pereira, 2017; Nigg, Lewis, Edinger, & Falk, 2012; 
Schab & Trinh, 2004). One examined the effects of the Feingold diet (Kavale & Forness, 
1983). Four examined the effects of the ‘few foods diet’ (Pelsser, Frankena, Toorman, & 
Rodrigues Pereira, 2017; Sonuga-Barke, et al., 2013; Benton, 2007; Nigg, Lewis, Edinger, & 
Falk, 2012). 
Some meta-analyses included uncontrolled and un-blinded studies, some amalgamated dif-
ferent types of diet interventions, and one included studies of the ‘few foods diet’ not spe-
cifically aimed at children with ADHD (Pelsser, Frankena, Toorman, & Rodrigues Pereira, 
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2017). Including just interventions conducted on children with ADHD using randomised con-
trolled trial designs reduced the number of analyses to four of artificial colours  (Sonuga-
Barke, et al., 2013; Schab & Trinh, 2004; Nigg, Lewis, Edinger, & Falk, 2012; Pelsser, 
Frankena, Toorman, & Rodrigues Pereira, 2017); two of the ‘few foods diet’ (Sonuga-Barke, 
et al., 2013 & Benton, 2007) and three of PUFAs  (Sonuga-Barke, et al., 2013; Pelsser, 
Frankena, Toorman, & Rodrigues Pereira, 2017; Gillies, Sinn, Lad, Leach, & Ross, 2012).  
No meta-analyses or systematic reviews were found of individual or multi-nutrient supple-
mentation or of a total nutritional approach. Therefore reviews by Stephenson (2014) (for 
the European ADHD Guidelines Group), by Rucklidge (2009), and Pellow (2011) were used to 
extract information regarding individual and multi-nutrient supplementation research. 
Fatty acids (PUFAs) 
The PUFAs were given for between four and 16 weeks, and consisted of omega-3 PUFA, 
omega-6 PUFA, or a combination of both. 
Effect sizes found in meta-analyses were small. Pessler, (2017) found effect sizes of 0.17 for 
parent ratings, and -0.05 for teacher ratings.  Sonuga-Barke, (2013) found an effect size of 
0.21 (most proximal measurement) and 0.17 when restricted to probably blinded assess-
ment. Gillies (2012) also found an effect size of 0.17 in blinded parent rated symptoms. 
Teacher ratings of overall ADHD symptoms found an effect size of 0.05.  
 A range of combinations of fatty acids were tested which makes it problematic to estimate 
the benefits of specific fatty acids. Researchers drew different conclusions on the differen-
tial efficacy of Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA), Gamma-linolenic 
acid (GLA) and combined omega-6 and omega-3 PUFA supplementation.  Some researchers 
suggest a combination of EPA, DHA and GLA is most likely to be efficacious (Hurt, Arnold, & 
Lofthouse, 2011; Schuchardt, Huss, Stauss-Grabo, & Hahn, 2010). Whilst others suggest a 
combination of EPA and GLA, without DHA (Puri & Martins, 2014). 
Few food diets 
The restricted elimination diets tested varied. Three studies tested few foods diets by giving 
children food challenges while on a few foods diet (Boris & Mandel, 1994; Carter, et al., 
1993; Egger, Carter, Graham, Gumley, & Soothill, 1985), and four studies tested few foods 
diets against control diets (Kaplan, McNicol, Conte, & Moghadam, 1989; Pelsser et al., 2009; 
Pelsser et al., 2011; Schmidt et al., 1997). 
Some diets only removed additives (Boris & Mandel, 1994; Kaplan, McNicol, Conte, & 
Moghadam, 1989; Schmidt, Mahle, Michel, & Pietz, 1987). Others were individually tailored 
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restricted elimination diets. Egger et al. removed foods found to be affecting individual chil-
dren, which included cow’s milk, wheat flour, citrus fruit, eggs, artificial colourings and pre-
servatives (Egger, Graham, Carter, Gumley, & Soothill, 1985). Pelssler’s diet consisted of wa-
ter, rice, turkey, lamb, lettuce, carrots, pears, and other whole foods that are unlikely to 
cause allergic reactions (Pelsser, et al., 2011).  Carter et al. tested a diet consisting of vege-
tables, fruits, rice and meat (Carter, et al., 1993).  
Meta-analyses of these elimination diets differ widely in their effect size estimation, and 
vary dependent on whether blinded or unblinded assessments are considered. Pelsser has 
conducted two analyses (2011 & 2017). She found an effect size of 1.2 in 2011, and 0.51 to 
0.80 in 2017 when only blinded RCTs were included for analysis. Nigg (2012) found a smaller 
effect size of 0.29; and Sonuga-Barke et al., (2013) found an effect size of 1.48 which fell to 
0.51 when analysis was restricted to assessments made by probably blinded raters. 
Trials were heterogeneous. Designs were a mix of cross-over and parallel group RCTs. Inter-
ventions varied in how strictly food elimination was applied. Results were inﬂuenced by two 
extreme SMDs from the same research group (Pelsser, Buitelaar et al., 2009; Pelsser et al., 
2011) where concerns were raised over the blinded assessments (Adesman, 2011; Barkley, 
2012). Concerns were due to the fact that the blinded assessments, whilst performed by a 
masked paediatrician, were partly based on information provided by parents who were not 
blinded. The primary outcome measures in these studies were based on parent and teacher 
reports which could not be blinded as they had to supervise the food intake of the child and 
knew whether the child was following an elimination diet.  
Food colourings 
Trials excluded certiﬁed food colours or implemented Feingold-type diets (described in 5.1). 
Results from the four meta-analyses varied. Sonuga-Barke (2013) found an effect size of 
0.42. Pessler, (2017) found effect sizes varying from 0.08 (teacher ratings) to 0.44 (parent 
ratings). Nigg (2012) found effect sizes varying from 0.12-0-18 (adjustment for publication 
biases). Schab & Trinh (2004) found effect sizes of 0.28 to 0.21 when lowest quality trials 
were excluded. 
The effects found are attenuated by the fact that in some trials, selected participants 
showed some prior intolerance (Stevenson, et al., 2014). In the three studies of children not 
already suspected to be responders to food colours (Conners, Goyette, Southwick, Lees, & 
Andrulonis, 1976; Harley et al., 1978; Williams, Cram, Tausig, & Webster, 1978) a SMD of 
0.24 was found (Sonuga-Barke, et al., 2013). This suggests that the value is greatest for 
those sensitive to food colours, but the approach may also be more broadly applicable.  
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It is unclear whether findings are still relevant, since studies were conducted before 2007, 
when the use of artificial food colourings was reduced in the UK in response to a voluntary 
ban requested by the Food Standards Agency (http://food.gov.uk/policy-
advice/additivesbranch/foodcolours/colourfree/#.Uoi-FxrxqjW). 
Multi-nutrients 
Studies of multi-nutrients for ADHD are mostly small, of poor quality, and/or not measuring 
blinded outcomes or ADHD symptoms (Kaplan, Fisher, Crawford, Field, & Kolb, 2004; 
Harding, Judah, & Gant, 2003; Patel & Curtis, 2007; Sinn & Bryan, 2007). For example, the 
study by Kaplan was a small open-label study of eleven children with a variety of psychiatric 
disorders including ADHD (5/11), who took EMPowerplus (consisting of 14 vitamins includ-
ing vitamins D, E, H, and a range of B group vitamins; 16 minerals including calcium, iron, 
magnesium, and zinc; and three amino acids (methionine, phenylalanine, and glutamine). 
After 16 weeks all children were rated as significantly improved in aggression, attention, 
anxiety, delinquency, and mood (Kaplan, Fisher, Crawford, Field, & Kolb, 2004). 
Two double-blinded RCTs have recently been conducted by the same research group 
(Rucklidge, Egglestone, Johnstone, & Frampton, 2017; Rucklidge, Frampton, Gorman, & 
Boggis, 2014). One in adults with ADHD also tested the efficacy of EMPowerplus (Rucklidge, 
Frampton, Gorman, & Boggis, 2014). Clinically significant improvements in inattention and 
hyperactivity/ impulsivity were found (effect size 0.46 to 0.67). The longer patients re-
mained on the micronutrients, the better the effect found. 
Most recently Rucklidge (2017) conducted a blinded RCT of medication-free children (n = 93) 
with ADHD (7– 12 years) who were given micronutrients or placebo for 10 weeks. Intention-
to-treat analyses favoured micronutrient treatment on the Clinical Global Impression scale 
(effect size 0.46). Clinician, parent and teacher ratings of ADHD symptoms did not show any 
group differences (effect size 0.03–0.17), although greater improvements in emotional regu-
lation, aggression and general functioning were found (effect size 0.35–0.66).  
Single supplements 
Three RCTs of zinc supplementation in ADHD have been conducted. Significant effects were 
seen in two trials (SMD 1.06) (Bilici, et al., 2004) (Akhondzadeh, Mohammadi, & Khademi, 
2004), but not in the third (SMD = 0.02) (Arnold, et al., 2011). 
Bilici et al.’s 12-week trial found a significant improvement on ADHD rating scales for hyper-
activity, impulsivity and socialization, but not for attention. Akhondzadeh et al. conducted a 
6-week, double-blind RCT comparing zinc supplementation with placebo in 44 children tak-
ing methylphenidate. Those receiving zinc plus methylphenidate showed significantly better 
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improvements on the DuPaul ADHD Rating Scale than those in the placebo group. Arnold 
randomly assigned 52 children aged 6–14 to zinc supplementation or matched placebo for 
13 weeks with equivocal results. 
Two RCTs have been conducted of supplementation with carnitine and results differed. Van 
Oudheusden & Scholte, (2002) found significant effects for carnitine (SMD = 1.38 (parent 
rating), 0.86 (teacher rating)) whilst Arnold et al. (2007) did not (SMD = 0.23). 
Two studies have examined the effects of iron supplementation on children with ADHD. One 
non-randomised study where 14 boys with ADHD were given iron for 30 days showed a sig-
nificant increase in serum ferritin levels, and a decrease in parent but not teacher ratings 
(Sever, Ashkenazi, Tyano, & Weizman, 1997). An RCT of 23 children with low serum ferritin 
levels (Konofal, et al., 2008) had similar results, but also found significant improvement on 
two clinician-based scales (the ADHD Rating Scale, and the Clinical Global Impression – Se-
verity score). 
The results of some further trials of single supplements are now summarised. Small benefi-
cial effects of low doses of caffeine were found in six participants (Barry, Christopher, & 
Sloman, 1981).  Significant effects of tryptophan (which can increase synthesis of serotonin) 
were found on parent (SMD = 0.99), but not teacher ratings (SMD = 0.03) (Nemzer, Arnold, 
Votolato, & McConnell, 1986).   
St John’s Wort has been noted to increase the levels of serotonin, dopamine and norepi-
nephrine in the brain. In an 8-week RCT (Weber, et al., 2008), 54 children with ADHD were 
randomized to St John’s wort extract three-times daily or a placebo. No significant differ-
ence was found in the ADHD Rating Scale-IV or Clinical Global Impression Improvement 
Scale, although a SMD of 0.56 was measured. One small open trial did however, find im-
provement in ADHD symptoms (Niederhofer, 2010).  
Supplementation with vitamin B6 and magnesium was found to increase serotonin levels 
and reduce hyperactivity in ADHD in a study of 40 children who took the supplements for 8 
weeks. Hyperactivity symptoms returned a few weeks after treatment was stopped 
(Mousain-Bosc, Roche, & Polge, 2006). Supplementation with a low/high dose of vitamin B6 
alone was compared with a low/high dose of methylphenidate and with placebo, in six hy-
peractive children over a 21-week period. Nonsignificant trends suggested that B6 and 
methylphenidate were more effective than placebo but B6 alone was not (Coleman, 
Steinberg, & Tippett, 1979). 
In a nine-week RCT of S-Adenosyl-L-Methionine (the active form of methionine,  required 
for the synthesis of norepinephrine, dopamine, and serotonin), 75% of adult ADHD patients 
showed improvement (Shekim, Antun, & Hanna, 1990). An RCT of 74 children found that a 
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daily dose of Dimethylaminoethanol (an acetylcholine precursor aiding memory, learning, 
and improved mood) for three months was as effective as Ritalin (Lewis & Young, 1975). 
No effects were found of vitamins (Haslam, Dalby, & Rademaker, 1984), bark extracts 
(Trebaticka, et al., 2006), tyrosine (Nemzer, Arnold, Votolato, & McConnell, 1986), or aspar-
tame (Shaywitz, et al., 1994). 
 A global nutritional approach 
A global nutritional approach is defined as being a combination of nutritional approaches: 
supplementation, elimination and eating a healthy diet.  No RCTs were found examining the 
effectiveness of a global nutritional approach, however, in 2007, Curtis and Patel conducted 
a preliminary study of 10 patients diagnosed with ADHD and autism. Over three to six 
months, they eliminated problematic foods (such as gluten, casein, and food additives); 
added more whole foods and supplements (such as probiotics, B group vitamins, and ome-
ga-3 fatty acids); and reduced the children’s exposure to toxins, including house-dust mites, 
mould-causing moisture, tobacco smoke, and pesticides.  
They concluded that children “showed significant improvement in many areas of social in-
teraction, concentration, writing, language, and behaviour”, and suggested that “until we 
know more, the bundling approach appears to be the best use of the environmental-
medicine arsenal”. To date this is the only (small) study of such a global nutritional approach 
(Patel & Curtis, 2007). 
5.5   Summary of the literature review 
The three most researched interventions are few foods diets, artificial food colour elimina-
tion and PUFA supplementation. Of these, the effect sizes of artificial colour elimination and 
PUFA supplementation are probably too small to contribute significantly alone, but may 
contribute to a multi-modal approach. Artiﬁcial food colour elimination in children with sen-
sitivities may be particularly helpful. Trials of vitamins, minerals, amino acids, single and 
multiple nutrients show varied results ranging from negligible to modest, which tend not to 
be replicated. More studies are required before conclusions can be reached on the value of 
any of the supplements tested thus far. 
Researchers concur that the few foods diet may offer novel treatment opportunities, alt-
hough further large-scale studies are needed on unselected children, including blinded as-
sessments and assessments of long-term outcomes (Stevenson, 2014). 
A substantial and growing body of research suggests that diet, both in terms of eliminating 
certain additives, eating healthy foods, and supplementing with an array of vitamins and 
 126 
minerals, may play a role in the treatment of ADHD. Single nutrient interventions are proba-
bly not effective for improving ADHD symptoms. It is suggested that this may be because 
the administration of one nutrient can cause an imbalance in others; and/or because sup-
plementing with one nutrient alone is unlikely to correct all the vulnerabilities present in 
such a complex and heterogeneous disorder as ADHD (Rucklidge, 2016). 
Symptom response to dietary change is likely to differ among individuals, and this needs to 
be considered when designing trials and when interpreting trial results. For example, in 
some studies, children are recruited on the basis of previous responses to foods. 
5.6   The safety of nutritional interventions 
Sonuga-Barke et al. (2013), found that 6 of 12 RCTs on supplementation with PUFAs ap-
praised adverse events. The events noted were minor episodes of symptoms such as dys-
pepsia (Manor, et al., 2012), diarrhoea (Gustafsson, et al., 2010) and occasional nose bleeds 
(Milte, et al., 2012). The studies on artiﬁcial food colour elimination and restricted elimina-
tion diets did not formally report on adverse effects, with the exception of Pelsser et al. 
(2011), where no incidents were found.  
5.7   Stakeholder position on a nutritional approach 
Current NICE guidelines (2008) say that health care professionals should stress the value of a 
balanced diet, good nutrition and regular exercise. They should ask about foods or drinks 
that appear to influence hyperactive behaviour as part of the clinical assessment of ADHD. If 
there is a clear link, then they should advise carers to keep a diary of food and drinks taken 
and ADHD behaviour. If the diary supports a relationship between specific foods and drinks 
and behaviour, then a referral to a dietitian should be offered.  Further management should 
be jointly undertaken by the dietitian, mental health specialist or paediatrician, and the car-
er and child.  
The recently updated NICE guidelines 
(https://www.nice.org.uk/guidance/ng87/chapter/Recommendations#dietary-advice) make 
several negative recommendations. Heath professionals are advised not to advise elimina-
tion of artificial colouring and additives from the diet; not to advise or offer dietary fatty ac-
id supplementation; and not to advise a few foods diet, because there is no evidence about 
the long-term effectiveness or potential harms, and only limited evidence of short-term 
benefits.  
To inform this update, workshops were conducted, which I attended. Elimination diets and 
supplementation with PUFAs were considered. For the assessment, most studies of elimina-
tion diets were excluded (4 because of an incorrect population; 3 because of an incorrect 
 127 
comparator; 13 due to incorrect study design (not RCT or systematic review); 2 with a 
treatment duration under 2 weeks; and 4 not in English), which left only two studies by a 
single author (Pessler 2009 & 2011). Their review of PUFAs found no clinically important dif-
ferences over placebo in ADHD symptoms in the short and long-term. 
Considerable frustration was expressed by the attending clinicians and lay reviewers at the 
workshop about the proposed lack of dietary advice in an area where in their experience it 
is of clinical benefit. The attendant NICE guideline reviewers highlighted the need to retain 
stringent protocols using GRADE (described in section 3.3.5), but acknowledged that such 
frustrations are a common problem.  
A post-workshop response stated that “the Committee agreed that the elimination of artifi-
cial colours and preservatives is an important issue and warrants specific research on its long-
term effectiveness in the management of ADHD. The Committee have therefore added a re-
search recommendation that a randomised controlled trial is conducted to address this ques-
tion. The Committee noted that dietary interventions can be associated with harms, burdens 
on families, and costs. Therefore the Committee were unable to recommend interventions 
without clear evidence of benefit for children and young people with ADHD.” 
(www.nice.org.uk/.../documents/workshop-notes-2). 
5.8   Trial design implications 
5.8.1 Identified issues with current research 
Nutrition is in particular need of testing as a complex intervention. Assessors have criticisms 
of the evidence base which preclude them from making positive dietary recommendations. 
The majority of NICE dietary recommendations (3/5) are negative. NICE furthermore have 
concerns regarding burden, cost and harms. 
The European ADHD guidelines group (Stevenson, 2014) also found the evidence insufficient 
regarding impact on core ADHD symptoms. This was mainly because some studies measure 
non-ADHD outcomes; reviews tend to include trials using nonrandomised designs or in non-
ADHD samples; and unblinded assessments are often used. They also raise the problem of 
generalisability since in some studies children were recruited on the basis of previous re-
sponses to foods.  
Blinded, placebo-controlled RCTs have tested the efficacy of specific nutritional interven-
tions, but no RCTs have yet tested the effectiveness of a total nutritional approach. Consid-
erable research, at considerable cost would be required to generate sufficient evidence for 
NICE of the efficacy of each specific dietary intervention. Furthermore, nutrients interact 
with each other, and, it is unlikely that any single nutrient or dietary approach will prove to 
be a panacea to improve ADHD. 
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Trials of nutritional interventions tend to be short, like trials of pharmaceutical medication. 
This may not be measuring optimum effects because it is likely that the dietary interven-
tions will be more effective if sustained over a long period of time. It is suggested that if diet 
changes are terminated, ADHD behaviours return. The longest trial of the ‘few foods diet’ 
was 5 weeks (Pelsser, 2009 & 2011); of artificial colour elimination 8 weeks (Adams, 1981);  
of PUFAs 4 months (Milte, 2012; Stevens, 2003; Voigt, 2001) (in Sonuga-Barke, 2013).  
5.8.2 Recommendations for future research 
Collectively research suggests that a nutritional approach is warranted:  nutrient supple-
mentation shows some, if inconsistent effects; few foods diets show more consistent evi-
dence of improvements; and there is evidence showing aggravation of ADHD symptoms 
with poor diets. 
Systematic reviewers have called for high quality, bias-proof clinical trials addressing the ef-
fects of dietary exclusions and supplements on children’s behaviour (Sonuga Barke, 2013; 
Stevenson, 2014). The European ADHD guidelines group recommend that in the future, chil-
dren should not be recruited on the basis of previous responses to food stuffs; studies 
should include blinded observations; they should control for nonspecific treatment effects; 
and the course of changes in response to treatment over the medium and long-term should 
be established (Stevenson, 2014). Measurement of a broader range of child, carer, and fami-
ly-related functional outcomes has also been called for (Kidd, 2000).  
5.8.3 The suitability of the TwiCs design  
The TwiCs design addresses some of the design recommendations listed above. Broad re-
cruitment criteria allow for maximum generalisability, with all children with ADHD random-
ised to be offered the intervention rather than just those with food sensitivities. Measure-
ment of the acceptability of the intervention can provide useful information because elimi-
nation diets are difficult to manage: previous studies were of children aged 4-8 because it 
was thought that older children may not be compliant.  
Reviewers specifically called for measurement of blinded outcomes, for non-specific effects 
to be controlled for and for long-term outcomes to be measured. Collection of observations 
from teachers can provide blinded assessment. Measurement of long-term outcomes is a 
feature of the design. But non-specific treatment effects are not controlled for using this 
design. The rationale for not doing so was discussed in section 3.1. 
Collecting real-world outcomes such as school performance, criminality, exclusion and well-
being measures a broad range of functional outcomes.  
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5.8.4 Rationale for treatment by a nutritional therapist 
Testing the effectiveness of a global nutritional approach, as opposed to multiple individual 
trials of separate nutrients or interventions, is indicated for practical and scientific reasons. 
One trial is much cheaper than multiple trials. Treatment by nutritional therapists includes 
individually tailored exclusion of identified aggravating substances, and/or supplementation. 
An individualised approach is indicated since sensitivity to substances is found in some ra-
ther than all those with ADHD. An initial study suggests this is a viable approach (Curtis & 
Patel, 2007). Arguably, improvements might be optimised by both eliminating aggravating 
factors and boosting nutritional deficits.  
Regular consultations with a nutritional therapist would monitor safety and adequate nutri-
ent intake, addressing concerns that children may not receive adequate nutrition. Nutrition-
al therapists can document compliance, which is an important consideration. Regular con-
sultations allow changes to be made gradually, and for each change to be consolidated be-
fore a new change is proposed. This may sustain momentum and provide an incentive to 
maintain dietary changes.  
Professionals working in the field of nutrition have different titles: nutritionists, dieticians, 
and nutritional therapists being just three. Whilst there is considerable overlap between the 
professions, nutrition within the NHS is usually managed by dieticians, who are statutorily 
regulated, only advise where evidence is well established; and tend to advise on optimum 
generic nutrition, for example the healthy plate, rather than on an individualised basis. Nu-
tritionists tend to work for public bodies in an advisory role (http://www.nutritionist-
resource.org.uk).  Nutritional therapists are considered complementary therapists, tend to 
work privately with individuals, take an individualised approach, and consider that dietary 
intervention can be used to prevent, mitigate or cure chronic disease (Kaput & Kaput, 2004). 
Nutritional therapists are not statutorily regulated but have their own code of ethics and 
procedures managed by the British Association of Nutritional Therapists (BANT).  
 
 
 130 
 
Chapter 6 Methods.  
6.1   Aims and Objectives of the pilot feasibility study 
Aims 
The long-term aim of the Sheffield Treatments for ADHD Research (STAR) project is to im-
prove outcomes for children with ADHD, by developing a facility for efficiently and objec-
tively testing multiple interventions for them over the long-term. 
The aim of this thesis is to assess the feasibility of the TwiCs design to provide information 
to enable the evaluation of treatments for ADHD. Therefore the aim of the pilot feasibility 
study is to assess whether the TwiCs trial design can provide suitable information for stake-
holders to enable evaluation of the clinical and cost effectiveness of some treatments for 
ADHD.  
This was done by conducting a small-scale test of the methods and procedures: a three-
armed internal pilot trial of the clinical and cost effectiveness of 2 treatments: (a) the offer 
of adjunctive treatment by homeopaths and (b) the offer of adjunctive treatment by nutri-
tional therapists, compared to (c) treatment as usual. A further aim is to assess the accepta-
bility, deliverability, clinical and cost effectiveness of the two treatments for children with 
ADHD. 
Objectives 
The objectives of this feasibility study are to: 
• assess the feasibility of recruiting to time and target a cohort of children with a diag-
nosis of ADHD  
• test the feasibility and acceptability of the study design  
• test the feasibility, deliverability, safety, acceptability, clinical and cost effectiveness 
of the interventions 
• assess the suitability, acceptability and deliverability of the outcome measures.  
• inform the sample size calculation for the full trial.  
 
Table 18 describes how these objectives will be met. 
6.2   Approvals for the pilot feasibility study 
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6.2.1 Research governance sponsorship 
In line with the Department of Health's Research Governance Framework for health care 
research studies (www.dh.gov.uk), the University of Sheffield was the research governance 
sponsor. The first version of the pilot trial conceived one arm as a trial of polyunsaturated 
fatty acids (PUFAs). When the University of Sheffield Research and Innovation services (RIS) 
were applied to, they recommended contacting the Medicines Health Regulatory Authority 
(MHRA) in case this arm might be considered a Clinical Trial of a Medicinal Product (CTIMP) 
and therefore require MHRA approval. The MRHA did indeed deem that the PUFAs were 
being tested as a medicinal product. Therefore to ensure that the study would not be classi-
fied as a CTIMP, with all the additional bureaucracy that would entail, the PUFA arm was 
substituted with ‘treatment by a nutritional therapist’.  
Sponsorship for the trial testing the effectiveness of treatment by nutritional therapists and 
treatment by homeopaths was received on 10/7/15. Additionally, the study was risk as-
sessed by University of Sheffield Research and Innovation services (RIS) because it was a 
human-interventional study. It was assigned University Research Management System 
(URMS) number 143647. 
6.2.2 Protocol for the pilot feasibility study 
The trial protocol received Independent Scientific Review from Professor Heather Boon 
(University of Toronto); Dr Jack Parker (ScHARR, UoS) and Dr Val Harpin (Consultant Paedia-
trician, Sheffield NHS).  
The trial was registered with the International Standard Randomised Controlled Trials regis-
try, registration number 17723526. (http://www.isrctn.com/ISRCTN17723526) on 
27/04/2015. It was subsequently published in the journal Pilot and Feasibility Studies (Fi-
bert, Relton, Peasgood & Daley, 2018). 
6.2.3 Ethical approval for the pilot feasibility study 
Ethical approval was received from the University of Sheffield School of Health and Related 
Research (ScHARR) Research Ethics Committee (REC). An amendment was subsequently 
sought for the PUFA arm to be replaced with ‘treatment by a nutritional therapist’. Further 
amendments were sought for questionnaires to be completed on-line, and consultations to 
take place in a variety of venues and modes, including on-line (Table 16). 
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Table 16. Ethical approval amendments 
Version Date Amendment 
1 30/4/15  
2 7/10/15. PUFA arm replaced with ‘Treatment by a nutritional therapist’ 
3 2/2/16 addition of an on-line questionnaire; addition of the SNAP out-
come measure; addition of the option for therapists to conduct 
consultations on-line; an additional letter sent to GPs on re-
cruitment of participants  
4 28/4/16 addition of the offer of a £10 Boots voucher incentive for those 
who completed 6 months onwards questionnaires; the option 
to complete questionnaires by phone 
The trial management team concluded that the study was not recruiting research partici-
pants identified from, or because of their past or present use of NHS services (HRA-
decisiontools.org.uk), therefore National Health Service (NHS) REC approval was not sought. 
6.3   Management of the pilot feasibility study 
The trial was overseen by an independent steering committee chaired by Professor David 
Daley, University of Nottingham, and a management committee consisting of myself (Princi-
ple Investigator) and Dr Clare Relton (Public Health, ScHARR, UoS). The committee met 6-
monthly and the management committee met monthly for the duration of the trial. 
6.3.1 Recruitment to the STAR cohort. 
Various recruitment strategies were explored. This included considering recruitment from 
ADHD facilities such as special schools, secure units, NHS facilities, and children engaged 
with nationally and locally funded support services. As no NHS approval was obtained, the 
STAR project recruited through a broad variety of non-NHS sources such as local authority 
based organisations, schools, university based events and listings, clinically relevant support 
groups, clinically relevant conferences, and social media.  
A variety of modes of communication were used: public talks, face to face meetings, phone 
conversations, flyer distribution (Appendix 3), emails, letters, and social media.  
Local Authority organisations 
Application to advertise the project was made to Sheffield Parent Carers, an independent, 
local authority funded group of 1,000+ carers of children with disabilities including 150+ 
with ADHD. They agreed to post an advertisement in their newsletter and send an email to 
all members registering a child with ADHD. 
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Sheffield city council Multi Agency Support Teams (MAST) and the research office for chil-
dren’s services were applied to. MAST were too busy to consider the application, but the 
city council felt the trial met their concerns regarding appropriate management of safe-
guarding, data protection, and consenting children (Appendices 9 & 10). They requested 
that literature refer to ‘carers’ rather than ‘parents’ which was done. They were particularly 
positive about the trial design because children would not be offered the possibility of 
something they may not get.  However, when the STAR project was presented to their 
‘Looked after children’ committee (chaired by an NHS CAMHS paediatrician) the committee 
considered that NHS ethical approval was a pre-requisite.  
Family Action Sheffield were approached. Sheffield City council contract Family Action Shef-
field to run 10-week parenting programmes and conduct home visits for newly diagnosed 
ADHD families. Permission was gained from national Family Action to advertise the trial to 
families they work with. Two weeks after the STAR project started recruiting there was a 
breach of protocol, whereby a Family Action worker erroneously handed out flyers within 
CAMHS: Family Action workers sometimes work alongside NHS staff in NHS premises, but 
since NHS ethical approval had not been obtained, recruitment should not have occurred 
during combined sessions or on NHS premises. It was made clear to Family Action workers 
that the study does not have NHS REC approval. 
The breach of protocol resulted in a challenge to the STAR project recruitment strategy. It 
was claimed that NHS approval is required for all children diagnosed with ADHD. This was 
refuted by ScHARR research ethics committee, University of Sheffield Research and Innova-
tion services, and the chair of the steering committee, who all confirmed that NHS ethical 
approval was not a pre-requisite (see discussion section 9.1.1). 
Schools 
All maintained, private special schools, and mainstream schools with integrated special re-
source units in Sheffield were contacted if they specialised in: Autism and Communication 
Difficulties, Behavioural, Emotional and Social Difficulties, or Learning Difficulties and Com-
plex Needs. They were sent an email describing the project, then visited, flyers left at recep-
tion, reception staff told about the project, and the offer made to speak with the Special 
Educational Needs Co-Ordinator (SENCO). If families recruited to the cohort provided the 
child’s school details, when those schools were contacted they were asked to promote the 
study to any other pupils with ADHD.  
(See Festival of the Mind below for further school-based activity). 
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University based events and listings 
A variety of Sheffield University public engagement events were used to promote the STAR 
project (http://www.sheffield.ac.uk/ris/publicengagement). Before each event, Sheffield 
proximal ADHD support groups were told about the event, and details were posted on the 
STAR Facebook page.  
An illustrated talk was given on a vintage bus in central Sheffield 
(http://www.sheffield.ac.uk/mobileuni). A keynote lecture for Holistic Health at the Hide 
hosted by Pending Coffee Sheffield was given. Talks were given at 24 hour Inspire, and Pint 
of Science, (http://www.sheffield.ac.uk/ris/publicengagement/festivals-and-other-
opportunities/pint-of-science).  
Information about the STAR project was circulated to staff and students at the University of 
Sheffield via University email lists. STAR joined the Sheffield Forum 
(www.sheffieldforum.co.uk) and placed an advertisement about the STAR project in the 
‘Disability and Carers’ and ‘Sheffield parenting’ groups on the forum. 
A Festival of the Mind (http://festivalofthemind.group.shef.ac.uk/) application linked the 
STAR project with Nathan Gordon, hip hop dancer, slam poet and stunt man. An award of 
£5,000 was received which enabled the creation of a performance and video entitled ‘Lost 
Voices’. The poem (Appendix 12) was created based on material gathered by conducting 
workshops in schools and asking STAR project participants for their stories. All special 
schools and schools with special units in Sheffield were offered a workshop and two accept-
ed. Participants were emailed and asked to contribute stories about their experiences of 
ADHD. Those who agreed were contacted by Nathan who listened to their stories. Lost 
Voices was performed on September 18th and 19th 2016 in Sheffield town centre 
https://www.facebook.com/starsheffieldADHD/videos/vb.514537418704645/67738700241
9685/?type=2&theater). 
Newcastle University host an autism spectrum database (ASD-UK) with the aim of helping 
researchers recruit families to studies about ASD that may lead to advances in the care and 
treatment of children, and allowing families to take part in research that aims to answer im-
portant questions about autism spectrum disorders. A formal application to use this data-
base was submitted. 
Clinically relevant groups 
A search on-line was made for local clinically relevant support groups and organisations, and 
the following groups contacted: the Sheffield Autistic Society, Autism plus, Little Rainbows 
(Doncaster), the Autism centre at Sheffield Hallam University, Sparkle Sheffield, Sheffield 
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Asperger’s Children and Carers Together, (ACCT), Ray of Hope (Sheffield Children’s Addi-
tional Needs Support Group). Where groups expressed interest, they were sent flyers, and 
linked with the STAR Facebook page.   
Requests to advertise the STAR project were made to the directors of national groups:  The 
Children’s Sleep Charity (www.thechildrenssleepcharity.org.uk); the Nation-
al Attention Deficit Disorder Information and Support Service (ADDISS) (www.addiss.co.uk); 
the Hyperactive Children’s support group Network, (www.hacsg.org.uk);  the Attention Defi-
cit/Hyperactivity Disorder Online information service (www.adders.org); ADHD solutions 
(cmsms.adhdsolutions.org). Groups placed information about the STAR project on their 
websites.   
The publications ‘Autism Eye’, ‘What the Doctors Don’t Tell You’, and ‘ADHD news’ (the 
quarterly publication of ADDISS) were approached but did not agree to advertise the STAR 
project. Information about the STAR project and requests for participants were made to the 
professional bodies of the therapies being tested: the British Association for Nutritional 
Therapists (BANT) (bant.org.uk); and the Society of Homeopaths (SOH) 
(http://www.homeopathy-soh.org) 
The UK Adult Attention Deficit group (AADD-UK) provide a list of ADHD support groups for 
adults and children throughout the UK (https://aadduk.org/help-support/support-groups/). 
From this list, relevant groups were emailed, including the newly opened Oxford ADHD Cen-
tre (www.oxfordadhdcentre.co.uk). 
Conferences 
The following conferences were attended and oral or poster presentations made (Appendix 
15): 
• World Federation of ADHD conference (Glasgow) (poster presentation) May 2015  
• Homeopathic Research Institute (HRI) Conference (Rome) (oral presentation) June 
2015 
• Research Council for Complementary and Integrative Medicine (RCCM) Conference 
(London) ’Demonstrating the Value of Integrative Medicine’ (poster presentation) 
June, 2015  
• Centre for the study of Childhood and Youth (CCYT) ‘Childhood and Food’ Seminar 
(Sheffield) (oral presentation) February 2016 
•  RCTs in the Social Sciences (York) (oral presentation) September 2016 
• Society of Homeopaths Annual Conference (Nottingham) (oral presentation) Sep-
tember 2016  
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In addition the following events were attended, and flyers distributed:   
• the Homeopathic Medical Association Annual Conference April 2016 
• NICE guideline ADHD (standard update) scoping workshop (London) December 2015 
•  NICE Nutrition Guidelines for ADHD workshop (Manchester) September 2015 
• Food and Behaviour (FAB) Conference (Sheffield) October 2015 
• Treating Autism Conference (Brunel University) (stand taken) June 2016 
 
Social media 
A STAR Facebook page was created with links to the on-line questionnaire, relevant events 
attended or spoken at, ADHD articles, STAR newsletters,  Facebook pages of ADHD organisa-
tions ADHD/ASD SUPPORT GROUP - UK/I, ADHD action, ADHD comms, ADHD Richmond, 
ADHD matters, ADHD solutions, and ADHD South Yorkshire 
(www.facebook.com/starsheffieldADHD). BBC Sheffield presenters were contacted and 
Twitter and LinkedIn accounts used to advertise the STAR project. 
6.3.2 Cohort inclusion and exclusion criteria 
These were kept to a minimum to maximise external validity.  
Inclusion criteria for the STAR cohort were children aged 5-18 (inclusive) with a carer re-
ported diagnosis of ADHD and a carer reported Conners’ Global Index (CGI) T score of at 
least 55, which denotes mild a-typicality (Table 17). All co-morbidities were eligible for inclu-
sion and children could be participating in any other interventions for their ADHD. 
Exclusion criteria to the STAR cohort were children below the age of 5 or adults over 18; 
children with terminal conditions such as cancer; families where English was not written or 
spoken (as the project does not have funds to provide a translation service at this stage). 
Table 17. Interpretive guideline for Conners Global Index  
T score Percentile Guideline 
70+ 98+ Markedly Atypical (Significant problem) 
66–70 95–98 Moderately Atypical (Significant problem) 
61–65 86–94 Mildly Atypical (Possible problem) 
56–60 74–85 Slightly Atypical (Borderline) 
<30–55 <2–73 Average (Typical: Should not raise concern)  
(Extracted from Conners. 2008) 
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Inclusion criteria for the pilot trial were a carer reported ADHD diagnosis and a carer re-
ported CGI T score of at least 65, which indicates a significant problem.  
Exclusion criteria for the pilot trial were children currently receiving treatment by a home-
opath or a nutritional therapist; and children with CGI T scores below 55 (Table 17).  
Emails were sent to families returning questionnaires whose child did not fulfil inclu-
sion/exclusion criteria explaining the reason for the exclusion and thanked them for their 
interest.  
6.3.3 Randomisation to the first pilot trial 
Randomisation was performed by an independent statistician at ScHARR: Professor Mike 
Campbell. There were three stratifying factors in blocks of 6: age (primary school 5-11 / sec-
ondary school 12-18); medication status (yes/no); ADHD severity (T score 80+/under 80) 
(Table 17). These stratifying factors were selected since they were considered likely to influ-
ence treatment response. Age and ADHD severity may influence both treatment response 
and drop out, whilst medication status was selected since other research into a CAM thera-
py has suggested that those on medication may respond differently to those not on medica-
tion (Hong, 2016). 
The randomisation list was housed in the locked drawer of another independent statistician 
at ScHARR: Dr Evangelos Kritsotakis. On recruitment to the cohort, age, ADHD T score, and 
medication status were extracted from the questionnaire. Participants fulfilling inclusion 
and exclusion criteria who consented to be contacted again were identified and their anon-
ymised information sent to Dr Kritsotakis by email, who randomly assigned them to one of 
three groups: the offer of treatment by homeopaths; the offer of treatment by nutritional 
therapists; or treatment as usual. Each participant was allocated a randomly generated 
three-digit code, by which participants were subsequently identified. Those randomised to 
treatment as usual were not informed that they had not been selected for a treatment. 
6.4   The offer of treatment 
Those randomly selected to be offered a treatment were sent a letter (Appendix 6) offering 
them one year of treatment. The letter gave a brief description of the treatment and what 
to expect; a request to the carer to ask their child if they are happy to participate; a consent 
form to treatment, to be signed by both carer and child and returned in a pre-paid enve-
lope; and an email address and telephone number as an alternate means of contact.  
The PI then rang the selected participants a week later to ask if they had any questions, and 
if they wished to take up the offer (if their form hadn’t yet been returned). If both carer and 
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child consented, they were told them the name of their designated therapist, and asked for 
their permission to pass on their contact details to that therapist. In the absence of a re-
turned ‘consent to treatment’ form, carer and child’s wish to participate on the telephone 
was taken as verbal consent, and the form completed at the first meeting with the therapist, 
who further explained what treatment will constitute, as befits usual practice. Appropriate 
marks by young children were taken as signatures. 
Participants were rung and emailed at least three times each before being considered non-
responders.  Both non-responders and participants refusing the offer of treatment were 
sent outcome measures to complete as usual every 6 months.  
6.5   Delivery of the interventions  
Treatment by homeopaths, and treatment by nutritional therapists are not currently offered 
in routine health care by the NHS. Both interventions are generally paid for privately and 
delivered at complementary health clinics. Therefore eight therapists (4 nutritional thera-
pists and 4 homeopaths) were initially recruited via Wellforce Integrated Medicine Clinic, 
which offers complementary therapies in Sheffield. 
Both interventions (the offer of treatment by homeopaths and the offer of treatment by nu-
tritional therapists) were offered to participants for a maximum of one year consisting of up 
to 8 appointments, resulting in up to 7 contact hours. Once participants had accepted the 
offer of a treatment, their contact details were given to the most proximal, available thera-
pist, who then arranged a mutually convenient time, and venue/mode for a consultation. If 
therapists failed to make contact with a participant after 3 phone calls and 3 emails, that 
participant was deemed a non-responder. 
Consultations took place in a variety of non-NHS premises (Wellforce Complementary Medi-
cine Centre (Sheffield); Western House Consulting rooms (Barnsley), Beighton Lifestyle Cen-
tre (Sheffield), and patient’s or practitioner’s homes. They were delivered face to face, by 
telephone, or on-line. Consultations mirrored usual practice in that any missed appoint-
ments were rebooked, and venues, times between consultations, and number of consulta-
tions all varied.  
Before the trial began, all therapists who were going to deliver the therapies attended 
workshops run by the PI. The workshops trained them in management of ADHD and how to 
recognise and respond to any serious adverse events (Appendices 9 & 10).  All therapists 
completed the on-line Sheffield safeguarding children child protection course 
(Safeguardingchildrentraining@sheffield.gov.uk). Homeopaths were given training in a spe-
cific homeopathic methodology for treatment of exposure to environmental toxins, which 
had been found to be useful in the case series (Fibert, Relton, Heirs, & Bowden, 2016). 
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After each consultation, therapists completed a form (Appendix 2) which included the date, 
consultation number, MYMOP score, treatment summary and progress, and reported any 
adverse event. On the occasion of an adverse event, an additional form was completed (Ap-
pendix 9). 
Therapists asked participants for their GP’s details and permission to contact them.  GPs 
were then sent a letter explaining that their patient was participating in a trial (Appendix 7) 
and describing the ethical approvals and safeguards in place. The letter explained that the 
interventions were adjunctive, and participants advised to continue with any treatments 
that had been prescribed by their GP; and that interventions shouldn’t interfere with phar-
maceutical medication.   
6.5.1 Treatment by homeopaths 
Homeopaths in the trial were all trained, insured and experienced in the treatment of 
chronic conditions. They were registered with one of the four main bodies representing 
homeopaths in the UK (Alliance of Registered Homeopaths, Faculty of Homeopathy, Home-
opathic Medical Association, or Society of Homeopaths). Initially only homeopaths living in 
or near Sheffield were included. After 4 months, 3 new homeopaths were recruited from 
another complementary health clinic (Marlow Homeopathy, in Buckinghamshire) to conduct 
on-line consultations.  
Treatment consisted of an initial consultation of up to 1½ hours between carer, child and 
homeopath, and up to seven follow up appointments with the same homeopath of 30-40 
minutes at approximately 4–6 week intervals. After each consultation, individually tailored 
homeopathic remedies were prescribed by the homeopath based on information obtained 
during consultations. Carers were free to contact the practitioner between appointments 
with queries. 
The initial consultation focussed on building up a complete picture of the participant, con-
sidering all aspects including diet, medical history, life events, likes and dislikes, lifestyle, be-
haviour and personality. Prescription of a homeopathic remedy was made by homeopaths 
matching the composite of symptoms as closely as possible with those of an appropriate 
remedy. Homeopathic remedies were provided in the homeopath’s usual manner: either at 
the end of the consultation, or sent by post, with instructions about how to take them. Fre-
quency and dosage varied according to the assessment of the homeopath.  
At follow up consultations, both carer and child were asked about any changes in symp-
toms. Depending on this information, the homeopath either continued with or changed the 
prescription. If carer and child reported improvements there was usually no change in pre-
scription. If no improvements were reported the prescription was usually changed. 
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6.5.2 Treatment by nutritional therapists 
All trial nutritional therapists were registered with the British Association of Nutritional 
Therapists and were members of the Complementary and Natural Health care Council. At 
the first consultation of 1 – 1 ½ hours, a health history was taken where nutritional thera-
pists asked about diet preferences, types of food eaten (e.g any ready meals, types of fats, 
types of drinks, any organic foods, sugar intake), typical daily diet, any food intolerances, 
lifestyle (sleep, smoking, mercury fillings, medication usage, activity levels), stressors, family 
history, diagnoses, health concerns, diet related symptoms.   
After documenting this information, a summary sheet, supporting handouts, supplement 
sheets, recipes, and meal ideas were sent to participants. At subsequent consultations of 
30-40 minutes, the plan was reviewed and revised, dependent on the family’s ability to as-
similate and put suggestions into practice.  
A range of options tailored to each participant were discussed during consultations. These 
included: elimination diets such as gluten free and/or casein free; reducing intake of known 
problematic substances (e.g food colourings, sugar, simple carbohydrates); increasing intake 
of healthy foods (oily fish, nuts and seeds, protein, fruit and vegetables); substituting less 
healthy foods with healthier ones; balancing blood sugar; improving drinks/fluids intake, 
lifestyle advice (sleep, activity, purpose, relaxation, time outdoors); specific dietary inter-
ventions for symptoms (particularly gut related); and supplements, which were provided 
free or discounted by three supplement companies: Igennus, Lamberts and Nutri-Link. 
These included  Vegepa  (a polyunsaturated fatty acid from Igennus); children’s multi-
vitamins, Saccharomyces Boulardii, and Lactobacillus rhamnosus GG probiotic combinations 
from Nutri-link and Lamberts). Recommended daily intake was 1 capsule each of the pro-
biotics and fatty acids, and 1-3 Multi-vitamin tablets daily depending on age and size. 
6.6   Adverse event management 
Adverse events were recorded according to the Common Terminology Criteria for Adverse 
Events (CTCAE, 2010) guidelines and European Commission (2011) guidelines, graded as fol-
lows:  
• Grade 1: Mild; asymptomatic or mild symptoms. Intervention not indicated.  
• Grade 2: Moderate; minimal, local or non-invasive intervention indicated.  
• Grade 3: Severe or medically significant but not immediately life-threatening; hospi-
talisation or prolongation of hospitalisation indicated; resulting in significant disabil-
ity or incapacity. 
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• Grade 4: Life-threatening consequences; urgent intervention indicated. Subject at 
risk of death. 
• Grade 5: Death related to AE. 
All therapists were provided with Adverse Event Assessment Guidelines (Appendix 9) which 
instructed them to ask about any adverse events experienced in response to treatment at 
each consultation, and report events of level 3 or more to the PI within 24 hours using an 
Adverse event form (Appendix 9) and ask participants to contact their GP. 
6.7   Risk Management 
Therapists were trained to identify and manage children suspected of experiencing any kind 
of abuse, since ADHD and abuse symptoms can present similarly. They were provided with 
Risk Guidelines (Appendix 10), based on section 47 of the Children Act 1989 outlined in the 
Department of Education Safeguarding Policy (2015). This recommends that confidentiality 
between therapist and family be maintained unless the therapist deems the risk of abuse 
great enough to require activating statutory safeguarding procedures. Therapists were ad-
vised to only breach confidentiality after discussion with the PI, who would then discuss the 
case with the management committee within 24 hours, and if appropriate, inform the par-
ticipant’s GP with the participant’s permission.  
6.8   Data collection and analysis methods 
6.8.1 Sample size for cohort and trial 
It was estimated that 140 participants needed to be recruited to the STAR cohort in order to 
have outcomes for 30 participants in each arm. 30 in each arm is considered sufficient to 
estimate the pooled standard deviation of the outcome with a reasonable degree of preci-
sion for the full trial (Sim, 2011; Hayman et al 2012).   
It was estimated that 20% of children joining the STAR cohort would either not meet trial 
inclusion criteria or not accept the offer of treatment: 80% of 140 = 112. Attrition of a fur-
ther 20% was estimated based on the author’s preliminary feasibility controlled case series 
(Fibert, et al., 2016). 80% of 112 = 90.   
6.9   Outcome collection and measurement 
Outcomes were collected from both carers and from children’s school teachers at baseline 
and 6 months. Carers completed on-line or paper questionnaires (Appendix 2a) in which 
they named the child’s school and suggested a member of staff who knew their child well. 
Schools were then sent a letter asking this member of staff (or someone else who knew the 
child well) to complete an enclosed paper questionnaire (Appendix 2b). Carers were re-
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minded to return 6-month and one-year questionnaires via 3 x emails and 3 x text messag-
es, after which they were considered non-responders. Teacher outcomes were requested 
just once by post, addressed to the Head teacher of the school. 
6.9.1 Primary Outcome Measure 
The primary outcome measure was the ten item Conners’ Global Index Rating Scale (CGI), 
and sub-scores: restless/impulsive (7 items) and emotional lability (3 items) (described in 
section 3.4.1). Unblinded carer and blinded teacher scores were analysed separately. Raw 
scores were analysed since ceiling effects occurred with T scores.  
6.9.2 Sub-group analyses 
Sub-group analyses were performed for those with autism, and those taking/not taking 
medication. Those with autism were selected since they may respond differently to treat-
ments and have an unmet need for effective treatments (section 2.3.1). Identification of 
those with co-occurring autism was possible since carers were asked to name all the co-
occurring diagnoses their child had received when they completed the CQ. 
Analysis was made of those taking or not taking medication for their ADHD to explore 
whether medication status had any effect on outcomes. When they completed the CQ, car-
ers were asked to name the medications their child was taking, which enabled the identifi-
cation of their medication status.  
6.9.3 Secondary Outcomes 
Health related quality of life (CHU 9D) was analysed to potentially enable an economic eval-
uation alongside the clinical trial. Preference weights were obtained from the creator of the 
measure (Stevens, 2010) described in section 3.4.5.  Responses to individual items at base-
line and 6 months were described (Appendix 14). 
Five months after the trial started (February 2016) the 18 item Swanson, Nolan and Pelham 
ADHD index (SNAP IV) was added (described in section 3.4.1). This was advised by the steer-
ing committee chair, who recommended measuring specific ADHD symptoms, and because 
it is free to use compared to Conners questionnaires which have to be purchased.  
Teachers, who did not know the allocation status of the children, were asked ‘how disrup-
tive has this child had been in the classroom during the last 2 weeks’; ‘how many days off 
school has this child had in the last 6 months’; ‘has this child been excluded from school dur-
ing the last 6 months’; ‘does this child has a teaching assistant and if so, for how many 
hours?’; and ‘does this child receive any other help in school for their ADHD?’ (Appendix 2b).  
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The carer questionnaire (CQ) asked carers to estimate the number of visits they had had 
with their child over the last 6 months with doctors, hospitals, social workers, and the po-
lice.  They were asked whether they had attended or were attending the Family Action or 
another parenting class, sessions with a psychologist, or homeopathic treatment. They were 
also asked to describe any other help they accessed for their child, and, on the request of 
the families piloting the questionnaire, a blank page was left for anything else they wanted 
to tell us (Appendix 2a).  
6.9.4 Cost effectiveness 
The cost of treatment by a homeopath and a nutritional therapist over one year was rec-
orded. This included the cost of consultations, venue hire, remedies, supplements, and 
therapist’s wages. Data was collected under guidance from a health economist from 
ScHARR, and as recommended by NICE (2008). The health related quality of life measure 
CHU 9D used enables QALY calculation (section 3.4.5). Rudimentary analysis was conducted 
as a preliminary test of the design and measures. 
6.9.5 Statistical methods  
Analysis was conducted by the PI. IBM SPSS 21 statistical software was used. All statistical 
exploratory tests were two-tailed with significance level (alpha) set to 5%.  95% confidence 
intervals were presented. Each treatment was compared with usual care by creating dummy 
variables.  
Outcomes were measured by carers and (blinded) teachers at baseline and 6 months. 
Change scores were calculated by subtracting 6 month scores from baseline scores (lower 
scores indicate better outcomes). This meant positive change scores indicated improve-
ment, and negative change scores indicated worsening. Statistical tests were conducted on 
the primary outcome (Conner’s Global Index Scale short form (CGI) (10 items) and its sub-
scales; and secondary outcome, health related quality of life. SNAP was not analysed since it 
was introduced 6 months into the trial and insufficient comparisons were available. Descrip-
tive statistics were presented for resource use.  
Statistical testing was exploratory since the study was not powered to detect statistical dif-
ferences. Analysis focussed on confidence interval estimation rather than hypothesis test-
ing. A General Linear Model (GLM) was used. Regression analysis explored the predictive 
power of the offer of treatment. CGI change score was the dependent variable. Group (the 
offer of homeopathic treatment or the offer of nutritional therapy, analysed separately) 
were independent variables.  Analyses controlled for the effects of gender 
(male=0/female=1), ADHD severity (CGI baseline score) and age by including them as covari-
ates.  
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Intention to Treat analysis 
For the primary analyses all participants offered treatment remained within the treatment 
group regardless of whether or not they took up the offer of treatment. Intention to treat 
(ITT) analysis is considered the most appropriate analytical approach for pragmatic trials 
(Campbell, 2007) and is advocated by the CONSORT guidelines for reporting trials (Moher et 
al., 2010; Zwarenstein et al., 2008).  
Numbers and percentages were calculated regarding the acceptability of the offer of treat-
ments. Statistical tests were carried out to identify any systematic characteristics of the age, 
gender and ADHD severity of those who did and did not accept and receive treatment. 
Clinical difference 
Standard mean differences (SMDs) (Cohen’s d) were calculated to ascertain the clinical ef-
fect. The minimal difference to proceed to a full trial was considered to be a SMD of 0.3 
(Table 18). The mean treatment change (baseline - 6 months) was subtracted from the 
mean usual care change, and divided by the pooled variance (collective standard deviation 
adjusted for sample size). The equation below, for comparison of independent samples, was 
followed (Lakens, 2013). The effect size calculator provided by Rstats was used 
(https://www.missouristate.edu/rstats/Tables-and-Calculators.htm). ds = the standardized 
mean difference between two groups of independent observations. 1 = intervention group.  
2 = control group.  M = mean change score. n = number of participants. SD = standard devia-
tion. 
ds =
M1 -M2
(n1 -1)SD1
2 + (n2 -1)SD2
2
n1 +n2 - 2  
Missing data strategy  
To assess whether data was missing completely at random (MCAR) or missing not at random 
(MNAR) (Rubin, 1976), baseline differences were compared across the three groups, and 
between those accepting and not accepting the offer of treatment. Post hoc tests were per-
formed if differences were identified. Missing data were imputed using mean substitution 
for baseline data and Last Observation Carried Forward (LOCF) for 6-month data. 
6.10 Feasibility criteria 
This pilot RCT assessed the feasibility of the design and interventions. Table 18 summarises 
the feasibility criteria. Key criteria were the ability to recruit a cohort and to recruit to the 
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interventions within the stated time frame of two years. This was assessed by measuring 
recruitment rates and time taken. Numbers recruited in two years were extrapolated to es-
timate the time needed to recruit to a full trial, and longer than 4 years not considered fea-
sible.  The feasibility of recruiting a representative cohort documented ADHD severity, num-
ber and type of co-morbidities, medications taken, resource usage, levels of exclusion and 
criminality, and recruiting from nationally funded ADHD facilities such as special schools, 
secure units, NHS facilities, and support services. These were presented narratively.  
Whether suitable homeopaths and nutritional therapists could be recruited was assessed, 
with recruitment of two therapists for each intervention considered the minimum required. 
The uptake and acceptability of treatment measured the number of appointments kept and 
missed; the taking of homeopathic remedies; the implementation of advice, diets, and the 
taking of supplements. At least 30% needed to have accessed treatment, and at least 70% of 
those to have attended at least three consultations. 
It was anticipated that there might be high dropout rate and chaotic uptake. The percentage 
of participants refusing treatment was therefore considered to determine acceptable levels 
of refusal since too many refusers may lead to high chance of a type II error, and inadequate 
information to estimate critical parameters for a full trial with reasonable precision.    
Adverse events were documented. Any severe adverse events as a result of treatment 
meant the intervention would not continue to full trial.  
The acceptability of the outcome measurements assessed rates of completion by parents 
and teachers at each time point in the study. Collection methods were adjusted if necessary. 
Their suitability was assessed by ascertaining whether information could be accurately and 
usefully collected about ADHD symptoms, health related quality of life, criminality, school 
exclusion, attendance, extra help, professional resource use, medication and other interven-
tion use, and adjusted as necessary. Whether CGI and SNAP are appropriate and sensitive 
enough to measure therapist and participant perceived change was assessed with measures 
to be adjusted accordingly if any systematically missing items are identified. The suitability 
and appropriateness of statistical analyses to interpret results was also assessed.
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Table 18. Feasibility Criteria 
Criteria Measurement Criteria for continu-
ation to a full trial 
Discussion 
Recruitment 
to cohort 
rates 
# recruited in 2 years % recruited /sample 
size estimation.  
The minimum to proceed to a full-scale trial will consider the number of years needed to recruit the 
required sample size. Numbers recruited in 2 years will be extrapolated to determine how long a full 
trial would need to be. The required sample size will be divided by the percentage recruited in 2 
years. Duration of the full trial of more than 4 years will not be considered feasible. 
Recruitment 
to treatment 
rates 
% accepting offer At least 30%.  The percentage of participants refusing treatment will be considered to determine acceptable levels 
of refusal. Too many treatment refusers may lead to a high chance of a type II error and inadequate 
information to estimate critical parameters for a full trial with reasonable precision. 
Treatment 
effects (statis-
tical signifi-
cance) 
Standard mean difference 
(SMD) CGI  
Mean = < .3.  Since neither intervention has been tested previously, estimation of the effect size cannot consider 
previous estimates. Since some preliminary evidence of helpfulness is required, a SMD of 0.3 in those 
having one or more consultations will be considered sufficient to proceed to full trial. 
Treatment 
effects (clini-
cal signifi-
cance) 
CGI T score 5 percentiles.  A T score change of 5 percentiles is considered clinically significant, since the child has moved from 
one level of severity to another according to Conners (2005) (see Table 4.4.1). 
Attrition: co-
hort 
# PQ’s returned at 6 
months 
At least 30%  
Attrition: con-
sultations 
# consultations attended 70% accepting the 
offer attend 3 con-
sultations.  
Therapists will note the number of consultations attended and missed and dropout rates. It is hy-
pothesised that there will be a high dropout rate and chaotic uptake. These statistics will inform the 
parameters of the full trial. The nutritional therapists will note the acceptability of the different 
treatments 
Acceptability 
of TQ and CQ 
#TQs and CQs completed at 
baseline and 6 months; # 
email/telephone/ paper 
responses 
Adjustment of 
measure, collection 
methods and trial 
parameters.  
Questions reworded or removed dependent on discussion with carers and teachers, and optimum 
means of delivering questionnaires explored. An initial scoping exercise suggests that some schools 
may be reluctant to disclose sensitive information and poor at returning questionnaires. 
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Adverse 
events 
Clinicians records No severe adverse 
events  
As defined by the Common Terminology Criteria for Adverse Events (CTCAE, 2010) guidelines and 
European Commission (2011) guidelines. 
Appropriate 
outcome 
measurement  
# missing items  Adjustment of 
measure.  
 
Recruitment 
of therapists 
# recruited fulfilling criteria At least 2 of each 
therapy 
 
Statistical 
analysis 
ANCOVA Meets assumptions  
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Chapter 7 Results of recruitment to the STAR cohort and 1st pilot trial  
The aim of this chapter is to describe the results of recruitment to the cohort, and the pilot 
trial, provide preliminary indications about the acceptability, clinical and cost effectiveness 
of the two potential interventions for ADHD, and inform sample size calculation for a full 
trial.  
Statistical testing is exploratory. It is suggested that pilot trial analysis should be mainly de-
scriptive because there is likely to be an imbalance in pre-randomisation co-variates, and 
imprecision in confidence interval estimation (Carfoot, 2002; Lancaster, Dodd, & 
Williamson, 2004). 
Results are considered as thresholds to be reached to see whether sufficient a priori speci-
fied differences (identified in Table 18) were seen from the interventions to proceed to the 
full trial. The statistical analyses are pilot tested to ensure their appropriateness. 
7.1   Recruitment to the cohort 
144 participants completed the carer questionnaire over a period of 13 months, between 
September 2015 and September 2016. This was the means by which participants were re-
cruited to the STAR cohort. 19/144 (13%) did not meet cohort inclusion criteria (Figure 2) 
(Inclusion criteria described in section 6.3.2) or could not be included. 140 completed an on-
line version (www.starsheffield.com) and four completed a paper version. The questionnaire 
was mostly completed by people describing themselves as mothers, with the exception of 
an adoptive mother, a legal guardian, an auntie, two foster mothers, a father, and a step 
mother. 
Figure 2. Reasons for exclusion from the STAR cohort 
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Figure 3. Study progression 
 
 
7.2   Recruitment to the trial 
125 cohort participants were eligible for the trial and randomised (stratified according to 
age, medication status and ADHD severity) to one of three groups. 84 were randomised to 
be offered a treatment: 42 to treatment by homeopaths (hom), 42 to treatment by nutri-
tional therapists (NT), whilst 41 were randomised to remain in the usual care group (TAU).  
A total of 20 participants were female, and the mean age was 10.21 (Table 19). 
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One child randomised to treatment by a homeopath was found to be very sick and awaiting 
a liver transplant when telephoned to be allocated a therapist. This was in violation of the 
protocol and he was withdrawn from the trial.  
7.3   The offer of treatment 
72 of the 83 participants offered a treatment accepted it. 50/72 (n=23 hom; n=27 NT) took 
up their offer and had at least one consultation. Figure 4 describes the progression from re-
cruitment to the cohort (n=144), through to take up of the offer, describing why n=33 (n=18 
hom; n=15 NT) did not take up the offer.  
Figure 4. Participant progression from cohort recruitment to first consultation 
 
7.3.1 Trial participant characteristics  
The groups were well matched at baseline regarding ADHD severity, age, and medication 
status due to stratification.  Groups were not stratified for gender or co-occurring autism 
and those with autism were disproportionately distributed, with fewer in the group random-
ised to the offer of NT than to the offer of hom or to TAU (Table 19). 
Those participants who received a treatment were less likely to have autism or be on ADHD 
medication. Loglinear analysis explored the effect of the disproportionately distributed 
ADHD medication status in those accessing treatment. The dichotomous variables entered 
were: group participants belong to (1,2); whether participants take ADHD medications (0,1); 
and accepting the offer of treatment (0,1). All two and three-way effects were non-
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significant regarding the acceptance or not of treatment and medication status (Table 20), 
although results may not be robust due to small numbers for some combinations. They are 
included but must be viewed with caution. 
Table 19. Baseline demographic and clinical characteristics of study participants according to carers 
Outcome Hom of-
fered  
Hom re-
ceived  
NT of-
fered  
NT re-
ceived  
TAU  All  
 Sample size 
Baseline  N=41 N=23  N=42  N=27  N=41  N=124  
 Mean (Standard Deviation) 
Age  10.17 
(2.42) 
9.78 (2.22) 10.05 
(2.46) 
10.22 
(2.68) 
10.41 
(2.49) 
10.21 
(2.44) 
Female 8 (19.5%) 5 (21,7%) 7 (16.6%) 4 (14.8%) 5 (12.2%) 20 
(16.1%) 
Taking pharmaceuti-
cal medication 
28 (68%) 13 (56.5%) 29 (69%) 20 (74%) 27 
(65.9%) 
84 
(67.7%) 
Have autism 13 (10%) 6 (5%) 9 (7%) 6 (5%) 15 (12%) 37 (30%) 
       
CGI T score baseline 88.44 
(3.65) 
82.40 
(5.55) 
86.69 
(7.52) 
76.29 
(8.73) 
86.9 
(6.45) 
87.34 
(6.1) 
CGI raw score base-
line  
24.0 
(3.48) 
23.48 
(3.27) 
23.07 
(4.12) 
23.4 
(3.87) 
22.27 
(4.62) 
23.1 
(4.17) 
Restless/Impulsive 
baseline 
17.61 
(2.63) 
17.3 (2.55) 17.4 
(3.09) 
17.67 (3) 16.98 
(3.41) 
17.33 
(3.05) 
Emotional lability 
baseline 
6.39 
(1.56) 
6.17 (1.59) 5.67 
(2.09) 
5.74 
(1.99) 
5.29 
(1.93) 
5.29 
(1.92) 
Table 20. Log-linear analysis checking whether medication status affected acceptance of treatment 
 
K df 
Likelihood Ratio Pearson 
Number of Iter-
ations Chi-Square Sig. Chi-Square Sig. 
K-way and Higher Order 
Effects (Tests that k-way 
and higher order effects 
are zero) 
1 7 66.528 .000 63.410 .000 0 
2 4 8.179 .085 7.832 .098 2 
3 
1 .904 .342 1.022 .312 3 
K-way Effects (Tests that 
k-way effects are zero) 
1 3 58.349 .000 55.577 .000 0 
2 3 7.275 .064 6.810 .078 0 
3 1 .904 .342 1.022 .312 0 
7.4   Collection of Outcomes 
7.4.1 Carer reported outcomes 
124 (100%) baseline questionnaires were returned since this was how participants regis-
tered to the STAR cohort.  88 (72%) six-month questionnaires were returned. Of those ran-
domised to a treatment, the majority (20/29 hom; 24/28 NT) of returned questionnaires 
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were returned by those who had that treatment (Table 21). There were no instances of 
missing data in baseline questionnaires, and five instances of missing data in 6-month CQs 
completed on paper. Last observation carried forward was used to impute data as stated in 
the protocol (section 6.9.5).  
Table 21. Number of carer questionnaire returns at 6 months 
Total number of 
questionnaires 
requested 
Number 
returned 
Number NOT 
returned 
 
Number returned by 
those NOT having a 
treatment 
Number returned by 
those having a 
treatment 
Total: 124 88 37   
Usual Care: 41 31 10 n/a n/a 
Hom: 41 29 12 9 20 
NT: 42 28 15 5 23 
7.4.2 Teacher reported outcomes 
Teacher outcomes were potentially available from a maximum of 100 teachers, since 20 
carers refused permission for their child’s school to be contacted and 4 children were home 
schooled (Table 22 shows the distribution according to group).  31 paired questionnaires 
(baseline and 6 months) were available for analysis (11 (hom), 8 (NT) and 12 (TAU), of which 
7/11 (hom) and 4/8 (NT) were from those accessing a treatment (Table 23). 
Table 22. Explanation for missing teacher questionnaire returns at baseline according to group 
 Permission given to request 
teacher questionnaire 
Carer does not give 
permission to request 
teacher questionnaire 
Child is home 
schooled 
 
 homeopathy 30 8 3 41 
Nutritional Therapy 37 5 0 42 
TAU 33 7 1 41 
Total 100 20 4 124 
Table 23. Teacher questionnaire returns at baseline and 6 months according to group. 
Number of 
questionnaires 
requested 
Number 
of base-
line re-
turns 
Number 
of 6 
month 
returns 
Number of 
paired ques-
tionnaire re-
turns 
Number of paired 
questionnaire 
returns by the 
same teacher  
Number of paired 
questionnaires re-
turned for those 
having a treatment 
Total:  100 72  34 31 20 23 
Hom: 30 21  14 11 10 7 
NT: 37 23 8 8 4 4 
Usual Care: 33 28  12 12 6 12 
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7.4.3 Data cleaning and screening 
The SPSS dataset was first cross-checked with the original google sheet and then screened 
for any missing values and outliers using SPSS descriptive statistics. Where missing values or 
values outside the correct range were found, values from the original data were checked 
and correct values input. In 3 instances where age was 0, the correct age was found to be 
11. In one instance age had been input as 9.5, and therefore categorised separately, so it 
was re-input as 9. In two instances the level of disruption (measured using a Likert-type 
scale from 0-5) was 22 and 33 and should have been 2 and 3. Likewise three SNAP scores of 
22 and 21 should have been 2. 
Missing values for CGI and SNAP baseline Teacher questionnaires were imputed using mean 
substitution in accordance with recommendations by tool developers (Conners, p31, 2009): 
1 item from CGI3 was missing; 1 item from SNAP8 was missing; 26 items from SNAP9 were 
missing due to a printing error; and 1 item from SNAP 17 was missing. 
7.5   Data analysis 
For the primary ITT analysis all paired, returned data was analysed. The per protocol primary 
analysis (described in section 6.9.5) measured the effect of the offer of a treatment on the 
10 item Global ADHD symptom (CGI) change score (and 7 item restlessness/excitability sub-
score and 3 item emotional lability sub-score) according to carers and teachers. The analysis 
compared the offer of adjunctive treatment by a homeopath with usual care, and the offer 
of adjunctive treatment by a nutritional therapist with usual care. The two treatments were 
analysed independently. 
Two analytic approaches were taken. Multivariate linear regression quantified the impact 
attributable to intervention and the likelihood that findings were down to chance, control-
ling for the effects of co-variates ADHD severity (CGI baseline score), age, and gender (being 
female). The total carer sample size of 88 entered into the regression model whilst consid-
ered sufficient to test the overall fit according to Green (1991), is not considered sufficient 
to test the fit of individual predictors according to Miles & Shevlin, 2001 (in Field, 2005), 
where suggested minimum sample size is 104 (+ 1 for each predictor), and more if a 
small/medium effect is expected. The total teacher sample size of 31 was also insufficient. 
Therefore results must be treated with caution. 
Standardised mean difference (SMD) explored the magnitude of the clinical effect (since sta-
tistical significance is a function of sample size) and provided estimates for the sample size 
required in the full trial (see section 6.9.5. for the formula used to calculate SMD). Effect size 
description considers the rule of thumb presented by Cohen (1992) which suggests that the 
effect size is small if SMD = 0.2; medium if SMD = 0.5; and large if SMD = 0.8. 
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Similar analyses were applied to subgroups of interest. The outcomes of those receiving at 
least one treatment were reported to explore the effect of receiving a treatment (per proto-
col analysis). The outcomes of the sub-group with co-occurring autism were reported to ex-
plore whether there were any differences in outcome between this group and those with-
out cooccurring autism. The outcomes of those taking/ not taking medication were reported 
to explore whether medication status might impact outcome. These sub-groups were very 
small and analyses treated with caution. 
Secondary outcomes health related quality of life measure CHU 9D were also analysed. The 
SNAP outcome introduced 6 months into the trial was not analysed due to insufficient data: 
only 38 carer and 10 teacher paired scores were available, of which there were none for 
treatment by homeopaths.  
7.5.1 The primary outcome  
Assumptions 
Carer ratings 
Data were tested for normality and found to meet the assumptions for conducting paramet-
ric tests. Histograms showed the data to be fairly normally distributed, and the normal P-P 
plot showed points close to the line. Values of skew (.433 (.255)) and kurtosis (1.49 (.506)) 
were below the significant level of absolute value 1.96. Standardised residuals (min -1.98, 
max 3.25) and scatterplots showed that the data met assumptions for homogeneity of vari-
ance (meaning the variance is similar across groups) and linearity (meaning a linear relation-
ship between the independent and dependent variables).  
Multicollinearity (a strong correlation between predictors) was not a concern. Tolerance 
values ranged from 1 to 1.48. Tolerance values below .10 to 0.25 are considered cause for 
concern (Tabachnick & Fidell, 1989 & Menard, 1995).  
 Variance Inflation Factor (VIF) ranged from 1 to 1.36. Bowerman (1990) suggests multicol-
linearity if VIF values are over 1, although Myers (1990) suggests >10. The Durbin-Watson 
statistic of 2.14 was sufficient to meet the assumption of independent errors. This statistic 
varies between 0 and 4, with a value of 2 generally meaning residuals are uncorrelated, alt-
hough this varies according to the number of predictors (Durbin & Watson, 1951). 
Teacher ratings 
The data met assumptions for conducting the analyses. Histograms showed the data to be 
normally distributed, and the normal P-P plot showed points that were not completely on 
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the line, but close.  According to the standard residuals, the data contained no outliers; mul-
ticollinearity was not a concern with tolerance ranging from .794 to .944, and VIF of around 
1.0. The data met the assumption of independent errors according to Durbin-Watson value 
which was 1.77, and values of skew (.73) and kurtosis (.32) were also within reasonable lim-
its. The scatterplot of standardised residuals showed that the data met the assumptions of 
homogeneity of variance and linearity. 
Descriptive statistics 
Tables 24 & 25 show carer and teacher descriptive data of the primary outcome at baseline 
and 6 months, according to those offered, and those receiving a treatment. Data show that 
all groups had reduced scores (which indicates improvement) after 6 months, but that im-
provement was greater in treatment groups than the usual care group.  
The six-month scores of those who accessed a treatment (per-protocol) were not markedly 
different from those offered a treatment (ITT) because the majority of those who returned 
questionnaires were accessing treatment. Teacher scores for nutritional therapy found a 
positive trend in the offer group of n=8, but a negative trend for the n=4 for those who ac-
cessed that treatment. 
Table 24. Carer descriptive data of the primary outcome at baseline and 6 months according to those 
offered treatments, receiving treatments, and continuing with their usual care who returned both 
baseline and 6-month questionnaires 
Outcome Hom offered  Hom received  NT offered  NT received  TAU  All  
 Sample size 
Paired outcomes  N=29 N=20 N=28 N=23 N=31 N=88 
 Mean (Standard Deviation) 
CGI total Baseline  24.03 (3.57) 23.48 (3.27) 23.07 (4.72) 23.41 (3.88) 22.27 (4.62) 22.91 (4.1) 
6 months  20.0 (6.15) 19.65 (5.83) 18.82 (5.59) 18.48 (5.27) 20.06 (5.29) 19.46 (5.4) 
Change score 4.03 (5.76) 3.7 (6.26) 4.25 (7.69) 4.96 (6.58) 1.55 (5.89) 3.21 (6.49) 
Restless-Impulsive base-
line 
17.66 (2.87) 17.2 (2.7) 17.18 (3.56) 17.6 (3.09) 16.68 (3.54) 17.16 (3.33) 
6-months 15.28 (4.59) 14.9 (4.35) 13.68 (3.89) 13.39 (3.59) 15.19 (3.73) 14.74 (4.1) 
Change score 2.38 (4.55) 2.3 (5.1) 3.5 (5.23) 4.2 (4.2) 1.48 (4.52) 2.42 (4.78) 
Emotional lability base-
line 
6.38 (1.47) 6.15 (1.53) 5.89 (2.13) 5.96 (1.96) 4.94 (1.95) 5.72 (1.95) 
6-months 4.72 (2.15) 4.75 (2.15) 5.14 (2.09) 5.09 (2.09) 4.87 (2.28) 4.9 (2.16) 
Change score 1.66 (1.95) 1.4 (1.79) .75 (3.01) .87 (2.96) .06 (2.08) .81 (2.44) 
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Table 25. Teachers descriptive data of the primary outcome at baseline and 6 months according to 
those offered treatments, receiving treatments, and continuing with their usual care who returned 
both baseline and 6-month questionnaires 
Outcome Hom offered  Hom received  NT offered  NT received  TAU  All  
 Sample size 
Paired outcomes  N=11 N=7 N=8 N=4 N=12 N=31 
 Mean (Standard Deviation) 
CGI total Baseline  15.36 (5.43) 15.43 (5.5) 18.12 (4.42) 16.75 (4.35) 10.25 (5.94) 12.45 (5.05) 
6 months  14.09 (6.1) 13.86 (8.37) 14.75 (2.82) 19.25 (8.38) 10.75 (5.97) 13.17 (7.37) 
Change score 1.27 (5.73) 1.57 (6.45) 4.13 (10.23) -2.5 (5.0) .83 (6.98) 1.84 (7.43) 
Restless-Impulsive baseline 13.18 (5.1) 13.57 (4.64) 14.75 (2.82) 14.5 (1.92) 10.25 (5.94) 12 (7.28) 
6-months 12.09 (6.33) 12.00 (7.28) 10.88 (7.16) 15.50 (4.2) 9.25 (4.83) 10.68 (5.95) 
Change score 1.09 (4.5) 1.57 (4.99) 3.87 (7.6) -1.0 (4.24) 1.0 (6.28) 1.77 (6.04) 
Emotional lability baseline 2.18 (1.72) 1.86 (1.86) 3.38 (2.72) 2.25 (2.87) 1.33 (1.37) 2.16 (2.02) 
6 months 2. (1.94) 1.86 (2.2) 3.13 (2.64) 3.75 (3.77) 1.5 (1.62) 2.(2.07) 
Change score .18 (1.47) .00 (1.63) .25 (3.01) -1.5 (1.73) -.167 (1.34) .065 (1.34) 
Primary outcome: ITT analysis  
Total score 
When CGI total change score was the dependent variable and group (hom or NT), age, gen-
der and ADHD severity the covariates, the model explained a significant amount of the vari-
ance in CGI change score (F (5,83) = 4.54, p = .001). This was due to the highly significant in-
fluence of ADHD severity (t = 4.225, p <.001) (Table 39; Appendix 13). Neither treatment 
group, age or gender explained a significant amount of variance. 
The influence of ADHD severity on the result may reflect between group differences at base-
line since treatment groups according to carers had higher baseline ADHD severity than 
TAU, but all had similar scores at 6 months (Table 24). However, including ADHD severity in 
the model reduced the effect due to treatment compared to a simple model, suggesting 
that this was not the case. It is more likely that regression to the mean occurred, and partic-
ipant’s scores clustered towards the population mean. 
Restlessness/Impulsivity 
The model explained a statistically significant amount of the variance in the restless-
ness/Impulsivity CGI subscale (F (5, 82) = 3.53, p=.006), explained by the significant influ-
ence of ADHD severity (t = 3.64, p < .000), although treatment by a nutritional therapist also 
neared statistical significance (t = 1.8, p = .075) (Table 41; Appendix 13). SMD = .418 (Figure 
5). 
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Emotional lability 
The model explained a statistically significant amount of the variance in the emotional labil-
ity CGI subscale (F (5,82) = 4.89, p= .001), due to the significant influence of ADHD severity 
(t=4.07, p = < .000) and treatment by a homeopath (t = 2.09, p=.04) (Table 41; Appendix 13). 
A medium/large effect size (SMD) of .793 was measured for the effect of treatment by a 
homeopath on emotional lability (Table 26; Table 54 in Appendix 13; Figure 5).  
Carer ratings of those accessing treatment (per protocol analysis) 
Results were generally similar to those of the offer group. Improvement in restless-
ness/impulsiveness in those receiving treatment by a nutritional therapist now reached sta-
tistical significance (t = 2.11, p= .038) (Table 26; Table 44 in Appendix 13). SMD = .623 (Fig-
ure 6). 
To proceed to full trial, the protocol specified that a CGI total SMD of at least .3 by those 
having (rather than offered) a treatment was required (see Table 18). This was reached: 
SMD = .36 hom; and .55 NT (Table 26; Figure 6). 
Teacher ratings 
Testing may not be valid given the very small number of questionnaire returns, particularly 
for those accessing treatment (Table 23) (n=7 hom, n=4 NT) meaning results must be viewed 
with extreme caution. None of the covariates entered into the model explained a significant 
amount of the variance in teacher-rated CGI total or sub-scores (Table 26; Tables 45,47 & 48 
in Appendix 13). There is additional uncertainty in the model due to the completion of out-
comes by different teachers (Table 23). The positive direction of improvements due to nutri-
tional therapy in the ITT analysis, and a SMD of .39 (Figure 5), became a negative direction 
when only those accessing treatment were considered, with a SMD of -.504) (Figure 6).  
Collection of more paired teacher outcomes is required before any conclusions can be 
drawn. 
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Figure 5. ITT analysis of the primary outcome (CGI): carer and teacher-rated effect sizes and confi-
dence intervals  
 
N = 88 carers, N = 31 teachers.   CGI: Conners Global Index.  RI: restlessness/impulsivity.  EL: emotion-
al lability.  Effect size calculation = mean treatment change (baseline - 6 months) subtracted from 
mean usual care change, divided by the pooled variance (collective standard deviation adjusted for 
sample size). 
 
Figure 6. Carer and teacher-rated effect sizes (with confidence intervals) between 0 & 6 months ac-
cording to the primary outcome (CGI), in those who received treatment.  
 
N = 74 carers, N = 19 teachers. CGI: Conners Global Index.  RI: restlessness/impulsivity.  EL: emotional 
lability. Effect size calculation = mean treatment change (baseline - 6 months) subtracted from mean 
usual care change, divided by the pooled variance (collective standard deviation adjusted for sample 
size). 
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Table 26. ITT and per protocol regression analyses and effect sizes of CGI and CHU 9D, according to carers and teachers  
Total number of observations = 88. Analysis controls for age, gender and ADHD severity. * outcome reached two-tailed statistical significance level <.05.     
** NICE stipulated minimal clinical important difference < .4 reached.    a Unstandardised coefficient.   b Effect size based on Cohen’s d. 
Outcome Completer ITT / per protocol  R2  Hom (n = 29 (ITT), n = 20 (received)  NT (n= 28 (ITT), n= 24 received) 
      Ba (S.E) t  C.I Effect sizeb  B (S.E) t  C.I Effect sizeb 
          
 
CGI 
Carer ITT  .215  1.7 (1.57) 1.08, p= .28 -1.48, 4.81 .425**  2.66 (1.55) 1.71, p= .09 -.347, 5.89 .388 
received  .207  1.65 (1.72) .96, p= .34 -1.84, 5.06 .356  3.05 (1.6) 1.9, p= .062 -.044, 6.44 .55** 
Teacher ITT  .290  .58 (2.89) .2, p= .84 -5.37, 6.53 .069  4.11 (3.14) 1.31, p= .2 -2.35, 10.58 .39 
received  .176  .572 (3.16) .18, p= .86 -6.09, 7.24 .109  -1.98 (4.15) -.477, p=.64 -10.74, 6.78 -.504 
               
 
Restless-Impulsive 
Carer ITT  .171  .437 (1.19) .368, p= .71 -1.9, 2.8  .198  2.13 (1.18) 1.8, p= .075 -.22, 4.47 .418** 
received  .181  .594 (1.3) .456, p= .65 -2.0, 3.19 .172  2.59 (1.22) 2.11, p=.038* .15, 5.03 .623** 
Teacher ITT  .264  .176 (2.39) .074, p= .94 -4.75, 5.1 .016  3.5 (2.6) 1.35, p= .19 -1.86, 8.85 .421** 
Per protocol  .144  .456 (2.74) .166, p= .87 -5.33, 6.24 .097  -.824 (3.6) -.229, p= .82 -8.42, 6.78 -.339 
               
Emotional lability Carer ITT  .230  1.23 (.59) 2.09, p=.04* .06, 2.4 .793**  .648 (.58) 1.11, p = .27 -.51, 1.81 .269 
Per protocol  .213  1.02 (.64) 1.59, p= .12 -.27, 2.3 .679**  .612 (.6) 1.01, p= .31 -.59, 1.82 .325 
Teacher ITT  .251  .403 (.75) .537, p= .6 -1.14, 1.95 .25  .615 (.82) .754, p= .46 -1.07, 2.3 .195 
Per protocol  .209  .117 (.737) .158, p= .88 -1.44, 1.67 .117  -1.16 (.968) -1.19, p= .25 -3.2, .89 -.93** 
               
CHU 9D Carer  ITT  .102  .057 (.031) 1.84, p=.069 -.12, .01 .43**  .084 (.031) 2.73, p= .008* -.15, -.023 1.1** 
Per protocol  .122  .05 (.035) 1.42, p= .16 -.12, .02 .3  .094 (.03) 2.84, p= .006* -.16, -.03 1.19** 
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7.5.2 Secondary outcomes and sub-group analyses 
Autism 
37 children had additional diagnoses of autism, of whom paired carer questionnaires were 
available for just 26 (n=8 hom; n=6 NT, n=12 TAU). Paired teacher questionnaires were 
available for just 6 (n=1 hom; n=1 NT and n=4 TAU). Due to the paucity of questionnaire re-
turns, only ITT analysis was conducted, and the results of that must be interpreted with ex-
treme caution. A significant effect and a large effect size were seen from those few offered 
treatment by nutritional therapists (t = 2.88, p = .009, SMD = .92) (Table 54 in Appendix 13). 
Medication 
Approximately one third of participants did not take ADHD medication, equally distributed 
across groups due to stratification. No significant differences were seen in groups taking or 
not taking medication (Tables 51 & 52 in Appendix 13), suggesting medication status did not 
affect outcome, although samples were very small so no conclusions can be drawn. ADHD 
severity was the only significant variable, implying that taking medication was associated 
with ADHD severity. 
Health Related Quality of Life CHU 9D 
Carers completed CHU 9D, which provided proxy ratings of children’s wellbeing. Preference 
weights were added to the data (section 3.4.5). An overall significant effect of the model 
was not seen (F (5,82) = 1.865, p= .109) although the impact of treatment by a nutritional 
therapist was statistically significant (t = 2.73, p = .008) (Table 55 in Appendix 14). Overall, 
treatment group’s health related quality of life improved whilst that of those continuing 
with their usual care declined (Figure 7 & Table 27). 
Table 27. Preference weighted Health Related Quality of Life measure CHU 9D scores at baseline and 
6 months for those offered and receiving treatment 
 Hom offered  Hom received  NT offered  NT received  TAU  All  
 Sample size 
Paired outcomes  N=29 N=20 N=28 N=23 N=31 N=88 
 Mean (Standard Deviation) 
CHU 9D baseline  .679 (.122) .666 (.121) .701 (.119) .704 (.129) .732 (.090) .705 (.112) 
CHU 9D 6 months .708 (.137) .684 (.149) .759 (.121) .769 (.116) .708 (.130) .724 (.130 
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Figure 7a. Health-Related Quality of Life CHU 9D utility values at baseline and 6 months 
 
Figure 7b. CGI scores at baseline and 6 months according to carers 
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The effectiveness of individual items. 
Health Relate Quality of Life measure CHU 9D consists of nine items asking about worry, 
sadness, pain, tiredness, annoyance, schoolwork, sleep, managing daily routines, and joining 
in.  At baseline, carers did not tend to rate their children as being in pain, sad, or tired and 
registered that schoolwork and management of the daily routine were the most problemat-
ic (Figure 21 in Appendix 14). 
According to the graphs showing the frequencies of each response (Figure 22 in Appendix 
14), carers of those offered treatment by homeopaths observed that their children had re-
duced concerns with annoyance, sadness, and pain at 6 months compared to baseline, and 
carers of those offered treatment by nutritional therapists observed that their children had 
reduced concerns with worry, sadness, and pain. Interventions did not make a difference to 
schoolwork, management of daily routine, sleep, or ability to join in. 
Regression analysis was performed on the sleep item, which asks the level of problems the 
child had sleeping last night (Table 56 in Appendix 14). No improvements in sleep were 
found in either treatment group. 
7.6   Costs associated with the first STAR pilot trial 
The cost of consultations was made up of therapist payments of £55 for the initial consulta-
tion and £35 for follow up consultations. Homeopathic remedies were included in this price 
as is usual in clinical practice. Nutritional supplements were provided free for this trial, 
however, in private practice it is usual for supplements to be purchased separately. Nutri-
tional therapists reported that they used more supplements than usual because they were 
free, and because participants struggled to implement dietary advice. Nutritional therapists 
were asked to calculate the cost of supplementation per 6 months for each of their partici-
pants according to their usual practitioner discounted prices.  
A travel subsidy of £5 was available for participants, but this was not taken up. Room hire 
cost an average £10 per session, whilst on-line or telephone consultations incurred occa-
sional postage costs of supplements/remedies averaging £1.50. The table below details the 
costs currently available. 
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Table 28. Cost of therapies  
 
 
# of ap-
pointments 
# appointments in 
consultation room 
Supplement 
costs Total cost Mean cost* 
First six months 
Homeopathy 91 35 0  £    3,555   £    122.59  
Nutrition 81 19 7627.94  £ 10,673   £    368.03  
Second six months 
Homeopathy 33 18 0  £    1,355   £      46.72  
Nutrition 43 5 3794.63  £    5,370   £    185.16  
Full year 
Homeopathy 124 53 0  £    4,910   £    169.31  
Nutrition 124 24 11422.57  £ 16,043   £    553.19  
      
*Mean cost = total cost/number of appointments attended 
7.7   Sample size calculation for a full trial 
The target difference considered when determining the sample size is an SMD .4, since this 
is considered the minimal clinically important difference by NICE, and was also the SMD ob-
tained in the pilot trial.  
If significance (alpha error) is 0.05, power 80 %, and effect size 0.4, it is estimated that the 
responses of approximately 100 participants are required. For power of 90%, responses of 
240 participants are needed (Altman, 1991).  
Based on pilot study results it is estimated that 40% attrition will occur. Therefore to ac-
count for this, for 80% power, randomisation of 166 participants (40% of 166 = 100) is re-
quired. And for 90% power randomisation of 400 participants (40% of 400=240) is required.  
The results of average 30 participants per group (29 hom; 28 NT, and 31 TAU) are already 
available from the pilot trial. Therefore randomisation of approximately 136 (80% pow-
er)(166 -30 = 136), or 370 (90% power)(400-30=370)) are required.  
Assuming equal sample sizes, testing both interventions (i.e 3 arms, but sharing the same 
control group), this means recruitment of an additional 204 participants to the STAR cohort 
in total for 80% power (136 + 68); and 555 participants in total for 90% power (370 + 185) 
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7.7.1 Use of services  
Participants provided information about service use at baseline, and at 6 months. No signifi-
cant change in resource use was found (Table 29).   
Table 29. Change in service use between baseline and 6 months 
Resource Hom  NT  TAU  All  
Sample size 29 28 31 88 
Doctor visits (mean) (SD) baseline 1.66 (1.696) 1.14(1.145) 1.55 (1.929) 1.45(1.632) 
6 months  1.28 (1.412) 1.04 (1.201) 1.16 (1.508) 1.16 (1.372) 
t .097 p= .923 .657, p= .513   
     
Hospital visits  total (mean) baseline 1.17 (1.605) .86(1.008) 1.10 (1.491) 1.05 (1.389) 
6-months .72 (1.066) .86 (1.008) .87 (2.141) .82 (1.505) 
t .428 , p= .67 .763, p = .448   
     
Social worker visits  total (mean) 
baseline 
.14 (,743) .25 (.701) .06 (.25) .15 (,598) 
6-months .31 (1.137) .46 (1.374) .16 (.735) .31 (1.097) 
t .284, p = .777 .53, p = .597   
     
Police visits  total (mean) baseline .03 (.186) .04 (.189) .10 (.539) .06 (.351) 
6 months .07 (.371) .04 (.189) .29 (1.616) .14 (.985) 
t .811, p = .419 .977, p = .331   
7.8   Summary 
Between September 2015 and 2016, 144 participants were recruited to the STAR cohort and 
125 randomised to the pilot trial (41 TAU, 41 Hom, 42 NT). Randomised groups did not differ 
significantly regarding age, gender, or medication use.  
72/83 (87%), accepted the offer of treatment. 50/83 (60%) attended at least one appoint-
ment. Those who attended at least one appointment were more (but not statistically signifi-
cantly more) likely to not take conventional medication and have a higher ADHD profile. 
Non-take up of the offer was greater than estimated, therefore crossover from treatment to 
usual care was high.  
Non-completion of 6-month outcomes was also greater than estimated: 88/124 paired carer 
questionnaires were returned of which 20/29 hom and 23/28 NT were from those who had 
treatment. Nevertheless the sample was deemed sufficient to enable sample size calcula-
tion for a full trial since paired outcomes were available from 88 participants (29 hom; 28 
NT; 31 TAU). Effect sizes of .4 (hom) and .55 (NT) were used to estimate that an additional 
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454 participants need to be recruited to the cohort in order to have sufficient participants 
for the full trial of both treatments. 
The primary outcome considered carer ratings of the Conners Global ADHD Index (CGI). No 
statistically significant change due to the offer of treatments was observed according to CGI 
total score, but statistically significant change was observed the emotional lability sub-score 
of those offered hom (p= .04, SMD .79). The restless/impulsive sub-score of those who re-
ceived NT also reached statistical significance (p=.038, SMD = .623). Standardised mean dif-
ferences for CGI total score was greater than the protocol-specified SMD of .3 for those re-
ceiving both treatments: .34 (hom); .55 (NT). 
Of a maximum 100 teacher questionnaires, 31 paired questionnaires were returned (11 
hom, 8 NT, 12 TAU). No changes were observed in CGI total or sub-scores according to the 
very small number of teacher scores, which were unstable, with teachers recording a nega-
tive effect in the clinical outcome of the n=4 who received treatment by a nutritional thera-
pist (SMD= -.504), but a positive effect (.39) according to the n = 8 teachers of those who 
were offered treatment. No effect of treatment by homeopaths was found by teachers. 
Improvements in health-related quality of life were seen in those offered treatments, par-
ticularly of those offered nutritional therapy, whilst reductions in the health-related quality 
of life of those continuing with their usual care were seen: NT (SMD = 1.1); hom (SMD .43).  
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Chapter 8 Feasibility results 
This chapter assesses the feasibility of the TwiCs design to test the effectiveness of interven-
tions for children with ADHD.  
8.1   Feasibility Criteria 
The thirteen protocol-specified feasibility criteria and their results are summarised below 
(Table 30). Some aspects of the TwiCs design did not have a priori stated parameters, and 
are also considered: the acceptability of the design; the representativeness of the cohort; 
the effectiveness and acceptability of methods used to recruit participants to the cohort; 
the acceptability of the interventions; and the acceptability and feasibility of the outcome 
measures and the collection methods.  
Table 30 summarises the protocol-specified feasibility criteria, parameters, results, and 
whether criteria were reached, with the section referenced where the results are described 
in full.  
8.2   Approvals and governance 
The trial received ethical approval from the School of Health and Related Research ethics 
committee and all subsequent amendments were also approved. University health care re-
search governance procedures classified it as a 'human-interventional study', requiring it to 
be risk assessed, and considered it low risk.  
NHS REC approval was not sought but this decision was challenged. ScHARR Research Ethics 
Committee (REC) and the University Research and Innovation Services (RIS) confirmed that 
NHS REC approval was not required. 
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Table 30. Achievement of protocol specified feasibility criteria parameters 
Criteria (Section) Measurement: criteria parameters Results Continuation to a full trial 
yes/no/recommendations 
Recruitment to co-
hort rates (8.3.1) 
# recruited in 2 years: % recruited /sample size esti-
mation 
144 recruited in 1 year Yes  
Recruitment to 
treatment rates (7.3) 
% accepting offer: At least 30%  60% (50/83) took up the offer (23 
hom; 27 NT) 
yes 
Treatment effects 
(statistical signifi-
cance) (7.5.1) 
Standard mean difference (SMD) CGI: mean = < .3 in 
those implementing a therapy 
 .36 hom; .55 NT 
 
Yes  
Treatment effects 
(clinical significance) 
(7.5.1) 
CGI T score: 5 percentiles  Use of T scores not feasible due to ceiling effects. 
SMD (above) used instead 
Attrition. Cohort (7.4) # PQ’s returned at 6 months: at least 30% 70% (88/124) six month question-
naires returned 
yes 
Attrition. Consulta-
tions (7.3) 
# consultations attended: 70% of participants accept-
ing intervention attend at least 3 consultations 
72/83 (87%) accepted the offer. 
50(69%) of those had at least 1 con-
sult. 35 (49%) had at least 3 con-
sults.  
no 
Acceptability of TQ 
(7.4) 
#TQs completed at baseline and 6 months: # of re-
minders needed; # email/telephone/ paper respons-
es. Adjustment of measure, collection method and 
trial parameters 
54 (43.5%) completed at baseline. 
46 (37.1%) completed at 6 months. 
Current methods not feasible: more reminders by 
a variety of methods needed 
Acceptability of CQ 
(7.4) 
# reminders needed: adjustment of measure, collec-
tion method and trial parameters 
Maximum reminders: 3 emails, 1 
text, 1 letter. 
 
£10 Boots vouchers introduced improved return 
rate 
Adverse events (8.9) Clinicians records: no intervention related severe 
adverse events, As defined by CTCAE (2010) and EC 
(2011) guidelines. 
No severe events Yes  
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Appropriate outcome 
measurement – CQ 
(7.4) 
# missing items: adjustment of measure.   5 items missing from paper ques-
tionnaires 
Continue using on-line questionnaires 
Recruitment of ther-
apists (8.8.1) 
# recruited fulfilling criteria: at least 2 for each thera-
py 
8 therapists (hom); 4 therapists (NT) One (hom) dropped out/unsuitable. Two (hom) 
using a receptionist & one (NT) only using email 
made poor contact with participants.  
Suitability of consul-
tation venues / mode 
(8.8.3) 
ANCOVA (venue/mode as variable): No venue/mode 
to have statistically significant impact on treatment 
effect 
This could not be calculated as 
some therapists used several 
modes. 
 
Statistical analysis 
(7.4.3) 
ANCOVA: meets assumptions Outliers not improved with trans-
formation 
Regression analysis used. Assumptions met. 
 169 
8.3   Recruitment to the cohort and the pilot trial 
8.3.1 Recruitment rates 
It was estimated that 140 participants needed to be recruited to the STAR cohort, to enable 
sufficient numbers for the first trial conducted within the cohort, which required at least 30 
participants in each of the three arms to have completed treatment (section 6.8.1). Suffi-
cient numbers (n=144) were recruited to the cohort. Half the planned time was required: 24 
months was planned, but sufficient numbers were recruited in 13 months. 
Sample size calculation allowed for 20% of those joining the STAR cohort to not meet trial 
inclusion criteria or not accept the offer of treatment. 19 would-be participants did not 
meet cohort inclusion criteria; and 11 participants offered a treatment refused it: 30/144 = 
20.8%.  
A further 20% attrition was allowed for to enable a final sample size of 90. 88 questionnaires 
were returned, deemed just sufficient for sample size calculation of ITT participants’ out-
comes. But insufficient for treatment effect sample size calculation, since not all of those 
returning outcomes accessed a treatment. Indeed only 50/83 had at least one consultation.  
8.3.2 Strategies for recruitment to the cohort 
Figure 8 describes the various recruitment strategies employed and numbers recruited, by 
month. 
Figure 8. Recruitment activities and recruitment numbers per month, and cumulatively 
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Four recruitment peaks (considered to be months when 10+ participants were recruited) 
coincided with the advertising of the study to: Sheffield Family Action and Sheffield Parent 
Carers (n=18 September 2015); the Facebook group ADHD UK (n=29 January 2016); the 
Northampton based ADHD group AdADHD (n=18 April 2016); and the national support 
group ADDISS (n=28 June 2016).  
The most successful means of recruitment were ADHD support groups, especially when en-
hanced by personal communication with the director. Successful recruitment also occurred 
as a result of the Festival of the Mind (FOTM) show: the performance video placed on the 
STAR Facebook page received 10,000 + views, reached 30,000 people, was shared 200 
times, and continues to help recruit participants to the cohort 
(https://www.facebook.com/starsheffieldADHD/videos/677387002419685/).  
Recruitment from nationally-funded ADHD facilities such as special schools, secure units, 
NHS based facilities, and children engaged with support services was not successful. Nor 
was it possible to recruit from the NIHR-funded Yorkshire and Humber CLAHRC ADHD health 
tracker cohort. Either NHS ethical approval would have had to be obtained, or there was 
minimal take up from advertisement, or the process of obtaining the approvals required was 
too lengthy and onerous. Nor was permission received to recruit from the Newcastle Uni-
versity autism spectrum database (ASD-UK). 
Minimal response was received from the 20+ schools contacted. No schools responded to 
emails, just two schools requested meetings after being visited and no children were re-
cruited from either of those schools. However, 21 participants were recruited from schools 
with already recruited participants: in 9 instances two children were recruited from the 
same school, and in one instance, three children were recruited from the same school.  
In summary, although recruitment from schools of all types was possible, there was minimal 
uptake. Recruitment from some nationally funded ADHD facilities was possible, but most 
required NHS ethical approval. Recruitment from Sheffield city council, CAMHS, and council 
managed facilities caring for troubled children may be feasible in the future if NHS ethical 
approval and other permissions are obtained. 
8.4   Characteristics of the STAR cohort 
This section describes the characteristics of the STAR cohort using data from Carer Ques-
tionnaires (CQs) and Teacher Questionnaires (TQs). This data enables an assessment of par-
ticipant representativeness and what constituted their usual care during the trial. Co-
occurring diagnoses, medication use, resources used to support the child, teacher-rated lev-
els of disruption, exclusion, and absenteeism are all summarised. 
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Co-occurring diagnoses 
Figure 9. STAR cohort participants’ co-occurring diagnoses according to carers 
 
ODD = Oppositional Defiant Disorder. ASC = autism spectrum condition 
Of the 125 participants recruited to the STAR cohort who fulfilled cohort inclusion criteria, 
carers reported that 48/125 (38%) had a sole diagnosis of ADHD (Figure 9), whilst 77/125 
(62%) had at least two diagnoses each (Figure 10). The most common co-occurring diagnosis 
was an autism spectrum condition 35/125 (28%) (Figure 9). The highest number of diagno-
ses per child was five (named as ADHD, ASC, dyspraxia, a heart condition, high blood pres-
sure, and learning difficulty) (Figure 10). 
Figure 10. The number of co-occurring diagnoses per STAR cohort participant according to carers 
 
Medication use 
 Carers reported that 90/125 (72%) of participants were taking ADHD medication (Figure 11) 
whilst 47/125 (38%) were not.  
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Figure 11. Medications taken by STAR cohort participants 
 
Supportive resources 
Carers were asked about usage of specific services for their children, and these are reported 
in Table 31. They were also asked to describe any additional help they had used for their 
child (see Appendix 2a) which is summarised in Table 32. 
Carers reported accessing help from a range of sources. They had made many visits to doc-
tors and hospitals: national support services, within school, parenting courses, physical aids, 
and other therapies - including Complementary and Alternative Medicine (CAM).  
Table 31. Services used by STAR cohort participants according to carers 
Service Total  
Hospital 189 visits (range 1-15) 
Doctor 171 visits (range 1-8 per participant) 
Social workers 19 visits (by 9 participants) 
Psychologist 17 participants (now). 41 participants (in the past) 
Police 12 visits (by 5 participants) 
Sheffield Family Action Parenting 
course 
5 participants (now). 43 participants (in the past) 
Other parenting class 2 participants (now). 69 (in the past) 
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Table 32. Extra help used by STAR cohort participants according to carers 
Category 
Number 
of families Name (number using) 
Parenting courses  19 
123 magic (4); Theraplay (3); triple P, TEACH, positive parent-
ing, change 4 life (1) 
Therapies 20 
Art therapy, psychotherapy (4); psychology (3); family thera-
py, play therapy, sensory therapy, occupational therapy, cog-
nitive behavioural therapy, counselling (2); sensory therapy 
(1) 
Physical or visual aids 15 
reward charts (7); wobble cushions, fiddle toys, Weighted 
blankets (2); quiet tent, time out space (1) 
CAMHS, Ryegate or 
MAST 12 
ADHD nurse (2); youth worker, MAST worker, gateway worker 
(1) 
Educational  8 SEN support (6), private tutors (2) 
Extra-curricular activities 5 
trampoline, running club, horse riding, beavers, swimming, 
theatre school, gymnastics, Pilates, tae kwon do, judo (1). 
Complementary and Al-
ternative Medicine ther-
apies (CAM)  22 
dietary (11) (fish oils (8), Feingold diet, restricted diet, healthy 
eating (1); cranial osteopathy, massage (3); homeopathy, 
hypnotherapy (2), relaxation CDs, crystals, reflexology, reiki, 
meditation, metamorphic technique (1). 
School help 
Teachers described providing academic, social, emotional and physical help to children with 
ADHD. They reported that this help was provided by deputy heads, key workers, classroom 
teachers, councillors, mentors, occupational therapists, and Special Educational Needs Co-
ordinators.  
Academic help consisted of part or full-time support in lessons, (particularly for numeracy 
and literacy), provision of extra time during tests or with homework, personal curricula, and 
reduced timetables. Several children had learning mentors. Emotional support was provided 
in the form of mentoring, counselling, involvement with the social intervention team and 
social skills teaching.  Children were part of friendship, nurture and/or social groups. They 
were provided with a safe haven or extra support at break times, and access to student 
support.  
Teachers described providing behaviour management in the form of visits to the behaviour 
support team; provision of personal report or break cards; and regular teacher checks re-
garding distraction. Physical aids used were: disco sit, wobble or ridged cushions; moving 
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seats; stress balls, twiddlers, fiddle toys; a laptop. Children also received extra sports, occu-
pational therapy, and regular movement breaks. One child had a visual timetable. 
School behaviour 
On average teachers did not rate the STAR cohort participants as disruptive. According to 
the 74 Teacher Questionnaires returned at baseline, the mean rating was 2 (SD 1.37) (po-
tential range 0-5). Nor did they have many days off: participants had had an average of 3.34 
days off during the last 6 months (SD 6.27). 4/74 (5 ½%) of participants had been excluded 
for 3.5, 5, 5.5 and 6 days respectively. 34/74 had a Teaching Assistant (TA), ranging from a 
couple of hours per week, to full time (32+ hours weekly) (n=16).  
Carer Issues 
The STAR cohort Carer Questionnaire provided an open section for carers to write anything 
they wanted to. This was completed by 61 participants and is summarised here. Comments 
are grouped into five emerging categories: friendship, school, home, family circumstances, 
medication and sleep.  
Friendship is an issue for many of the children. Several carers said their child had been bul-
lied, and described their child’s struggle with social interaction, lack of friends, that their 
child is never invited out or wants friends round. Respecting other children’s wishes and lis-
tening were particular problems. Two carers described how other children actively avoided 
their children. One child is frightened that children will laugh at him so won’t join in with 
activities. Another child tries hard to be accepted at school and supresses her aggression, 
which then explodes at home.  Some carers said their children did have ‘a few good friends’, 
and made friends easily, although in one case also got easily annoyed. One carer said her 
child’s impulsive socialising got in the way of his academic work. 
School causes problems for the children and their carers trying to help them participate: 
‘today he didn't get up until I physically made him, he then missed his bus to school and then 
had an argument with other students at school during lunch break. When finally I got him 
organised to sit down and do some homework it turned out he'd lost it on the way home. 
Quite a typical day!’. ‘He got his first detention today for forgetting his planner’. ‘He is unset-
tled by his new class teacher’. ‘A five-minute task can take an hour to complete’. ‘Every 
school trip I have to fight to get him included’. ‘Her school work does not reflect her abilities 
and she is in danger of failing’. ‘He does not remember anything he has done at school and 
constantly gets into trouble’. 
Home life was described as stressful, particularly in the mornings ‘before medication kicks 
in’. Children struggle to organise themselves and get ready for school on time. One child was 
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“still not dressed today at 5pm despite numerous prompts”, whilst another child was awake 
and hyperactive from 2am onwards. Routine was important to several children and changes 
upsetting.  One child only wears shorts, needs a particular tightness to his shoes, and ‘it is a 
battle to get him to eat’.  
Relationships within the family were described as challenging: carers described their chil-
dren as being ‘derogatory’ and ‘demanding’ at home towards their siblings and carers; car-
ers struggled to manage sibling relationships and ‘to get much conversation’. 
Medication received six negative and two positive comments Positive comments were: “the 
drug works really, really well. It helps him concentrate on his school work, get along with 
peers and be more sociably acceptable”; “my son’s life has significantly improved since start-
ing medication”. Negative comments were: “he can’t take anything for his ADHD due to his 
blood pressure”; “we’ve stopped ADHD medication as he hates it”; “we tried Medikinet, El-
vanse, Strattera, Equasym - none have worked – he has terrible reactions to these medica-
tions”; “we tried Equasim tablets no effect. Now on 36 mg Concerta which was working 
slightly but since started higher dose he was getting stomach pains and headaches so now 
reduced back and still same symptoms happen”; “Equasym Xl had terrible side effects! Body 
jerking that was quite violent”; “can't take any due to bad reaction on her stomach, tried 5 
different ones”; “we tried Concerta (made him aggressive); Strattera (same as Concerta); 
Equasym-little effect. Ritalin is having a moderate effect, but his heart rate is reacting to it, 
so he is only on a small dose”. 
Sleep was mentioned by nine carers whose children struggled to get to sleep. Children were 
described as like a motor that does not switch off even though they are clearly tired. One 
child had started experiencing night terrors. His carer described him as using the night time 
as ‘a new control time’. One child is anxious on going to sleep and shouts ‘I love you’ every 5 
minutes and will get out of bed if he does not get a reply. 
Family circumstances. Several carers used the space to describe their child’s particular cir-
cumstances. Two carers explained that their child was adopted, one expanding that their 
child ‘was removed from birth mum at birth, was in foster care until 17 months old when she 
was placed with us’. One child is looked after by his aunt and grandmother (who describe 
him as being very aggressive towards them) due to his mother’s death.  Another child ‘has 
had a stressful short life, his father died 2 years ago to a heart attack and he has suffered a 
lot of bullying, all on top of coping with mild learning difficulties and ADHD. His life is better 
now. The bullying has stopped, and he has come to terms with the death of his father as 
much as he can. He is a survivor and I am so proud of him’.  
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8.4.1 Summary (cohort representativeness) 
For a pragmatic trial, there is a need for the cohort to be broadly representative of those 
with ADHD diagnoses. This means representation across areas highlighted in chapter 2, such 
as co-occurring diagnoses, difficulties at school and at home, involvement with the police 
and/or social services.  This section has described the level of co-occurring diagnoses and 
resources being utilised by STAR cohort participants.  
Co-diagnoses are considered to occur in 40-65% of those with ADHD (section 2.1.1). They 
occurred in 62% of the STAR cohort. The resources being used by participants in the STAR 
cohort suggest a high level of health needs and use of NHS services: the majority were tak-
ing ADHD medication; 67% had made at least one visit to the doctor, and 60% at least one 
visit to hospital; and one third were also taking sleep medications.  
Difficulties at home are suggested by the fact that: 95% of families had accessed or were 
accessing a parenting class; 46% of families had also visited or were visiting psychologists; 
and according to the narratives in the free writing section, where just under half the carers 
in the STAR cohort used the ‘anything else you’d like to tell us’ section to describe problems 
with friendships, family life, and school. Difficulties at school are further suggested by the 
multiple social, emotional and physical as well as educational support being provided by 
schools. According to the 73/100 teacher questionnaires returned, 56% of children had a 
teaching assistant, of whom 22% had one full time. 59% of children also received some form 
of ‘other help’. 7% of families were involved with social workers, 5 ½% had been excluded, 
and 5% had been involved with the police.  
8.4.2 Summary (usual care) 
Usual care is defined as what participant’s carers and teachers said they were currently do-
ing to help the child in their baseline questionnaires. Mainstream healthcare consisted of 
ADHD medication, which was being used by 72% of the cohort, and sleep medications which 
were being used by 30%.  5% of families were participating in behaviour change pro-
grammes (90% had participated in in the past). 14% were seeing a psychologist. 18% were 
using some kind of CAM, of which the most popular was dietary, particularly fish oils. 16% 
were participating in some kind of therapy, such as Art Therapy, (which is currently offered 
by Sheffield CAMHS), or Play Therapy. 16% reported use of other personnel such as ADHD 
nurses. 56% had a teaching assistant, of which 22% had one full time.  
8.5   The feasibility of randomisation procedures  
Stratification according to age and gender was feasible. However, stratifying ADHD severity 
using CGI T test scores (specified a priori in the protocol) was not sufficiently sensitive, since 
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n=89 (72%) of participants registered 90+ T scores. Raw scores of 16-23/30 or more are con-
sidered ‘90+’ T scores according to the Conners scoring grid.  
8.6   The acceptability of the offer of treatment 
Figure 12 describes the reasons for refusal of the offer, and Figure 13 describes the reasons 
for subsequent non-take up of the offer according to each treatment group. 
Figure 12. Reasons for refusal of the offer of treatment 
 
 
Figure 13. Reasons the offer of treatment was accepted but subsequently not taken up 
 
8.7   Feasibility of outcome collection 
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144 STAR cohort participants completed baseline Carer Questionnaires (CQs). 124 random-
ised participants (which included treatment acceptors, non-acceptors and those continuing 
with their usual care) were requested to complete CQs again six months after completion of 
their baseline CQ.   
An initial request to carers was sent by email, with further emails sent monthly for three 
months, a text one week after the third email, and a paper questionnaire a week after that. 
Despite the number of requests, eight months into the trial, return rate of six-month CQs 
was 17%. After discussion with the steering committee and approval from the ethics com-
mittee (amendment number 4, Table 16), an incentive was added. From 28/4/16 onwards, 
on receipt of CQs, participants were sent a £10 Boots voucher in a card thanking them for 
being part of the STAR project. Vouchers were also sent to those who had previously re-
turned CQs. This improved the return rate to 72% (section 7.4.1). 
A single request, with no reminders, was made for Teacher Questionnaires (TQs) by post. 
Only one teacher opted to complete the questionnaire on-line. One school replied that they 
did not want to be involved in the project. 34 six-month outcomes were returned resulting 
in 31 paired outcomes. Missing cases were excluded list-wise, so only data from participants 
or teachers providing paired outcomes at baseline and 6 months was analysed. 20 ques-
tionnaires (65%) were completed by different teachers each time (section 7.4.2). 
Outcome completion: item response 
There was very little missing data within the returned CQs and TQs, indicating that outcome 
completion methods were manageable. Five six-month paper CQs had an item missing (on-
line questionnaires stopped participants moving on until all items were complete). Last ob-
servation carried forward was used to impute data in the five instances, as stated in the pro-
tocol (Fibert, Relton, Peasgood, & Daley, 2018).  
Teacher outcomes were only available from a maximum of 100 teachers, since 20 carers re-
fused permission for their child’s school to be contacted and 4 children were being home 
schooled (see Table 22). There is no explanation for why a further 45 baseline and 53 six-
month questionnaires were not returned.   
Outcome collection: which measure to use 
CGI was purchased from Pearson Assessment company. The free SNAP measure was added 
at 6 months. Since the majority of baseline questionnaires had already been completed by 
then, there were minimal paired outcomes for analysis, so the results of the two measures 
could not be compared. However, SNAP does not provide sub-scores, nor does it measure 
any aspects of emotional lability since it is now regarded as an associated feature rather 
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than a cardinal symptom. Since the CGI measures emotional lability, and its sub-scores pro-
vided useful information, it was decided to continue with CGI despite the additional cost.  
8.8   The acceptability of the interventions 
8.8.1 Recruiting homeopaths  
In September 2016 five homeopaths were recruited from Sheffield or nearby and saw par-
ticipants at Wellforce clinic, Sheffield, Western House consulting rooms, Barnsley, or in par-
ticipants own homes. Homeopaths did not have particular experience with ADHD, however, 
3/5 had experience of working with challenging families. All were registered with the Society 
of Homeopaths. 
In January 2017 the study started recruiting participants from across the UK requiring on-
line consultations. Since two homeopaths did not want to conduct on-line consultations and 
three were inexperienced in conducting on-line consultations (no experience, or just one 
experience), three more homeopaths, experienced in conducting on-line consultations, 
were recruited from a Complementary Therapies clinic in Marlow, Buckinghamshire, of 
whom one (myself) had experience of treating children with ADHD, whilst two had experi-
ence of working with challenging families. 
One homeopath with no experience of working with challenging families, dropped out of 
the study. Of her five allocated participants: one could not be contacted; one experienced 
two adverse events (out of a total 7 (section 8.9). Unusually two of her allocated partici-
pants contacted me to discontinue treatment; and uniquely, negative mean change scores 
in the primary outcome (carer) were recorded (see Therapist 1, Figure 17).  
8.8.2 Recruiting nutritional therapists 
Four nutritional therapists were recruited to the study in September 2016. All therapists had 
experience working with children with behavioural disorders, and in delivering on-line con-
sultations, so no further therapists were recruited. 
8.8.3 Delivery of interventions  
This section describes delivery of the interventions according to the checklist developed by 
Hoffmann et al. (2014) for describing individualised interventions (see section 3.1.7). 
Homeopathic treatment 
Consultations 
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Homeopaths offered up to eight regular in-depth consultations to participants over one 
year, consisting of a first appointment of 1-1/2 hours, and follow ups of 30-40 minutes. De-
pending on participant locality and convenience, consultations were conducted face to face 
at complementary health clinics, at participant’s homes, on-line using VSee or skype (Figure 
14). 
Notes were taken by homeopaths during consultations, and afterwards scrutinised for 
emerging themes, which were then matched with the themes of a homeopathic remedy. 
The remedy was then delivered to the participant according to homeopaths’ usual practice, 
to be taken in-between consultations. 
Homeopaths mostly felt it was important to see the child in person and talk directly to them 
at each session, either with or without their carer. In one case this led to a participant dis-
continuing treatment as the carer reported that the child “didn’t like to talk about his feel-
ings”, and several participants found consultations too great a time and emotional commit-
ment. However, others told their homeopaths they valued the experience and appreciated 
the unusual approach. 4/23 participants opted to continue with private consultations after 
trial consultations finished. Homeopaths felt that part of their role was being supportive to 
the children’s carers. 
Figure 14. Consultation venues used by therapists 
 
Homeopaths reported that carers needed explanations about what to expect from a home-
opathic remedy, sometimes found the different approach difficult to grasp, but were often 
intrigued. They reported that homeopathic remedies were well adhered to. 
Those therapists who conducted on-line consultations commented that they liked them, 
and that they may have improved attendance: “you can see the child a bit, then talk to mum 
whilst the child plays”; “it helps when they live very chaotic lives”; “you can better observe 
their normal behaviour”.  
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The therapist who dropped out felt that carers’ parenting style contributed to children’s bad 
behaviour, but the majority of therapists expressed great admiration for carers, who they 
felt “were up against it”. 
Observed difficulties 
Homeopaths said that on average, trial participants had more serious symptoms compared 
with their private clients. They expressed frustration at missed consultations, difficulty con-
tacting participants, and the influence of life events. They felt that their intervention was at 
times “a drop in a turbulent ocean”. The therapist who dropped out said that “treating these 
children makes me feel incompetent, it’s hard not to take missed appointments personally”. 
Homeopaths commented that at times they found it difficult to identify a suitable individu-
ally-tailored homeopathic remedy. They said that separating the child’s story from the car-
er’s story was sometimes difficult since information was delivered by carers, some of whom 
had traumatic life histories themselves. They found that the symptoms of those children 
who were on medication were subdued, which was problematic because prescription relies 
on accurate observation of symptoms. They felt that the child’s behaviour was sometimes 
inhibited in the consultation room.  
The interaction between ADHD medication and homeopathic remedies was sometimes a 
concern for homeopaths, participants and/or their GPs or consultants. Several participants 
either stopped or didn’t start homeopathic treatment on the advice of their doctors. Some 
participants changed conventional medications during homeopathic treatment which ho-
meopaths reported made analysis of change due to homeopathic remedy difficult. And two 
participants wanted homeopathic treatment specifically to manage the side effects of con-
ventional medication. 
Observed Improvements 
Homeopaths reported good improvements with emotional aspects such as anger, melt-
downs, anxiety and fear (see 7.5.1 for statistical analysis of emotional aspects). The homeo-
pathic remedies nux vomica, stramonium, pulsatilla and aconite are particularly prescribed 
for these emotional issues (Vermeulen, 2002)(see Figure 15). Improvements in digestive 
problems were also reported, particularly in those where the problem was considered a side 
effect of conventional medication. The homeopathic remedies lycopodium, nux vomica and 
pulsatilla are particularly prescribed where there are digestive complaints (Vermeulen, 
2002). Sleep was also an area which homeopaths felt improved. 
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Homeopathic Remedies 
A total of nineteen different remedies were prescribed by homeopaths (Figure 15).  
Figure 15. Homeopathic remedies prescribed to participants 
 
Nutritional Therapy 
Consultations 
Nutritional therapists provided information about healthy eating, advice on individually-
indicated food exclusions, and provided individually indicated supplementation. Like the 
homeopaths, individual therapists offered up to eight regular consultations to participants 
over one year, consisting of a first appointment of 1- 1 ½ hours, and follow ups of 30-40 
minutes. Nutritional Therapists generally felt that after 5 sessions they had imparted most 
of their information.  
Therapists offered carers the choice about whether to attend with or without their child. 
Most chose not to attend with their child for the majority of consultations. Unlike the ho-
meopaths, this was not seen as a problem by nutritional therapists, since much of the con-
sultation discussion was with the carer, who was responsible for family meals. In one case 
the carer didn’t want the child to attend as the child didn’t know he has a diagnosis of 
ADHD. Depending on participant locality and convenience, consultations took place at be-
spoke consultation rooms, participant’s homes, by telephone, on-line, or a combination 
(Figure 14). 
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Supplementation 
Four supplement companies supported the study and provided free supplements: Igennus, 
Nutrilink, Lamberts, and Biocare. Therapists utilised products from all companies, depend-
ent on product availability, participant sensitivity and therapist preference. Texture and 
smell sometimes affected participant’s ability to take supplements. In routine clinical prac-
tice, supplements are paid for by patients in addition to consultation fees, but for this study 
participants were provided with free supplements. Therapists said they used more supple-
ments than usual, partly because they were freely available, and partly because often partic-
ipants did not change their bad dietary habits, so supplementation was their main dietary 
intervention. 
Sometimes nutritional therapists had to change the mode, make and texture of the supple-
ments to make them acceptable: some children didn’t like capsules, and several wouldn’t 
take fish-smelling oils. Taking a variety of supplements was often found to be overwhelming 
by participants, so therapists limited prescriptions to a minimum, once daily, to ensure 
compliance. 
Most participants were prescribed polyunsaturated fatty acids. Therapists also provided 
probiotics and multi-nutrients, and in some cases supplements to aid sleep, anxiety and 
support neurological issues. 
Good eating information.  
Therapists reported that best changes were seen where advice was followed. Generally they 
felt that better results were seen in younger children than teenagers, due to greater carer-
control of diets. This was not however, supported by the statistical results, where entering 
age as a dichotomous variable (primary and secondary age range) had a non-statistical ef-
fect on nutritional therapy change score (t= .127, p= .899).  
Suggestions to help children who had extremely restrictive diets, obsessions, or were unwill-
ing to try new foods, were: to work within restricted parameters; change the brand; and/or 
replace unhealthier with healthier foods, e.g. ham/sausage with chicken/fish. 
Therapists said that carers reported being exhausted and overwhelmed which limited their 
ability to implement new menus. In these cases they only suggested 1-2 recipes at a time, 
suggested getting the child involved in cooking, and/or focussing on only one mealtime. 
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Dietary change advice.  
Nutritional therapists felt that their advice was variably followed. They reported that those 
participants advised to and implementing gluten free casein free and/or dairy free diets, 
saw improvements in soiling, behaviour, general health, and anxiety. 
Teenagers tended to have high use of sugar. Therapist’s suggestions to manage this were to 
talk to the teenagers themselves; to suggest they home cook from scratch, e.g. blitz balls; to 
eat reduced sugar biscuits; to not keep treats at home; and to offer either a pudding or a 
chocolate bar, but not both. Teenagers also tended to drink fizzy drinks and squash. Thera-
pist’s advice to help them reduce their consumption was to start by replacing some of their 
fizzy drink consumption; to drink water; and to have the occasional sugar free squash 
sweetened with stevia & sucralose rather than aspartame or saccharin. 
To help participants reduce their use of ready meals, processed foods, and wheat and dairy 
where appropriate, therapists suggested substitutes such as vegan cheese, potato waffles, 
almond or soy milk, and advised participants to ask their butcher for additive-free meat. 
Other advice was to always have a (preferably healthy) breakfast, and to increase intake of 
protein and fibre. 
Therapists found that increasing omega 3 intake (e.g. oily fish, nuts, seeds, eggs) was prob-
lematic when children were sensitive to tastes and textures. In these cases they suggested 
hiding seeds in smoothies; having a little at every meal; adding nut seed to cereal; snacking 
on nuts; putting nut butter on toast; and eating fish twice a week. 
Observed difficulties. 
Like homeopaths, nutritional therapists expressed frustration at participants who repeated-
ly missed consultations, and/or didn’t follow advice, and commented on the difference be-
tween trial participants and their private clients: “frequent changes to plans (cancellations 
the day before or 'forgetting' appointments) can be extremely frustrating and obviously 
happen far more often than with my usual clients, which took some getting used to”. Anoth-
er therapist said, “I feel like a supplement pharmacist or I stroke the carers”. Therapists felt 
that much depended on the carer’s attitude: “if mum has decided it won’t work, it does not 
stand a chance”.  
Participants often had poor diets consisting of junk food, sweets, fizzy drinks, and other sug-
ary products. Children, particularly teenagers, bought sweets on the way home from school, 
which carers could not monitor. Some carers felt unable to implement dietary advice. 
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Therapists felt that restrictive diets and sensory issues of those with co-occurring ASCs was a 
problem that often needed working around.  They felt that the nutritional intervention was 
just one cog in a complex wheel with confounding factors which often interfered with 
treatment. One therapist said “Sometimes nutrition seems unimportant compared to what 
I've been hearing about (violent criminal behaviour, trouble with police etc)”.  
Observed Improvements 
Therapists commented that “those who put in the effort see the greatest change”. Carers 
were better able to implement advice when it was kept simple and only one change at a 
time suggested. They also felt that when families implemented the advice, the health of the 
whole family improved.  
Therapists reported that the best improvements they saw were in children with gastric dis-
turbances, who usually had co-occurring ASCs and supportive carers willing to implement 
advice. They noted that in some cases carers only acknowledged that change had occurred 
when supplements were stopped, and behaviour worsened. 
When carers were able to implement changes, often all the family did so. Some carers told 
therapists they appreciated their advice because it validated their parenting, for example 
carers refusing their children sweets and sugary drinks.   
8.8.4 The acceptability of the interventions 
How acceptable interventions were was explored by looking at the number of participants 
accepting the offer of treatment, and the number of consultations attended by participants 
who had accepted their offer of treatment.  Feasibility criteria were at least 70% of those 
accepting the offer having at least three consultations. This was not reached because alt-
hough 72/83 participants accepted the offer, only 50/72 (69.4%) then had one consultation. 
35/72 (49%) had at least 3 consultations 17/23 (hom); 18/27 (NT) (Figure 16)).  
Therapists 
Therapists were responsible for contact with their allocated participants once participants 
had accepted the offer of treatment. Most therapists arranged consultations with partici-
pants themselves. Two homeopaths (numbers 7 & 8 in Figure 18), used the clinic reception-
ist at Marlow Complementary therapies clinic, to contact participants (during working 
hours), and only managed to contact 33% and 25% of their allocated participants. Two ther-
apists (therapists 4 & 10) were particularly good at contacting and retaining their partici-
pants and had the highest average number of consultations.  One nutritional therapist 
(Therapist 11) relied only on email to contact participants, and had few consultations. 
 186 
Figure 16. Number of appointments attended per participant 
 
 
Figure 17. Mean CGI change per therapist 
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Figure 18. Average number of consultations conducted by therapists, and number of allocated partic-
ipants receiving consultations  
 
8.9   Adverse Events 
Two researchers (PV and PF) independently assessed each reported event to determine the 
probable causality using the WHO-UMC guidelines, and the severity using the CTCAE guide-
lines (European Commission, 2011). Where initial assessments did not correspond, cases 
were discussed, and consensus reached. 
A total of seven adverse events were reported by therapists (4 x NT, 3 x hom). The research-
ers concurred that one of the reports (hom) was not an adverse event, and that two serious, 
CTCAE Grade 3 events (1 x NT, 1 x hom) resulting in hospitalisation were unlikely to be re-
lated to the trial interventions according to WHO criteria. The hospitalisation incidents 
were: a child with a history of hospitalisation and bad reactions to conventional medications 
was put on a new conventional medication and subsequently hospitalised; and a child had 
appendicitis. 
Two moderate Grade 2 events (hom/NT) were recorded. One was a worsening of behaviour 
after provision of supplements; and the other a skin rash considered a probable reaction to 
a homeopathic remedy (such events are termed homeopathic aggravations). 
Three mild Grade 1 adverse events were recorded (NT). Two were considered probable re-
actions to nutritional supplements (itchy skin, increased aggression) which stopped once the 
supplements were stopped.  One was considered unlikely to be linked to supplements since 
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stopping them had no effect on the behaviour, and the family considered other life events 
to have been the trigger.  
8.10 Summary 
In the previous chapter the statistical analyses, data collection and results were described. 
This chapter has described the feasibility of the study design and interventions. Nine of the 
thirteen feasibility criteria were met. Two were not met and two could not be calculated. 
The suitability of therapist’s consultation venues could not be calculated since some thera-
pists used a variety of modes with each participant (section 8.8). Conners T scores could not 
be used to calculate the clinical outcome since the wide range of scores denoted ‘70+’ 
meant the measure was not sensitive enough to record any changes (Table 19). Instead 
SMDs were used. 
 The single, postal request for TQs did not yield enough responses: TQs were poorly re-
turned both at baseline and 6-months. Furthermore 20/31 Teacher Questionnaires were 
completed by different teachers each time which reduced consistency and possibly intro-
duced bias. Furthermore, the few paired outcomes returned were unstable (section 7.4). 
Drop-out from consultations was greater than expected. Although high levels accepted the 
offer, less than the stipulated 70% then took up the offer and had three consultations. 
Therefore crossover from treatment to usual care was high. 
Recruitment of sufficient numbers to the observational cohort was achieved in half the des-
ignated time. A variety of recruitment strategies were used, and recruitment was most suc-
cessful via social media, ADHD support groups, and Sheffield based Parent Carers, but less 
successful via schools and publicly funded institutions.  
Sufficient participants accepted a treatment, more than the protocol-specified criteria of at 
least 30%. Carer-rated treatment effects reached criteria for continuation to the full trial 
(section 7.5.1). CQ return rates were initially very low but they improved with the addition 
of an incentive. Despite this, return of 6-month outcomes was low from those who had not 
accepted the offer of a treatment. Nevertheless, the sample was deemed sufficient to ena-
ble sample size calculation for a full trial, since paired outcomes were available from 88 par-
ticipants (29 hom; 28 NT; 31 TAU). 
The two serious adverse events which occurred during the trial were unlikely to be related 
to treatment. However, two of the moderate/mild events reported (NT & hom) were 
probably due to treatment. 
Regarding measurement of outcomes, CGI was suitable to capture the effects of the inter-
ventions. The longer (18 item) SNAP measure added at 6 months was considered unsuitable 
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since it does not measure emotional lability. Measuring emotional lability using the CGI sub-
scale only measures three aspects: mood, temper and tearfulness so finding a broader 
measure would be useful. It was possible to measure sleep using one item from the CHU 9D, 
but again, a measure with more items might better measure this important issue. The 
measurement of hospital, doctor, police and social worker visits, levels of absenteeism, ex-
clusion, disruption, and extra help, all required carers and teachers to recall the previous 6 
months, which may not be the most accurate way of obtaining such information since they 
may forget. 
Sufficient therapists were recruited, but one was not suitable for this group of patients. All 
therapists expressed frustration at the difficulty of making contact, the amount of last-
minute cancellations, and non-attendance. Those therapists who contacted participants 
themselves using a variety of modes were better at making contact than those using a clinic 
receptionist or single modes.   
The sample of participants recruited to the STAR cohort appears to be broadly representa-
tive of those with ADHD. The sample reported a range of life-limiting difficulties, high ser-
vice use within both medical and educational spheres, and multiple services accessed both 
free at the point of delivery and paid for by carers. The majority of participants had at least 
two co-morbidities, and several participants were involved with the police or social workers. 
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Chapter 9 Discussion 
This chapter discusses the aims and objectives for the STAR project, for this thesis, and for 
the pilot feasibility trial. It also considers to what extent the aims and objectives for con-
ducting pilot and feasibility trials in general were achieved. Pilot and feasibility studies are 
conducted to test the integrity of the study protocol for the future trial; gain estimates for 
sample size calculation; test data collection questionnaires; test randomisation procedures; 
estimate rates of recruitment and consent; determine the acceptability of the intervention; 
and select the most appropriate primary outcome measures (Lancaster, Dodd, & 
Williamson, 2004).  
The long-term aim of the Sheffield Treatments for ADHD Research (STAR) project is to im-
prove outcomes for children with ADHD, by developing a facility for efficiently and objec-
tively testing multiple interventions for them over the long-term. The aim of this thesis is to 
assess the feasibility of the TwiCs design to provide information to enable the evaluation of 
treatments for ADHD. The aim of the pilot feasibility study is to assess whether the TwiCs 
trial design can provide suitable information for stakeholders to enable evaluation of the 
clinical and cost effectiveness of some treatments for ADHD.  
One thesis objective was to describe ADHD, its impact across services, the range and effec-
tiveness of mainstream interventions, gaps in provision, and key issues. This was done in 
chapter 2, which looked at the evidence base for current mainstream interventions for 
ADHD, highlighting areas of unmet need, risks of long-term negative outcomes, areas with 
limited evidence, limitations of current evidence, and challenges in creating the evidence 
required by stakeholders. Another objective was to identify key stakeholder requirements 
to assess the acceptability, clinical and cost effectiveness of treatments. This was explored 
in chapter 3, and the TwiCs methodology was proposed as a potentially efficient and effec-
tive way to provide this information to stakeholders.  
A range of novel treatments for ADHD being used which have some evidence for their effec-
tiveness were identified. The two selected treatments for ADHD, treatment by homeopaths 
and treatment by nutritional therapists, were described, and a review of their evidence base 
conducted in chapters 4 and 5, which was another thesis objective.  
Key issues regarding trial designs for these interventions were explored. It was identified 
that trials to date of both interventions have focussed on the testing of the efficacy of spe-
cific elements. Rather than replicating such designs, the decision was made to conduct 
pragmatic research with pragmatic outputs because explanatory trials do not directly an-
swer the research question as to how effective interventions are to improve outcomes. 
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Moreover a critique of explanatory designs when applied to complex interventions revealed 
that they do not in fact measure efficacy as defined in this thesis (section 1.5.4).  Neverthe-
less there will be those who will not consider results from an effectiveness trial valid with-
out prior evidence of the efficacy of specific components, and this may be a limitation of the 
research. 
The STAR project was initiated as a research platform and participants recruited to an ob-
servational cohort to achieve the thesis aim. A small-scale test of the methods and proce-
dures – the STAR pilot trial - was conducted, whereby, using a TwiCs approach, the two se-
lected treatments were compared to usual care. The methods by which this was done were 
described in chapter 6. The results of the STAR pilot trial were described in chapter 7 and 
the feasibility of the design and interventions were described in chapter 8.  
This chapter discusses the thesis objectives outlined above and addresses the remaining 
thesis objectives, which are to assess the feasibility of a TwiCs approach with regard to: re-
cruiting to time and target a cohort of children with a diagnosis of ADHD; the suitability, ac-
ceptability, and deliverability of the outcome measures; the feasibility, acceptability, deliv-
erability, safety, clinical and cost effectiveness of treatment by homeopaths and nutritional 
therapists for children with ADHD; and the sample size calculation for a full trial. 
9.1   The feasibility of the TwiCs design 
9.1.1 Recruiting a cohort of children with a diagnosis of ADHD to time and target 
Recruiting people to trials in general, and ADHD trials in particular, is difficult. ADHD is dis-
proportionately represented in those for whom life is particularly difficult and such families 
are unlikely to prioritise involvement in research although they are often desperate for sup-
port (Koerting, et al., 2013). Furthermore a feature of ADHD is difficulty in using long-term 
motivation to inform short-term behaviour, and therefore for families with ADHD, altruism 
may not be a motivational factor for trial participation which can be acted upon (altruism 
has been identified as one reason why carers and children (Tromp, Zwaan, & van de 
Vathorst, 2016), and adolescents (Midgley, Isaacs, & Weitkamp, 2016) may participate in 
trials). Inefficiency in research is considered an ethical problem (Treweek, 2017).   
The TwiCs design is considered well suited to conditions with poor recruitment (Relton, 
O'Cathain, Nicholl, & Torgerson, 2010) because it requires minimal commitment and no un-
certainty. Recruitment to the cohort is more similar to recruitment to longitudinal observa-
tional studies than to traditional RCTs (although these can also have recruitment difficulties 
in ADHD populations (Peasgood, et al., 2016). The TwiCs approach to conducting pragmatic 
trials is potentially more efficient than standard approaches because embedding trials with-
in existing observational cohorts can facilitate fast and efficient recruitment of participants. 
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Recruitment to the STAR cohort was successfully achieved in half the predicted time and 
without use of incentives (section 7.1), and may have been successfully accomplished due to 
these advantages of the TwiCs design.  
Successful recruitment strategies 
Whilst it is not possible to definitively assess which recruitment strategies were most suc-
cessful, the feeling of belonging, personal recommendation, being understood (section 8.3), 
trying something different, and lack of additional commitment seem to have been motiva-
tional. The University of Sheffield is well known and respected by the local population, and 
the study is called the Sheffield Treatments for ADHD Research. During the first four months 
recruitment was restricted to Sheffield and environs and 40 participants were recruited.  In 
contrast advertisement on a national ADHD Facebook page with 33,000 members led to just 
5 recruits over 3 months, until the study was promoted by an active group member, when 
there was a sudden upsurge ( Figure 8).  
Personal recommendations by directors of other websites also led to spikes in recruitment 
when websites included personal endorsements from them alongside the STAR flyer, but 
not when flyers posted were unendorsed. 
The many responders to the Festival of the Mind video (Appendix 12. Lost Voices) depicting 
life with ADHD (section 8.3.2) emphasised how much they valued being understood, as ex-
pressed in the poem. In the free writing section of the questionnaire carers referred to lack 
of understanding being a particular issue (section 8.4). Frustration about lack of understand-
ing also dominates posts on an ADHD Facebook page 
(www.facebook.com/groups/adhduksupport). STAR’s strapline is ‘making life easier for 
ADHD’. It is possible that this non-treatment seeking, but ‘understanding seeking’ popula-
tion joined the STAR project because they felt allegiance to a project which recognised the 
difficulties of having ADHD and was committed to ‘making life easier’.  
Minimal commitment apart from completion of questionnaires, and no delusion regarding 
interventions may also have influenced recruitment. By comparison another on-going trial 
of homeopathy using more traditional methods has needed to double their recruitment pe-
riod. This randomized, double-blind, placebo-controlled clinical trial being conducted in To-
ronto, Canada has a wait list (usual care) control and a placebo control. It is designed to in-
vestigate if there are: a) any specific effects of homeopathic remedies in the treatment of 
ADHD; b) any specific effects the homeopathic consultation alone in the treatment of ADHD; 
and c) an overall effect of homeopathic treatment (homeopathic remedies plus consulta-
tion) in the treatment of ADHD.  
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Their estimated recruitment time was based on the results of an open label pilot feasibility 
study (Brulé, et al., 2014). For the current trial, participants registering interest are informed 
that they may get placebo interventions, and excluded if they have a diagnosis of an addi-
tional mental health disorder including, but not limited to Conduct Disorder, Autism Spec-
trum Disorder, Bipolar Disorder, and Major Depressive Disorder 
(https://clinicaltrials.gov/ct2/show/NCT02086864)(Brulé, 2016).  The trial started recruiting 
in 2014 and is still recruiting. The aim is to recruit 177 participants.  
A comparison of the two trial designs highlights important differences: STAR used a two 
stage approach to informed consent, whilst the Toronto trial uses one stage. STAR easily re-
cruits participants to the cohort (the first stage), but less easily retains them at the second 
stage (the trial). The Toronto study has had less success recruiting participants, since the tri-
al is associated with uncertainty and inclusion criteria are tight. However, the Toronto trial is 
retaining most of those it has recruited, in contrast to the STAR trial.  
Recruitment setting 
The STAR project recruited participants in non-treatment seeking settings outside of their 
NHS based care. Some other studies using the TwiCs design have higher acceptance and 
take up of the offer of interventions when participants are recruited in the setting where 
they are diagnosed and attend regularly (Table 34). For example, high acceptance rates 
were found in studies using the TwiCs design in hospital settings where patients attended 
for their cancer treatments. However, in a similar setting, (the oncology department of 
Utrecht University hospital) two trials (Van der Velden and Verkooijen) had contrasting ac-
ceptance rates (19% & 90%) suggesting recruitment setting may not be such an influential 
variable. The amount of effort required by participants to implement the intervention was 
considered most influential in these two trials (van der Velden, et al., 2017).  
Speedy recruitment to the cohort, and take up of a treatment by 60% of those offered it 
suggests an unmet need by conventional services. The greater uptake of homeopathic 
treatment by those not on conventional medication also suggests that those participants 
may have been looking for an alternative. 
Recruitment of a representative sample 
In the STAR cohort 64% had at least two diagnoses, which is broadly representative of the 
population (section 2.1). N=7 (6%) had ODD, n=36 had an ASC (29%), n = 8 (6.5%) had been 
involved with the police, and n=9 (7%) with social workers in the last year (section 8.4), 
which is less than population estimates (section 2.1). Whilst it was an aim of the STAR pro-
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ject to recruit specifically from these groups, where there is most need of effective interven-
tions, the bureaucracy was unmanageable within the time frame.  
Therapists reported that participants generally had high levels of need compared to their 
private patients (section 8.8.3) with several dropping out because they could not manage 
the extra intervention in chaotic, stressful lives. For example two children (NT) were re-
moved from their home/foster home during the study, and could no longer be involved. 
One child (hom) was also removed from his mother, but after a short break continued par-
ticipation with his grandmother.  
It was not possible to systematically analyse to what extent the STAR cohort attracted diffi-
cult to engage families. This data is important since ADHD is associated with one of the 
highest dropout rates (Johnson, Mellor, & Brann, 2008), and drop outs have more severe 
ADHD (Daley & O'Brian, 2013 & Johnson & Jassy, 2007). It has been found that parenting 
groups tend to be attended by carers with few risk factors, missing those with higher levels 
of need (Axford, Lehtonen, Kaoukji, Tobin, & Berry, 2012), and that difficult to engage fami-
lies slip through the net and are service resistant, predicted by low income, single carer sta-
tus, education/occupation, family size, minority status, severity of child’s behaviour, mater-
nal psychopathology and maternal age (Doherty, Stott, & Kinder, 2004). Future collection of 
data to assess some of these things would be useful but needs to be requested simply and 
minimally. 
The decision was made not to apply for NHS ethical approval to recruit through the NHS 
(section 6.2) because sufficient numbers of participants were recruited outside of NHS ser-
vices. Furthermore the process is lengthy and can be difficult to obtain for trials of homeop-
athy (Viksveen, http://etheses.whiterose.ac.uk/11875/). It is disputable whether this influ-
enced recruitment of a representative sample. One the one hand it may have contributed to 
recruitment of hard-to reach participants, since those satisfactorily engaged with usual care 
do not look elsewhere, whilst those joining the STAR cohort may have been motivated by a 
feeling of unmet need. On the other hand it restricted access to specific target groups of ‘at 
need’ children such as the ‘looked after’ children under the care of Sheffield City council.  
The question of whether NHS ethical approval was a pre-requisite for a study of ADHD was 
resolved (section 8.2), but raised interesting questions and was not a clear-cut decision. The 
question centred on response to the Medicines Health Authority (MHA) algorithm: “Will 
your study involve research participants identified from, or because of their past or present 
use of services (adult and children’s health care within the NHS and adult social care)”. RIS 
stated that “the STAR study only recruited children where the carers self-reported that their 
child has received a diagnosis of ADHD.  The diagnosis itself could have come from an NHS 
service, but it may have come from elsewhere (e.g. a health service in another country) and 
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hence the participants have not be identified from, or because of, their use of the NHS specif-
ically”. The STAR management team concurred with this. The ADHD population intersects 
with, and impacts on many publicly funded systems and services, of which health care is on-
ly one, such as social care, the criminal justice system and education. However, NHS clini-
cians maintain that all children with ADHD are under the care of the NHS and therefore NHS 
ethical approval is required. Furthermore, care within other services tends to include NHS 
care.  
9.1.2 Adherence to the STAR cohort 
Although efficient and timely recruitment to the STAR cohort was successfully accom-
plished, subsequent adherence to that cohort, in terms of completion of questionnaires at 6 
months, was less successful. Adherence to treatments and studies is an issue in ADHD re-
search (section 2.3). It is suggested that the disorganization that is a feature of adult ADHD 
leads to carers being prone to forgetting appointments for their children, and misplacing or 
forgetting to complete questionnaires (Hay, McStephen, Levy, & Pearsall-Jones, 2001). This 
issue is likely to be further exacerbated by the six-month stretch between requests for out-
comes. 
Short-term measurement is likely to achieve better compliance compared to longer term 
measurement, but long-term measurement is important if long-term outcomes are to be 
improved. The average length of trials of pharmaceutical medication is 75 days (Storebo, et 
al., 2015), and evidence suggests that the effects of medication plateau or decrease over 
time (2.3.1). In comparison, in two small samples, homeopathic treatment improved over 
time (Fibert, Relton, Heirs, & Bowden, 2016) (von Ammon, et al., 2012), and it is hypothe-
sised that holistic interventions, which attempt to improve the overall health of the individ-
ual, may become more effective over time as overall health improves. It is in the interests of 
stakeholders for these effects to be confirmed or refuted, by measuring the effectiveness of 
all interventions over the longer term to find long-term, effective interventions. Trials using 
the TwiCs methodology can do so. The study will also measure 12-month outcomes, alt-
hough these results are not included in this thesis. 
Return of 6-month carer questionnaires (CQs) was initially poor. The return rate was im-
proved by introduction of a £10 voucher (section 7.4), and by asking therapists to remind 
their participants. Six-month CQs were returned by 88/124 cohort participants. It was esti-
mated that 20% would not return CQs. In reality 29% (36/124) did not return them (Table 
21), which meant that paired CQs were available for 88 participants (29 hom; 28 NT; 31 
TAU). This was deemed just sufficient to enable sample size calculation.  
Of the 83 participants offered a treatment, 44 CQ returns were by those accessing it, and 
just 14 by those not taking up the offer (section 7.4). So questionnaire return was worst in 
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those offered a treatment who did not take it up. This suggests that by not accessing a 
treatment, participants considered that they were no longer part of the STAR cohort. In the 
usual care group 31/41 CQs were returned, suggesting that they did still consider them-
selves part of the cohort. This unbalanced questionnaire return occurred in another study 
using the design (Viksveen, Relton, & Nicholl, 2017). It is of concern because samples may 
be biased if there are systematic differences between those accessing and not accessing in-
terventions which are not being captured despite use of randomisation and ITT.  
9.1.3 The feasibility of recruitment to the 1st STAR trial 
The TwiCs design generated fast and efficient recruitment to the STAR cohort and also to 
the first STAR trial embedded within the STAR cohort. 72/83 participants randomly offered a 
treatment accepted it. It was estimated (section 6.9) that 20% of children joining the cohort 
would not meet trial inclusion criteria or not accept the offer of treatment. This estimate 
was accurate, since 21% (30/144) either did not meet trial inclusion criteria (n=19) or did not 
accept the offer of treatment (n=11). 
The reasons for refusal of the offer of a treatment were time/work pressures, not wanting 
homeopathy, anxiety/refusal by the child, and no interest (section 7.3). Three participants 
were uncontactable, despite attempts to contact them by email, phone and letter. It is of 
course not possible to understand why they did not want to participate. The reasons for 
non-participation in behavioural interventions (section 2.3.2) concur with some of the rea-
sons given for not wanting to participate in the STAR pilot trial.  
9.1.4 Take up of interventions in the STAR pilot trial 
Participants allocated to an intervention arm are considered more likely to refuse the inter-
vention using the TwiCs design compared to a traditional RCT design, since those not happy 
to accept a treatment or a placebo do not consent to join trials, and refuse to participate at 
the recruitment stage prior to randomisation (van der Velden, 2017). This leads to problems 
recruiting trial populations: only 33-50% of trials of standard RCTs recruit to time and target  
(McDonald, et al., 2006 & Sully, Julious, & Nicholl, 2013), and numbers declining to recruit 
are generally not recorded. However, whilst traditional RCTs may struggle to recruit suffi-
cient participants, they may better retain those they did recruit, as is occurring in the Toron-
to study described above. 
 In the STAR pilot trial, attrition and non-participation were shifted downstream (section 
7.3). Despite high acceptance (72/83) of the offered interventions, 22/72 did not then take 
up the offer (Figure 4). This was when the greatest attrition occurred, largely due to thera-
pist’s inability to contact them, or due to their not attending a booked 1st appointment and 
subsequent uncontactability (section 7.3).  
 197 
It may be that participants did not like to refuse the offer there and then, but having ac-
cepted, decided that they did not want to take part and opted out by becoming un-
contactable. Or it may be that due to the chaotic and overwhelming nature of participant’s 
lives, initial enthusiasm on a whim could not be sustained. In October 2016, an administra-
tor was brought in to try and contact participants, but was no better at contacting them 
than therapists.   
What is known, is that some therapists were better at contacting and meeting with their 
participants than others: three therapists (one NT, two hom) had high rates of participation 
(80%). All were ex-teachers, possibly used to managing communication with parents. In con-
trast one therapist (NT) only sent emails and contacted just 30%, and two other therapists 
(hom) relying on a clinic receptionist to contact participants also only recruited 30%. Em-
ploying multiple and persistent contact strategies such as emails, texts, and telephone calls 
at varying times of day had a significant effect on participation. For the full trial, acknowl-
edging this necessity, including those therapists who had high rates of contact and ensuring 
that other therapists are prepared to be flexible and persistent in contacting participants, 
may improve take up of the interventions, but may reduce the pragmatism of the trial if 
therapists usual contact methods are changed. In real-life, therapists employ different strat-
egies and have varying success in contacting and retaining patients. 
The higher non-compliance in the experimental arm using TwiCs designs compared with 
traditional RCTs has so far been found to be influenced by the popularity of the offered in-
terventions (van der Velden, et al., 2017), and the timing of the offer (May, et al., 2017). Ta-
ble 33 shows the acceptance rates available for trials of a variety of interventions for a varie-
ty of conditions using the TwiCs design, with subsequent treatment rates where known. 
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Table 33. Acceptance rates of trials using the TwiCs design 
Research/PI. Trial Condition Acceptance 
of the offer 
rate 
Reference 
Lenny 
Verkooijen 
Radiotherapy 
rectal boost, 
n=64 
Cancer >90% ac-
cept and 
participate 
https://www.TwiCs.global/ethics-
symposium-2016 
SPIN (Linda 
Kwakkenbos) 
hand exercises 
(ongoing) 
Scleroderma Approx. 
62% 
Word of mouth + 
https://www.TwiCs.global/ethics-
symposium-2016 
UMBRELLA 
(Anne May) 
Exercise during 
chemo (n=130) 
Breast can-
cer 
 55% accept 
and partici-
pate 
https://www.TwiCs.global/ethics-
symposium-2016 
PRESENT 
(Van der 
Velden) 
stereotactic 
body radio-
therapy, n=53 
Cancer, bone 
metastases,  
30% accept, 
19% partic-
ipate  
https://www.TwiCs.global/ethics-
symposium-2016 
DEPSY (Pet-
ter Viksveen) 
Homeopathic 
treatment 
(n=566) 
Depression 51.4% ac-
cept, 40% 
participate 
Viksveen, 2017. 
Clare Relton Homeopathic 
treatment 
(n=48) 
Menopausal 
hot flushes 
71% accept 
and partici-
pate 
Relton, 2012. 
SWELL (Ru-
dolph Uher) 
Skills for Well-
ness, (n=38) 
Children at 
risk of men-
tal illness 
83% accept 
and partici-
pate 
https://www.TwiCs.global/ethics-
symposium-2016 
STAR (Philip-
pa Fibert) 
Homeopathic 
treatment or 
Nutritional 
Therapy 
(n=124) 
ADHD  87% accept, 
60% partic-
ipate 
 
REFORM  Podiatry 
(n=1010) 
Older people 87.6% ac-
cept and 
participate 
Cochayne, 2017 
Information extracted from presentations at the TwiCs symposium (https://www.TwiCs.global/ethics-
symposium-2016), the TwiCs website (https://www.TwiCs.global/) and subsequent communication with study 
PIs. 
9.1.5 The acceptability of the STAR pilot trial interventions 
For the interventions to be feasible, it was deemed that at least 70% of those accepting the 
offer should have at least three consultations since this is what therapists typically recom-
mend to their new patients. Although there were high levels of acceptance, there were low 
levels of take up: 72/83 participants accepted the offer, 50/72 (69.4%) had at least one con-
sultation, and 35/72 (49%) at least 3 consultations.  
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70% (35/50) of those taking up the offer had at least three consultations, which may be a 
better assessment of the acceptability of the interventions. When designing the trial, it was 
erroneously assumed that those accepting the offer would then start treatment. Therapist’s 
contacting strategy rather than intervention’s acceptability was probably a more influential 
factor on poor take up than the acceptability of the interventions. Greater refusal of the of-
fer is to be expected (van der Velden, 2017) and needs better factoring into the trial design. 
Despite attrition, lack of uptake and poor outcome return, levels of uptake and outcome 
measurement in the STAR pilot trial compared favourably with ADHD trials of non-
pharmaceutical interventions. Results for behavioural interventions were presented in sec-
tion 2.3.2., where they were found to vary widely (Daley & O'Brian, 2013; Thompson, et al., 
2009; Taylor, et al., 2015; Barkley, et al., 2000). These, and results for other non-
pharmaceutical interventions similar to those tested were summarised in Table 34.   
ADHD trials of individualised, CAM, course attending, and/or therapist administered inter-
ventions were identified by searching Web of Science, Google Scholar, Clinical Trials.gov, 
and the International Standard Randomised Controlled Trials Registry (ISRCTR) for pairs of 
protocols and results of RCTs of non-pharmaceutical interventions between 2006 and 2016. 
The search terms RCT + ADHD + neurofeedback/acupuncture/parenting/behavioural/non-
pharmaceutical were used. Hand searches for the protocols of studies were also made. Nine 
studies were found where study protocols and study results could be compared for planned 
and actual recruitment numbers. 
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Table 34. Recruitment and retention rates. Comparing the STAR trial with trials of comparable interventions 
Trial author, 
publication 
date. Venue 
Interventions Planned 
sample size 
Actual no: 
randomised 
Drop out 
no: % 
Reasons given for drop out. Final data 
analysis no: 
Recruitment 
period 
Gelade 
(2016).Holland 
NF v meds v exercise 186 112 9 (8%) Motivational, practical, medical contraindications 102 4 years 
Duric (2012). 
Norway 
NF v meds 285 130 39 (30%) Didn’t start treatment (carers’ decision,30; subject’s 
decision, 6); didn’t complete follow up question-
naires (3) 
91 3 years 
Thompson, 
(2009). UK 
NFPP v TAU 77 
screened 
41 11 (27%) no assessments, more severe ADHD 30 18 months 
Daley (2013). 
UK 
NFPP-SH v wait list ? 43 7 (16%) Lost to follow up 36 ? 
Sayal (2016). 
UK 
TAU v 123 magic: carer 
v carer+teacher  
288 199 107(54%) Interested but didn’t attend (19). Not interested/ 
not contactable (88) 
76 ? 
Sprich (2016). 
USA 
CBT v wait list 50 46 3 (7%) No longer living nearby (1); lost to follow up (3) 36 2 ½ years 
Boyer (2015). 
Holland 
CBT-PML v CBT-SFT ? 159 31 (19%) No interest (6); suicidal ideation (1); acute family 
crisis (1); lost to follow up (15) 
136 ? 
Axford (2012). 
UK. 
IY v wait list 144 110 53 (48%) Lost to follow up 57 1 year 
Hong (2016). 
Korea 
Acupuncture v TAU 80 93 32 (34%) Fearful (2). Refused to participate (26). Took addi-
tional ADHD medications during the study (4).  
61 2 years 
Fibert, 2018. 
UK 
Treatment by homeo-
paths & Treatment by 
nutritional therapists v 
TAU 
112 124 35 (28%) time/work pressures (2); could not be contacted 
(11); did not want homeopathy (3); child's ill-
ness/anxiety (2); child's refusal (1); not interested 
(1); too much going on (5); Lost to follow up (10) 
89 13 months 
NF= neurofeedback. Meds = stimulant medication. NFPP= New Forest Parenting Programme. NFPP-SH = New Forest Parenting Programme Self Help. IY= In-
credible Years. TAU= Treatment as Usual. PML= Plan My Life. SFT= solution focused therapy
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Two studies, of acupuncture by Hong (2016) and CBT by Sprich (2016) recruited close to 
their planned sample sizes, but the required numbers were less, and more recruitment time 
allowed, compared to the STAR trial. The remainder of studies failed to recruit their planned 
sample.  
Information about acceptability is not routinely collected using traditional designs, but is 
captured when using the TwiCs design. The levels of drop out described in Table 34 are like-
ly to reflect the degree of pragmatism of the trial. Information across trials with similar de-
grees of pragmatism would be useful to ADHD stakeholders wanting to make decisions 
about ADHD interventions and improve negative outcomes, because the population is con-
sidered difficult to engage with (Koerting, et al., 2013). There is little point in having effica-
cious or effective interventions if they are not acceptable to their population. 
9.1.6 Compliance with interventions 
Compliance with interventions is considered one of the most important outcomes of prag-
matic trials (Godwin, et al., 2003). Poor adherence to interventions by those with ADHD has 
been identified as a problem (section 2.3.2). For the STAR pilot trial, 8 sessions, or one year’s 
treatment, were potentially available to participants, which is more than is commonly ac-
cessed in private care. N=50 (60%) had at least one consultation, n=69 (43%) had at least 
three consultations, and n=16 (19%) had all 8 sessions (section 7.3 & Figure 16). The mean 
number of appointments accessed was 3, which is interesting since this is what therapists in 
private practice recommend to establish treatment (section 4.2.5). Nutritional therapists felt 
that they had delivered the majority of their information after 5 sessions.  
Therapists tended to reduce the frequency of consultations once they felt progress was be-
ing made, and participants then contacted therapists for renewal of their prescriptions.  Par-
ticipants who attended all available consultations tended to be carers of fostered or adopt-
ed children. For the full trial, the offer of a maximum of 5 sessions over one year might be 
more cost effective. 
Research to manage compliance issues recommends: clear recruitment processes; good 
communication and liaison with stakeholders; incentives for recruitment and retention; ac-
tive and creative outreach work; investment in building relationships with carers; making 
programmes easily accessible; having realistic expectations (Axford, Lehtonen, Kaoukji, 
Tobin, & Berry, 2012); collaboration with teachers; individually tailored, flexible interven-
tions incorporating additional contact in-between sessions if required; a positive therapeutic 
relationship; and good inter-agency collaboration (Koerting, et al., 2013). Koerting identified 
28 barriers to participation which are listed below in Table 33 with their relevance to the 
STAR study and some possible solutions. 
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Table 35. Barriers to, and facilitators of, participation by ADHD families identified by researchers, and their relationship to the STAR project  
Barriers Relevance to the STAR study Possible improvements 
Situational barriers 
Practical difficulties (transport; childcare; financial difficulties; 
location; inconvenient timings; unpleasant venue; parking) 
 
Yes, especially initially where participants were required 
to attend face to face. 
Most therapists were flexible about time and venue 
On-line consultations (implemented) 
Paying for travel (implemented) 
 
Time constraints due to other commitments (work; issues associ-
ated with having several children) 
 
Yes, cited by most carers who dropped out/ failed to at-
tend/didn’t accept offer 
Extreme flexibility: offer times to suit indi-
viduals, flexibility about attendance of the 
child; keep persisting. 
Psychological barriers 
Fears/Worries (lack of confidence; shyness; concern about being 
judged; concern about not having skills) 
 
Yes, fear/worry about explaining to therapists about 
missed appointment, or inability to implement interven-
tion (particularly NT) 
Understanding by therapists. Regular su-
pervision to help therapists not take can-
cellations personally 
Stigma (shame about needing help; service use perceived as pa-
rental failure; fear of being labelled) 
 
n/a  
Distrust (concern about lack of confidentiality/anonymity; dis-
trust of professionals) 
 
Confidentially/anonymity emphasised throughout 
Therapists may be seen as professionals and distrusted 
Emphasise the non- conventionality of 
treatments? 
Lack of information/misconception about services  
 
Initial enthusiasm to recruit to the cohort and trial not 
followed up by attending a consultation 
More information about treatment com-
mitment on recruitment to the cohort 
Availability of services  
 
n/a  
Poor interagency collaboration  
 
STAR project not accepted by NHS clinicians Apply for NHS ethical approval 
Dislike of group activities  
 
n/a  
Programme regarded as unhelpful  
 
 Changes may be slow to manifest Therapists provide realistic explanations  
Difficulty following the programme  
 
NT ask carers to implement difficult dietary changes NTs suggest small changes over time. 
Change in circumstances (illness of any family member; move to 
a different area 
 
Yes, several carers cited this as the reason for dropping 
out 
Flexibility in the programme to drop in 
and out according to circumstances  
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Facilitators Relevance to the STAR study Possible improvements 
Effective advertisement/service promotion 
 
Yes, multiple sources used, and personal communication  
Effective advertisement content (clear, easy to understand—
regardless of literacy levels; conveyance of tangible benefits of 
programme and inclusive nature of services) 
 
Yes, although conveyance of tangible benefits of interven-
tions may have been downplayed in order not to contam-
inate research and introduce bias. 
Up-play tangible benefits? 
Specifically target hard to reach groups  
 
Yes: Sheffield City council looked after children pro-
gramme, special schools. Criminal justice system. Lack of 
NHS ethics precluded use of this source  
NHS ethics would have allowed access to 
Sheffield City Council programmes. Target 
correction facilities. 
Offer multiple, ‘soft’ entry points  
 
Yes  
Personalised recruitment  Yes  
Effective, direct channels (other carers/word of mouth; outreach 
work; emails; phone calls; text message 
Yes  
Good interagency collaboration  No, interventions currently seen as alternative and not 
promoted/supported  by mainstream services 
Continue to develop relationships with 
service providers. 
Programme addresses families’ actual needs  Yes, programmes are individually tailored to family’s 
needs. Participants without gut problems or where nutri-
tion is not an issue may find NT irrelevant.  
Work towards sub-group randomisation, 
e.g. NT for those with identified gut is-
sues.  
Positive group experience (homogenous groups; establishment 
of ground rules [e.g. confidentiality, safety]; provision of food) 
Homeopaths fails to make tangible, immediate differ-
ences 
Homeopaths to provide clearer expecta-
tions of treatment progression 
Additional contact (home visits or one-to-one support; phone 
support; catch up sessions if any were missed) 
Yes  
Positive personal qualities of therapist  
 
One therapist was judgemental and less flexible than the 
others. 
Therapist not feasible 
Therapist skills/background  
 
Therapists experienced in working with this population 
had better retention rates. 
 
Use therapists with experience of working 
with challenging families 
Identified from ‘Barriers to, and facilitators of, parenting programmes for childhood behaviour problems: a qualitative synthesis of studies of parents’ and professionals’ perceptions (Koerting, et al., 2013)
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9.1.7 The TwiCs approach to providing information about interventions. 
Trials using the TwiCs design take a variety of approaches to the information they provide to 
participants, and the extent of this disclosure about future research within the cohort varies 
among studies (Kim, Flory, & Relton, 2017). The majority of researchers using the TwiCs de-
sign inform would-be participants that they may be offered interventions in the future when 
recruiting them to the cohort, although some do not (Relton, et al., 2017). 
The comparative case series of treatment by a homeopath which informed this study 
(Fibert, Relton, Heirs, & Bowden, 2016), told would-be participants which group they were 
allocated to on recruitment to the study, found that those offered treatment were more 
likely to join the study than those who were not. The study successfully recruited 20 partici-
pants to the intervention arm, but only 10 to the control arm (section 4.3.3). Therefore the 
decision was made to interpret the TwiCs design as a Dutch group using the design have 
done (Young-Afat, et al., 2016), by making it known to cohort recruits that they might be 
offered an intervention at a later date.  
This was done by posting occasional articles about the interventions on the STAR Facebook 
page (www.facebook.com/starsheffieldADHD). Some participants mentioned that the po-
tential opportunity to try a novel therapy influenced their decision to enrol to the cohort. 
However, participants recruited via flyers and ADHD support groups, who were the majority, 
(Figure 8) were unlikely to have seen the Facebook page when being recruited, therefore 
knowledge that there may be interventions did not impact recruitment significantly.  
9.1.8 The validity of the trial design 
This section discusses the internal, external, and ecological validity of the trial design. Exter-
nal validity is assessed using the PRECIS (PRagmatic, Explanatory Continuum Indicator Sum-
mary) tool (Loudon, 2015). Internal validity is assessed using the Cochrane Collaboration’s 
tool for assessing risk of bias (Higgins, 2011). There is no tool to assess ecological validity 
(the extent of concordance between a trial study design and the core principles and con-
cepts of the tested intervention). 
External validity 
The idea of the TwiCs design in particular, and pragmatic studies in general, is to closely mir-
ror the experience of routine clinical practice, since the greater the similarity between pa-
tients’ experiences in trials and their experiences in routine health care, then the greater the 
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generalisability of the trial results to patients in routine health care (Relton, O'Cathain, 
Nicholl, & Torgerson, 2010).  
The PRECIS tool is used to assess the pragmatism of the study (http://www.precis-2.org/) by 
assessing domains using a Likert type scale: 1. Very explanatory 2. Rather explanatory 3. 
Equally pragmatic/explanatory 4. Rather pragmatic 5. Very pragmatic. It was separately 
scored by myself and Kirsty Loudon, who developed the PRECIS tool, and any discrepancies 
were resolved through discussion. 
Table 36. PRECIS-2 scores assessing the external validity of the study 
Domain Criteria Score Rationale 
1 Eligibility 5 Participants with ADHD and all additional diagnoses are eligible. Only 
those with life-threatening illnesses or not speaking English excluded 
2 Recruitment 
Path 
4 Recruitment from domains where ADHD manifests: schools, particu-
larly special schools, support groups, local events, looked after chil-
dren, ADHD family workers, ADHD support groups. Recruitment not 
through the NHS 
3 Setting 5 Interventions occurred in the same settings as those used by thera-
pists in clinical practice: complementary health care settings, partici-
pant’s homes, or on-line.  
4 Organisation 
intervention 
3 Some extra training provided in: CEASE methodology, NSPCC child pro-
tection, and ADHD management. 
5 Flex of exper-
imental inter-
vention – Deliv-
ery 
4 Intervention tailor made to needs of those with ADHD – no specific 
protocol for interventions that had to be adhered to. No specific in-
structions regarding co-interventions that are not allowed to be taken 
during treatment. 
6 Flex of exper-
imental inter-
vention – Ad-
herence 
5 Some measures to improve adherence were used: participants were 
reminded about their appointments and missed appointments were 
re-booked. However, no action taken if appointments were missed. 
Non-compliers still included.  Medication provided for free which is 
not available on the NHS.  
7 Follow up 3 The interventions offered more opportunity for follow up than is usual 
in private care where clients choose how often they return. Question-
naires were completed independent of treatment by those accessing 
treatment and TAU participants.  £10 voucher incentive to complete 
questionnaires. 
8 Outcome 5 ADHD questionnaires are used in diagnosis and assessment of ADHD. 
Other outcomes were selected for their objective, evidence based rel-
evance to ADHD. 
9 Analysis 5 ITT with all available data 
The two assessors concurred that the STAR pilot trial was highly pragmatic in terms of anal-
ysis and selection of outcomes, setting, and eligibility (broad inclusion criteria). Delivery was 
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also considered pragmatic. It was less pragmatic in terms of organisation of the interven-
tion, since therapists had received some extra training in understanding of ADHD, and ho-
meopaths some extra training in specific homeopathic methodologies.  Return of question-
naires was considered less pragmatic since incentives and several reminders were used. Re-
cruitment was considered less pragmatic since those seeking help generally go through their 
GP or the NHS, whilst only a minority search out complementary therapies.  
Internal validity 
The study’s internal validity was considered according to Cochrane collaboration criteria 
(Higgins, 2011) in Table 37. Judgement was made as to whether risk of bias was high, low or 
unclear. It was separately rated by myself and Petter Viksveen, a colleague who has used 
the TwiCs trial design (Viksveen, 2017). Any discrepancies were resolved through discussion. 
Table 37. Assessment of the internal validity of the study 
Domain Risk of bias Rationale 
Domain I: selection bias, 
random sequence genera-
tion.   
 
low Computer generated random sequence generated 
by independent researcher  
Domain II: selection bias, 
concealment of allocation 
sequence 
 
 
low PI emailed age, CGI T score and medication status of 
participants to a second independent researcher, 
who allocated treatment status and an identifier 
according to randomised, stratified list kept in a 
locked drawer 
Domain III: performance 
bias, blinding of partici-
pants and researchers  
 
high Neither participants or researcher were blind to al-
location 
Domain IV: detection bias, 
blinding of outcome as-
sessment  
 
high/low Outcomes were collected from carers who were 
unblinded, and teachers who were blinded. 
Domain V: attrition bias, 
incomplete outcome da-
ta.  
 
low All attrition and outcome data reported 
Domain VI: reporting bias, 
selective reporting of out-
comes  
 
low Outcomes reported as specified in the pre-
published protocol 
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Validity Comparison 
A strength of STAR pilot trial is its high external validity, and the high ecological validity of 
the interventions tested, but internal validity is inevitably low in the domain of detection 
and blinding: of participants, researcher and carer.  
This is an issue because only once internal validity is considered adequate are other do-
mains considered (Torgerson & Torgerson, 2008). External validity is not systematically as-
sessed for its quality in reviews, and the PRECIS tool far less integrated than the internal va-
lidity tool. There is not even a tool to assess ecological validity. 
The TwiCs design may not be considered suitable by NICE. Standardised, easily blinded in-
terventions tested using explanatory designs are rated more highly than unblinded, prag-
matic studies which are considered de facto low quality (Thornton, et al., 2013). Despite 
guidelines stating that they assess the ‘effectiveness’ of interventions, guideline developers 
appear to be prioritising evidence of efficacy rather than effectiveness. One of the aims of 
this thesis was to provide useful information to stakeholders such as NICE, but it is unlikely 
that the TwiCs design will be acceptable to them due to their preference for blinded, place-
bo-controlled designs, desire to measure specific effects, and concern with therapist effects 
(section 9.3.2).  
It is difficult to see how this paradox can be resolved. Therapist led interventions cannot be 
compared to placebos. Effectiveness testing is recommended for such interventions but has 
lower internal validity, therefore such interventions are at a disadvantage when assessed. 
Demonstrating efficacy with a top down approach (does it work in clinical practice, before 
unpacking the black box of how/why it works) is less acceptable than a bottom up, hypothe-
sis testing, theory generated, approach. Interventions with explanatory evidence of efficacy 
give credibility to clinical results. This is a problem for the acceptability of results of treat-
ment by homeopaths but less so for the acceptability of results of treatment by nutritional 
therapists, which builds upon considerable explanatory evidence and theoretical models for 
aspects of nutrition. 
 Homeopathy lacks an accepted explanation for its mechanism, so evidence generated 
stands on shaky foundations. Clinical trials to date have attempted to address this issue by 
testing the efficacy of the homeopathic remedy using designs which mostly compare home-
opathic remedies with placebos. However, despite the percentages of positive, negative and 
inconclusive results being similar in homeopathy and conventional medicine (Figure 19), this 
approach has neither increased the acceptability of the intervention, nor provided useful 
information regarding homeopathic treatment in real-life. Meta-analyses may disagree on 
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the conclusions they reach, but concur that trials do not represent homeopathic treatment 
as experienced in clinical practice (e.g Linde, et al., 1997 & Bornhöft, et al., 2006).  
Figure 19. Comparison of RCTs of homeopathy and conventional medicine 
                   
Chart A information extracted from https://facultyofhomeopathy.org/research. Chart B extracted from El Dib, Atallah, & 
Andriolo, 2007) 
The premise of pragmatic trials is that if interventions are safe, effective, cost effective and 
helpful to patients, implausibility is secondary to its therapeutic benefit. There is a trade-off 
between the testing of specific effects, and the generalisability of results. The TwiCs trial de-
sign may not have sufficient internal validity for some assessors, nevertheless it has im-
portant contributions to make to the research canon in terms of data about recruitment, 
acceptability, feasibility, and the effectiveness of treatments in real-life, with the much 
needed emphasis on improving outcomes.  
9.1.9   The feasibility of the TwiCs design to contribute to research priorities 
Problems have been identified regarding the paucity of research into interventions to im-
prove long-term negative outcomes in ADHD specifically, and child and adolescent mental 
health in general. The TwiCs trial design can usefully contribute to the research landscape 
since it can test multiple (potentially multi-component) interventions comparatively and 
cheaply, in at-risk, representative populations, to see whether their outcomes are improved 
over the long-term. 
It has been identified that the evidence base for child and adolescent mental health inter-
ventions is minimal (Kennedy, 2015), particularly for the long-term effects of treatments 
(Fonagy, et al., 2015) (section 2.3). The majority of research funding in mental health is di-
rected towards understanding biological, psychological and socioeconomic processes, risks 
and causes with “considerably less funding going directly towards the development of 
treatments and therapeutic interventions research” (MQ, 2015).  
Interventions for child mental health are “generally complex and multi-
dimensional”(Kennedy, 2009). The MRC review of Mental Health Research (Medical 
 209 
Research Council, 2010) highlighted co-morbidity as an obstacle to progress in mental 
health research. They found that trials testing interventions in populations with mental dis-
orders (5% according to the Cochrane database) were typically underpowered, the research 
was expensive, labour intensive and required specially trained staff.   
The TwiCs design is particularly well placed to assess these identified research issues. Indeed 
it is being successfully implemented in five cohorts similar to STAR in that they have identi-
fied populations at risk of negative outcomes in areas where there is little evidence regard-
ing the effectiveness of interventions to improve outcomes in the longer-term. They are tak-
ing innovative pre-emptive approaches to testing multiple interventions to try and improve 
these outcomes (studies were described in section 3.2.2). 
For example, the BIBBS (Born in Bradford Better Start) cohort are considered at risk of ad-
verse health and social outcomes which are well described. But whilst the early years have 
been identified as having a lifelong effect on health and well-being, there is a paucity of high 
quality research into the effectiveness of interventions implemented in the early years to 
improve later outcomes. Researchers aim to implement 22 interventions in children aged 0–
3 in the areas of social and emotional development; communication and language develop-
ment; and nutrition and obesity, to see whether long-term outcomes are improved.  
In Canada, FORBOW (Families Overcoming Risks and Building Opportunities)  recruits a co-
hort of offspring of parents with severe mental illness.  Such offspring are well documented 
as being at risk of severe mental illness themselves. Currently interventions are implement-
ed at the prodromal stage, where they are found to ameliorate but not prevent the devel-
opment of severe mental illnesses. FORBOW takes an innovative approach by implementing 
interventions at an earlier stage, with the idea that developmental trajectories may be in-
fluenced with smaller investment and to greater effect. 
FORBOW’s first pre-emptive early intervention RCT is currently underway testing Skills for 
Wellness (SWELL), providing skill training to parents of younger children. By 2016 the cohort 
had recruited 306 youth, of whom 38 were eligible for the first RCT.  The FORBOW research 
team also plan to trial courses in emotional well-being skills based on cognitive behavioural 
therapy for older children and youth. They selected the TwiCs design since it “saves the par-
ticipants from the unnatural and possibly harmful effect of being allocated to a control 
group after hearing about the details of a potentially beneficial intervention” and “mirrors 
the practice of offering a preventive intervention to non-treatment seeking participants” 
(Uher, et al., 2014) 
The CEDAR Project has identified an at-risk cohort of young indigenous people using drugs in 
Canada, and is testing an intervention to see if it reduces HIV. Another Canadian cohort of 
youth presenting with violence related injuries at a Canadian hospital has been created. 
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They are trialling an intervention (wraparound care) to see if it reduces repeat admissions. 
TARGet Kids! (The Applied Research Group for Kids) recruits children aged 0-5 years who 
present at SickKids Hospital in Toronto. It aims to conduct preventative research in the areas 
of obesity, micronutrient deficiencies, and developmental problems 
(http://www.targetkids.ca/our-research). 
These studies using the TwiCs design in cohorts of children are all testing preventative inter-
ventions in at-risk populations, and this appears to be an emerging strength and potential of 
the design. They also have in common that the interventions they are testing tend to be 
complex, implemented by practitioners trying to change negative behaviours and outcomes. 
The utility of the design in the studies described above highlights the potential utility of the 
STAR cohort of children with ADHD, who are similarly at risk of negative outcomes and in 
need of pre-emptive strategies implemented as early as possible. 
9.1.10 Cost-efficiency of the TwiCs design 
This study has pilot tested two novel interventions relatively cheaply. By developing an ob-
servational cohort, and providing a research platform for multiple trials, the TwiCs design 
provides a cheap, cost effective way to test interventions. 
The cost of running the STAR pilot trial, excluding an investigator’s salary, was less than 
£50,000. Now that the cohort has been established, the cost of testing further interventions 
should be less than this sum, and certainly less than testing using a standard RCT, and hav-
ing to start from scratch. Trials are expensive to conduct, and funding applications highly 
competitive. Because trials using TwiCs methodology are relatively cheap to conduct, inter-
ventions can be trialled which may be in the public interest but struggle to attract industrial 
funding.  
Funding for research is highly competitive, and depends either on financial patronage of 
companies looking to develop products, charities, or national bodies. Currently the majority 
of funding is directed towards the testing of pharmaceutical medications, whilst just 
0.0085% allocated to CAM interventions in the UK (Lewith, 2007). Evidence for non-
mainstream interventions is less likely to be conducted due to lack of industrial funding and 
failure to attract national funding. 
9.2   The feasibility of outcome measurement 
This section discusses the thesis objective to assess the suitability, acceptability, and deliv-
erability of the outcome measures. It discusses the means of collecting outcomes, the suita-
bility of the measures and the statistical tests used.  
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9.2.1 Collection of outcomes  
Collection of carer outcomes 
On-line collection of outcomes by carers was feasible, and only a few participants without 
computers requested paper versions. Completion of on-line forms enabled on-line availabil-
ity of data, which saved time and was more efficient. Missing data was reduced since partic-
ipants could not continue to the next page until all items were completed. In comparison, 
teacher outcomes were mostly completed on paper, and had more missing items (section 
7.4). 
Some small adjustments are needed to the on-line website and questionnaires. Some partic-
ipants completed the wrong option on-line regarding baseline, 6-month and 12-month out-
come measures. This required transferral of the data by the PI. Clearer signposting is need-
ed. Participants were only asked for the child’s school information in the baseline question-
naire. This was problematic because children changed schools and teachers, so question-
naire requests were sometimes out of date, compounding the TQ return problem. School 
information needs to be requested each time a questionnaire is completed so school details 
are current. 
Collection of teacher outcomes 
Several problems with the collection of teacher outcomes reduce their reliability: poor re-
turn, missing items from paper questionnaires, completion of questionnaires by different 
teachers, and lack of completion during school holidays. 
55% of teacher outcomes were returned at baseline and just 27% at 6 months. Outcomes 
were only requested once, by post, via headteachers, which was not sufficient. Of the 31 
paired outcomes returned, 11 were completed by different teachers. Outcomes could not 
be completed during the summer holidays, when several children moved school and their 
outcomes were lost. 
The poor return of teacher outcomes, which were blinded, is problematic, since blinded re-
sults increase internal validity, and some researchers only consider blinded results valid. The 
concern regarding unblinded results is that carers may have been invested in treatment suc-
cess, (section 3.1.8) (Sonuga-Barke, et al., 2013). However, collection of teacher-rated out-
comes is also associated with problems (section 3.1.8), and the difficulties identified by oth-
er researchers around procurement, multiple teachers and school holidays (Biederman, 
Faraone, Monuteaux, & Grossbard, 2004) were borne out in this study. 
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An informal summary of parent and (blinded) teacher results (Table 38) across a variety of 
interventions, shows that teachers, whether blinded or unblinded, tend to report higher ef-
fects of pharmaceutical medication than carers, and that carers report higher effects for 
non-medication interventions than teachers. There are several possible explanations for 
this. Some effects may be more easily identified in 1: 1 environments by those most proxi-
mal to the child, and others in group settings: for example busy teachers in large classrooms 
may not observe subtle changes. Children may suppress usual behaviour in some settings, 
for example classrooms. Carers and teachers may value different aspects and therefore rate 
them differently: for example teachers might value sitting still and not calling out more than 
carers. Carers and teachers may have differing value judgements regarding treatments. And 
most non-medicine interventions are implemented by carers who may be invested in treat-
ment outcome. 
Despite difficulties in collection, and possible differences in perspective, the full trial should 
continue to measure teacher outcomes: to provide an additional perspective; because the 
majority of the costs of ADHD are in education (section 2.2.6); to increase internal validity 
since these outcomes are blinded; and to address demand characteristics, whilst acknowl-
edging limitations. Better collection methods must be used to increase response rates, by 
making several requests using various media, as was done to collect carer outcomes, and by 
developing relationships with schools. 
9.2.2 The primary outcome 
Intention-to-treat analysis assessed the effectiveness of the offer of treatment on ADHD 
global symptoms (CGI). That is, participants remained in the group they were randomly se-
lected to irrespective of whether they received a treatment. The data were analysed using 
linear regression assessing statistical impact and standard mean difference assessing clinical 
impact. 
Regression analysis 
Covariates age, gender and ADHD severity were included in the model due to their consid-
ered influence (Conners, 2009). For example, younger children find it more difficult to stay 
seated in the classroom than teenagers, and differences between males and females are 
found for many items in statistical analyses of the Conner’s data. The most accurate way to 
assess whether a child is typical for his/her chronological age and gender, is to control for 
these differences.  However, only ADHD severity significantly influenced the model (Table 
39), with the significance of the regression analysis driven by this. Since all groups improved, 
this suggests regression to the mean (section 7.5.1).   
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The study was not sufficiently powered to detect statistically significant differences between 
usual care and treatments, and total scores did not tend to find any. Mean improvements 
were greater in treatment groups according to carers, but with wide confidence intervals in 
all groups (Table 24). The un-feasible homeopath influenced the wide confidence intervals 
in the homeopathy arm.  
Significant effects were observed in carer-rated sub-scores: the effect of treatment by ho-
meopaths on emotional lability, and the effect of treatment by nutritional therapists on 
restlessness/impulsivity. Whilst these underpowered results are not robust, they are of in-
terest, since results support therapist’s opinions about the aspects their therapies are con-
sidered to address:  homeopaths consider and treat emotional symptoms (section 6.5.1), 
whilst nutrition is considered to effect neuro-developmental pathways (section 5.2.2).  
Emotional lability was measured using 3 items: temper, mood change and crying. Given the 
importance of this aspect, a tool measuring other facets of emotional lability would be more 
robust, however, there is not yet a universally accepted measure (van Stralen, 2016). The 
role of emotional problems is less researched and established (Mordre, Groholt, Kjelsberg, 
Sandstad, & Myhre, 2011), despite being a better indicator of impairments in daily living, 
problems in adulthood and criminality than ADHD symptoms per se. (section 2.1.1). Clinical 
trials may focus on measuring ADHD symptoms rather than emotional dysregulation be-
cause there is little evidence suggesting mainstream interventions improve it (Shaw, 
Stringaris, Nigg, & Leibenluft, 2014).    
The Difficulties in Emotion Regulation Scale (DERS) (Gratz & Roemer, 2004), was suggested 
as a commonly used tool by an expert in the field (personal communication with Professor 
David Coghill). It assesses the impact of six dimensions of emotion regulation: lack of 
awareness; lack of clarity; nonacceptance; limited access to emotion regulation strategies; 
difficulties controlling impulses; and difficulties engaging in goal-directed behaviours when 
experiencing negative emotions. However, the measure is long (40 items), and is not specific 
to ADHD, or to children.  
The Strengths and Difficulties Questionnaire (SDQ) is designed to gather information on 
emotional and behavioural difficulties, (and daily functioning) but is not specifically designed 
for ADHD populations (www.sdqinfo.com; Goodman, 2001). It may be worth considering for 
future research, and is widely used in the UK.  It categorises strengths and difficulties into 
five scales, of five items each, of which emotional problems are: unhappy, fears, clingy, so-
matic and worries.   
The Child Mania Rating Scale, Parent Version (CMRSP) has also been used to measure emo-
tional lability (Rucklidge, 2017). It is a 21-item rating scale based on DSM-IV criteria for ma-
nia (Pavuluri, Henry, Devineni, Carbray, & Birmaher, 2006). Items cover symptoms such as 
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feeling irritable, racing thoughts, rage attacks and rapid mood swings. (West, Celio, Henry, & 
Pavuluri, 2011).Emotional lability is an important outcome that should continue to be 
measured, and the search for optimum means to do so should continue. 
Standard Mean Differences (SMDs) 
Carer-rated SMDs were above protocol specified threshold of .3, and close to the NICE and 
European guideline development group’s SMD of .4, considered to constitute a clinically 
meaningful change (personal communication with Professor David Daley & NICE, 2008). In 
this small pilot study, unblinded carer-rated results for both interventions appear compara-
ble to some mainstream and non-mainstream interventions (see Table 38).  
The small number of paired blinded teacher-rated outcomes available suggest that the 
blinded teachers observed effects of the offer of treatment by nutritional therapists which 
were similar to those observed by the unblinded carers. However, the teacher-rated results 
found for those offered treatment by a nutritional therapist (SMD = .39) were then reversed 
in those who accessed treatment (SMD = -.504), suggesting the results are un-trustworthy 
(Table 26). 
To compare the results of the STAR pilot trial with other ADHD trials, an informal compari-
son was made by extracting the SMDs from trials or meta-analyses of mainstream interven-
tions identified earlier in this thesis, interventions like those tested, and other homeopathy 
trials (Table 38). The highest level and most recently published evidence was used. Infor-
mation was found by searching google scholar and web of science, and by extracting data 
from publications already identified in this thesis. 
Large SMDs were found in two trials of homeopathic remedies (Frei, (-1.67) & Oberai (-15.6) 
and for the pooled results of medium doses of methylphenidate (-1.69 (teacher rating) -1.34 
(carer rating). Small SMDs were found for the pooled results of PUFAs (-.28), although re-
sults were moderated by type of PUFA.  Minimal change was found in one study of homeo-
pathic remedies (Jacobs (.13); or from teacher-rated PUFAs (-.07); or from psychological in-
terventions 3-6 months on (-.05). Table 38 contains the results of both efficacy trials (of 
medication, homeopathic remedies and nutritional supplements) and effectiveness trials (of 
behavioural interventions, and the STAR pilot RCT interventions). Effectiveness trials are ex-
pected to have smaller effect sizes than efficacy trials, (section 3.3.2) because noise is great-
er due to non-specific factors such as natural history of the disorder, regression to the 
mean, co-interventions as part of routine care outside the trial, expectations, therapist ef-
fects, ITT analysis and more (Gold, et al., 2017). Comparing effect sizes of efficacy and effec-
tiveness trials is problematic. A more equitable comparison might be to compare the real-
world effectiveness of all interventions, as the TwiCs design can.  
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Clinically meaningful differences 
One aspect of whether positive findings from trials generalise to real world settings con-
cerns the clinical meaningfulness of results found according to the outcome measures used. 
However what constitutes a clinically meaningful change in ADHD symptoms is debated. The 
debate centres around comparisons of pharmaceutical and behaviour change trial results 
and clinically meaningful differences therefore need considering within the context of validi-
ty, as discussed above. Pharmaceutical medication trials find large changes in ADHD symp-
toms according to validated outcome measures, but discrepancies between these and real-
life clinical benefits (Hazell et al. 2005). Behaviour change programmes find small changes, 
but arguably useful clinical benefits.  
The only published minimal clinically relevant difference for ADHD scales found (identified 
by Storebo, 2015) are: 6.6 points for the ADHD rating scale (scale ranges from 0 to 72 
points) (Zhang, 2005); and 7 points for the child health quality of life questionnaire (scale 
ranges from 0 to 100) (Rentz, 2005). Both compared pharmaceutical medication with place-
bo over the short term in tightly controlled studies where effect sizes are expected to be 
high, so are not sufficiently relevant to this study.  
NICE (2018 update) found an absence of values identified in the literature, For ADHD symp-
toms the committee therefore agreed that a >20% difference between groups represented 
a minimally important difference, based primarily on consensus. For other outcomes the 
GRADE default method is used with the proviso that any levels set can be amended subject 
to guideline committee discussion.   
Conners (2008), who developed the CGI measure which was the primary outcome in this 
study, suggests that a change in classification  indicates a clinically meaningful change. Clas-
sification changes occur if a T score shifts from anything above 70 (markedly atypical) to 66-
70 (moderately atypical) or 61-65 (mildly atypical). This however means that a change of a 
few points (from 71 to 69) is considered clinically meaningful, whilst a change of 20 points 
(from 90+ to 70) is not. This stance is also controversial, nor is it recommended when evalu-
ating experimental interventions, where statistical significance is recommended (Conners, 
2008). 
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Table 38. Comparison of Standard Mean Differences for some ADHD interventions 
Study description  Type Sample size Unblinded SMD ADHD symptoms (Confi-
dence intervals) 
Blinded SMD ADHD symptoms (Confi-
dence intervals) 
NICE (2009). Efficacy of methylpheni-
date (v placebo)   
Meta-analysis 
(12 studies) 
1582 Low dose = .40 (-.95, .15) 
Medium dose = -1.69 (-2.24, -1.14) 
High dose = -.84 (-1.06, -.62) 
Low dose = .66(-.06, 1.37) 
Medium dose = -1.34 (-3.26, .58) 
High dose = -.79 (-1.14, -.45) 
Storebo (2015). Efficacy of 
methylphenidate (v placebo) 
Meta-analysis 
(19 trials) 
1698  Teacher: 0.77 (-0.90 to -0.64)  
Carer: -0.53 (-0.78 to -0.27) 
NICE (2009). Efficacy of atamoxetine 
(v placebo)  
Meta-analysis 
(10 studies) 
1850 Low dose = .33 (-.70, .04) 
Medium dose = .43(-.73, -.12)/- 
High dose = .59(-.71, -.47) 
 
Medium dose = .65 (-.87, -.43) 
High dose = -.59(-.71, -.47) 
NICE (2009) Effectiveness of psycho-
logical interventions (v TAU, wait list, 
no Treatment)  
Meta-analysis 
(10 studies) 
549  .57 (-1.0, -.14)/ -.91 (-.1.23, .59) -.25(56, .07)/-.05(-.44, .35) 
 
Storebo (2011) Effectiveness of social 
skills training (v TAU) 
Meta-analysis 
(6 studies) 
515  0.02 (-0.19, 0.16)   
Sonuga Barke (2013) Efficacy of CBT  Meta-analysis 
(5 studies) 
286 0.64 (0.33, 0.95) 0.24 (0.24, 0.72)  
Sonuga-Barke (2013) Efficacy of Be-
havioural interventions  
Meta-analysis 
(7 studies) 
528 0.4 (0.2, 0.6) 0.02 (0.30, 0.34) 
Sonuga -Barke (2013) Efficacy of Re-
stricted elimination diets  
Meta-analysis 
(6 studies) 
200 1.48 (0.35, 2.61) 0.51 (0.02, 1.04) 
Sonuga-Barke (2013) Efficacy of Arti-
ficial colour exclusion (v placebo) 
Meta-analysis 
(8 studies) 
320 0.32 (0.06, 0.58) 0.42 (0.13, 0.70) 
Puri (2014) Efficacy of Polyunsaturat-
ed fatty acids (v placebo) 
Meta-analysis 
(18 studies) 
? .28(-.42, -.13)/ -.07(-.2,.05)  
Sonuga Barke (2013) Efficacy of fatty   0.21 (0.35, 2.61) 0.16; 95% CI=0.01, 0.31  
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acids (v placebo) 
Frei (2005) Efficacy of Homeopathic 
remedies (v placebo)  
RCT 62  -1.67 ( -3.32, -.02) 
Jacobs (2005) Efficacy of Homeo-
pathic remedies (v placebo) 
Pilot RCT 37  0.13 (-.47, .73) 
Oberai (2013) Homeopathic remedy 
(v placebo) 
Pilot RCT 54  -15.6 (-19.5, -11.6) 
Fibert, (2016) Effectiveness of treat-
ment by a homeopath (v similar time 
and attention) 
Controlled 
case series 
30 .71 (-1.47,.054)  
Fibert (2018) Effectiveness of treat-
ment by a homeopath (v TAU) 
RCT 50 .43 (-1.22, 4.29) .07 (-1.67, 3.75)  
Fibert (2018) Effectiveness of treat-
ment by a Nutritional Therapist (v 
TAU)  
RCT 50 .39 (-1.29, 5.08) .39 (-1.75, 6.05)  
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9.2.3 Secondary outcomes 
As well as ADHD symptoms, the STAR study measured the effects of treatments on health-
related quality of life, sleep, ADHD in autism and resource use. 
Health related quality of life 
CHU 9D asks about worry, sadness, pain, tiredness, annoyance, schoolwork, sleep, daily rou-
tine and ability to join in everyday activities. At baseline, carers did not generally rate their 
children as being in pain, tired, worried or sad (Figures 21 & 22). These proxy observations 
are similar to those found by Peasgood et al. (2016) who asked the children themselves, 
which is interesting.  In the STAR study the tool was not used as designed, since it was origi-
nally designed for self-completion rather than by proxy. It was originally developed for chil-
dren aged 7-11 years, and has since been validated for adolescents (11-17 years). Proxy ver-
sions with children age 5-7 and under 5s have also been trialled. 
Interventions had effects on more emotional items such as sadness, worry, and annoyance, 
but not on more practical items such as management of schoolwork or daily routine, sleep, 
or joining in. The items considered most problematic by carers at baseline were not signifi-
cantly helped by the interventions. 
It is suggested that carers’ observations are influenced by the extent of their involvement 
(Sonuga-Barke et al. (2013). Certainly carers of children receiving treatment by nutritional 
therapists registered significant improvements in CHU 9D for their child (Table 26), and re-
ported to their therapists that the whole family benefitted from implementation of their 
nutritional changes.  
Future plans are to perform a cost-effectiveness analysis once the 12-month results are ana-
lysed. Indications are that both interventions may be cost-effective. This is likely down to 
the low cost of therapists who are un-regulated, increased use of on-line consultations re-
quiring no venue hire, and the low number of hours therapists spend with participants. The 
cost effectiveness of NT varies depending on whether supplement costs are included. 
Sleep 
No improvement in sleep was found according to a single item in the CHU 9D which asks the 
level of problems the child had sleeping last night. A more sensitive measure of this im-
portant issue is needed to ask about other aspects such as difficulty getting to sleep, waking 
at night, waking early, or nightmares. 
ADHD in ASCs 
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ADHD in ASCs has only been recognised since publication of DSMV in 2013, allowing co-
occurring diagnosis. 37 children had additional diagnoses of autism, but few paired carer 
questionnaires were available (24 (n=6 hom; n=6 NT, n=12 TAU). Treatment by nutritional 
therapists was helpful for this very small sub group of children according to carers. There 
were not sufficient outcomes to measure teacher ratings (section 7.5.2). Results must be 
viewed with extreme caution. 
Given that medication for ADHD for those with co-occurring autism may be more associated 
with side effects without commensurate benefits (section 2.3.1), it is important to continue 
to measure results in this sub-group, and to recruit sufficient numbers to enable robust 
comparisons.  
Resource use 
No impact on publicly funded resource use was found (section 7.7.1). It may be that the in-
terventions did not impact resource use, the time span was too short to capture an effect, 
the number of participants was insufficient, or measures not sufficiently sensitive. The 
numbers involved with police services and social workers were particularly small.  It has al-
ready been emphasised that greater effort is needed in future research to access those 
most ‘at need’, which would enable comparison of larger numbers to produce more robust 
results. Measurement over longer stretches of time may be needed to capture the effect of 
interventions on resource use. 
9.3   The feasibility of treatment by homeopaths and nutritional therapists 
 This section assesses the thesis objective regarding the feasibility, acceptability, deliverabil-
ity, safety, clinical and cost effectiveness of treatment by homeopaths and nutritional ther-
apists for children with ADHD. 
9.3.1 Case management 
Regular supervision was provided throughout the trial. Such supervision is encouraged by 
both therapy’s professional organisations, and is not a variation from usual practice. During 
supervision therapists needed support in understanding and managing the frequently chaot-
ic, often troubled families.  
Therapists with prior experience of challenging families were confident in their management 
of participants, and had higher take up and retention rates (section 8.8.4). More inexperi-
enced therapists were challenged by the high levels of missed and cancelled appointments, 
changes of plans, lack of response to emails, texts or phone messages. One homeopath felt 
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herself unequal to management of these participants, where interestingly, all her partici-
pants reported negative outcomes (section 8.8.4).  
Some experience with management of challenging families needs to be a pre-requisite for 
trial therapists. This need not reduce the level of pragmatism of the intervention, since it is 
likely that only experienced therapists would work with challenging families in real-life prac-
tice. 
Treatment by homeopaths 
Homeopaths were recruited from a complementary medicine clinic in Sheffield. Treatment 
was delivered as it would be in private practice: homeopathic remedies were individualised 
to each patient, and length and frequency of consultations was tailored to the needs of the 
patient. Homeopaths increasingly conduct consultations with patients on-line in routine 
practice, so the addition of on-line consultations was also in accordance with usual practice. 
Homeopaths attended several workshops preceding participation in the trial concerning 
specific methodologies for treating ADHD cases (section 6.5). It is common for homeopaths 
to attend courses as part of their continuous practitioner development (CPD) so this was not 
necessarily a deviation from usual practice, although the courses were paid for as part of the 
research, which is. However, none of the homeopaths utilised the methodologies they were 
trained in during these courses, preferring to use the methods they normally used. Recruit-
ment of future homeopaths will not offer this extra training as it was not cost effective and 
reduced the pragmatism of the intervention, but will try to recruit homeopaths who have 
already incorporated the techniques into their routine practice. 
Treatment by nutritional therapists 
The nutritional intervention was delivered by NTs who worked at the same complementary 
medicine clinic as homeopaths (www.wellforce.org) or in and around Sheffield. They did not 
attend any specialised nutrition for ADHD courses prior to the trial, however, during the trial 
consultants from Biocare came to talk to them, and provided free supplements and ongoing 
advice about supplements and a nutritional approach to ADHD. Like homeopaths they re-
ceived regular supervision, where support in case management was required.  
Although treatment was delivered as closely as possible to the way it is in private practice, it 
differed in two ways: completion of initial questionnaires, and provision of supplements. 
Initially therapists sent questionnaires to be completed by participants prior to their first 
consultation, as occurs in private practice. However, few had completed them when they 
attended their first consultation, and one participant dropped out post-acceptance citing 
the stress of having to do so. Therefore therapists completed questionnaires with partici-
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pants at the first consultation, and then arranged a second consultation soon afterwards. In 
private practice, supplements are purchased separately by clients. For this trial they were 
provided free by supplement companies. ADHD families would be unlikely to purchase 
them.  
Nutritional therapists felt trial participant’s attitudes differed from those of their private cli-
ents, who, having sought them out and paid for a consultation, would follow advice, buy 
recommended supplements and make recommended dietary changes. Unlike their private 
clients, trial participants had not sought out treatment, and did not have the same level of 
motivation to follow advice, so when participants did not implement dietary advice, thera-
pists relied on provision of supplements.  
Nutritional therapists felt that they first needed to listen and develop rapport with carers 
before they could focus on nutrition, and that this was vital to retaining participation. They 
felt that nutrition was just one element and often secondary to other life events, which 
sometimes confounded any nutritional changes. 
Nutritional therapists reported difficulties in treating participants with co-occurring autism 
(section 8.8.3) due to their particularly severe food sensitivities. However, the small number 
of participants with autism who received nutritional therapy reported that a dietary inter-
vention was particularly helpful to them.  
9.3.2 Consultations 
Homeopathy 
Trial homeopaths felt it was important to include the child in each consultation, despite my 
advice to the contrary which ran counter to my personal experience as a homeopath, and 
led to the drop out of at least one participant. Attendance of the child at every consultation 
can be stressful: they may hear negative things about themselves when their carer recounts 
their history to the therapist; carers may find it logistically difficult to bring children to all 
consults; it may be difficult to find care for other children in the family; children may not 
want to talk about their feelings, especially teenagers, and not in front of their carers; and 
children may not be able to sit still for the whole consultation.  
On the other hand, presence of the child validates their central importance in the therapeu-
tic process, can be valued by children, and can provide vital information to enable a suitable 
homeopathic prescription. Homeopaths felt that meeting with the child was important to 
assess changes by asking children directly and observing them, and were unconfident about 
relying on carer observations. But meeting carers alone provided the opportunity to get im-
portant historical information which carers may be reluctant to raise in front of the child.  
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On-line consultations introduced after six months, worked well for the 3/5 homeopaths who 
used them, and for carers. It meant homeopaths could obtain information from carer and 
child separately with carers relating any negative behaviour without it being heard by their 
child. Less commitment was required from carers compared with having to travel to attend 
a consultation with their child, which helped sustain participation. It allowed recruitment of 
families beyond Sheffield, and was cheaper, since room hire was not required. However, 
management of the technology was an issue for a few, and led to the drop-out of at least 
one participant. 
Nutritional Therapy 
Nutritional therapists were more flexible regarding consultation mode than homeopaths, 
and often conducted follow ups by telephone or on-line, without children. This was not seen 
as a problem for carers with younger children, since much of the consultation is between 
carer and therapist, and children’s diets controlled by carers. However, teenagers manage 
their own diets, and therapists felt that only when the teenagers were engaged with the in-
tervention did dietary changes have a chance of being implemented.  
NTs reported that the opportunity to talk was sometimes the most valuable role they pro-
vided, in the absence of carer’s ability to implement dietary changes. 
9.3.3 Therapist effects 
Both interventions were delivered by therapists, and there is potential for the treatment 
effect to be mediated by therapist effects. Indeed the negative effects of one therapist had 
a significant impact (section 8.8.1).  
NICE are concerned about the generalisability of therapist delivered interventions. The di-
rector of NICE guidelines considers therapist effects to constitute 1/3 of effects seen, the 
other 2/3 being attributable to setting and therapy (meeting with Prof Mark Baker on 
30/6/17). An example of his concern is borne out in two trials of the New Forest Parenting 
Programme (NFPP), which was effective when well-trained providers in an ideal setting 
were used, but not when tested in a more standard community setting with less highly 
trained practitioners (section 2.3.2). Concern regarding therapist effects influences NICE 
recommendations regarding interventions delivered by therapists compared to pharmaceu-
tical medications. 
The TwiCs design may provide some solutions to the vexed question of therapist effects, 
since testing the effectiveness of interventions provided by several standard practitioners in 
routine clinical practice provides more generalisable results than using well trained provid-
ers in ideal settings. Conducting sub-group analysis comparing mean outcome per therapist 
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would provide useful information regarding the influence of therapists on the interventions, 
however this will entail far larger sample sizes and increased costs beyond the budget and 
scope of this study. 
9.3.4 Comparison of interventions 
Nutritional therapy and homeopathic treatment were similar in terms of the length and 
number of appointments provided (section 8.8.3); in having something to ingest (a homeo-
pathic remedy or a nutritional supplement) between consultations; and being delivered by 
empathic practitioners. However, they differed regarding the amount of effort required to 
implement the interventions. The implementation of dietary changes required considerable 
effort by carers unlike homeopathic treatment where little effort is required beyond occa-
sional ingestion of homeopathic remedies. Likewise, pharmaceutical drugs require minimal 
effort beyond ingestion, whilst behavioural interventions require concerted effort to im-
plement taught practices.  
Consultation delivery was different: during homeopathic consultations child and carer might 
be asked in-depth, challenging questions, about potentially sensitive subjects, in comparison 
nutritional therapists asked more practical questions. Who needed to attend consultations 
differed: homeopaths required attendance by carer and child, whilst nutritional therapists 
didn’t need the child to be present.   
The evidence base for the two interventions also differs. Nutritional therapy is backed by 
explanations of mechanism and a number of trials demonstrating the efficacy of individual 
supplements and dietary approaches, whilst an explanation for a mechanism of action 
eludes homeopathic remedies. Public attitudes towards the two therapies also differ. The 
therapeutic modality of homeopathy is largely discredited in the UK, receiving sustained at-
tacks, and negative press (https://www.hri-research.org/resources/homeopathy-the-
debate/) whilst good nutrition is increasingly acknowledged and promoted and receives fre-
quent positive press.  
During the first month of recruitment Jamie Oliver presented a TV documentary on health 
and nutrition, and several participants commented that this motivated them to accept the 
offer of nutritional therapy. Conversely during the same time the media published reports 
about legal action by a sceptic group to the Liverpool Clinical Commissioning Group over its 
funding of referrals to the Liverpool Medical Homeopathy Service 
(https://goodthinkingsociety.org/projects/nhs-homeopathy-legal-challenge/). Such posi-
tions may have influenced take up of the offer of treatment in this trial since three partici-
pants refused the offer due to their doctor’s disapproval during this time. 
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9.3.5 The acceptability of interventions to stakeholders 
Nutritional interventions are already considered by NICE (NICE, 2008), and the results of this 
trial can contribute to the evidence base for nutritional recommendations for ADHD, which 
are currently mostly negative (section 5.7). However, there may be problems with NICE con-
sidering the effectiveness of a total nutritional intervention when they prioritise the meas-
urement of specific effects, have concern regarding therapist effects, and concern regarding 
unregulated therapists.  
It is unlikely that NICE will consider homeopathy as a therapy for ADHD in the near future. 
Although there are several trials demonstrating that homeopathic remedies are effective 
compared to placebos for ADHD, studies are small and underpowered, and an acceptable 
explanation of their mechanism of action according to current scientific thinking is yet to 
emerge. The NICE Director of Guidelines, Professor Mark Baker (personal communication) 
indicated that exceptional standards would be required to consider any additional treat-
ments for ADHD since answering each question costs £30,000. He added that NICE would be 
extremely unlikely to consider a CAM treatment such as homeopathy due to the implausibil-
ity of its mechanism of action, and the fact that homeopathy trials are unlikely to have posi-
tive GRADE assessments.  
9.3.6 Adverse events  
Overall supplements were well tolerated, but three minor adverse events were probably 
linked to reactions to supplements: itchy skin with a magnesium spray; increased aggression 
with ingestion of a fish oil; and increased aggression with a multi-nutrient. 
One adverse event, a skin rash, was considered to be attributable to homeopathic treat-
ment. Those who believe homeopathy is implausible would disagree with this attribution. 
Homeopaths describe this as a homeopathic aggravation, (a mild, transient increase in 
symptoms generally associated with improvements in wellbeing) and can be a feature of 
homeopathic treatment) (Stub, Musial, & Alræk, 2012), since appearance of the skin rash 
coincided with improvements in the child’s ADHD (section 8.9). 
1/41 (2.4%) (hom) and 3/42 (4.8%) (NT) non-serious adverse events are far fewer than the 
29% calculated in the meta-analysis assessing the benefits and harms of methylphenidate 
(Storebo, et al., 2015). However, the trial is not adequately powered to generalise about the 
safety of treatments. 
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9.3.7 Sample size calculation 
Calculation of the sample size required for the full trial of the two treatments is based on 
the carer-rated effect size obtained in the STAR pilot trial of .36 for homeopathic treatment 
and .55 for nutritional therapy. It was decided to estimate the numbers needed for a full 
trial by assuming an effect size of .4.The homeopathic treatment estimate was rounded up 
since the effect size obtained for treatment by homeopaths may be a slight underestimate 
due to the negative effect of the one unfeasible homeopath. Estimations of the required 
sample size considered different levels of power (section 7.7). For 80% power, just over 200 
additional participants are required, for which sufficient funds are available. For 90% power, 
555 additional participants are needed, for which considerable investment would be re-
quired.   
Based on pilot study results, attrition estimates may need adjusting. However, it was identi-
fied that substantial attrition was due to therapist’s contacting strategies, and effort will be 
made to better manage this, so attrition estimates may not need to be increased.  Therefore 
40% attrition is allowed for, requiring randomisation of 166 homeopathy and usual care par-
ticipants (40% of 166 = 100) where an effect size of .4 is assumed; and 150 nutritional ther-
apy participants where an effect size of .55 is assumed (40% of 150 = 90).  
9.4   Summary 
This chapter has discussed the feasibility of the trial design and interventions and made sug-
gestions for improvement in delivery. Most feasibility criteria parameters were met. The 
small-scale test of the design and procedures suggests that the design is feasible with minor 
adjustments, and that it can be implemented relatively cheaply. The primary outcome is suf-
ficiently sensitive and measures outcomes of importance to those with ADHD. Recruitment 
procedures were satisfactory. Outcome collection from carers worked well after the addi-
tion of an incentive, although could still be further improved.  
In comparison to effectiveness trials of other interventions, the interventions trialled in the 
STAR pilot trial were relatively acceptable and showed indications of effectiveness in areas 
of need such as emotional dysregulation (hom), restlessness/impulsivity (NT), and health 
related quality of life (NT). Sufficient participants were recruited to the cohort efficiently. 
Sufficient therapists were recruited to the trial and most were broadly competent, although 
they had to learn about case management of this particular patient group, at which some 
were better than others. Flexibility and a compassionate approach appears to have been 
key to retention in both therapies.   
Poor return of teacher outcomes, resulting in insufficient numbers and instability of those 
outcomes collected was a significant flaw in the assessment of results, and is of concern 
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since they provide a perspective considered important by significant stakeholders. In retro-
spect, considerably more time should have been invested and different approaches used, to 
collect teacher outcomes. This is one of the main recommendations for procedure to a full 
trial (recommendations are described in full in the following chapter).  
A feature of the trial design is that it tests the effect of the offer of treatment, as opposed to 
the actual effectiveness of that treatment. Results are further diluted due to attrition, non-
return of outcomes and crossover from treatment to usual care. However, in ADHD particu-
larly, where mainstream treatments offered are not particularly acceptable, and attrition 
and non-take up are a feature, measuring acceptability is important and provides important 
additional information to stakeholders.  
Therapists contacting strategies contributed to non-take up. These can be improved accord-
ing to the results of the pilot feasibility trial and successful contacting strategies implement-
ed.  The greater uptake of homeopathic treatment by those not on pharmaceutical medica-
tion suggests that those participants may have been looking for an alternative.  
The two interventions tested may contribute information regarding effective treatments for 
ADHD. Prioritisation of internal validity compared to external and ecological validity by NICE 
may mean that the design will not be considered useful by them. However, other stake-
holders such as families wanting to decide what treatments to try, and local health authori-
ties who prioritise reducing costs and affecting long-term negative outcomes, may be more 
interested in this method of testing potential treatments for ADHD.  
The two tested interventions now require adequately powered testing. The sample size cal-
culation based on pilot trial data, estimates that approximately 400 more participants need 
to be recruited to the STAR cohort to enable an adequately powered trial of the two inter-
ventions.  
There are interesting comparisons to be made between nutritional therapy and homeo-
pathic treatment. Both are complex, one has a more established evidence base for the 
mechanism and aspects of its approach than the other. Both implement individually tailored 
advice/therapy, via therapists. The effects of treatment by nutritional therapists, where im-
provements according to ITT analysis by both teachers and carers was seen, may be consid-
ered the logical next step in the development of the evidence base for a nutritional ap-
proach, with therapists considered useful to provide optimum management of the interven-
tion. The effects of treatment by a homeopath may parsimoniously be attributed to time, 
attention and therapist effects, particularly since no improvement in teacher outcomes was 
seen. However, the paucity and instability of the teacher outcomes means that no conclu-
sions can be drawn for teacher’s observations of the effects of either treatment. 
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It is to be hoped that implementation of the totality of a nutritional approach can be tested 
in a full trial, and provide useful information to NICE, who currently conclude there is insuf-
ficient information to advise on a nutritional approach. It is unlikely that homeopathic 
treatment will be considered by publicly funded stakeholders in the UK without much more 
robust evidence. However, should the effects of homeopathic treatment on emotional labil-
ity prove robust, this may provide useful information to families about an intervention to 
help their children’s emotional dysregulation, which is often the most troubling aspect of 
ADHD.  
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Chapter 10 Conclusions, recommendations and future directions  
This thesis addressed the research question: Is the TwiCs design suitable to assess the effec-
tiveness of interventions to improve outcomes for ADHD? A small-scale test of the design 
and measures was conducted to answer the question, and the results suggest that the TwiCs 
approach to pragmatic trial design, with some modifications to its implementation, is feasi-
ble and appropriate for trials testing interventions for children with ADHD.  
Recruitment to the STAR cohort was successfully accomplished ahead of time. Results from 
the pilot RCT give preliminary indications that the two novel interventions tested may be 
helpful to improve important aspects of ADHD. However, further research with larger num-
bers, better collection of blinded teacher outcomes, and continued collection of outcomes 
over the long-term is required to confirm this. 
10.1 Contributions to research priorities 
10.1.1   Timeliness of the research 
This PhD was conducted at a time when research is questioning the hegemony of 
methylphenidate as a treatment option, suggesting that the benefits may not outweigh the 
harms, that long-term outcomes are not improved, and are associated with adverse effects 
(Storebo, et al., 2015; Swanson, et al., 2017). Effectiveness trials deployed in routine circum-
stances can aid policy evaluation and health care decisions of both providers and patients 
regarding pharmaceutical medication and other treatments. Such trials are being increasing-
ly called for, particularly to assess interventions for mental health and psychological condi-
tions (Holmes, et al., 2018; Kennedy, 2015).  
The TwiCs design is well placed to address some important questions in ADHD research con-
cerning the impact of current mainstream interventions over the long-term. Also, to test 
other interventions, with the purpose of improving long-term outcomes. Studies with simi-
lar aims, in different populations, have already recognised the potential of TwiCs methodol-
ogy. Of particular interest are studies recruiting cohorts of at-risk children to see whether a 
variety of interventions may influence their potential negative trajectory. I have argued in 
this thesis for the same approach to be used in ADHD research, where children are similarly 
at risk, where the majority of research is focussed on short-term symptom relief, and where 
there is an unmet need for interventions to improve long-term outcomes. 
With the re-publication of the seminal Schwartz and Lellouch article (1967 & 2009) identify-
ing the differences between pragmatic and explanatory designs, health care assessors are 
calling for more pragmatic designs as being better suited than explanatory trials to inform 
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clinical practice and health policy decisions (Patsopoulos, 2011; Thorpe, et al., 2009; Conway 
& Clancy, 2009), whilst explanatory trials are more relevant for regulatory drug approval. 
However discussions with NICE directors, attendance at NICE workshops and exploration of 
the literature have revealed a concerning anomaly. NICE originally appraised drugs before 
its remit was expanded to include public health and clinical guidelines. It does not appear to 
have conceptually adapted its approach to accommodate these new roles assessing all types 
of intervention (section 9.3.5). Despite its stated objective to focus on effectiveness, it con-
tinues to prioritise efficacy research methods. For the benefits of effectiveness trials to be 
understood, a shift in priorities by assessors such as NICE will be required. 
10.1.2   Innovativeness of the research 
There are considerable pressures on our public health system, and more need than ever for 
effective, safe interventions and efficient, cheap research methods to help assess their clini-
cal and cost effectiveness. This research has demonstrated that the TwiCs design provides a 
viable approach, and that trials can be run relatively cheaply and answer relevant research 
questions. It is the first time that TwiCs methodology has been used in ADHD research, and 
it can provide important contributions. 
To my knowledge, this is also the first time that an RCT has been conducted which tests the 
real-life effectiveness of either treatment by a homeopath or treatment by a nutritional 
therapist for ADHD. The question of a homeopathic or nutritional approach as experienced 
in clinical practice had remained unanswered until now because trials to date measured as-
pects of them rather than the whole process of treatment. This doctoral work therefore 
contributes to the evidence base of both interventions. There are preliminary indications 
that both interventions may have a role to play in the improvement in long-term outcomes 
of those with ADHD. The research provided preliminary insights into their acceptability, 
safety and effectiveness adjunctive to usual care. 
The STAR project furthermore demonstrated that the TwiCs design is an appropriate re-
search design to capture the effects of CAM therapies. This can resolve the discrepancy be-
tween what clinicians and patients report anecdotally, and traditional placebo-controlled 
RCT design results. The design has now been used to test the effectiveness of treatment by 
a homeopath for menopausal hot flushes (Relton, O'Cathain, & Nicholl, 2012), irritable bow-
el syndrome (Peckham, et al., 2014), and depression (Viksveen, Relton, & Nicholl, 2017), and 
it has been used to test the effectiveness of acupuncture for lower back pain (Dascanio, 
Birks, & Torgerson, 2011). This is the first time it has been used to test the effectiveness of 
nutritional therapy.  
This study contributes to the development of the TwiCs approach, which is gaining credibil-
ity in other domains and becoming established in the research landscape as a pragmatic trial 
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design suitable to answer real-life questions of interest to stakeholders in a wide variety of 
fields, across a wide age range, and testing a wide variety of interventions to improve long-
term negative outcomes. Cohorts of the elderly have been created and interventions im-
plemented to prevent or aid their recovery from hip fractures and falls. Cohorts of those 
suffering from particular illnesses have been created and interventions such as exercise and 
novel surgical procedures implemented. Cohorts of children at risk of negative long-term 
outcomes have been created, and interventions implemented such as CBT, wraparound 
care, provision of health care via mobile phones, and skills for wellness teaching 
(https://www.TwiCs.global/use-of-the-design). 
10.1.3   Learning from the research endeavour 
This thesis was motivated by the desire to conduct appropriate academic research according 
to approved methods into an intervention I have perceived that patients find helpful.  
Through doing this research I have understood and learned a great deal about research pro-
cesses and health care decision making.  
I have gradually assimilated and exemplified an understanding of pyramid of evidence crea-
tion as my research has progressed. Initially I thought collecting the outcomes of patients 
receiving homeopathic treatment sufficient to demonstrate the effectiveness of treatment. 
Then I understood that these patient outcomes needed a comparator, and baseline was not 
enough. Having provided a comparator I then realised that this was not sufficient, and that 
participants needed to be randomly assigned. So for this PhD I conducted research in ran-
domised participants. This has led to the discovery that randomised outcomes may need to 
be blinded for results to be taken seriously by most ADHD researchers and assessors. I pre-
dict that future research with blinded outcomes will not be sufficient either, and these re-
sults will then need to be replicated, and in larger numbers. I have understood that research 
is a process with no finite conclusion.  
I have also understood the difficulties inherent in capturing the non-specific effects of non-
specific treatments. I have developed an understanding of the rationale for, and methods to 
reduce bias and subjectivity in research, but have observed that these methods are some-
times unequally applied.  I have also observed the influence of market forces on opinion. 
Although the trial design and interventions attract interest in some venues, such as recently 
at an international ADHD conference largely attended by clinicians 
(http://adhdcongress.co.il/), it has been frustrating to understand the higher hill which non-
pharmaceutical interventions have to climb to be recommended by NICE, our national 
health care regulator.  
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10.1.4   My contribution to the research endeavour 
At the beginning of this doctoral research I explored appropriate research designs to test 
the effectiveness of homeopathic treatment. The majority of published research into the 
effect of ‘homeopathy’ compares homeopathic remedies with placebo remedies. I realised 
that such tests were not appropriate to answer the question of how effective treatment by 
a homeopath is to patients. Having selected a TwiCs approach, and understood its strength 
as a platform for research evaluating multiple interventions, I searched for another promis-
ing intervention to demonstrate this aspect of the design. I selected treatment by a nutri-
tional therapist, where again, the effectiveness of a nutritional approach for patients had 
not been tested in trials to date. The intervention also provided similar time and attention 
to that provided by homeopaths. 
Having selected the interventions, I then needed to identify key stakeholders involved in the 
care of those with ADHD and the outcomes of importance to them, decide how to best 
measure those outcomes, and create a simple questionnaire to do so. Having done this, 
written and published the study protocol, acquired the necessary permissions, and subject-
ed the proposal to external scientific review, the majority of my time and energy was spent 
recruiting participants to, and managing the administration of, the STAR cohort and the first 
pilot trial. I visited schools, networked with ADHD stakeholders, attended conferences and 
embraced all recruitment opportunities that offered themselves. 
On recruitment, I extracted the age, ADHD status and gender of participants who had com-
pleted baseline questionnaires, and sent the information regarding those who were eligible 
to the independent statistician for randomisation. Recruitment of participants to the trial 
involved posting out letters to those offered treatment and following up with telephone 
calls giving them the details about their therapist. I recruited local therapists, and was in 
regular contact with them for the duration of the trial: supervising them monthly; providing 
them with participant contact details; and receiving reports from them after each consulta-
tion.  
Recruitment was on a rolling basis, which meant all correspondence relating to each partici-
pant at baseline, six and twelve months required individually requesting at the appropriate 
time. Carer requests often needed following up with multiple reminders. Once question-
naires were returned, participants needed to be sent thank-you vouchers. Sending letters 
and questionnaires to schools required identification of the current headteacher and cor-
rect, full address of the school. Further reminders were not sent to schools due to the ad-
ministrative burden, and the assumption that teachers would efficiently return question-
naires. In retrospect this was an erroneous assumption. 
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Data organisation and analysis made up the last stage of the research process, and was 
largely conducted alone, with some help and advice from the University Maths and Statistics 
help (MASH) service and supervisors. 
The following sections relate the results of the STAR project to the general body of 
knowledge on the subject and prevailing research environment and makes recommenda-
tions for future directions. 
10.2 Strengths and weaknesses of the TwiCs design 
10.2.1   Challenges of taking a pragmatic approach 
Whilst reviewing the evidence base it became clear how difficult it is currently to compare 
the effectiveness of interventions to improve outcomes for ADHD. Different trial designs are 
used, of varying length (usually short), in varying populations, measuring various outcomes, 
to test different types of interventions. The clinical meaningfulness of trials (i.e. their exter-
nal and ecological validity) is not systematically assessed, and the PRECIS tool assessing ex-
ternal validity far less used or respected than Higgins’ internal validity tool. ‘Quality’ in pub-
lications refers only to risk of bias, so trials with good external validity are described as ‘poor 
quality’, but trials with poor external or ecological validity do not necessarily receive nega-
tive summation. 
Most trials of pharmaceutical medicines compare them to placebo medicines in carefully 
controlled conditions. The other category of intervention offered – behavioural change pro-
grammes – are tested in clinical practice, in comparison with usual care or baseline. The two 
types of testing are expected to differ in their levels of internal, external and ecological va-
lidity, and their effect sizes (effectiveness trials are expected to have smaller effect sizes 
(section 3.3.2)). Carefully controlled conditions may maximize potential to detect an effect, 
but “the attempt to achieve methodological purity tends to result in clinically meaningless 
results” (Witt, et al., 2012).   
The different designs answer different questions. However, double-blinded, placebo-
controlled designs are being used comparatively to make decisions about effectiveness in 
clinical practice. This means that interventions which can be best tested using such designs 
(pharmaceutical medicines) tend to be preferenced compared to those which can’t (thera-
pist led interventions) (section 3.1.7). This appears to be paradoxical and not in the interests 
of improving patient outcomes, and may explain why negative outcomes for ADHD are not 
being affected despite numerous studies demonstrating the short-term effectiveness of 
pharmaceutical medications compared to placebos, and resultingly large increases in pre-
scriptions (section 2.3.1). 
 233 
The decision to employ effectiveness testing rather than efficacy placebo-controlled testing 
was a decision to conduct pragmatic research with practical outputs. The more used and 
respected double-blinded placebo-controlled RCT design was clearly unsuitable because not 
only does it not measure real-world effectiveness, it is unsuited to the testing of therapist 
led or complex interventions. However attempting to achieve full generalizability in a trial 
design can result in unreliable results and potential measurement of other factors, therefore 
achieving a creative tension between the two is crucial, and this is what the TwiCs design 
importantly attempts to do.  
The STAR project is unusual in not testing the specific effects of therapists, supple-
ments/dietary advice/homeopathic remedies etc. for those with ADHD. These effects are of 
interest to health care assessors in the UK (NICE) and those sceptical of the benefits of ho-
meopathic remedies. They are unlikely to consider evidence about the effectiveness of the 
interventions tested sufficient without prior evidence of an explanatory mechanism for spe-
cific elements such as those described above, or demonstration that more parsimonious ex-
planations are not responsible for effects observed.  
Like any pragmatic trial, there is inevitable variation (noise) amongst participants since con-
ditions are less tightly controlled. There is potential for variables outside the trial to influ-
ence outcomes and acceptance. For example, media and mainstream medical opinion may 
have influenced acceptance rates. Participants may have tried other interventions or 
changed medication dosage during the trial which may have influenced their measurement 
of outcomes. Outcome completion by different teachers and children changing schools may 
have influenced the precision of teacher outcome completion. 
10.2.2   Benefits and challenges of using the TwiCs design 
Benefits 
The TwiCs design is suitable to test multiple interventions comparatively and provide a good 
balance of internal, external and ecological validity. Regarding internal validity, biases are 
equally distributed across groups, and the more trials conducted using this method, the 
more generalizable and robust the results become. For example, in tests of therapist led in-
terventions, potential biases such as Hawthorne and practitioner effects are equally distrib-
uted across trials of such interventions. The design is appropriate to assess the comparative 
effectiveness of all interventions, be they complex, holistic, therapist led or pharmaceutical.  
The TwiCs design enabled speedy recruitment of sufficient numbers, comparing favourably 
with recruitment to comparable trials (Table 34), to UK trials in general, and to the compar-
ative case series preceding this trial (section 4.3). Full, fast and efficient recruitment is 
emerging as a significant benefit of the design (Viksveen, Relton, & Nicholl, 2017). 
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Recruitment may have been easily achieved because participants’ experiences were closer 
to real-life practice than conventional designs. For example, because they were not initially 
told they may receive an intervention and then later told they wouldn’t, the risk of resentful 
demoralization in the usual care group was reduced (Torgerson & Torgerson, 2008). Nor was 
any deception involved, or participants  told they may receive a placebo treatment, where 
patients have been found to become frustrated (Dunn, et al., 2003).  Trial conditions were 
as close as possible to what patients could expect if they consulted therapists in clinical 
practice, and health care assessors might expect were they to commission the treatment, 
and this can contribute important information to stakeholders and the ADHD research can-
on. 
ADHD is associated with negative outcomes that assert considerable impact on society. 
There is a need to focus on improving those outcomes. This can be done by testing the po-
tential of interventions in real-life populations, and measuring important objective out-
comes over the long-term in a representative ADHD population. TwiCs methodology pro-
vides an innovative, robust means of assessing the usefulness of interventions over the 
longer-term. 
Challenges 
The TwiCs design is novel and unusual, and challenges conventional ways of testing inter-
ventions. Until established, some may find it unacceptable. Consort guidelines for TwiCs are 
in development, but until published, there are no guidelines on how to report trials con-
ducted using the design. 
The trial design measures the effect of the offer of treatment, i.e its acceptability. The effec-
tiveness of the treatment itself is a secondary analysis. Those deciding whether to commis-
sion treatment, such as NICE, may be more interested in the potential treatment benefit to 
patients as opposed to its acceptability, as may those looking to promote the benefits of 
their therapy. However, measuring acceptability is of particular importance in the field of 
ADHD research (section 9.1.2). 
Non-acceptance and non-compliance is a key challenge to the use of the design. Standard 
designs screen out potential non-compliers and non-acceptors prior to randomisation. Use 
of the TwiCs design runs the risk of a type II error due to lower follow up rates and crossover 
from treatment to usual care (Viksveen, Relton, & Nicholl, 2017). ITT analysis estimates the 
effect of the offer of treatment, but instrumental variables analysis is recommended as a 
secondary analysis.  This complier average causal effect (CACE) analysis considers baseline 
values to assess the effectiveness of treatment received. It compares offer group partici-
pants who have received the intervention with participants not offered the intervention, but 
who would have received the intervention had they had been offered it (Greenland, 2000). 
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Collection of blinded outcomes is not an intrinsic aspect of the TwiCs design, indeed is not 
an aspect of pragmatic designs in general.  However, without measurement of blinded out-
comes, and/or prior efficacy evidence, there are those who will not consider results at-
tributable to treatment. It is therefore questionable whether testing treatments using the 
pragmatic TwiCs design is appropriate without prior explanatory evidence.  
10.3 Interpretation of results of the first RCT in the STAR project  
In this small pilot study, carer-rated unblinded ITT results suggest both interventions may be 
helpful for different aspects of ADHD, and effect sizes are comparable to some other main-
stream and non-mainstream interventions (Table 38). Blinded teacher results were few in 
number, and not robust (section 7.5.1). The paucity of teacher returns is a significant failing 
of this research because the inability to consider blinded teacher results reduces the inter-
nal validity of the study.  
The results for both interventions are similar according to the carer-rated primary outcome 
(ITT analysis of CGI total score). Treatment by nutritional therapists showed a medium effect 
of the carer-rated primary outcome (SMD .388) and in the sub-score restless-
ness/impulsivity  (SMD .623). The results of treatment by homeopaths also showed a medi-
um effect size for the carer-rated primary outcome (SMD .425), and the sub-score emotion-
al lability (SMD .793). Despite results being similar, treatment by a homeopath and treat-
ment by a nutritional therapist are likely to be viewed differently since one intervention is 
more plausible than the other. 
10.3.1   Treatment by a nutritional therapist 
The results for nutritional therapy will hopefully to contribute to the on-going discussion by 
NICE regarding nutrition, particularly if an adequately powered full trial can now be con-
ducted. The design meets NICE’s stipulated objectives, which are to be a controlled RCT 
measuring ADHD symptoms, with a usual care comparator, and reaches the GRADE default 
minimally important difference of -0.5/0.5 standard deviations for several outcomes 
(Hopkins, 2015).  
It is surprising that there has not already been a trial of a nutritional approach for ADHD, 
since it is the logical next step in building evidence; the question is theoretically of interest 
to stakeholders; and the NICE guidelines already recommend asking about nutrition and re-
ferral to a dietician where relevant, although this policy is not evidence based.  
There are numerous trials prioritising understanding of mechanisms of action and the effi-
cacy of individual elements or specific approaches, for which there is weak evidence. Such 
studies provide explanatory evidence and theoretical models for aspects of nutrition which 
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the STAR pilot trial builds upon. The STAR trial suggests a combined, total nutritional ap-
proach may have a larger, composite effect. 
10.3.2   Treatment by a homeopath 
Considerable opposition exists to this therapy, and much debate about the evidence base, 
so the results for treatment by homeopaths are unlikely to be considered by NICE. There will 
continue to be those who will not be persuaded of any clinical improvements until a plausi-
ble explanation for its mechanism of action is found and homeopathic remedies have irrefu-
tably been shown to work better than placebo remedies. To date just four RCTs have been 
conducted testing the clinical efficacy of homeopathic remedies for ADHD, of which three 
found positive results (chapter 4).  
Interventions with explanatory evidence for their mechanisms of action lend credibility to 
clinical results. So-called energy medicines such as homeopathy, who cannot explain their 
mechanisms of action using concepts in line with current scientific understanding, are given 
more parsimonious explanations for any effects found. However, it could be argued that if 
an intervention is safe, effective, cost effective and helpful to patients, its implausibility may 
be considered secondary to its therapeutic benefit.  
Advocates of the scientific method may not consider any results using the TwiCs trial design 
sufficient to generate evidence about the effectiveness of treatment by homeopaths with-
out prior evidence of an explanatory mechanism or demonstration that more parsimonious 
explanations are not responsible for effects observed. ADHD stakeholders however, may 
take a more pragmatic approach, and prioritise improved outcomes, safety and reduced 
costs over explanations. 
10.3.3   Implications of the results for ADHD treatment 
The two interventions tested were selected: because carers are turning to them; because 
there is preliminary evidence supporting them; because there is building evidence that 
mainstream approaches are not making a substantial difference to outcomes and therefore 
novel approaches require exploration; and because a holistic approach (as compared to a 
unitary approach), may be appropriate to improve and sustain long-term outcomes in this 
heterogeneous condition. The first three reasons have been discussed elsewhere in this the-
sis (sections 1.5.3, 4.2.8, 5.5 & 1.5.1). The fourth reason is briefly discussed here.  
ADHD is characterised by heterogeneity, multi-morbidity, and the influence of diverse aeti-
ologies. Holistic or ‘whole systems’ approaches suggest interconnectedness and non-linear 
outcomes (Koithan, Bell, Niemeyer, & Pincus, 2012), in contrast with a biomedical model 
presupposing unidimensional simple causes and individually testing single aspects. Holistic 
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approaches take account of all aspects of patients as individuals, assessing them on mental, 
emotional, physical and general levels, accommodating heterogeneity, aiming to improve 
overall health and stimulate self-cure.  
Improving long-term outcomes may be better achieved by using a multi-modal approach. 
For example, focussing on improving long-term overall health as well as on symptom reduc-
tion. Indeed a multi-modal approach is recommended in the European Clinical guidelines 
(Taylor, 2004). The effects of mainstream treatments tend to disappear over the long-term, 
whilst in two small studies of homeopathic treatment improvement continued for eight 
years and one year respectively (von Ammon, et al., 2012 & Fibert, Relton, Heirs, & Bowden, 
2016). These underpowered results need validating. With regards to nutrition, studies in-
creasingly show that improved nutrition impacts on all aspects of health.  
10.4 Recommendations for improving the STAR project 
This section makes some practical recommendations for improving the delivery and perfor-
mance of the STAR project (cohort and trial) emerging from the results and discussion con-
cerning recruitment, outcomes, interventions and the trial design.  
10.4.1 Recruitment to the STAR cohort 
Future work should prioritise recruitment from ‘hard to engage’ families (predicted by low 
income, single carer status, education/occupation, family size, minority status, severity of 
child’s behaviour, maternal psychopathology and maternal age (Doherty, Stott, & Kinder, 
2004). Collection of data regarding these predictors can measure the extent to which this 
occurs. Not only are such families most in need of effective help, but given that recruitment 
to the STAR cohort was satisfactorily achieved, and recruitment to trials is considered rela-
tively problematic, this can explore whether recruitment is a factor of recruiting easier fami-
lies, or whether it continues to be successful with more ‘difficult to engage’ families.  
For similar reasons, effort should be made to recruit those involved in the criminal justice 
system or in care. This may necessitate applying for NHS ethical approval, to allow access to 
‘looked after’ children under the care of Sheffield city council and a large ADHD patient data 
base of over 2,000 registered with CAMHS, NHS Sheffield; may lead to recruitment of a 
more representative sample; and may improve the acceptability of the STAR project to 
ADHD stakeholders, many of whom work within the NHS. However, it could restrict the 
scope and freedom of the project by limiting recruitment to NHS approved locations, and 
obtaining NHS ethical approval can be time consuming, so the benefits and disadvantages of 
such a decision would need to be weighed carefully. 
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Recruiting larger numbers of those with co-occurring autism and ADHD is also required to 
see if interventions may be helpful in this ‘at need population’. Recruitment strategies 
should continue developing ways of improving understanding of those with ADHD, not only 
because this has been identified during the STAR project as a need, but also to contribute to 
recruitment. Application is currently being made for funding to develop the ‘Lost Voices’ 
video and workshops and tour UK schools with them. If successful, this link with schools may 
have the added benefit of improving understanding of how to best obtain teacher out-
comes. 
10.4.2  Adherence to the STAR trial 
If adherence to the trial is to be improved, it needs to improve the treatment accessing 
rates of those accepting but not accessing treatments. To this end, contacting strategies 
need improving. One suggestion is to ask all therapists to employ the successful strategies 
used by some other therapists, namely use of different means of contact, and at different 
times of day, and reminders about consultations the day before appointments. Another 
suggestion is for consultation dates to be arranged by the PI when participants are first tel-
ephoned to be offered a treatment rather than requiring contact by participants with an as 
then unknown therapist, which may be off putting. Another suggestion, funds permitting, is 
to employ an administrator to be the main point of contact with participants, who can offer 
them the treatment, get to know them, understand their preferred communication modes 
and times, and liaise between therapists and participants regarding consultation dates and 
times.  
To improve the collection of carer and teacher outcomes, those who have not responded to 
requests to complete questionnaires could be telephoned and questionnaires completed 
over the telephone. Another suggestion is to improve communication with all participants, 
but particularly those offered treatments, regarding the importance of regular completion 
of the STAR questionnaire regardless of their decision regarding treatment. Participants 
could be made better aware of this when they recruit to the cohort. This may result in par-
ticipants dropping out at this stage rather than post acceptance, which would reduce pres-
sure on therapists, and provide explanations for drop out (un-explained when they become 
uncontactable). Qualitative work with participants might further enlighten this issue. 
Regarding consultations, eight available sessions over one year are more than tend to be 
accessed by private patients, so offering less than 8 sessions would better represent real-life 
care and make the trial cheaper to run, since consultation cost is the main trial expense. 
Participants could be offered five sessions further apart after the first three appointments, 
instead of eight appointments at 6 weekly intervals. Future research might explore the min-
imum number of consultations necessary to make the intervention cost-effective. 
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10.4.3 Outcome collection and measurement 
Means of collection 
Outcomes are collected three times over the course of one year. Ideally, they would be reg-
ularly collected over the longer term. Regular, annual collection might improve seasonal var-
iation problems, however, it would not improve the problem of completion by different 
teachers, since most children change classes annually. 
There are problems regarding the consistency and sensitivity of observation with teacher 
outcomes which raise concerns about their reliability even were they able to be collected. If 
money was no object, independent assessment by a different blinded source, such as a cli-
nician, might enable more sensitive blinded observations. One study using the TwiCs design 
in a cohort of children at risk of mental health problems, invites all participants for such an 
annual, day long clinician assessment (Uher, et al., 2014). However, this is impractical both 
financially, and geographically. Therefore it will be important to improve the return of 
teacher outcomes in future research, despite concerns regarding their reliability. Blinded 
outcomes and a teacher perspective are important, not least since this is where the majority 
of the cost of ADHD is incurred (section 2.2.6). 
Requesting teacher outcomes just once by post was insufficient. In the future, after the ini-
tial letter has been sent, the school office should be rung to notify them of the letter, and to 
make initial contact. If possible, the teacher’s contact details should be obtained during this 
phone call (email addresses and telephone numbers), so that outcomes can then be re-
quested from the teachers themselves in a variety of ways, rather than in a letter via the 
head-teacher as currently occurs. Teacher contact details are not available on school web-
sites. Teachers should also be better directed towards on-line completion, where less miss-
ing items occur. The link was provided in the letter, but not used. A direct link in an email 
may be better acted upon.  
6 and 12-month carer questionnaires need altering so that the child’s school and teacher 
details are requested every time (currently they are only requested at baseline) in order to 
have up to date information about the school, teacher and educational status of the child. 
The signposting for completion of baseline, 6-month, or 12-moth questionnaires on the 
STAR website also needs improving, since several participants completed the wrong ques-
tionnaire. 
Outcome measurement 
A more sensitive measure of sleep difficulty might better capture this important outcome. It 
might include questions about difficulty getting to sleep, waking early, waking during the 
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night, nightmares etc. However, care must be taken to balance the need for information 
with ease of completion in order not to discourage participants from completing question-
naires. 
It might be worth measuring autism symptoms in those participants with co-occurring au-
tism. It may be that their global autism symptoms as well as their ADHD may improve with 
treatment. Since this would not be relevant to all STAR cohort participants, participants with 
co-diagnoses would need to be contacted, and asked to complete an additional measure 
such as the Autism Treatment Evaluation Checklist (ATEC) (Magiati, Moss, Yates, Charman, 
& Howlin, 2011).   
How to best measure emotional lability requires further thought. For this study a sub set of 
the CGI was used. Since it only measured three aspects, it may not capture the breadth of 
emotional dysregulation in ADHD. Some potential measures were discussed in section 9.2.2. 
There is a need for agreement regarding the definition and measurement of emotional labil-
ity since there are currently discrepancies across measures: the SDQ (Goodman, 2001) cate-
gorises temper tantrums as a behavioural problem, whereas the CGI (Conners, 2008) cate-
gorises it as an emotional one. CGI (carer) considers 3/10 items to be measures of emotional 
lability, but CGI (teacher) using the same scale, considers 4/10 items to be measures of 
emotional lability and ‘demands must be met immediately’ is categorised as an emotional 
problem. 
Should emotional lability continue to be measured via the CGI, this will necessitate the con-
tinued use of the CGI outcome measure. This measure was sufficiently sensitive and appro-
priate to measure the effectiveness of the non-specific interventions, whilst the other 
measure (SNAP) trialled, may not have been, although there were too few results to be 
sure. Despite SNAP being cheaper, evidence favours the continued use of CGI. The fears of 
the steering committee chairman that CGI results may not be considered adequate to 
demonstrate improvements in ADHD symptoms (a further reason for the inclusion of SNAP) 
were unfounded. The measure was not questioned at any conferences where the protocol 
or results were presented.  
Some outcomes, such as levels of criminality and exclusion might be more accurately meas-
ured by accessing national registers rather than asking carers or teachers. Accessing educa-
tional records can also provide an opportunity to measure whether interventions improve 
educational attainment. 
10.4.4  The Interventions 
Further work is needed to explore for which sub-groups treatments might be most effective, 
and for which aspects of ADHD might they be most helpful. It is self-evident that nutritional 
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therapy may be helpful for those children with digestive problems and less so for those 
without them. Homeopathic treatment may be helpful for those with accompanying emo-
tional problems, but less so for those without them. How to identify these sub-groups needs 
exploring. One suggestion could be to ask specifically about gut dysbiosis and emotional la-
bility in questionnaires.  Another suggestion could be to ask all participants to complete 
MYMOPs (currently only treatment groups are asked during consultations), and identify 
those with gut dysbiosis and emotional lability via their MYMOP responses (section 10.4.3).  
Another suggestion to recruit those with emotional problems might be to target recruit-
ment at those involved in criminality, where research suggests that the emotional element 
predicts criminality (Young, Taylor, & Gudjonsson, 2016). This would have the added benefit 
of specifically targeting those most at need.  
The therapists 
Improving therapist knowledge of ADHD may improve contacting strategies, case manage-
ment, intervention acceptance, participant retention and therapist wellbeing. Continuing to 
provide a pre-trial ADHD workshop and NCPCC risk course for therapists is indicated. Based 
on therapist’s experiences in the first STAR trial, the course should focus more on case man-
agement to prepare therapists. 
Regular supervision is also still indicated to support therapists in managing their patients. 
Such supervision is often a component of working with troubled families. For example when 
I worked with school refusers at St George’s Hospital psychiatric unit I received daily super-
vision. Therefore such support should not reduce the level of pragmatism provision. Ideally 
therapists should have experience of working with ‘troubled’ families, either as homeopaths 
or in other disciplines such as social work or education, in order to be able to communicate 
effectively with them, and manage the levels of disorganisation which may manifest.  
It is not recommended that homeopaths gain extra training in specific homeopathic meth-
odologies, since the methods learned were not accessed. Not only will this save money, it 
will make the trial more pragmatic. 
Recruitment of therapists working in the NHS could explore the feasibility of treatment 
within the NHS. NHS doctors who are also homeopaths in Bristol (The Portland Centre for 
Integrative Medicine) and London (The Royal London Hospital of Integrative Medicine) are 
interested in participating. There may be impediments to using nutritional therapists within 
the NHS, where nutritional advice is mostly provided by dieticians, who would therefore 
need to be recruited instead of nutritional therapists. Exploration of the effectiveness and 
cost-effectiveness of such NHS clinicians compared with professional therapists would be of 
interest. Practitioner costs of those working outside the NHS are less, and such practitioners 
an untapped resource. 
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Questions about therapist effects are not answered using the TwiCs design and were of con-
cern to the NICE director of guidelines. Testing multiple therapist led interventions as expe-
rienced in clinical practice can distribute therapist effects across those interventions. Using 
multiple therapists, potentially randomly selected from a general registry of therapists can 
also address this concern. 
The consultations 
Future recommendations are to keep intervention delivery pragmatic and flexible, and to 
continue to use multiple consultation modes, according to carer preference. As long as 
therapists do not compromise their ability to deliver good treatment, they should offer flex-
ibility about who attends consultations and venue, particularly regarding attendance of the 
child at every consultation, which may lead to greater retention of participants. It appeared 
that the introduction of skype/VSee consultations made life easier for families, possibly be-
cause it required less effort to attend. 
Therapists should continue to implement changes pragmatically according to the tolerance 
of the carers and their children. The extent to which participants are able to follow advice, 
particularly nutritional advice, should be monitored more systematically, since such infor-
mation is of interest.  
10.4.5  The trial design  
The research question asked whether the TwiCs design is suitable to assess the effectiveness 
of interventions. In reality, the primary analysis using ITT is the effect of the offer of inter-
ventions, that is their acceptability, and effectiveness is a secondary outcome.  Analysis if 
the full trial should include CACE analysis as a non-biased way of assessing the actual treat-
ment effect (Hewitt, Torgerson, & Miles, 2006). 
Factors not related to treatment acceptability, which appear to influence acceptability, need 
to be taken in to account, such as setting, media influence and the amount of effort re-
quired to implement interventions. A future development of the TwiCs design might com-
pare these across studies to provide more generalised information to trialists. 
Mainstream treatments for ADHD, such as pharmaceutical medication and behavioural 
change programmes, as well as other potential interventions should be tested using the 
TwiCs design so they can be compared and their real-world long-term effectiveness as-
sessed. Considerable economies of scale can be achieved should multiple trials be conduct-
ed.  
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A final recommendation is to promote the benefits and approach of TwiCs methodology and 
draw attention to shortfalls and inequalities of currently preferred designs.  This can be 
done by highlighting the successful use of the design in other similar cohorts, and through 
academic publications, presentations, and discussions with NICE. 
10.5 Real-world/political context 
The aim of this thesis is to test whether the TwiCs design is feasible to generate evidence to 
improve outcomes for ADHD. Although the design appears feasible and useful, it may en-
counter obstacles due to the current evidential paradigm and real-world situation. In this 
next section, I will describe some examples hindering both the generation and acceptance 
of evidence. 
I took a more positivist perspective in conducting empirical research (section 1.2.4), with the 
understanding that Evidence Based Medicine (EBM) and the scientific method inform health 
care decisions. However, over the course of this PhD I have observed interpretivist influ-
ences on EBM. 
10.5.1 Bias against homeopathy 
Considerable resources are employed by a small group of very effective detractors in the UK 
to influence public, media and government opinion against homeopathy. They largely refer 
to two biased documents: a meta-analysis by Shang et al. (2005) which fails sensitivity anal-
ysis (Lüdtke & & Rutten, 2008); and a House of Commons technology report (House of 
Commons Science and Technology Committee, 2010) which is based on Shang et al, and was 
dismissed by the department of health in an early day motion. Nevertheless detractors have 
succeeded in creating an environment where debate and media coverage is one sided and 
limits the acceptability and publication of any positive homeopathy results generated. 
For example, I co-authored a systematic review of homeopathy for depression which was 
initially accepted by sub-editors of a well-known journal but then rejected by the editor. He 
provided a negative opinion piece and a blog to justify the journal’s stance that homeopathy 
is not an effective treatment for any health condition. In other words, only articles informing 
the journal’s interpretive stance were acceptable. In another incident, I was interviewed on 
BBC Oxford describing my research, whereupon a well-known sceptic blogger complained to 
the BBC, who responded to his complaint by assuring him that homeopathy will never again 
be discussed without the prior proviso that it does not work.  
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10.5.2 Industry bias 
The many industry funded trials testing the short-term efficacy of drugs for ADHD (Storebo, 
et al., 2015), and other conditions (Booth, 2010) suggests that financial gain and desire to 
promote products may be influencing trial design. Although the aim of health interventions 
should be to improve the health of the target population, other drivers are influential and 
important questions are not being addressed. It is argued that the evidence based ‘quality 
mark’ has been misappropriated and distorted by vested interests (Greenhalgh, Howick, & 
Maskrey, 2014). 
It is suggested that even publicly-funded research is not being orientated in the best inter-
ests of patients or public health (Davis, 2015), with resources allocated to drug discovery 
and development to the neglect of other types of investigation (European Commission, 
2007; Food and Drug Administration, 2004; Kanavos, et al., 2010). This means there may be 
poor correspondence between both public and private-sector research priorities and the 
concerns of patients and clinicians.  
Despite numerous trials, questions still remain concerning the effectiveness of pharmaceu-
tical products, that is, do they work in the real-world with the average patient and improve 
long-term outcomes? This latter question, whilst of interest to stakeholders, may not be in 
the interests of drug companies looking to showcase their product, best showcased using 
short-term, tightly controlled trials, but not longer-term trials of real-world effectiveness. 
Nor may it be of interest to scientists looking to further scientific knowledge.  Whilst the 
TwiCs design provides a comparatively impartial way of testing interventions with the aim of 
improving outcomes for children with ADHD, it may conflict with these other drivers. 
Evidence is emerging that commercial conflicts of interest suggest we cannot be confident 
of the results of industrially funded trials. John Ioannidis suggested that “the greater the fi-
nancial interests in a given field, the less likely the research findings are to be true” 
(Ionnadis, 2005). Professor Gotzsche claims much of the behaviour of the pharmaceutical 
industry fulfils the criteria for 'organised crime' (Gotzsche, 2013). The most recent Cochrane 
systematic review concluded that all 185 double-blinded, placebo-controlled RCTs of 
methylphenidate were at high risk of vested interest (Industry) bias and selective reporting 
bias (Storebo, et al., 2015). The editor of the New England Journal of Medicine states that “it 
is no longer possible to believe much of clinical research published”, giving as examples two 
prominent ADHD researchers, Biederman and Wilens, (both cited in this PhD) investigated 
for not disclosing 1.5 million dollars received from pharmaceutical companies (Angell, 2009). 
Angell further attests that trials are biased through use of designs chosen to yield favourable 
results for sponsors.  
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The predominance of pharmaceutical medication as the treatment option for ADHD despite 
NICE’s recommendation that it only be used in severe cases (NICE, 2008), the lack of clear 
evidence that long-term outcomes are effective, and the promotion of the blinded placebo-
controlled RCT trial design, suggests vested interest bias may be at play in the assessment of 
interventions for ADHD. The possible influence of vested interests are a further reason for 
using a trial design such as TwiCs to efficiently and objectively test multiple interventions. 
Whilst the TwiCs design has important contributions to make to the research canon, consid-
erable work may be required to promote its benefits and draw attention to shortfalls and 
inequalities of currently preferred designs and vested interests.  
10.6 Future directions and recommendations 
The STAR project demonstrated the feasibility and utility of the TwiCs approach to pragmat-
ic RCT design for children with ADHD. It is my aspiration to develop the STAR cohort as a fa-
cility, so it can continue to be used to rigorously evaluate a variety of main and non-
mainstream interventions in a timely and efficient manner using TwiCs methodology, to 
clarify whether they improve both short and long-term outcomes for children with ADHD.  
This will entail expanding the STAR cohort, focussing on recruitment of those most at need: 
teenagers, hard to reach families, those with co-occurring autism, looked after children, and 
those involved in criminality. Effort should also be made to recruit those with multiple co-
morbidities to the cohort. 
Focus should be on aspects of ADHD which presage poor outcome, such as emotional 
dysregulation and criminality. This can be done by exploring how to best measure changes 
in these aspects in future questionnaires, and prioritising the testing of interventions which 
may be helpful in such populations. This can contribute evidence-based information to the 
discussion of how best to improve outcomes for those with ADHD. Development of relation-
ships with academics in the field through academic publications and presentations and 
promotion of the benefits of a TwiCs approach can further support this.  
There is sufficient preliminary evidence now to justify a full trial of the two piloted interven-
tions, with modifications based on the findings from the feasibility study. Applications have 
been made to a variety of sources for funding to do this, and funding received from the Brit-
ish Homeopathic Association to enable a full trial of treatment by homeopaths to now be 
conducted. Future plans are also to test other mainstream and complementary interven-
tions. It is also recommended that the design be promoted as suitable to capture the effects 
of CAM interventions for other conditions. To this end I am making an oral presentation at 
the British Homeopathic Association Conference in October 2018. 
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It is recommended to work on future studies with health care assessors such as NICE. NICE 
have recommended that clinical research should ideally be designed, conducted, and ana-
lysed with GRADE in mind to maximize the use of research in decision making (Thornton, et 
al., 2013). Communication with stakeholders other than NICE, such as city councils and edu-
cationalists, initiated during this PhD, should be continued. 
The importance of improving outcomes for ADHD cannot be overstated. Despite it being an 
‘invisible’ condition, its impact is widely and deeply felt.  The TwiCs design can make an im-
portant, impartial contribution in the search to improve outcomes for those with ADHD.  
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 Appendices 
Appendix 1 Steering Committee Procedures for the STAR project. 
Summary of the STAR project. 
A pragmatic cohort randomised controlled trial of the clinical and cost effectiveness of 
treatment by homeopaths or nutritional therapists in addition to usual care, will be com-
pared to usual care alone, for children with ADHD. 
The feasibility of the cohort multiple randomised controlled trial design to assess the clinical 
and cost effectiveness of interventions for ADHD will be trialled. 
Trial Approvals and Registration.  
Independent Scientific Review has been obtained from Professor Heather Boon (University 
of Toronto); Dr Jack Parker (ScHARR, UoS) and Dr Val Harpin (Consultant Paediatrician, Shef-
field NHS).  
ScHARR research ethics approval was received 30/4/15. Reference number 003424. 
University of Sheffield Research Governance sponsorship was received 10/7/15. University 
Research Management System (UMRS) number: 143647. 
ISRCTN  registration number 17723526. (http://www.isrctn.com/ISRCTN17723526) 
Composition of the Steering Committee (SC). 
The SC will consist of an independent Steering Committee Chair and at least two other indi-
viduals independent of the Management Team whereof at least one is a lay member and 
the remaining academics. The SC shall be independent and shall not be outnumbered by the 
Management Team members.  
The Management Team is responsible for sending out invitations for SC meetings and for 
preparing the meeting agenda, in agreement with the SC Chair. Any SC member may put 
forward items for the agenda. 
Personnel. 
Principle Investigator: Philippa Fibert (ScHARR, UoS) 
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Management Team: Philippa Fibert and Dr Clare Relton (ScHARR, UoS) 
Steering Committee: Prof David Daley (Nottingham University)(Chair) 
Philippa Fibert (Principle Investigator) 
Dr Clare Relton (Public Health, ScHARR, UoS)  
Prof Mike Campbell (Medical Statistics, ScHARR, UoS) 
Dr Tessa Peasgood (Health Economics and Decision Science (HEDS), ScHARR, UoS) 
Dr Liz Williams (Human Nutrition, Oncology, UoS) 
Catherine Witzmann (Doncaster NHS) 
Gill Badby (parent representative, Sheffield NHS) 
Heather Wingfield (parent representative) 
Role of the Steering Committee (SC). 
The Committee oversees the project. This involves ensuring that the project stays aligned 
with its aims and objectives; that it is carried out in line with the protocol; and that it com-
plies with ethical, legal and safety requirements.  
If necessary, the SC ensures that necessary actions are taken, such as reporting to the Spon-
sor (the University of Sheffield). 
The SC provides advice to the Principle Investigator (PI), who is responsible for the day-to-
day management, supported by the Management Team. The PI provides the SC with infor-
mation on any significant changes to the protocol or any accompanying documents. Such 
changes must be agreed by the SC. 
A sub section - the Data Monitoring and Ethics Committee (DMEC) - will be created at the 
first SC meeting.  Its role will be to detect any potential harm to patients as early as possible. 
It will consider actions following any reported serious adverse events.   
The DMEC will follow European Medicines Agency Guidelines (2005) 
www.emea.europa.eu/docs/en_GB/document_library.  It will focus on ethical and safety 
monitoring (not data monitoring) since the trial is unblinded and adequate data monitoring 
can be managed by the steering committee.  
Meetings of the Steering Committee. 
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The Steering Committee (SC) will meet a minimum of two times annually. A quorum is de-
fined as a minimum of four SC members. Management Team member votes shall not out-
number independent members. Meetings will be chaired by the SC Chair. Any decision will 
be carried by a majority vote. Abstentions are not counted. The SC Chair has a casting vote. 
Formal minutes of SC meetings will be available to anyone by request and will be sent to the 
Sponsor as appropriate. SC members will be paid travel expenses for attending meetings. 
The Steering Committee also has the power to make decisions on a case-by-case basis via 
email, unless an SC member has any objections. 
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Appendix 2a Carer Questionnaire 
ADHD QUESTIONNAIRE 
 
Welcome to the STAR project. 
Please complete this questionnaire as best as you can. It should take about 10 
minutes. Try and fill in every question even if you don’t remember exactly. An ap-
proximate answer is better than nothing. 
 
When you have completed it, please put it in the freepost envelope and post it to the 
researchers at the University of Sheffield. Please return the questionnaire as soon as 
you can. 
 
Your answers will help us understand how to make life easier for children and their 
families with ADHD. 
Child’s name.......................................Age………………………….. 
Your relationship to the child..................................................... 
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Please tick a box on each line that best describes your child  
 NOT AT 
ALL 
TRUE  
(never, 
seldom)  
JUST A LIT-
TLE TRUE 
(occasionally)  
PRETTY 
MUCH 
TRUE 
(often, quite 
a bit) 
VERY MUCH 
TRUE 
(very often, 
very frequent-
ly) 
Temper outbursts; 
explosive, unpre-
dictable behaviour 
    
Excitable, impulsive     
Restless or overac-
tive 
    
Cries often and easi-
ly 
    
Inattentive, easily 
distracted 
    
Fidgeting     
Disturbs other chil-
dren 
    
Demands must be 
met immediately – 
easily frustrated 
    
Fails to finish things 
he/she starts 
    
Mood changes 
quickly and drastical-
ly 
    
 
 
Your child’s health  
Please tell us about all your child’s diagnoses, e.g. autism spectrum, 
conduct, oppositional or learning disorder, anxiety or depression, Tou-
rette’s, asthma etc 
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Diagnosis Any medication taken 
ADHD  
Other (name)  
Other (name)  
Other (name)  
In the last 6 months, how often have you been visited/ visited the follow-
ing about your child?  
 Number of visits 
Doctor  
Hospital  
Social worker  
Police  
Other (please describe)  
What else have you used to help your child? 
 In the past Now 
 
Family Action parenting course yes   
no    
yes   
no    
Other parenting class yes    
no    
yes    
no    
Sessions with a psychologist yes    
no    
yes    
no    
homeopathy yes    
no    
yes    
no    
Other (name) …………………………….. yes    
no    
yes    
no    
Other (name) …………………………….. yes    
no    
yes    
no    
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The next questions ask about how your child is today. For each ques-
tion, read all the choices and decide which one is most like your child to-
day  
Then put a tick in the box next to it like this . Only tick one box for each 
question.  
Example: Today my child feels quite upset so I will tick this box.  
Upset 
   My child does not feel upset today 
   My child feels a little bit upset today 
   My child feels a bit upset today 
   My child feels quite upset today 
   My child feels very upset today 
1. Worried 
   My child does not feel worried today 
   My child feels a little bit worried today 
   My child feels a bit worried today 
   My child feels quite worried today 
   My child feels very worried today 
 
 
2. Sad 
   My child does not feel sad today 
   My child feels a little bit sad today 
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   My child feels a bit sad today 
   My child feels quite sad today 
  My child feels very sad today 
3. Pain 
    My child does not have any pain today 
    My child has a little bit of pain today 
    My child has a bit of pain today 
    My child has quite a lot of pain today 
    My child has a lot of pain today 
 
 
4. Tired 
   My child does not feel tired today 
   My child feels a little bit tired today 
   My child feels a bit tired today 
   My child feels quite tired today 
   My child feels very tired today 
 
 
5. Annoyed 
   My child does not feel annoyed today 
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   My child feels a little bit annoyed today 
   My child feels a bit annoyed today 
   My child feels quite annoyed today 
   My child feels very annoyed today 
 
 
6. School 
Work/Homework (such as reading, writing, doing lessons) 
   My child has no problems with their schoolwork/homework today 
   My child has a few problems with their schoolwork/homework today 
   My child has some problems with their schoolwork/homework today 
   My child has many problems with their schoolwork/homework today 
   My child can’t do their schoolwork/homework today 
7. Sleep 
   Last night my child had no problems sleeping 
   Last night my child had a few problems sleeping 
   Last night my child had some problems sleeping 
   Last night my child had many problems sleeping 
   Last night my child couldn’t sleep at all 
 
8. Daily routine 
(things like eating, having a bath/shower, getting dressed) 
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   My child has no problems with their daily routine today 
   My child has a few problems with their daily routine today 
   My child has some problems with their daily routine today 
   My child has many problems with their daily routine today 
   My child can’t do their daily routine today 
 
 
9. Able to join in 
activities (things like playing out with their friends, doing sports, 
joining in things) 
   My child can join in with any activities today 
   My child can join in with most activities today 
   My child can join in with some activities today 
   My child can join in with a few activities today 
   My child can join in with no activities today 
 
(©University of Sheffield) 
(©University of Sheffield) 
Please use this space if there’s anything else you’d like to tell us about 
your child 
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Please post this as soon as possible in the accompanying freepost envelope, or 
send it to Philippa Fibert, Sheffield School of Health and Related Research, Regent 
Court, 30 Regent Street, Sheffield, S1 4DA.  
 
Thank you very much for completing this questionnaire. We just need a bit more 
information, and confirmation that you and your child are happy to continue being 
part of the STAR project. 
Are you happy for us to contact you again:  yes    no  
Signature…………………………………………………………Date………………… 
Child’s date of birth ……………………………………………………………………… 
Contact details:  
Address:…………………………………………………………………………………… 
Phone number……………………………………………………………………… 
Email………………………………………………………………………………………. 
We would like to ask a teacher of your child to fill in a questionnaire as well. May 
we contact your child’s school? yes   no  
School name…………………………………………………………………………….. 
Can you suggest the name of a teacher who knows your child well?  
...................................................................................... 
Date of child’s ADHD diagnosis.............................................................................. 
Which doctor gave the diagnosis? ….………………………………………………… 
Where they were diagnosed? (e.g Ryegate children’s centre, CAMHS, etc) 
………………………………………………………………………………………… 
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Appendix 2b Teacher Questionnaire 
 
I understand that you work with …………………………………………….  
Thank you so much for your help with this project. Your information is a very 
important component of our research. 
Please complete the questions below as best you can. Approximate answers are 
better than nothing. Then return it in the accompanying FREEPOST envelope; or 
send it to Philippa Fibert, Sheffield School of Health and Related Research, Regent 
Court, 30 Regent Street, Sheffield, S1 4DA; or email it to p.fibert@sheffield.ac.uk 
Your name……..…………………………………………………………………………… 
Your relationship to the child (e.g class teacher, classroom assistant, head teacher) 
……………………………………………………………………………………………….. 
School name………………………………………………………………………………… 
Educational year of the child……………………………………………………………… 
How disruptive has this child been in the classroom during the last 2 weeks (please circle) 
(As good as it gets)  0…….1….……2…..…3……..4………5   (as bad as it gets) 
How many days off school has this child had in the last 6 months?  
 
Has this child been excluded from school over the last 6 months?   
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yes     no  If yes, number of days  
1. Does this child have a teaching assistant?  yes    no     If yes, how 
many hours a week? 
2. Does this child have other help in school for their ADHD? yes   no      
If yes, please describe it, and how often they have it 
………………………………………………………………………………………………… 
ADHD diagnosis. Please tick a box on each line that best describes this child  
 NOT AT 
ALL TRUE  
(never, 
seldom)  
JUST A LITTLE 
TRUE 
(occasionally)  
PRETTY 
MUCH TRUE 
(often, quite a 
bit) 
VERY MUCH 
TRUE 
(very often, very 
frequently) 
Temper outbursts; explo-
sive, unpredictable behav-
iour 
    
Excitable, impulsive     
Restless or overactive     
Cries often and easily     
Inattentive, easily dis-
tracted 
    
Fidgeting     
Disturbs other children     
Demands must be met 
immediately – easily frus-
trated 
    
Fails to finish things 
he/she starts 
    
Mood changes quickly 
and drastically 
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 NOT AT 
ALL  
JUST A 
LITTLE  
 
QUITE 
A BIT 
 
VERY 
MUCH  
 
Often fails to give close attention to details or 
makes careless mistakes in schoolwork, work, or 
other activities 
    
Often has difficulty sustaining attention in tasks 
or play activities 
    
Often does not seem to listen when spoken to di-
rectly 
    
Often does not follow through on instructions and 
fails to finish schoolwork, chores, or duties 
    
Often has difficulty organizing tasks and activities     
Often avoids, dislikes, or is reluctant to engage in 
tasks that require sustained mental effort (e.g., 
schoolwork or homework) 
    
Often loses things necessary for tasks or activi-
ties (e.g., toys, school assignments, pencils, books, or tools) 
    
Often is distracted by extraneous stimuli     
Often is forgetful in daily activities     
Often fidgets with hands or feet or squirms in seat     
Often leaves seat in classroom or in other situa-
tions in which remaining seated is expected 
    
Often runs about or climbs excessively in situa-
tions in which it is inappropriate 
    
Often has difficulty playing or engaging in leisure 
activities quietly 
    
Often is "on the go" or often acts as if "driven by 
a motor" 
    
Often talks excessively     
Often blurts out answers before questions have 
been completed 
    
Often has difficulty awaiting turn     
Often interrupts or intrudes on others (e.g., butts into 
conversations/games) 
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Appendix 3. Therapists Consultation form. 
STAR Therapist Form  
Please complete this questionnaire at the end of each consultation. You can 
either leave it at Wellforce Reception;  email it to p.fibert@sheffield.ac.uk; or 
send it to Philippa Fibert, The Coppins, Horsleys Green, High Wycombe, Bucks 
HP14 3UX 
Your Name……………………………………………………………Date……………………… 
Patient name…………………………………………………………………. 
Consultation date……………………Consultation   venue ………………………………….. 
Prescription. (name, potency, frequency)………………………………………………………….  
…………………….…………………………………………………………………………………………………… 
Did your patient take the remedy as suggested by you? y/n.  If no, please de-
scribe what they did. 
…………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………… 
Did your patient have a homeopathic aggravation/adverse event not related to 
your treatment? y/n. Please describe if yes (and fill in the Adverse event 
form)………………………………………………………………….. 
…………………………………………………………………………………………………………………………
…….……………………………………………..……………………………………………………………………
…………………………………………………………………………………………………………………………  
Anything else important you were told at this consultation (e.g they were in 
trouble with the law; did well at school; a non-ADHD sx improved 
etc)……………………………………………………………………………………… 
..……………..…………………………………………………………………………………………………………
………………………………………………………………………………………………………………………… 
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Appendix 4. Flyer 
 
Does your child have 
ADHD? 
Researchers at the University of Sheffield are studying ADHD, and testing 
some treatments to see how helpful they are in relieving symptoms and im-
proving long-term outcomes. 
We are looking for as many families as possible to take part, from all over the 
UK. So please get in touch. To do so, go to: 
www.starsheffield.com 
Or contact Philippa: 07543345046, p.fibert@sheffield.ac.uk 
www.facebook.com/starsheffieldADHD 
The School of Health and Related Research, University of Sheffield, Regent 
Court, 30 Regent St, Sheffield. 
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Appendix 5. Letter to Headteachers 
Dear …………………,  
A child from your school is participating in research we are conducting at the Univer-
sity of Sheffield observing children with ADHD. Our aim is to improve understanding 
and test novel interventions to see if they make life easier for all stakeholders.  
We would appreciate your input particularly as ADHD has such an impact in school. 
Please could you ask the member of staff who spends most time 
with…………………., age ….., suggested by her carer to be………….., to complete 
the enclosed questionnaire and return it as soon as possible in the attached Free-
post envelope. Alternately the questionnaire can be completed on line by visiting 
www.starsheffield.com.  
We will be sending out a similar questionnaire in 6 months’ time. We will ring you in 
the near future to give you the opportunity to ask any questions about the project and 
check how her teacher would prefer to be contacted next time (post, email or tele-
phone). 
Carers have given their consent for this information to be given and all the infor-
mation that you give us will be anonymous and treated as confidential.  
I have enclosed a project flyer in case there are any other children in your school 
with diagnoses of ADHD who you think might be happy to participate in the project. 
We are trying to contact as many families as possible. We will keep you updated 
about our findings. Please feel free to contact me meanwhile for any further infor-
mation. 
Many thanks in advance for your assistance. 
Yours, Philippa Fibert  
Sheffield School of Health and Related Research, Regent Court, 30 Regent Street,  
Sheffield, S1 4DA.  
Mobile 07543345046  
p.fibert@sheffield.ac.uk 
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Appendix 6. Invitation to Treatment letters. 
 
Dear ……………………………………… 
Thank you for recently completing and returning the STAR Questionnaire. Your child 
is one of 38 who have been chosen to try a course of homeopathic treatment for 
their ADHD. You are being offered the opportunity for your child to receive free 
treatment for up to one year so researchers at the University of Sheffield can investi-
gate whether homeopathic treatment provides some extra help for your child’s 
ADHD. 
What is homeopathic treatment? 
Homeopathy is considered to be a gentle, safe, natural form of healing where the 
body is stimulated to heal itself. More information about homeopathy can be found at 
www.homeopathy-soh.org/about-homeopathy.  
Homeopathic treatment focusses on the individual, not the diagnosis: the things that 
are unique and different about your child not their common ADHD symptoms. We 
are interested in whether homeopathic treatment provides any extra help. Homeo-
pathic remedies should not interact with any medications your child is currently tak-
ing, and you should continue to take any medications provided by your doctor and 
keep up your usual contact with them. 
What will my child’s homeopathic treatment consist of? 
In homeopathy the individual symptoms of your child are matched with an appropri-
ate homeopathic medicine (known as a remedy), which is believed to trigger self-
healing. To find the most appropriate remedy for your child, you will meet with a pro-
fessionally trained homeopath who will ask all about your child and their unique 
symptoms. Homeopathic treatment is a process, and remedies will be reviewed and 
modified at follow up consultations according to your child’s needs and the improve-
ments they make. 
You and your child will be offered a series of up to 8 consultations with a homeopath 
during one year, and appropriate homeopathic remedies to take in-between.  
Who is organising the research? 
This study is being carried out at the University of Sheffield School of Health and Re-
lated Research, by Philippa Fibert 
Will the information I give be kept private? 
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Yes. All information you provide will be kept strictly confidential. Once we have col-
lected the information, all the data will be made anonymous and your child will not be 
identifiable. 
What do I do now? 
Please ask your child if they are happy to participate. Once everyone is happy, you 
can let us know. Or Philippa will be ringing you to answer any questions you may 
have, and you can let her know then. With your permission, she will then give your 
details to a homeopath who will ring you to arrange to meet. 
 
I am happy to take part in the STAR Project. I agree to attend consultations approx-
imately every 6 weeks, and take the homeopathic remedies prescribed by my home-
opath, or inform them if I can’t. 
I understand that I may stop participation at any time I wish to. 
Child’s name…………………………  
Child’s signature……………………………. 
Adult’s name…………………………  
Adult’s signature……………………….…… 
 
You can let us know if you’d like to take up this offer by returning this page in the 
FREE envelope provided; texting 07543345046; or emailing Philippa 
p.fibert@sheffield.ac.uk 
 324 
 
Dear ……………………………………… 
Thank you for recently completing and returning the STAR Questionnaire. Your child 
is one of 38 who have been chosen to try a course of nutritional therapy for their 
ADHD. You are being offered the opportunity for your child to receive free treatment 
for up to one year so researchers at the University of Sheffield can investigate 
whether nutritional treatment might help ADHD and can learn more about your 
child’s experience with such treatment.  
What is nutritional therapy? 
Nutritional therapy is individually tailored supplements, information, and advice about 
nutrition to help ADHD. This means you might be given some supplements consid-
ered helpful for ADHD, some information about foods which might be aggravating 
your child’s ADHD, and an individually tailored plan with some menu suggestions. 
What will my child’s nutritional treatment consist of? 
You and your child will be offered a series of up to 8 consultations with a nutritional 
therapist. They will discuss a range of options shown to be helpful for ADHD, and 
devise a plan together with you. Your nutritional therapist will then provide an indi-
vidually tailored summary sheet, recipe ideas and/or supplements. These will be re-
viewed and modified at follow up consultations. You can continue to take any medi-
cation or treatment provided by your GP or other health practitioners and should 
keep up your usual contact with them. 
Who is organising the research? 
This study is being carried out at the University of Sheffield School of Health and Re-
lated Research, by Philippa Fibert. 
Will the information I give be kept private? 
Yes. All information you provide will be kept strictly confidential. Once we have col-
lected the information, all the data will be made anonymous and your child will not be 
identifiable. 
What do I do now? 
Please ask your child if they are happy to participate. Once everyone is happy, sign 
and return the consent form at the end of this letter, or contact Philippa by email or 
text (details below). 
What happens next? 
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Philippa will ring you to answer any questions. With your permission, she will then 
give your details to a nutritional therapist who will ring you to arrange to meet.  
I am happy to take part in the STAR Project. I agree to attend consultations with a 
nutritional therapist, or inform them if I can’t. 
I understand that I may stop participation at any time I wish to. 
 
Child’s name………………………… Child’s signature……………………….  
Adult’s name………………………… Adult’s signature……………………….  
To let us know you’d like to take up this offer, either return this page in the FREE en-
velope provided; text 07543345046; or email Philippa p.fibert@sheffield.ac.uk 
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Appendix 7. Letter to GPs 
School of Health and Related Research (ScHARR), University of Sheffield, 
Regent Court,  30 Regent Street, 
Sheffield. 
Dear…………………. 
I am a researcher in the field of ADHD at the School of Health and Related Research, Univer-
sity of Sheffield. 
This letter is to let you know that we are conducting a clinical trial exploring the effective-
ness of two complementary treatments for ADHD. The trial is to investigate whether the 
treatments might help children aged 5-18 with ADHD, and learn more about their experi-
ence with such treatment. 
The treatments we are trialling are treatment by nutritional therapists, and treatment by 
homeopaths, and these are being compared to treatment as usual to explore whether the 
therapies provide any extra help. 
 The treatments are adjunctive to what they are currently doing, and participants are ad-
vised to continue with all their prescribed medication and maintain their usual contact with 
you. The treatments are considered to be safe and non-invasive, and no known interaction 
with conventional medication or side effects has been observed. Families are recruited 
through non NHS charities and support groups. 
The study has been ethically approved under the University of Sheffield's Ethics Review Pro-
cedure. As a health care research study, the project also underwent the University's health 
care research governance procedure in line with the Department of Health's Research Gov-
ernance Framework, including appointing the University as the Research Governance Spon-
sor and ensuring all relevant approvals were in place. The project was additionally risk as-
sessed under the University's quality assurance procedure for human intervention studies, 
and confirmed to be low risk.   
Please contact us should you like any further information about the study. 
Yours Philippa Fibert (Principle Investigator, The STAR project) 
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Appendix 8. Adverse event guidelines. 
Introduction 
This document has been developed for the STAR project, and its first trial: 
comparing the clinical and cost effectiveness of treatment of ADHD by homeo-
paths and nutritional therapists with treatment as usual, being run at the 
School of Health and Related Research (ScHARR), University of Sheffield.  
The aim is to assess the acceptability and comparative clinical and cost effec-
tiveness of adjunctive treatment provided by homeopaths and nutritional 
therapists in addition to usual care for children with ADHD. A random selection 
of children recruited to an ADHD cohort will be offered treatment by homeo-
paths or treatment by nutritional therapists and their outcomes will be meas-
ured every 6 months.  
It is an important aspect of this trial that any adverse events are reported to 
the research management team to ascertain the safety of the interventions, 
and ensure best care of participants. Therapists must check for any adverse 
events each time they meet with families. Carers may also report adverse 
events directly to the research management team. They are informed of this 
when they are first offered a treatment. 
The Adverse Event (AE) guidelines below are based on: the Common Terminol-
ogy Criteria for Adverse Events (CTCAE) (U.S. Department of Health and Human 
Services 2010); European Commission Guidelines (2011); the Standard Operat-
ing Procedure developed by the Clinical Trials Research Unit (CTRU) at the Uni-
versity of Sheffield (2012); STAR trial protocol; and existing homeopathy litera-
ture.  
What is an adverse event? 
Many definitions exist. The CTCAE guidelines will be used which define an ad-
verse event (AE) as: “… any unfavourable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with 
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the use of a medical treatment or procedure that may or may not be consid-
ered related to the medical treatment or procedure.” 
Different grades of adverse events 
Adverse events may be categorised in various ways. The CTCAE guidelines use 
5 categories:  
Grade 1: Adverse Event.   Mild or asymptomatic or mild symptoms. Clinical or 
diagnostic observations only.  
Intervention not indicated. 
Grade 2: Adverse Event.  Moderate or minimal or limiting age-appropriate in-
strumental activities of daily living (ADL) (Instrumental ADL refers to preparing 
meals, shopping for groceries or clothes, using the telephone, managing mon-
ey, etc.). 
Local or non-invasive intervention indicated. 
Grade 3: Serious Adverse Event. Severe or medically significant but not imme-
diately life-threatening. Resulting in significant disability or incapacity. Limiting 
self-care ADL (Self-care ADL refers to bathing, dressing and undressing, feeding 
self, using the toilet, taking medications, and not bedridden). Congenital 
anomaly or birth defect. Events that may require intervention to prevent any 
of the mentioned consequences. 
Hospitalisation or prolongation of hospitalisation indicated 
Grade 4: Serious Adverse Event.  Life-threatening consequences. This refers to 
events where the subject was at risk of death, not where the event hypotheti-
cally could have caused death. 
Urgent intervention indicated 
Grade 5: Serious Adverse Event. Death related to Adverse Event. 
Urgent intervention indicated 
 329 
Adverse events in homeopathy and homeopathic aggravations  
Homeopathic remedies are considered to be safe (Bornhöft et al. 2006). They 
do not represent a risk of toxicological effects or interactions with convention-
al drugs (Woodward 2005). Nevertheless some adverse events have been re-
ported by various authors (e.g. Dantas & Rampes 2000, Grabia & Ernst 2003, 
Haidvogl et al. 2007). These have been characterised as transient and mild 
(Dantas & Rampes 2000) or mild to moderate (Grabia & Ernst 2003).  
No serious adverse events have been reported (ECCH 2009). The adverse 
events most commonly reported include: headaches, tiredness, skin eruptions, 
dizziness, diarrhoea or loose stools, and aggravations of patients’ pre-existing 
symptoms (Dantas & Rampes (2000).  
Mild and transient aggravations of patients’ pre-existing symptoms, usually as-
sociated with increased feelings of wellbeing, are commonly referred to as 
‘homeopathic aggravations’ in the homeopathy literature. They occur relatively 
soon after taking a homeopathic medicine and are normally considered fa-
vourable and part of patients’ curative process (Endrizzi et al. 2005, Thompson 
et al. 2004). Such aggravations occur more commonly with a particular home-
opathic protocol to be used in this trial (CEASE, Smits, 2010). 
What should therapists in the STAR project do? 
Therapists should check for adverse events at each consultation. They should 
note and complete the adverse event form for any adverse event (including 
homeopathic aggravations). They should immediately report anything consid-
ered to be a serious adverse reaction: i.e at least the grade 3 criteria as defined 
in the CTCAE guidelines. This would include: 
• any severe or medically significant reaction, even though they may not be 
life-threatening 
• reactions resulting in hospitalisation or prolongation of hospitalisation 
• reactions limiting patients ability for self-care, including daily living activi-
ties such as bathing, dressing and undressing, feeding themselves, using 
the toilet, taking medications 
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When in doubt, therapists should contact the management team (see emails 
below) who will determine what should be done and whether the event re-
quires reporting to the Data Monitoring and Ethics committee (DMEC). 
The form should be completed within 24 hours of the event and should be 
emailed to the STAR management team: either the Chief Investigator, Philippa 
Fibert at p.fibert@sheffield.ac.uk or Dr Clare Relton at c.relton@sheffield.ac.uk  
What should the STAR Management Team do? 
When the Management Team receives reports of adverse events from thera-
pists and/or patients, they will report serious events to the STAR Data monitor-
ing and ethics committee (DMEC) within 24 hours. 
The DMEC will then report the SAE as deemed appropriate to the Head of the 
School of Health and Related Research (ScHARR); the sponsor (University of 
Sheffield); the STAR Steering Committee; the patient’s family and/or their 
GP. 
The Management Team will complete the University of Sheffield Adverse Event 
Report Form in line with the Standard Operating Procedure developed by the 
Clinical Trials Research Unit (CTRU) at the University of Sheffield (2012).  
They will report: their assessment of the seriousness, frequency and intensity 
of the Adverse Event; concomitant treatment; the assessed relationship to the 
therapist’s treatment; any actions taken and the outcome. When in doubt, the 
Management Team will discuss the issue with the DMEC. 
1. Seriousness: Death; life threatening; inpatient hospitalisation; prolonged 
hospitalisation; persistent or significant disability/incapacity; congenital 
abnormality/birth defect. 
2. Frequency: Isolated; intermittent; continuous; unknown. 
3. Intensity: Mild; moderate; severe. 
4. Concomitant treatment: Any treatment other than the treatment pro-
vided by the homeopath. 
5. Assessed relationship to therapist’s treatment: Definite; probable; pos-
sible; unlikely; unrelated; not assessable. 
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6. Action taken: None; reduce dose; treatment withdrawn; specific treat-
ment; other. 
7. Outcome: Recovered; improved; unchanged; deterioration; persisted; 
death. 
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Appendix 9. Adverse event form 
An adverse event includes, but is broader than, unintended errors and mis-
takes arising from research activity, resulting in one or more research partici-
pants having symptoms or being caused physical or psychological harm or seri-
ous distress. Refer to the STAR Adverse Events Guidelines for clarification. 
Please complete this form within 24 hours of the event occurring and email it 
to Chief Investigator Philippa Fibert p.fibert@sheffield.ac.uk  and/or ring her 
on 07543345046.  
Date:    
Therapist’s name: 
Patient’s name, date of birth and contact details: 
 
Patient’s GP name and contact details: 
Details: 
When did the event take place and for how long? 
What happened and what was the impact? 
Any thoughts on why it occurred: 
Action taken: 
 
Any action or planned action to limit the risk of the event re-occurring? 
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Appendix 10. Risk Guidelines for therapists treating children with 
ADHD 
Introduction. 
This document has been developed for homeopaths and nutritional therapists interacting 
with families included in the pragmatic cohort randomized controlled trial of the clinical and 
cost effectiveness of treatment of ADHD (STAR) project at the School of Health and Related 
Research (ScHARR), University of Sheffield. 
The policy is derived from: ‘A guide to inter-agency working to safeguard and promote the 
welfare of children’; ‘Information Sharing: Advice for practitioners providing safeguarding 
services to children, young people, carers and carers’. (Department for Education, March, 
2015); and www.safeguardingsheffieldchildren.org.uk (local safeguarding children board).  
Clinical risk is the possibility of something negative happening as a direct result of the be-
haviour of a patient or people in their surroundings. ADHD families are considered a vulner-
able population, with more prevalent risk factors (Biederman, 2002) and the symptoms of 
ADHD and abuse can overlap. This document covers information about: the context; recog-
nising signs and symptoms of abuse; what to do if there are concerns about the child or 
family; how to manage those concerns; recording and managing confidential information. 
Training in child protection policy is considered imperative for this study, and all therapists 
will complete the ‘awareness of child abuse and neglect’ emodule:  
(www.safeguardingsheffieldchildren.org.uk), which trains therapists to recognise the signs 
of, and respond correctly to physical, sexual, emotional abuse and neglect.  
This policy document recognises that effective safeguarding systems are those where the 
child’s needs are paramount, and the needs and wishes of each child are put first. Therapists 
need to be alert to any risks of harm that individual abusers, or potential abusers, may pose 
to children; know how to share appropriate information in a timely way; and use their 
judgement to put the child’s needs at the heart of safeguarding. 
Confidentiality 
• Confidentiality between therapists and families should be maintained at all times, 
UNLESS the therapist deems that the risk of abuse is great enough to require activat-
ing statutory safeguarding procedures. 
• Therapists should only make a decision to breach confidentiality after discussion 
with the Principle Investigator of the project. 
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Competency 
• Therapists should work within the limits of their competency and seek ad-
vice/supervision when they feel outside those limits 
• They should work according to the code of ethics developed by their professional or-
ganisation 
• They should attend the regular supervision provided for the trial, and individual su-
pervision dependent on need and experience 
What is abuse? 
This is covered more fully in the emodule accessible at 
www.safeguardingsheffieldchildren.org.uk.  
The definition of abuse is ‘a form of maltreatment of a child by inflicting harm, or by failing 
to act to prevent harm’. It can be Sexual, Physical, Emotional, or due to Neglect. Children 
may be abused in a family, in an institutional or community setting, by those known to 
them, or by others (e.g. via the internet). They may be abused by an adult or adults, or an-
other child or children. 
Several of the signposts for abuse are common ADHD symptoms. You will need to consider 
these very carefully and use your professional judgement and try to understand what might 
be behind the symptoms. For example is lack of eye contact between carer and child a 
symptom of ASD spectrum or a sign of neglect? Is poor educational achievement due to in-
nate concentration difficulties or abuse etc. Ask yourself what is provoking the behaviour? 
You also need to consider that ADHD may possibly manifest as a response to abuse. You 
therefore need to be aware of the signs and symptoms, and what to do in the unlikely cir-
cumstance that you suspect abuse.  
ADHD children can be exasperating and drive carers to their limits. Discipline may appear 
extremely harsh verging on abusive. Be compassionate in your understanding of the carers 
attempts to manage their child’s behaviour and considerate that the carers may also have 
ADHD, but aware where parental response seems extremely disproportionate. 
The four identified types of abuse are defined below: 
1. Sexual. This involves forcing or enticing the child to be involved in sexual activity, 
whether or not they are aware of it. It may be physical, or just making them watch. 
This is very difficult to diagnose, and should only be suspected it the child actually 
says something. 
Signposts are: loss of concentration, enuresis, soiling, poor performance at school, 
self-harm, and inappropriate sexualised behaviour. 
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2. Physical. Hitting, shaking, poisoning, burning, drowning, suffocating, carers fabricat-
ing symptoms or deliberately inducing symptoms. Smacking is not illegal, but if it 
causes bruising, swelling, cuts, grazes or scratches it is, and liable to 5 years impris-
onment. 
If you are concerned about the injury: 1. Ask the child how it happened. 2. Ask the 
carer how it happened. Note the exact words. Be concerned if the child isn’t allowed 
to tell you; the story seems inconsistent, medical help wasn’t sought when you think 
it should have been; or carers appear hostile. However, consider that the child’s car-
ers may have ADHD, and  expect hostile responses and defensive reactions. 
A series of marks may indicate repeated injury. Consider the positioning of the bruis-
ing, how well it matches the story and how easy it might be to obtain accidentally. Eg 
two bruised eyes or bruising of the outer ear may be difficult to obtain accidentally. 
If you suspect a fracture, ensure families seek medical help. Never undress a child for 
examination without consent from carer/carer and child and in the presence of car-
er/carer. 
3. Emotional. This is defined as ‘Persistent emotional maltreatment conveying to the 
child that they are worthless, unloved or inadequate’.  Consider that ADHD carers 
may have received this kind of modelling themselves and therefore use it on their 
children. Signposts include: head banging or other forms of self stimulation; hyperac-
tivity, reduced attention span, developmental delay, aggression at school, low self 
esteem, self harm. 
4. Neglect is defined as ‘persistent failure to meet a child’s physical and emotional 
needs, likely to result in serious impairment of health and development’. 
This can be failure to provide adequate clothing, food or shelter; protect the child 
from physical or emotional danger and harm; ensure adequate supervision and med-
ical treatment. 
There are degrees of neglect. Be careful about imposing your own standards.  
Signposts are: developmental problems, recurrent minor infections, poor education-
al performance, language delay, failure to thrive, conduct disorders, indiscriminate 
attachment to strangers, lack of eye contact 
 
Notifiable incidents  
Local authorities have a duty to make enquiries under section 47 of the Children Act 1989 if 
they have reasonable cause to suspect that a child is suffering, or is likely to suffer, signifi-
cant harm, to enable them to decide whether they should take any action to safeguard and 
promote the child’s welfare. There may be a need for immediate protection whilst the as-
sessment is carried out.  
A notifiable incident requires immediate notification to safeguarding authorities and in-
cludes: 
• death of a child (including cases of suspected suicide), whether or not abuse or ne-
glect is known or suspected. 
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• a child has been seriously harmed and abuse or neglect is known or suspected 
Monitoring and measuring the level of risk 
When you first suspect potential risk of abuse: 
• Explore this directly with the family using every day language, open questions (who, 
when, what, how) not leading, closed questions.  
• Record exactly what they have said. Record in detail why you suspect the abuse and 
your observations using the project risk assessment form. Record any actions taken 
with dates and times.  
• Share your anonymised concerns immediately with the PI and/or your supervisor. 
Procedures to manage identified risk of abuse 
If you, the PI, and/or your supervisor are in agreement that the child is at serious risk of 
abuse in their current circumstances, you have a statutory duty to report the perceived risk. 
Please consider the following: 
• If the child has disclosed that they have suffered abuse to you, be aware that 
this has been extremely hard for them and means they trust you. You will 
need to tell them that you need to pass on to other people what they have 
told you because they or other children may be hurt. Whilst your primary 
concern is always the wellbeing of the child, you have a duty to refer child 
protection concerns. Similarly, if the child’s carer chooses to disclose that 
they or their child has suffered from abuse, you will similarly need to make 
them aware if you need to pass this information on. 
• Ask the family if they are already under supervision by social services, who 
their care worker is, and tell them that you will be contacting them. Reassure 
them at all times that this is with the best interests of the child.  
Actions 
For non-urgent concerns, discuss with PI and/or your supervisor. 
For urgent concerns, contact the PI immediately (07543345046). If she is unavailable con-
tact Dr Clare Relton (0114 2220796/07879872892).  
If neither are available, ring the free Sheffield safeguarding advisory desk helpline for advice 
(Monday to Friday, 9 until 5 pm) 0114 2053535. Out of hours, ring emergency service 0114  
2734855 
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The PI and Dr Relton will bring any urgent concerns to the Data monitoring and Ethics Com-
mittee (DMEC) within 24 hours of being alerted to the concern. 
Appendix: SOH code of conduct. 
64. Avoid physical examination unless in the presence of the carer and with the child’s per-
mission 
78. Avoid disclosing any information about patients….and preserve confidentiality at all 
times, unless clear and ethical or legal concerns overrule this 
80. The following legal and moral exceptions may justify information being given to third 
parties. a) in an emergency or other dangerous situation where in the opinion of the thera-
pist, the information may assist in the prevention of possible injury to the patient or another 
person. b) when required to do so by rule of law. By virtue of employment in an or-
ganoisation operating local protocols, eg under the Children’s Act 1989. 
Appendix B. We are legally required to take action in any case where we suspect a child is at 
risk through mental, emotional, physical abuse or neglect (Barkley & Fischer, 2010) 
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Appendix 11. Description of homeopathy ADHD research studies  
Studies excluded from the systematic review on screening, with reasoning.  
Study Reason for exclusion 
Lottering Unpublished MSc thesis of a complex formula ‘Quietude’ 
Smith 2001 Unpublished MSc thesis of complex formulas cerbo and nerva 
Cockcroft Unpublished MSc thesis of the single remedy phosphorous 
Barnard 2010 Unpublished MSc thesis: uncontrolled case series.  
Goetz 2012 This RCT was found not to include homeopathy on full reading 
Mc Clean and 
Garland 2005 
Unpublished observational study of children in danger of exclusion (not 
necessarily with an ADHD diagnosis) 
Studies included in the literature review  
Lamont 1997 
A quasi-randomised controlled trial with partial cross-over (alternate allocation) of 43 chil-
dren with ADHD conﬁrmed by psychological testing, mean age of 10years, of which 6 were 
already taking stimulant medication but still displayed symptoms. All children were in foster 
homes, in care or under the supervision of a social worker. Individualised homeopathic 
remedies were prescribed for each child following a consultation using classical homeo-
pathic prescribing. This was the only contact between child and homeopathic physician. 
Medicines were given as 6 x 200c pills daily for up to 5 days. Progress was followed-up every 
10 days by phone with carers or carers with the option of changing the medicine on two fur-
ther occasions. The placebo group received an indistinguishable placebo pill. Later they 
were crossed-over to receive verum homeopathy as described above.  
Outcomes were reported by carer to the researcher by telephone 10 days after each pre-
scription using an un validated ﬁve-point rating scale of “change in hyperactivity” which 
spanned -2 ’much worse’ to 0 ’no change’ to +2 ’much better’. Explanation for the use of 
this measure was justified by the author, who explained that a pilot study had found a halo 
effect ’eliminating the utility of most items’ and that carers were better able to understand 
and respond to the simple scale. 
Strauss 2000 
An RCT (no details of randomisation) of 20 children with previously diagnosed ADHD (no 
conﬁrmation) aged between 7-10 years of which half (equally distributed) were already tak-
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ing stimulant medication.. A complex formula homeopathic medicine was used containing 
selenium in 10X, 15X, 30X, 200X and potassium phosphate in 2X, 10X, 30X, 200X (sold com-
mercially in South Africa to improve concentration, memory and alertness). Ten drops were 
taken three times daily. The placebo group received an identical liquid solution with the 
same instructions. Drops were taken for two months.  
Outcomes were measured at baseline, 30 days and 60 days using The Conners’ Rating Scales 
(CRS); and a child performance task termed the Childrens’ Checking Task to assess sustained 
attention. 
Frei 2001 
This open label study evaluated 115 children (mean age 8.3) at diagnosis of ADD/ADHD by 
the consultant paediatrician, who ran a conventional practice which provided homeopathic 
treatment. The children were first treated with individualised homeopathic remedies. Chil-
dren who did not improve sufficiently (50% improvement in CGI) were changed to Ritalin. 
After an average treatment time of 3.5 months, 75% (N=86) children attained an improve-
ment rating of 73% with homeopathic remedies. 22% (N=25) children subsequently treated 
with Ritalin attained an improvement rating of 65%. 3 children didn’t respond to either 
treatment and 1 left the study.  
Frei 2005 
From the research above (Frei, 2001) it had been found that gains whilst taking remedies 
were only maintained whilst continuing to take them, allowing a controlled comparison of 
deterioration in symptoms under placebo and maintenance of improvement under verum. 
A screening phase identified responders who successfully responded to homeopathy by 
demonstrating at least a 50% reduction in their ADHD symptoms. 83 children with ADHD 
conﬁrmed by neuropsychological examination entered the screening phase. Individualised 
homeopathic remedies were prescribed as daily liquid doses (LM potencies) according to 
Bönninghausen’s methodology which is somewhat used on the continent, but not in the UK. 
Children were seen only once by the homeopathic physician with treatment progress as-
sessed by carers at 4-weekly intervals and remedy adjusted as necessary. All other medica-
tion or treatments for ADHD had to be stopped for the duration of the screening and the 
trial.  
62 children (mean 10 yrs) entered the RCT phase when their symptoms had improved by 
50% under homeopathic treatment. In the trial phase participants received either the suc-
cessful remedy (n=31) or an identical placebo (n=31) to be taken daily for 6 weeks followed 
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by cross-over. No contact with the homeopathic physician occurred during the cross-over 
trial phase. 
Outcomes. Screening stage: CPRS-R Carer and Teacher forms, Kinsbourne Attention Ques-
tionnaire. Baseline: CGI-P, Questionnaire of Change of Behaviour (QCB), VLMT (auditory 
learning test), WISC (Wechsler intelligence test),K-ABC Kaufman Assessment Battery for 
Children, TAP Test Assessment battery for Attention Performance. Final outcomes: CGI-
Carer, VLMT, QCB, WISC. 
Jacobs 2005 
An RCT (computer generated, blocked, stratiﬁed algorithm) of 43 children with conﬁrmed 
ADHD diagnosis, mean age of 9 years. 9 participants were already taking stimulant medica-
tion (n=5 active, n=4 placebo). 
Individualised homeopathic remedies were prescribed using the Sankaran method with op-
tion to vary prescription at 6 and 12 week follow-up. 21 children received a single remedy  
and 22 children received an indistinguishable placebo. The trial lasted for 18 weeks in total.  
Outcomes Baseline: CPRS, CGI-P(Carer), CGI-T (teacher), Continuous Performance Test 
(CPT). Follow-up at 18 weeks: CPRS, CGI-P, CGI-T, CPT, Stimulant Side Effects Checklist, Clini-
cal Global Impression (Clinicians) 
Barvalia 2011. 
This was a nonrandomized, within subjects pre and post‑intervention study of sixty autistic 
children of both sexes, ≤12 years. Autism was measured using the ATEC, and ADHD symp-
toms using the Autistic Hyperactivity Scale.  Children were observed for the initial 6 months 
(control period) and the same children were then treated for 1 year.  
Razlog 2012 
An RCT (no details of randomisation) of 30 children aged 5-11 pre-diagnosed with ADHD and 
not taking medication. A non-individualised remedy considered to be indicated for symp-
toms such as impatience, irritability and inattention was given in two different potencies. 
Group 1 took mother tincture Valeriana officinalis; group 2 took low homeopathic potency 
Valeriana officinalis 3X; and group 3 took a placebo consisting of an identical liquid solution. 
All groups took 10 drops, three times a day after meals, for two weeks. 
Outcomes: Barkley and DuPaul teacher rating scale, the children’s checking task (CCT), and 
CPRS  measured at baseline, week one, week two and week three.  
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Brule 2012 
An open label pilot study with no comparator, of 30 children (mean age 9.5) with a diagnosis 
of ADHD by clinical psychiatrist. Children received homeopathic treatment of 10 consulta-
tions and individually prescribed homeopathic remedies) from two homeopaths. Children 
on regular stimulant medication were included. 
Outcomes were measured at baseline and at each of the 10 appointments using CGI-P and 
Measure your Own Medical Outcome Profile (MYMOP) which asks for selection of two most 
bothersome symptoms; an activity influenced by the condition; and wellbeing; and 
measures them on a likert scale of 0-6. 
Oberai 2013 
An RCT of 61 children (mean age 9.3) on no other medications, with ADHD confirmed by 
psychiatrist. Children were randomly assigned to receive individualised homeopathic reme-
dies or an identical placebo, daily for one year.Remedies could be changed every 3 months. 
Consultations are not described. 
Outcomes: CPRS-R; CGI-SS; CGI-IS at baseline and every month up to one year. Academic 
performance recorded at baseline and one year. 
Fibert 2016 
An open label comparative consecutive case series of 30 children with a prior diagnosis of 
ADHD. 20 children who received individualised homeopathic treatment for one year (visits 
every 6 weeks + I-HMPs), were compared with 10 children enrolled subsequently, who re-
ceived similar time and attention from the same practitioner for 4 months.  
Comparative outcomes were measured at baseline and after 4 months and long-term out-
comes of treated children were measured after one year using DSMIV characteristics (CPRS-
R-L) and MYMOP. Via MYMOP symptom choices it was found that 20/30 participant’s carers 
considered anger to be the issue that was most bothersome  
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Appendix 12. Lost Voices 
[Nathan enters stage, puts glass of water on small table 
and addresses the audience] 
I guess from a humanistic perspective, 
we often fear what we don't understand. 
Keep at arms length things that don't make sense, 
daily, bombarded by 1000s of messages, advert and influ-
ences  
- our minds are in high demand. 
So whether we like it or not, we all stereotype, 
we create snap judgements in the blink of an eye  
based upon a wealth of experience across the span of our 
lives.  
I’d hate to admit I’d judge a book by the exterior of it  
• but if i said, I'd read every book I’d ever picked 
up, that’d be a lie. 
Now we’ve all had a requirement to fill a desire. Then 
found it difficult before the age of retirement. 
Imagine wanting what you cant have, because you have 
what you didn’t want, 
knowing the message to write, but not being able to 
choose the font. 
So I guess this is the part where I should introduce me; 
they call me attention deficit hyperactivity disorder, 
ADHD 
and we know the difference between knowing and 
KNOWING. 
So I’ve been invited here to explain a little more about 
me. 
[enter Dan, puts wallet on table next to glass of water and 
looks at Nathan] 
Imagine talking to your mate 
and everything he says is great,  
you like his idea and energy, 
of course you concentrate. 
Then you notice something strange, [piano starts] 
your eyes drift the other way. 
The piece of paper becomes louder  
than everything he has to say. 
So your feet follow your mind  
and your body walks away, [dan walks towards paper, 
leaving his wallet on table] 
you’re off on a tangent 
your friend has something left to say. 
It’s not because you don't love him 
and we know you care about what he said,  
you just have a fantastic idea  
you need to get outside your head. 
[Dan’s solo — Dancing with a piece of paper and creating 
a paper plane] 
Mate!?? [Nathan hands Dan his wallet back] 
Now i’m going to take ADHD and split it in half; [Rip 
paper with ADHD in half] 
now we have AD & HD. 
Does not this feel like art?? [to Dan]. 
Attention Deficit, that’ll be the first part. 
Now I feel like this part of my name 
is slightly misleading 
because there is no deficit 
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of attention in the examples I’m seeing. 
I just don't hold the attention down,  
it’s all over the ceiling. it is just 
simultaneously firing 
on several cylinders. 
At this point I should mention that I’m heterogeneous  
(definition) I display a different mixture of traits in every 
single case. 
Now let us take 50% creativity, 7% stress, 40% emotion, 
3% rest and shove it in a potion.  
But sometimes the mixture will have me exploding…  
[enter Anton] 
[Anton… Sword Play.] 
Now let’s speak about the outbursts and negative connota-
tions, 
general misconceptions bring all types of complications. 
From outside looking in this behaviour can be unsettling, 
emotional outburst can be seen as quite threatening. 
And this is the loudest part of me. Snap judgements,  
200 mph of over-evaluation can lead to isolation. 
I’m as smart as any counter part I've ever faced,  
this exam paper’s in front of me but my minds all over the 
place. 
My intelligence cannot be defined by standard evaluation, 
a SATS test to me is evaluating a fish by its ability to climb 
a tree. 
My imagination extends to the sky and warps with the 
time, 
you will not find it can be simply defined.  
But don't think I don't care. 
I fear that you think I don't care, 
when I care more than I could explain. 
I’m charged from emotions that I display, simple and 
plain. 
Every morning I wake up with a renewed sense of hope 
and enthusiasm, 
an almost genuine belief that the issue I face on a daily 
basis will escape from me, 
that is until the remote’s in the fridge  
and I’ve misplaced my keys with the excitement for the 
day on which I leave. 
Now picture the child you imagine me to be. 
I live with ADHD but whats it like to live with me??? 
A good thing to address so  
we asked a mother and she eloquently said: 
“Everything seems like a battle, 
walking to school, getting dressed, 
an ungodly hour when you’re woken from your sleep,  
by the loveliest little terror, tugging on your linen sheets. 
The days you go for a wee 
when you find the floor coated in washing powder”.  
And she knows, that he knows better and thinks this is 
enough, 
so she despairs and asks why, he answers “just because”.  
The stress is condensed for hours straight, so she sits  
on her hands and gathers the strength to not retaliate. 
Then there are the times that she lashes out with 
screams and shouts, the apex of stressing out. 
Followed by nights of sobbing at the foot of the bed 
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‘cause she sees her child's angelic face and regrets what 
was said. 
Feels like she failed the person that’s closest to her, 
like she didn't give the emotional support, feeling a mess. 
Now it seems like all the arguments were over  
insignificant events in the absence of heated emotions, 
because we sometimes forget that life is just  
a collection of moments. Plus he’s only 4 for God’s 
sake. 
Then she spoke of the times of parental pride, 
her heart bursts at the seams with love, she feels ec-
static.  
Every time her boy’s creativity shines through  
he does something bloody fantastic. 
And the moment when a stranger plays their part  
simply by showing a look of compassion rather than 
contempt. 
Sees her child having a meltdown and praises her for 
how well it was handled 
then says something positive about her boy in the 
same event. 
And the nights she goes to bed knowing that she 
smashed the day, 
the boy was completely and utterly perfect in every 
single way. 
His heightened emotions radiating love and expressing 
it openly, 
knowing without her son she’d be completely and 
hopelessly, lost. 
…….. 
I guess now it feels right to address a  
professional and educational setting.  
I’m seen as disrupted because  
I struggle with focus in a lesson. 
But it’s more that I spread my focus in a lesson. 
My mind’s awesome, I solve problems, 
maybe not the one on the board in front of me, 
but i did design a ecosystem based on the workings of a 
tree.  
And there’s a way to get rid of the energy  
that is living within; 
medication - 
so they riddle me with Ritalin.  
My mind numb, no longer in an excited state, 
the pro of this is, now I can concentrate. 
One tablet lasts somewhere between 6 to 8 
hours, so that keeps me calm for a working day. 
My predicament is kinda’ scary, 
feel less and work more 
and a fix is only temporary. 
… 
I don’t profess to have an answer, 
I doubt anybody ever will, 
I just wanted to explain 
both the pride and the pain that I have obtained,  
due to a mind that works differently,  
and I guess I wanted to tell you that I care.  
So if I'm in a chair, and my behaviour makes you want to 
stare, 
I'm inviting you to sit with me,
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Appendix 13. Primary Outcome Statistics. 
ITT analyses of the primary outcome – carer-rated. Influence of predictors. 
Table 39. ITT, carer-rated regression analysis. CGI total change between baseline and 6 months. The 
influence of covariates 
 Overall effect of the model: F (5,82) = 4.54, p =.001 Number of observations = 88 
Predictors 
Unstandardized Coefficients  
t Sig. B Std. Error  
 (Constant) -4.721 3.267  -1.445 .152 
hom 1.698 1.573  1.079 .284 
NT 2.661 1.553  1.713 .090 
Age  .242 .273  .889 .377 
ADHD severity 6.040 1.430  4.225 .000 
Male vs female -1.969 1.743  -1.129 .262 
 Dependent Variable: CGI change score (carer) 
 
Table 40. ITT, carer-rated regression analysis. Emotional lability change between baseline and 6 
months. The influence of covariates 
Overall effect of the model: F (5,82) = 4.89, p= .001 Number of observations = 88 
Predictors 
Unstandardized Coefficients  
t Sig. B Std. Error  
 (Constant) -1.385 1.226  -1.130 .262 
hom 1.227 .588  2.089 .040 
NT .648 .583  1.112 .269 
Age .011 .103  .104 .918 
ADHD severity 2.177 .535  4.067 .000 
Male vs female -.548 .651  -.841 .403 
 Dependent Variable: emotion change score (carer) 
Table 41. ITT, carer-rated regression analysis. Restlessness/Impulsivity change between baseline and 
6 months. The influence of covariates. 
Overall effect of the model: F (5, 82) = 3.53, p=.006 Number of observations = 88 
Predictors 
Unstandardized Coefficients  
t Sig. B Std. Error  
 (Constant) -3.119 2.479  -1.258 .212 
hom .437 1.188  .368 .714 
NT 2.125 1.179  1.802 .075 
Age .208 .208  1.001 .320 
ADHD severity 3.939 1.082  3.639 .000 
Male vs female -1.483 1.317  -1.126 .264 
a. Dependent Variable: restless/impulsive change score (carer) 
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Per protocol analyses of the primary outcome – carer-rated. Influence of predictors. 
Table 42. Per protocol, carer-rated regression analysis. CGI total change between baseline and 6 
months. The influence of covariates 
Overall effect of the model: F (5,69) = 3.61, p= .006                     Number of observations = 75 
Predictors 
Unstandardized Coefficients 
t Sig. B Std. Error 
 (Constant) -3.721 3.456 -1.077 .285 
hom 1.653 1.722 .960 .340 
NT 3.045 1.605 1.898 .062 
Age .184 .288 .640 .525 
ADHD severity 5.417 1.521 3.562 .001 
Male vs female -1.709 1.850 -.923 .359 
Dependent Variable: CGI change scores (carer) 
 
Table 43. Per protocol, carer-rated regression analysis. Emotional lability change between baseline 
and 6 months. The influence of covariates 
Overall effect of the model: F (5,68) = 3.69, p= .005  Number of observations = 74 
Predictors 
Unstandardized Coefficients 
t Sig. B Std. Error 
 (Constant) -1.157 1.298 -.892 .376 
hom 1.015 .642 1.580 .119 
NT .612 .603 1.014 .314 
Age -.009 .108 -.085 .932 
ADHD severity 2.088 .568 3.674 .000 
Male vs female -.195 .691 -.282 .779 
Dependent Variable: emotion change score (carer) 
 
Table 44. Regression analysis. Excitability/restlessness change between baseline and 6 months. Per 
protocol analysis, carer-rated. The influence of covariates 
Overall effect of the model: F (5,68) = 3, p=.017 Number of observations = 74 
Predictors 
Unstandardized Coefficients 
t Sig. B Std. Error 
 (Constant) -2.261 2.631 -.859 .393 
hom .594 1.302 .456 .650 
NT 2.585 1.223 2.114 .038 
Age .162 .220 .736 .464 
ADHD severity 3.403 1.152 2.955 .004 
Male vs female -1.583 1.400 -1.131 .262 
 Dependent Variable: restlessness/impulsivity change score (carer) 
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ITT analyses of the primary outcome – teacher-rated. Influence of predictors. 
Table 45. ITT, teacher-rated, regression analysis.  CGI total change between baseline and 6 months. 
The effect of Predictors 
Overall effect of the model: F (5,25) = 2,047, p=.106 Number of observations = 31 
Predictors 
Unstandardized Coefficients 
t Sig. B Std. Error 
 (Constant) -13.908 6.476 -2.147 .042 
hom .579 2.887 .201 .843 
NT 4.113 3.140 1.310 .202 
Age 1.194 .569 2.100 .046 
ADHD severity 1.338 2.895 .462 .648 
Male vs female 6.580 3.843 1.712 .099 
Dependent Variable: CGI change score (teacher) 
 
Table 46. ITT, teacher-rated, regression analysis.  CGI emotional lability change between baseline and 
6 months. The influence of Predictors 
Overall effect of the model: F (5,25) = 1.68, p= .177 Number of observations = 31 
Predictors 
Unstandardized Coefficients 
t Sig. B Std. Error 
 (Constant) -3.559 1.683 -2.114 .045 
hom .403 .750 .537 .596 
NT .615 .816 .754 .458 
Age .271 .148 1.830 .079 
ADHD severity .308 .752 .409 .686 
Male vs female 1.789 .999 1.792 .085 
Dependent Variable: emotional lability change (Teacher) 
 
Table 47. ITT, teacher-rated regression analysis.  CGI restlessness/impulsivity change between baseline and 6 months. The 
influence of Predictors 
Overall effect of the model: F (5,25) = 1.8, p= .15 Number of observations = 31 
Predictors 
Unstandardized Coefficients 
t Sig. B Std. Error 
 (Constant) -10.349 5.362 -1.930 .065 
hom .176 2.390 .074 .942 
NT 3.498 2.599 1.346 .190 
Age .924 .471 1.962 .061 
ADHD severity 1.030 2.397 .430 .671 
Male vs female 4.790 3.182 1.506 .145 
Dependent Variable: restlessness/impulsivity change(Teacher) 
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.  
Per protocol analyses of the primary outcome – teacher-rated. Influence of predictors 
Table 48. Per protocol, teacher-rated regression analysis.  CGI total change between baseline and 6 
months. The effect of Predictors.  
Overall effect of the model: F (5,17) = .727, p=.613 Number of observations = 23 
Predictors 
Unstandardized Coefficients 
t Sig. B Std. Error 
 (Constant) -7.161 8.113 -.883 .390 
hom .572 3.161 .181 .858 
NT -1.980 4.154 -.477 .640 
Age .773 .667 1.159 .263 
ADHD severity -1.025 3.301 -.310 .760 
Male vs female 3.472 4.458 .779 .447 
Dependent Variable: CGI change (Teacher) 
Table 49. Per protocol, teacher-rated regression analysis. CGI emotional lability change between 
baseline and 6 months. The effect of Predictors.  
Overall effect of the model: F (5,17) = .897, p= .505 Number of observations = 23 
Predictors 
Unstandardized Coefficients 
t Sig. B Std. Error 
 (Constant) -1.669 1.891 -.883 .390 
hom .117 .737 .158 .876 
NT -1.156 .968 -1.194 .249 
Age .162 .156 1.043 .312 
ADHD severity -.352 .769 -.458 .653 
Male vs female .296 1.039 .285 .779 
Dependent Variable: emotional lability change (Teacher) 
Table 50. Per protocol, teacher-rated regression analysis. CGI restlessness/impulsivity change be-
tween baseline and 6 months. The effect of predictors.  
Overall effect of the model: F (5,17) = .571, p= .722 Number of observations = 23 
Predictors 
Unstandardized Coefficients 
t Sig. B Std. Error 
 (Constant) -5.493 7.035 -.781 .446 
hom .456 2.741 .166 .870 
NT -.824 3.602 -.229 .822 
Age .611 .579 1.056 .306 
ADHD severity -.672 2.862 -.235 .817 
Male vs female 3.176 3.866 .821 .423 
 Dependent Variable: restlessness/impulsivity change(Teacher) 
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Medication status. 
Table 51. Regression analysis. CGI change between baseline and 6 months in those taking medica-
tion. The effect of predictors.  
Overall effect of the model: F (5,54) = 4.28, p = .002 Number of observations = 60 
Predictors 
Unstandardized Coefficients 
t Sig. B Std. Error 
 (Constant) -2.736 1.572 -1.740 .088 
hom -1.062 1.860 -.571 .570 
NT 3.112 1.737 1.791 .079 
Age  2.010 1.638 1.227 .225 
ADHD severity 6.400 1.642 3.898 .000 
Male vs female -2.029 1.959 -1.036 .305 
 Dependent variable: CGI change score 
Selecting only cases where participants take medication 
Table 52. Regression analysis. CGI change between baseline and 6 months in those not taking medi-
cation. The effect of predictors.  
Overall effect of the model: F (5,23) = 2.095, p = .103 Number of observations = 29 
Predictors 
Unstandardized Coefficients 
t Sig. B Std. Error 
 (Constant) .827 3.666 .226 .824 
hom 4.500 2.767 1.627 .117 
NT .422 2.997 .141 .889 
Age  -3.101 2.446 -1.268 .217 
ADHD severity 4.188 3.073 1.363 .186 
Male vs female -4.252 3.814 -1.115 .276 
 Dependent variable: CGI change score 
Selecting only cases where participants do not take medication 
Those with co-occurring autism  
Table 53.Regression analysis. CGI change in those with co-occurring autism. Effect of Predictors.  
Overall effect of the model: F (5,20) = 2.242, p = .09 Number of observations = 26  
Predictors 
Unstandardized Coefficients 
t Sig. B Std. Error 
 (Constant) -11.658 6.365 -1.831 .082 
hom 4.222 3.178 1.328 .199 
NT 8.531 2.965 2.878 .009 
Age .681 .476 1.429 .168 
Male vs female -.416 2.913 -.143 .888 
ADHD severity 5.143 2.308 2.229 .037 
 Dependent variable: CGI change score 
Selecting only cases where participants do have autism 
 350 
Table 54. Effect size calculations.  
Outcome Completer  Hom  NT  TAU 
  Mean SD  n Effect size  Mean SD n Effect size  Mean SD n 
 
 
CGI 
Carer  ITT 4.03 5.766 29 .425  4.17 7.56 29 .388  1.55 5.893 31 
 Per Protocol 3.7 6.258 20 .356  4.96 6.577 24 .55**  
Teacher  ITT 1.27 5.729 11 .069  4.13 10.232 8 .39  .83 6.978 12 
 Per Protocol 1.57 6.451 7 .109  -2.5 5 4 -.504**  
                 
 
Restless-Impulsive 
Carer  ITT 2.38 4.547 29 .198  3.5 5.225 28 .418  1.48 4.523 31 
 Per Protocol 2.3 5.11 20 .172  4.22 4.223 23 .623**  
Teacher  ITT 1.09 4.505 11 .016  3.88 7.643 8 .421  1 6.281 12 
 Per Protocol 1.57 4.995 7 .097  -1 4.243 4 -.339  
                 
Emotional lability Carer  ITT 1.66 1.95 29 .793**  .75 3.014 28 .269  .06 2.08 31 
 Per Protocol 1.4 1.789 20 .679**  .87 2.959 23 .325  
Teacher  ITT .18 1.471 11 .25  .25 3.012 8 .195  -.17 1.337 12 
 Per Protocol 0.0 1.633 7 .117  -1.5 1.732 4 -.93**  
                 
  ** medium effect size of < .5 (in either direction).
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Appendix 14 Health Related quality of life statistics. 
Table 55. Regression analysis. Effect of Predictors. Health related Quality of Life 
 
 
 
 
 
 
 
Table 56. Regression analysis. The effect of the interventions on sleep 
 
 
 
 
Overall effect of the model: F (5,82) = 1.873, p = .108          Number of observations = 88 
Predictors  
Unstandardized Coefficients  
t Sig. B Std. Error  
 (Constant) -.014 .073  .192 .848 
hom -.057 .031  1.841 .069 
NT -.084 .031  2.730 .008 
Age -.002 .005  .360 .720 
ADHD severity .008 .028  -.268 .789 
Male vs female .047 .034  -1.377 .172 
Dependent Variable: wellbeing change (weighted) 
Overall effect of the model: F (5,82) = .481, p= .789          Number of observations = 88 
Model 
Unstandardized Coefficients 
t Sig. B Std. Error 
 (Constant) .307 .637 .482 .631 
hom .340 .270 1.258 .212 
NT .265 .268 .989 .325 
Age .001 .047 .021 .984 
ADHD severity -.103 .246 -.417 .678 
Male vs female -.223 .299 -.743 .459 
Dependent variable: sleep change 
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Figure 20. Baseline carer-rated HRQOL status of participants according to CHU-9D individual items 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Number of observations = 124 
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 Figure 21. Descriptive graphs of individual CHU 9D items at baseline and 6-months according to group    
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